February 2022 Volume 29 Number 0
Editors:
Kaye Wilson, & Sophie Molloy
email: enquiry@pharmac.govt.nz
Telephone +64 4 460 4990
Facsimile +64 4 460 4995
Level 9, 40 Mercer Street
PO Box 10 254 Wellington
Freephone Information Line

Freeph 0800 66 00 50 (9am - 5pm weekdays)

Circulation

Accessible in an electronic format at no cost from the Pharmac website www.pharmac.govt.nz/schedule.

You can register to have an electronic version of the Pharmaceutical Schedule (link to PDF copy) emailed to your nominated email address each month by subscribing at pharmac.govt.nz/subscribe.

Production

Typeset automatically from XML and T_FX. XML version of the Schedule available from schedule.pharmac.govt.nz/pub/schedule

Programmers

Anrik Drenth & John Geering

BY

email: texschedule@pharmac.govt.nz

©Pharmaceutical Management Agency $(\mathbf{\hat{H}})$ cc

ISSN 1179-3686

This work is licensed under the Creative Commons Attribution 4.0 International licence. In essence, you are free to copy, distribute and adapt it, as long as you attribute the work to Pharmac and abide by the other licence terms. To view a copy of this licence, visit: creativecommons.org/licenses/by/4.0/. Attribution to Pharmac should be in written form and not by reproduction of the Pharmac logo. While care has been taken in compiling this Schedule, Pharmac takes no responsibility for any errors or omissions, and shall not be liable for any consequences arising there from.

Section A	General Rules	5
Section B	Alimentary Tract & Metabolism	6
	Blood & Blood Forming Organs	37
	Cardiovascular System	47
	Dermatologicals	62
	Genito Urinary System	72
	Hormone Preparations – Systemic	79
	Infections – Agents For Systemic Use	90
	Musculoskeletal System	111
	Nervous System	119
	Oncology Agents & Immunosuppressants	146
	Respiratory System & Allergies	225
	Sensory Organs	234
	Various	239
Section C	Extemporaneous Compounds (ECPs)	241
Section D	Special Foods	244
Section I	National Immunisation Schedule	265
	Index	277

Introducing Pharmac

The Pharmaceutical Management Agency (Pharmac) makes decisions that help control Government spending on pharmaceuticals. This includes community pharmaceuticals, hospital pharmaceuticals, vaccines and increasingly, hospital medical devices. Pharmac negotiates prices, sets subsidy levels and conditions, and makes decisions on changes to the subsidised list. The funding for pharmaceuticals comes from District Health Boards.

Pharmac's role:

"Secure for eligible people in need of pharmaceuticals, the best health outcomes that can reasonably be achieved, and from within the amount of funding provided."

New Zealand Public Health and Disability Act 2000

To ensure our decisions are as fair and robust as possible we use a decision-making process that incorporates clinical, economic and commercial issues. We also seek the views of users and the wider community through consultation. The processes we generally use are outlined in our Operating Policies and Procedures.

Further information about Pharmac and the way we make funding decisions can be found on the Pharmac website at https://www.pharmac.govt.nz/about.

Purpose of the Pharmaceutical Schedule

The purpose of the Schedule is to list:

- the Community Pharmaceuticals that are subsidised by the Government and to show the amount of the subsidy paid to contractors, as well as the manufacturer's price and any access conditions that may apply;
- the Hospital Pharmaceuticals that may be used in DHB Hospitals, as well as any access conditions that may apply; and
- the Pharmaceuticals, including Medical Devices, used in DHB Hospitals for which national prices have been negotiated by Pharmac.

The Schedule does not show the final cost to Government of subsidising each Community Pharmaceutical or to DHB Hospitals in purchasing each Pharmaceutical, since that will depend on any rebate and other arrangements Pharmac has with the supplier and, for Pharmaceuticals used in DHB Hospitals, on any logistics arrangements put in place.

This book contains sections A to D and Section I of the Pharmaceutical Schedule and lists the Pharmaceuticals funded for use in the community, including vaccines, as well as haemophilia and cancer treatments given in DHB hospitals. Section H lists the Pharmaceuticals that that can be used in DHB hospitals and is a separate publication.


The Pharmaceuticals in this book are listed by therapeutic group, which is based on the WHO Anatomical Therapeutic Chemical (ATC) system. The listings are displayed alphabetically under each heading.

The index lists both chemical entities and product brand names.

Explaining pharmaceutical entries

The Pharmaceutical Schedule lists pharmaceuticals subsidised by the Government, the subsidy, the supplier's price and the access conditions that may apply.

Example



Glossary

Units of Measure

gram g	
kilogram kg	
international unit iu	

Abbreviations

Capsule Cream Device Dispersible Effervescent Emulsion	Amp Cap Crm Dev Disp Eff Emul EC
Enteric Coated	EC

microgram me	cg
milligramn	ng
millilitreı	ml

millimole	mmol
unit	u

Gelatinous	Gel	SolutionSoln
Granules	Gran	SuppositorySupp
Infusion	Inf	TabletTab
Injection	Inj	Tincture Tinc
Liquid	Liq	Trans Dermal Delivery
Long Acting	LA	SystemTDDS
Ointment	Oint	-
Sachet	Sach	

Read the General Rules : https://www.pharmac.govt.nz/section-a.

SECTION B: ALIMENTARY TRACT AND METABOLISM

	Subsidy		Fully	Brand or
	(Manufacturer's Price) \$) Sub: Per	sidised ✓	Generic Manufacturer
Antacids and Antiflatulents				
Antacids and Reflux Barrier Agents				
ALGINIC ACID Sodium alginate 225 mg and magnesium alginate 87.5 mg p sachet		30	✔ G	aviscon Infant
SODIUM ALGINATE				
Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg - peppermint flavour	1.80	60		
	(8.60)	00	G	aviscon Double Strength
Oral liq 500 mg with sodium bicarbonate 267 mg and calciur carbonate 160 mg per 10 ml		500 ml		
	(5.24)	500 m	A	cidex
Phosphate Binding Agents				
ALUMINIUM HYDROXIDE				
* Tab 600 mg CALCIUM CARBONATE	12.56	100	✓ A	lu-Tab
Oral liq 1,250 mg per 5 ml (500 mg elemental per 5 ml) – Subsidy by endorsement Only when prescribed for patients unable to swallow cal	cium carbonate table	500 ml ets or where		oxane n carbonate tablets are
inappropriate and the prescription is endorsed according	yıy.			
Antidiarrhoeals				
Agents Which Reduce Motility				
LOPERAMIDE HYDROCHLORIDE – Up to 30 cap available on				
* Tab 2 mg * Cap 2 mg		400 400	✓ N ✓ <u>D</u>	odia iamide Relief
Rectal and Colonic Anti-inflammatories				
BUDESONIDE				
Cap 3 mg – Special Authority see SA1886 below – Retail pharmacy		90	√ E	ntocort CIR
SA1886 Special Authority for Subsidy				
Initial application — (Crohn's disease) from any relevant prac the following criteria: Both:	titioner. Approvals v	alid for 6 n	nonths f	or applications meeting
 Mild to moderate ileal, ileocaecal or proximal Crohn's dise Any of the following: 	ease; and			
2.1 Diabetes; or2.2 Cushingoid habitus; or				
2.3 Osteoporosis where there is significant risk of frac	ture; or			
				continued.

6

Subsidy	Full	/ Brand or
(Manufacturer's Price)	Subsidise	d Generic
\$	Per 🖌	Manufacturer

continued...

- 2.4 Severe acne following treatment with conventional corticosteroid therapy; or
- 2.5 History of severe psychiatric problems associated with corticosteroid treatment; or
- 2.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or
- 2.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated).

Initial application — (collagenous and lymphocytic colitis (microscopic colitis)) from any relevant practitioner. Approvals valid for 6 months where patient has a diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies.

Initial application — (gut Graft versus Host disease) from any relevant practitioner. Approvals valid for 6 months where patient has a gut Graft versus Host disease following allogenic bone marrow transplantation*.

Note: Indication marked with * is an unapproved indication.

Initial application — (non-cirrhotic autoimmune hepatitis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has autoimmune hepatitis*; and
- 2 Patient does not have cirrhosis; and
- 3 Any of the following:
 - 3.1 Diabetes; or
 - 3.2 Cushingoid habitus; or
 - 3.3 Osteoporosis where there is significant risk of fracture; or
 - 3.4 Severe acne following treatment with conventional corticosteroid therapy; or
 - 3.5 History of severe psychiatric problems associated with corticosteroid treatment; or
 - 3.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or
 - 3.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated); or
 - 3.8 Adolescents with poor linear growth (where conventional corticosteroid use may limit further growth).

Note: Indication marked with * is an unapproved indication.

Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (non-cirrhotic autoimmune hepatitis) from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

Note: Clinical trials for Entocort CIR use beyond three months demonstrated no improvement in relapse rate.

HYDROCORTISONE ACETATE

Rectal foam 10%, CFC-Free (14 applications)26.55	15 g OP 21.1 g OP	 ✓ Cortifoam ^{S29} ✓ Colifoam
HYDROCORTISONE ACETATE WITH PRAMOXINE HYDROCHLORIDE		
Topical aerosol foam, 1% with pramoxine hydrochloride 1%	10 g OP	 Proctofoam S29
MESALAZINE		
Tab 400 mg	100	Asacol
Tab EC 500 mg	100	Asamax
Tab long-acting 500 mg56.10	100	Pentasa
Tab 800 mg85.50	90	✓ Asacol
Modified release granules, 1 g	100 OP	 Pentasa
Enema 1 g per 100 ml41.30	7	 Pentasa
Suppos 500 mg	20	Asacol
Suppos 1 g	28	 Pentasa
(Asamax Tab EC 500 mg to be delisted 1 March 2022)		
OLSALAZINE		
Tab 500 mg93.37	100	 Dipentum
Cap 250 mg53.00	100	 Dipentum

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy		Fully	Brand or
	(Manufacturer's Price) \$	Per	Subsidised	Generic Manufacturer
PREDNISOLONE SODIUM	Ŷ	1.01		Manufacturor
Rectal foam 20 mg per dose (14 applications)	74.10	1 OP	1	Essential Prednisolone S29
SODIUM CROMOGLICATE				
Cap 100 mg	92.91	100	~	Nalcrom
SULFASALAZINE				• • •
K Tab 500 mg Tab EC 500 mg		100 100		Salazopyrin Salazopyrin EN
J.		100	•	
Local preparations for Anal and Rectal Disorder	S			
Antihaemorrhoidal Preparations				
LUOCORTOLONE CAPROATE WITH FLUOCORTOLONE PIV	ALATE AND CINCH	OCAI	NE	
Oint 950 mcg, with fluocortolone pivalate 920 mcg, and cinchocaine hydrochloride 5 mg per g	6.25 2	30 g O	D 🖌	Ultraproct
Suppos 630 mcg, with fluocortolone pivalate 610 mcg, and	0.00 0	o y o	г •	Onapioci
cinchocaine hydrochloride 1 mg	2.66	12	1	Ultraproct
IYDROCORTISONE WITH CINCHOCAINE				
Oint 5 mg with cinchocaine hydrochloride 5 mg per g		30 g O		Proctosedyl
Suppos 5 mg with cinchocaine hydrochloride 5 mg per g	9.90	12	1	Proctosedyl
Management of Anal Fissures				
GLYCERYL TRINITRATE - Special Authority see SA1329 below ₭ Oint 0.2%		30 g O	D 🖌	Rectogesic
SA1329 Special Authority for Subsidy		io y O	•	neciogesic
initial application from any relevant practitioner. Approvals valid hronic anal fissure that has persisted for longer than three weeks		ewal u	nless notif	ied where the patient has
Antispasmodics and Other Agents Altering Gut	Motility			
GLYCOPYRRONIUM BROMIDE				
Inj 200 mcg per ml, 1 ml ampoule – Up to 10 inj available on	а			
PSO		10	1	Max Health
YOSCINE BUTYLBROMIDE				
* Tab 10 mg	6.35	100		Buscopan
Inj 20 mg, 1 ml – Up to 5 inj available on a PSO	6.35	5	~	Buscopan
	0.00	~~		0.1.6.
 Tab 135 mg 	9.20	90	~	Colofac
Antiulcerants				
Antisecretory and Cytoprotective				
/ISOPROSTOL				
Tab 200 mcg – Up to 120 tab available on a PSO	41.50	120	1	Cytotec
				-

	Subsidy (Manufacturer's Price)		Fully Subsidised	Brand or Generic
	(Manulacturer's Frice) \$	Per		Manufacturer
Helicobacter Pylori Eradication				
 CLARITHROMYCIN Tab 500 mg – Subsidy by endorsement a) Maximum of 28 tab per prescription b) Subsidised only if prescribed for helicobacter pylo Note: the prescription is considered endorsed if or is highlight and other servicible and other services of the service of the service	ori eradication and prescri		is endorsed	
inhibitor and either amoxicillin or metronidazole. H2 Antagonists				
AMOTIDINE – Only on a prescription				
K Tab 20 mg	4.91	100	🗸 F	amotidine Hovid ©29
 Tab 40 mg 	8.48	100	✓ F	amotidine Hovid S29
 Inj 10 mg per ml, 4 ml – Subsidy by endorsement		10 of pa		lylan S29
Proton Pump Inhibitors		0. 00		
ANSOPRAZOLE				
€ Cap 15 mg		100	🗸 L	anzol Relief
€ Cap 30 mg		100		anzol Relief
MEPRAZOLE				
For omeprazole suspension refer Standard Formulae, pa	•			
← Cap 10 mg		90		meprazole actavis 10
€ Cap 20 mg	1.86	90	✓ <u>0</u>	meprazole actavis 20
€ Cap 40 mg	3.11	90	✓ <u>0</u>	meprazole actavis 40
Powder – Only in combination		5 g	🗸 M	lidwest
Only in extemporaneously compounded omeprazole Inj 40 mg ampoule with diluent		5	✓ <u>D</u>	<u>r Reddy's</u> Omeprazole
ANTOPRAZOLE	0.00		()	
 ✓ Tab EC 20 mg ✓ Tab EC 40 mg 		100 100		<u>anzop Relief</u> anzop Relief
•	2.00	100	• <u>r</u>	
Site Protective Agents				
OLLOIDAL BISMUTH SUBCITRATE				
Tab 120 mg	14.51	50	✓ G	astrodenol S29
UCRALFATE Tab 1 g	35.50 (48.28)	120	С	arafate
Bile and Liver Therapy				
RIFAXIMIN – Special Authority see SA1461 on the next page Tab 550 mg		56	✓ X	ifaxan

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Pri \$	ce) Per	Fully Subsidised	Brand or Generic Manufacturer
➤SA1461 Special Authority for Subsidy nitial application only from a gastroenterologist, hepatologist nepatologist. Approvals valid for 6 months where the patient has olerated doses of lactulose. Renewal only from a gastroenterologist, hepatologist or Practiti nepatologist. Approvals valid without further renewal unless no benefiting from treatment.	as hepatic encephal ioner on the recomm	opathy d	espite an a n of a gastro	dequate trial of maximur penterologist or
Diabetes				
Hyperglycaemic Agents				
DIAZOXIDE – Special Authority see SA1320 below – Retail ph Cap 25 mg Cap 100 mg Oral liq 50 mg per ml ⇒SA1320 Special Authority for Subsidy		100 100 30 ml C	✓I DP ✓I	Proglicem S29 Proglicem S29 Proglycem S29
nitial application from any relevant practitioner. Approvals vanypoglycaemia caused by hyperinsulinism. Renewal from any relevant practitioner. Approvals valid without appropriate and the patient is benefiting from treatment. GLUCAGON HYDROCHLORIDE Inj 1 mg syringe kit – Up to 5 kit available on a PSO	ut further renewal ur		fied where	
Insulin - Short-acting Preparations				
NSULIN NEUTRAL ▲ Inj human 100 u per ml		10 ml C 5	 I I	Actrapid Humulin R Actrapid Penfill
Inculing Intermediate entire Dreservations			• 1	Humulin R
Insulin - Intermediate-acting Preparations				
NSULIN ASPART WITH INSULIN ASPART PROTAMINE ▲ Inj 100 iu per ml, 3 ml prefilled pen NSULIN ISOPHANE	52.15	5	√ I	NovoMix 30 FlexPen
Inj human 100 u per ml	17.68	10 ml C		Humulin NPH Protaphane
▲ Inj human 100 u per ml, 3 ml	29.86	5	🗸 I	Humulin NPH Protaphane Penfill
NSULIN ISOPHANE WITH INSULIN NEUTRAL				
Inj human with neutral insulin 100 u per ml	25.26	10 ml C		Humulin 30/70 Mixtard 30
Inj human with neutral insulin 100 u per ml, 3 ml	42.66	5	✓ ✓ ✓	Humulin 30/70 PenMix 30 PenMix 40 PenMix 50

10

	Subsidy (Manufacturer's Price \$) S Per	Fully ubsidised	
INSULIN LISPRO WITH INSULIN LISPRO PROTAMINE				
Inj lispro 25% with insulin lispro protamine 75% 100 u per ml, 3 ml		5	1	Humalog Mix 25
Inj lispro 50% with insulin lispro protamine 50% 100 u per ml, 3 ml		5	1	Humalog Mix 50
Insulin - Long-acting Preparations				
NSULIN GLARGINE ▲ Inj 100 u per ml, 10 ml ▲ Inj 100 u per ml, 3 ml	94.50	1 5 5	1	Lantus Lantus Lantus SoloStar
Insulin - Rapid Acting Preparations				
INSULIN ASPART ▲ Inj 100 u per ml, 10 ml ▲ Inj 100 u per ml, 3 ml ▲ Inj 100 u per ml, 3 ml syringe INSULIN GLULISINE ▲ Inj 100 u per ml, 10 ml	51.19 51.19 27.03	1 5 5	1 1 1	NovoRapid NovoRapid Penfill NovoRapid FlexPen Apidra
 Inj 100 u per ml, 3 ml Inj 100 u per ml, 3 ml disposable pen NSULIN LISPRO Inj 100 u per ml, 10 ml Inj 100 u per ml, 3 ml 		5 5 0 ml OF 5	✓ ✓	Apidra Apidra SoloStar Humalog Humalog
Alpha Glucosidase Inhibitors				
ACARBOSE * Tab 50 mg * Tab 100 mg Oral Hypoglycaemic Agents		90 90		Accarb Accarb
GLIBENCLAMIDE ₩ Tab 5 mg GLICLAZIDE	7.50	100	1	<u>Daonil</u>
* Tab 80 mg		500	1	Glizide
GLIPIZIDE * Tab 5 mg Minidiab to be Principal Supply on 1 March 2022	4.58	100	•	Minidiab
METFORMIN HYDROCHLORIDE * Tab immediate-release 500 mg	8.63 14.74	1,000		Apotex Metformin Mylan
* Tab immediate-release 850 mg		500	✓	Apotex Metformin Mylan
(Apotex Tab immediate-release 500 mg to be delisted 1 March 20 (Apotex Tab immediate-release 850 mg to be delisted 1 March 20	,			

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
PIOGLITAZONE				
* Tab 15 mg	6.80	90	 	Vexazone
* Tab 30 mg	7.30	90	 	Vexazone
* Tab 45 mg		90	 V 	/exazone
VILDAGLIPTIN Tab 50 mg	35.00	60	√ (Galvus
VILDAGLIPTIN WITH METFORMIN HYDROCHLORIDE				
Tab 50 mg with 1,000 mg metformin hydrochloride		60	✓ (Galvumet
Tab 50 mg with 850 mg metformin hydrochloride	35.00	60	✓ (Galvumet

GLP-1 Agonists

⇒SA2065 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Patient has previously received an initial approval for an SGLT-2 inhibitor; or
- 2 All of the following:
 - 2.1 Patient has type 2 diabetes; and
 - 2.2 Any of the following:
 - 2.2.1 Patient is Māori or any Pacific ethnicity*; or
 - 2.2.2 Patient has pre-existing cardiovascular disease or risk equivalent (see note a)*; or
 - 2.2.3 Patient has an absolute 5-year cardiovascular disease risk of 15% or greater according to a validated cardiovascular risk assessment calculator*; or
 - 2.2.4 Patient has a high lifetime cardiovascular risk due to being diagnosed with type 2 diabetes during childhood or as a young adult*; or
 - 2.2.5 Patient has diabetic kidney disease (see note b)*; and
 - 2.3 Target HbA1c (of 53 mmol/mol or less) has not been achieved despite the regular use of at least one blood-glucose lowering agent (e.g. metformin, vildagliptin, or insulin) for at least 3 months.
- Notes: * Criteria intended to describe patients at high risk of cardiovascular or renal complications of diabetes.
 - a) Pre-existing cardiovascular disease or risk equivalent defined as: prior cardiovascular disease event (i.e. angina, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, transient ischaemic attack, ischaemic stroke, peripheral vascular disease), congestive heart failure or familial hypercholesterolaemia.
 - b) Diabetic kidney disease defined as: persistent albuminuria (albumin:creatinine ratio greater than or equal to 3 mg/mmol, in at least two out of three samples over a 3-6 month period) and/or eGFR less than 60 mL/min/1.73m2 in the presence of diabetes, without alternative cause.

 DULAGLUTIDE
 Special Authority see SA2065 above
 Retail pharmacy

 Note:
 Not to be given in combination with a funded SGLT-2 inhibitor.

 *
 Inj 1.5mg per 0.5 ml prefilled pen
 115.23

SGLT2 Inhibitors

⇒SA2068 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

continued...

4

Trulicity

Subsidy	F	ully	Brand or
(Manufacturer's F			Generic
\$	Per	1	Manufacturer

continued...

- 1 Patient has previously received an initial approval for a GLP-1 agonist; or
- 2 All of the following:
 - 2.1 Patient has type 2 diabetes: and
 - 2.2 Any of the following:
 - 2.2.1 Patient is Māori or any Pacific ethnicity*; or
 - 2.2.2 Patient has pre-existing cardiovascular disease or risk equivalent (see note a)*: or
 - 2.2.3 Patient has an absolute 5-year cardiovascular disease risk of 15% or greater according to a validated cardiovascular risk assessment calculator*: or
 - 2.2.4 Patient has a high lifetime cardiovascular risk due to being diagnosed with type 2 diabetes during childhood or as a young adult*; or
 - 2.2.5 Patient has diabetic kidney disease (see note b)*; and
 - 2.3 Target HbA1c (of 53 mmol/mol or less) has not been achieved despite the regular use of at least one blood-glucose lowering agent (e.g. metformin, vildagliptin, or insulin) for at least 3 months.

Notes: * Criteria intended to describe patients at high risk of cardiovascular or renal complications of diabetes.

- a) Pre-existing cardiovascular disease or risk equivalent defined as: prior cardiovascular disease event (i.e. angina, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, transient ischaemic attack, ischaemic stroke, peripheral vascular disease), congestive heart failure or familial hypercholesterolaemia.
- b) Diabetic kidney disease defined as: persistent albuminuria (albumin:creatinine ratio greater than or equal to 3 mg/mmol, in at least two out of three samples over a 3-6 month period) and/or eGFR less than 60 mL/min/1.73m2 in the presence of diabetes, without alternative cause.

EMPAGLIFLOZIN - Special Authority see SA2068 on the previous page - Retail pharmacy

Note: Not to be given in combination with a funded GLP-1 agonist.

*	Tab 10 mg	58.56	30	 Jardiance
*	Tab 25 mg	58.56	30	 Jardiance

EMPAGLIFLOZIN WITH METFORMIN HYDROCHLORIDE - Special Authority see SA2068 on the previous page - Retail pharmacy

Note: Not to be given in combination with a funded GLP-1 agonist.

*	Tab 5 mg with 1,000 mg metformin hydrochloride	58.56	60	 Jardiamet
*	Tab 5 mg with 500 mg metformin hydrochloride	58.56	60	 Jardiamet
*	Tab 12.5 mg with 1,000 mg metformin hydrochloride	58.56	60	 Jardiamet
*	Tab 12.5 mg with 500 mg metformin hydrochloride	58.56	60	 Jardiamet

Diabetes Management

Ketone Testing

BLOOD KETONE DIAGNOSTIC TEST STRIP - Subsidy by endorsement

- a) Not on a BSO
- b) Maximum of 20 strip per prescription
- c) Up to 10 strip available on a PSO
- d) Patient has any of the following:
 - 1) type 1 diabetes; or
 - 2) permanent neonatal diabetes: or
 - 3) undergone a pancreatectomy; or
 - 4) cystic fibrosis-related diabetes; or
 - 5) metabolic disease or epilepsy under the care of a paediatrician, neurologist or metabolic specialist.

The prescription must be endorsed accordingly. Т

est	strips	 1	5.50	0

 KetoSens 10 strip OP

	Subsidy (Manufacturer's Price) \$		ully Brand or sed Generic Manufacturer
Dual Blood Glucose and Blood Ketone Testing			
 DUAL BLOOD GLUCOSE AND BLOOD KETONE DIAGNOSTIC a) Maximum of 1 pack per prescription b) Up to 1 pack available on a PSO c) A dual blood glucose and blood ketone diagnostic test n type 1 diabetes; or permanent neonatal diabetes; or undergone a pancreatectomy; or cystic fibrosis-related diabetes; or metabolic disease or epilepsy under the care of a The prescription must be endorsed accordingly. Only 1 the avoidance of doubt patients who have previously rec funded CareSens meter. 	neter is subsidised for paediatrician, neurolog meter per patient will seived a funded meter	a patient who gist or metabo be subsidised) has: blic specialist. d (no repeat prescriptions). Fo
diagnostic test strips		1 OP	✓ CareSens Dual
Blood Glucose Testing			
 BLOOD GLUCOSE DIAGNOSTIC TEST METER – Subsidy by a) Maximum of 1 pack per prescription b) Up to 1 pack available on a PSO c) A diagnostic blood glucose test meter is subsidised for a 1) is receiving insulin or sulphonylurea therapy; or 2) is pregnant with diabetes; or 3) is on home TPN at risk of hypoglycaemia or hyperies 4) has a genetic or an acquired disorder of glucose h syndrome. The prescription must be endorsed accordingly. Only or prescriptions). Patients already using the CareSens N F meter, unless they have: 1) type 1 diabetes; or 2) permanent neonatal diabetes; or 3) undergone a pancreatectomy; or 4) cystic fibrosis-related diabetes. For the avoidance of doubt patients who have previously funded CareSens meter. Meter with 50 lancets, a lancing device and 10 diagnostic te strips 	a patient who: glycaemia; or omeostasis, excluding ne CareSens meter pr POP meter and CareS y received a funded m	er patient will ens N meter a eter, other tha 1 OP	be subsidised (no repeat are not eligible for a new

	Subsidy		Fully	Brand or
	(Manufacturer's Price		sidised	Generic
	\$	Per		Manufacturer
BLOOD GLUCOSE DIAGNOSTIC TEST STRIP - Up to 50) test available on a PSC)		
The number of test strips available on a prescription is	restricted to 50 unless:			
1) Prescribed for a patient on insulin or a sulphonylu	irea and endorsed accoi	dingly. Phar	macists	may annotate the
prescription as endorsed where there exists a rec	ord of prior dispensing o	of insulin or si	ulphony	lurea; or
2) Prescribed on the same prescription as insulin or	a sulphonylurea in whic	h case the pr	escripti	on is deemed to be
endorsed; or	and a surple second as a surplus of			
3) Prescribed for a pregnant woman with diabetes a	0.	· ·		and a second sector and
4) Prescribed for a patient on home TPN at risk of h	, , , , , , , , , , , , , , , , , , , ,	,		0,1/
5) Prescribed for a patient with a genetic or an acqu		nomeostasis	exclual	ng type 1 or type
2 diabetes and metabolic syndrome and endorse	a accordingly.			
Test strips	10.56	50 test OP	v c	areSens N
		00 1001 01	_	areSens PRO
BLOOD GLUCOSE TEST STRIPS (VISUALLY IMPAIRED)			-	
The number of test strips available on a prescription is				
 Prescribed for a patient on insulin or a sulphonylu 		dinaly Dhor	magiata	may appatata the
prescription as endorsed where there exists a rec				
 Prescribed on the same prescription as insulin or 	1 1 0			,
endorsed; or	a sulpriorigitiea in whic	ii case iiie pi	escriptio	
 Prescribed for a pregnant woman with diabetes a 	nd endorsed accordingly	/: or		
4) Prescribed for a patient on home TPN at risk of h			lendors	ed accordingly: or
5) Prescribed for a patient with a genetic or an acqu				0.7
2 diabetes and metabolic syndrome and endorse			enter a a	
······, ·····,	5,			
Blood glucose test strips		50 test OP	✓ S	ensoCard
Insulin Syringes and Needles				
Nakaiska in particula for sline particula particular second	a and non-mandles if you	بالاحد أدحيا أبر		farmer an the area
subsidy is available for disposable insulin syringes, needles				
ne supply of insulin or when prescribed for an insulin patien nnotate the prescription as endorsed where there exists a			coruing	iy. Fharmacisis may
NSULIN PEN NEEDLES – Maximum of 200 dev per preso	cription			
€ 29 g × 12.7 mm	•	100	✓ В	-D Micro-Fine
¥ 21 a ∨ 5 mm		100	./ D	D Miero Eine

*	31 g × 5 mm	100
	31 g × 6 mm	100
	31 g × 8 mm	100
	32 g × 4 mm	100
	5	

•	B-D Micro-Fine
1	B-D Micro-Fine
✓	Berpu

- ✓ B-D Micro-Fine
- ✓ B-D Micro-Fine

		Subsidy (Manufacturer's Price)	Der	Fully Subsidised	Generic
_		\$	Per	1	Manufacturer
INS	SULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE	E – Maximum of 200	dev j	per prescri	ption
*	Syringe 0.3 ml with 29 g × 12.7 mm needle		100	✓	B-D Ultra Fine
		1.30	10		
		(1.99)			B-D Ultra Fine
*	Syringe 0.3 ml with 31 g × 8 mm needle		100	✓	B-D Ultra Fine II
		1.30	10		
		(1.99)			B-D Ultra Fine II
*	Syringe 0.5 ml with 29 g × 12.7 mm needle	()	100	✓	B-D Ultra Fine
	-, 3	1.30	10		
		(1.99)			B-D Ultra Fine
*	Syringe 0.5 ml with 31 g × 8 mm needle	()	100	1	B-D Ultra Fine II
•		1.30	10		
		(1.99)			B-D Ultra Fine II
*	Syringe 1 ml with 29 g × 12.7 mm needle	()	100	1	B-D Ultra Fine
		1.30	10	-	
		(1.99)	10		B-D Ultra Fine
*	Syringe 1 ml with 31 g × 8 mm needle	()	100	1	B-D Ultra Fine II
~		1.30	100	•	
		(1.99)	10		B-D Ultra Fine II
		· · · /			
1r	eulin Pumne				

Insulin Pumps

INSULIN PUMP - Special Authority see SA1603 below - Retail pharmacy

a)	Maximum of 1 dev per prescription			
b)	Only on a prescription			
c)	Maximum of 1 insulin pump per patient each four year pe	riod.		
Ń	in basel rate 0.025 L1/b	0 000 00	4	

Min basal rate 0.025 U/h		1	 MiniMed 770G
Min basal rate 0.1 U/h	4,500.00	1	 Tandem t:slim
			X2 with Basal-IQ

► SA1603 Special Authority for Subsidy

Initial application — (permanent neonatal diabetes) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has permanent neonatal diabetes; and
- 2 A MDI regimen trial is inappropriate; and
- 3 Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy; and
- 4 Patient/Parent/Guardian has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an appropriate health professional); and
- 5 Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care; and
- 6 Either:
 - 6.1 Applicant is a relevant specialist; or
 - 6.2 Applicant is a nurse practitioner working within their vocational scope.

Renewal — (permanent neonatal diabetes) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

16

- 1 Patient is continuing to derive benefit according to the treatment plan agreed at induction; and
- 2 Patient remains fully compliant and transition to MDI is considered inappropriate by the treating physician; and
- 3 It has been at least 4 years since the last insulin pump received by the patient or, in the case of patients qualifying under previous pump therapy for the initial application; the pump is due for replacement; and

Subsidy		Fully	Brand or
(Manufacturer's Price)	Su	lbsidised	Generic
\$	Per	1	Manufacturer

continued...

4 Either:

4.1 Applicant is a relevant specialist; or

4.2 Applicant is a nurse practitioner working within their vocational scope.

Initial application — (severe unexplained hypoglycaemia) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes; and
- 2 Has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an appropriate health professional); and
- 3 Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care; and
- 4 Has adhered to an intensive MDI regimen using analogue insulins for at least six months; and
- 5 Has had four severe unexplained hypoglycaemic episodes over a six month period (severe as defined as requiring the assistance of another person); and
- 6 Has an average HbA1c between the following range: equal to or greater than 53 mmol/mol and equal to or less than 90 mmol/mol; and
- 7 Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy; and

8 Either:

- 8.1 Applicant is a relevant specialist; or
- 8.2 Applicant is a nurse practitioner working within their vocational scope.

Renewal — (severe unexplained hypoglycaemia) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient is continuing to derive benefit according to the treatment plan agreed at induction of at least a 50% reduction from baseline in hypoglycaemic events; and
- 2 HbA1c has not increased by more than 5 mmol/mol from baseline; and
- 3 Either:
 - 3.1 It has been at least 4 years since the last insulin pump was received by the patient; or
 - 3.2 The pump is due for replacement; and
- 4 Either:
 - 4.1 Applicant is a relevant specialist; or
 - 4.2 Applicant is a nurse practitioner working within their vocational scope.

Initial application — (HbA1c) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes; and
- 2 Has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an appropriate health professional); and
- 3 Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care; and
- 4 Has adhered to an intensive MDI regimen using analogue insulins for at least six months; and
- 5 Has unpredictable and significant variability in blood glucose including significant hypoglycaemia affecting the ability to reduce HbA1; and
- 6 In the opinion of the treating clinician, HbA1c could be reduced by at least 10 mmol/mol using insulin pump treatment; and
- 7 Has typical HbA1c results between the following range: equal to or greater than 65 mmol/mol and equal to or less than 90 mmol/mol; and
- 8 Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy; and
- 9 Either:
 - 9.1 Applicant is a relevant specialist; or

Subsidy		Fully	Brand or	
(Manufacturer's Price	e)	Subsidised	Generic	
\$	Per	· · ·	Manufacturer	

continued...

9.2 Applicant is a nurse practitioner working within their vocational scope.

Renewal — (HbA1c) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient is continuing to derive benefit according to the treatment plan agreed at induction of achieving and maintaining a reduction in HbA1c from baseline of 10 mmol/mol; and
- 2 The number of severe unexplained recurrent hypoglycaemic episodes has not increased from baseline; and
- 3 Either:
 - 3.1 It has been at least 4 years since the last insulin pump was received by the patient; or
 - 3.2 The pump is due for replacement; and
- 4 Either:
 - 4.1 Applicant is a relevant specialist; or
 - 4.2 Applicant is a nurse practitioner working within their vocational scope.

Initial application — (Previous use before 1 September 2012) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes; and
- 2 Was already on pump treatment prior to 1 September 2012 and had been evaluated by the multidisciplinary team for their suitability for insulin pump therapy at the time of initiating that pump treatment and continues to benefit from pump treatment; and
- 3 The patient has adhered to an intensive MDI regimen using analogue insulins for at least six months prior to initiating pump therapy; and
- 4 The patient is continuing to derive benefit from pump therapy; and
- 5 The patient had achieved and is maintaining a HbA1c of equal to or less than 80 mmol/mol on pump therapy; and
- 6 The patient has had no increase in severe unexplained hypoglycaemic episodes from baseline; and
- 7 The patient's HbA1c has not deteriorated more than 5 mmol/mol from baseline; and
- 8 Either:
 - 8.1 It has been at least 4 years since the last insulin pump was received by the patient; or
 - 8.2 The pump is due for replacement; and
- 9 Either:
 - 9.1 Applicant is a relevant specialist; or
 - 9.2 Applicant is a nurse practitioner working within their vocational scope.

Renewal — (Previous use before 1 September 2012) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 The patient is continuing to derive benefit according to the treatment plan and has maintained a HbA1c of equal to or less than 80 mmol/mol; and
- 2 The patient's HbA1c has not deteriorated more than 5 mmol/mol from the time of commencing pump treatment; and
- 3 The patient has not had an increase in severe unexplained hypoglycaemic episodes from baseline; and
- 4 Either:
 - 4.1 It has been at least 4 years since the last insulin pump was received by the patient; or
 - 4.2 The pump is due for replacement; and
- 5 Either:
 - 5.1 Applicant is a relevant specialist; or
 - 5.2 Applicant is a nurse practitioner working within their vocational scope.

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufact

ic Manufacturer

Insulin Pump Consumables

⇒SA1985 Special Authority for Subsidy

Initial application — (permanent neonatal diabetes) only from a relevant specialist or nurse practitioner. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 Patient has permanent neonatal diabetes: and
- 2 A MDI regimen trial is inappropriate; and
- 3 Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy; and
- 4 Patient/Parent/Guardian has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an appropriate health professional); and
- 5 Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care; and
- 6 Fither:
 - 6.1 Applicant is a relevant specialist; or
 - 6.2 Applicant is a nurse practitioner working within their vocational scope.

Renewal — (permanent neonatal diabetes) only from a relevant specialist or nurse practitioner. Approvals valid for 2 years for applications meeting the following criteria:

All of the followina:

- 1 Patient is continuing to derive benefit according to the treatment plan agreed at induction; and
- 2 Patient remains fully compliant and transition to MDI is considered inappropriate by the treating physician; and
- 3 Either:
 - 3.1 Applicant is a relevant specialist; or
 - 3.2 Applicant is a nurse practitioner working within their vocational scope.

Initial application - (severe unexplained hypoglycaemia) only from a relevant specialist or nurse practitioner. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes; and
- 2 Has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an appropriate health professional); and
- 3 Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care; and
- 4 Has adhered to an intensive MDI regimen using analogue insulins for at least six months; and
- 5 Has had four severe unexplained hypoglycaemic episodes over a six month period (severe as defined as requiring the assistance of another person): and
- 6 Has an average HbA1c between the following range: equal to or greater than 53 mmol/mol and equal to or less than 90 mmol/mol: and
- 7 Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy; and
- 8 Fither:
 - 8.1 Applicant is a relevant specialist: or
 - 8.2 Applicant is a nurse practitioner working within their vocational scope.

Renewal — (severe unexplained hypoglycaemia) only from a relevant specialist or nurse practitioner. Approvals valid for 2 vears for applications meeting the following criteria:

All of the following:

- 1 Patient is continuing to derive benefit according to the treatment plan agreed at induction of at least a 50% reduction from baseline in hypoglycaemic events: and
- 2 HbA1c has not increased by more than 5 mmol/mol from baseline; and
- 3 Fither:
 - 3.1 Applicant is a relevant specialist; or

Subs	sidy	Fully	Brand or
(Manufactu	rer's Price) Subsid	lised	Generic
\$	S Per	1	Manufacturer

continued...

3.2 Applicant is a nurse practitioner working within their vocational scope.

Initial application — (HbA1c) only from a relevant specialist or nurse practitioner. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes; and
- 2 Has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an appropriate health professional); and
- 3 Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care; and
- 4 Has adhered to an intensive MDI regimen using analogue insulins for at least six months; and
- 5 Has unpredictable and significant variability in blood glucose including significant hypoglycaemia affecting the ability to reduce HbA1; and
- 6 In the opinion of the treating clinician, HbA1c could be reduced by at least 10 mmol/mol using insulin pump treatment; and
- 7 Has typical HbA1c results between the following range: equal to or greater than 65 mmol/mol and equal to or less than 90 mmol/mol; and
- 8 Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy; and
- 9 Either:
 - 9.1 Applicant is a relevant specialist; or
 - 9.2 Applicant is a nurse practitioner working within their vocational scope.

Renewal — (HbA1c) only from a relevant specialist or nurse practitioner. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Patient is continuing to derive benefit according to the treatment plan agreed at induction of achieving and maintaining a reduction in HbA1c from baseline of 10 mmol/mol; and
- 2 The number of severe unexplained recurrent hypoglycaemic episodes has not increased from baseline; and
- 3 Either:
 - 3.1 Applicant is a relevant specialist; or
 - 3.2 Applicant is a nurse practitioner working within their vocational scope.

Initial application — (Previous use before 1 September 2012) only from a relevant specialist or nurse practitioner. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes; and
- 2 Was already on pump treatment prior to 1 September 2012 and had been evaluated by the multidisciplinary team for their suitability for insulin pump therapy at the time of initiating that pump treatment and continues to benefit from pump treatment; and
- 3 The patient has adhered to an intensive MDI regimen using analogue insulins for at least six months prior to initiating pump therapy; and
- 4 The patient is continuing to derive benefit from pump therapy; and
- 5 The patient had achieved and is maintaining a HbA1c of equal to or less than 80 mmol/mol on pump therapy; and
- 6 The patient has had no increase in severe unexplained hypoglycaemic episodes from baseline; and
- 7 The patient's HbA1c has not deteriorated more than 5 mmol/mol from baseline; and
- 8 Either:
 - 8.1 Applicant is a relevant specialist; or
 - 8.2 Applicant is a nurse practitioner working within their vocational scope.

Renewal — (Previous use before 1 September 2012) only from a relevant specialist or nurse practitioner. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

20

1 The patient is continuing to derive benefit according to the treatment plan and has maintained a HbA1c of equal to or less

	Subsidy (Manufacturer's Price) 6	Fully sidised	Brand or Generic
	(Manulacturer's Frice \$	Per		Manufacturer
continued				
than 80 mmol/mol; and				
2 The patient's HbA1c has not deteriorated more than 5 mr	nol/mol from initial a	oplication;	and	
3 The patient has not had an increase in severe unexplained	ed hypoglycaemic ep	isodes fro	m baseli	ne; and
4 Either:				
4.1 Applicant is a relevant specialist; or				
4.2 Applicant is a nurse practitioner working within the	eir vocational scope.			
INSULIN PUMP CARTRIDGE - Special Authority see SA1985	on page 19 – Retail r	harmacy		
a) Maximum of 3 sets per prescription	- F 5 F	,		
b) Only on a prescription				
c) Maximum of 13 packs of cartridge sets will be funded pe	r year.			
Cartridge 300 U, t:lock × 10		1 OP	🖌 Т	andem Cartridge
INSULIN PUMP INFUSION SET (STEEL CANNULA) - Special	Authority see SA198	5 on page	19 – Re	etail pharmacy
a) Maximum of 3 sets per prescription	,, ,	1.0		···· [· ··· ···]
b) Only on a prescription				
c) Maximum of 13 infusion sets will be funded per year.				
10 mm steel needle; 60 cm tubing × 10		1 OP	🗸 N	/iniMed Sure-T
				MMT-884A
10 mm steel needle; 80 cm tubing × 10		1 OP	🗸 N	/iniMed Sure-T
				MMT-886A
6 mm steel needle; 60 cm tubing × 10	130.00	1 OP	🗸 N	/iniMed Sure-T
				MMT-864A
6 mm steel needle; 80 cm tubing × 10		1 OP	✓ N	AiniMed Sure-T
				MMT-866A
8 mm steel needle; 60 cm tubing × 10		1 OP	✓ N	AiniMed Sure-T
0 mm staal naadlas 00 an tukina s 10	100.00	1.00		MMT-874A
8 mm steel needle; 80 cm tubing × 10		1 OP	• 1	/iniMed Sure-T MMT-876A
6 mm steel needle; 29 G; manual insertion; 60 cm tubing ×				WIWIT-070A
10 with 10 needles; luer lock	130.00	1 OP	10	Sure-T MMT-863
8 mm steel needle; 29 G; manual insertion; 60 cm tubing ×		101	• 3	
10 with 10 needles; luer lock	130.00	1 OP	1 S	Sure-T MMT-873
-			-	
INSULIN PUMP INFUSION SET (STEEL CANNULA, STRAIGH Retail pharmacy	1 INSERTION = 5p	ecial Autri	only see	- 5A 1965 on page 19 -
a) Maximum of 3 sets per prescription				
b) Only on a prescription				
c) Maximum of 13 infusion sets will be funded per year.				
6 mm steel cannula; straight insertion; 80 cm line \times 10 with				
10 needles		1 OP	🗸 1	ruSteel
8 mm steel cannula; straight insertion; 80 cm line × 10 with			•	
10 needles	130.00	1 OP	√ T	ruSteel
6 mm steel cannula; straight insertion; 60 cm line \times 10 with				
10 needles	130.00	1 OP	🗸 I	ruSteel
8 mm steel cannula; straight insertion; 60 cm line \times 10 with				
10 needles		1 OP	🗸 I	ruSteel

A Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	
SULIN PUMP INFUSION SET (TEFLON CANNULA) – Spec	ial Authority see SA19	85 on	page 19 -	- Retail pharmacy
a) Maximum of 3 set per prescriptionb) Only on a prescription				
 c) Maximum of 13 infusion sets will be funded per year. 13 mm teflon needle, 110 cm tubing × 10 	130.00	1 OP	1	MiniMed Silhouette MMT-382A
13 mm teflon needle, 45 cm tubing × 10	130.00	1 OP	1	MiniMed Silhouette MMT-368A
13 mm teflon needle, 60 cm tubing × 10	130.00	1 OP	1	MiniMed Silhouette MMT-381A
13 mm teflon needle, 80 cm tubing × 10	130.00	1 OP	1	MiniMed Silhouette MMT-383A
17 mm teflon needle, 110 cm tubing × 10	130.00	1 OP	1	MiniMed Silhouette MMT-377A
17 mm teflon needle, 60 cm tubing × 10	130.00	1 OP	1	MiniMed Silhouette MMT-378A
17 mm teflon needle, 80 cm tubing × 10	130.00	1 OP	1	MiniMed Silhouette MMT-384A
6 mm teflon needle, 110 cm tubing × 10	130.00	1 OP	1	MiniMed Quick-Set MMT-398A
6 mm teflon needle, 45 cm blue tubing × 10	130.00	1 OP	1	MiniMed Mio MMT-941A
6 mm teflon needle, 45 cm pink tubing × 10	130.00	1 OP	1	MiniMed Mio MMT-921A
6 mm teflon needle, 60 cm blue tubing × 10	130.00	1 OP	1	MiniMed Mio MMT-943A
6 mm teflon needle, 60 cm pink tubing × 10	130.00	1 OP	1	MiniMed Mio MMT-923A
6 mm teflon needle, 60 cm tubing × 10	130.00	1 OP	1	MiniMed Quick-Set MMT-399A
6 mm teflon needle, 80 cm blue tubing	130.00	1 OP	1	MiniMed Mio MMT-945A
6 mm teflon needle, 80 cm clear tubing × 10	130.00	1 OP	1	MiniMed Mio MMT-965A
6 mm teflon needle, 80 cm pink tubing × 10	130.00	1 OP	1	MiniMed Mio MMT-925A
6 mm teflon needle, 80 cm tubing × 10	130.00	1 OP	1	MiniMed Quick-Set MMT-387A
9 mm teflon needle, 110 cm tubing × 10	130.00	1 OP	1	MiniMed Quick-Set MMT-396A
9 mm teflon needle, 60 cm tubing × 10	130.00	1 OP	1	MiniMed Quick-Set MMT-397A
9 mm teflon needle, 80 cm clear tubing × 10	130.00	1 OP	1	MiniMed Mio MMT-975A
9 mm teflon needle, 80 cm tubing × 10	130.00	1 OP	1	MiniMed Quick-Set MMT-386A

22

	Subsidy (Manufacturer's Price \$		Fully Brand or lised Generic Manufacturer
INSULIN PUMP INFUSION SET (TEFLON CANNULA, ANGLE SA1985 on page 19 – Retail pharmacy a) Maximum of 3 sets per prescription b) Only on a prescription c) Maximum of 13 infusion sets will be funded per year.	NSERTION WITH II	NSERTION D	EVICE) – Special Authority see
13 mm teflon cannula; angle insertion; insertion device; 110 line × 10 with 10 needles		1 OP	✓ AutoSoft 30
13 mm teflon cannula; angle insertion; insertion device; 60 c line x 10 with 10 needles		1 OP	✓ AutoSoft 30
 INSULIN PUMP INFUSION SET (TEFLON CANNULA, ANGLE Retail pharmacy a) Maximum of 3 sets per prescription b) Only on a prescription c) Maximum of 13 infusion sets will be funded per year. 17 mm teflon cannula; angle insertion; 60 cm line × 10 with 10 needles; luer lock		cial Authority	see SA1985 on page 19 – ✓ Silhouette MMT-373
INSULIN PUMP INFUSION SET (TEFLON CANNULA, STRAIG see SA1985 on page 19 – Retail pharmacy a) Maximum of 3 sets per prescription b) Only on a prescription c) Maximum of 13 infusion sets will be funded per year. 6 mm teflon cannula; straight insertion; insertion device;	HT INSERTION WIT	'H INSERTIO	N DEVICE) – Special Authority
110 cm line × 10 with 10 needles 6 mm teflon cannula; straight insertion; insertion device; 60 line × 10 with 10 needles	cm	1 OP 1 OP	 AutoSoft 90 AutoSoft 90
9 mm teflon cannula; straight insertion; insertion device; 110 cm line × 10 with 10 needles		1 OP	✓ AutoSoft 90
9 mm teflon cannula; straight insertion; insertion device; 60 line × 10 with 10 needles		1 OP	✓ AutoSoft 90
 INSULIN PUMP INFUSION SET (TEFLON CANNULA, STRAIG Retail pharmacy a) Maximum of 3 sets per prescription b) Only on a prescription c) Maximum of 13 infusion sets will be funded per year. 6 mm teflon cannula; straight insertion; 60 cm tubing × 10 w 	ith		
10 needles; luer lock 9 mm teflon cannula; straight insertion; 60 cm tubing × 10 w	ith	1 OP	✓ Quick-Set MMT-393
10 needles; luer lock INSULIN PUMP RESERVOIR – Special Authority see SA1985 (1 OP oharmacy	✓ Quick-Set MMT-392
 a) Maximum of 3 sets per prescription b) Only on a prescription c) Maximum of 13 packs of reservoir sets will be funded pe 10 × luer lock conversion cartridges 1.8 ml for Paradigm pur Cartridge for 5 and 7 series pump; 1.8 ml × 10 	r year. nps50.00	1 OP 1 OP	 ✓ ADR Cartridge 1.8 ✓ MiniMed 1.8 Reservoir MMT-326A
Cartridge for 7 series pump; 3.0 ml × 10	50.00	1 OP	 MiniMed 3.0 Reservoir MMT-332A

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer	
Digestives Including Enzymes					
PANCREATIC ENZYME					
Cap pancreatin 150 mg (amylase 8,000 Ph Eur U, lipase 10,000 Ph Eur U, total protease 600 Ph Eur U)		100	√ (Creon 10000	
Cap pancreatin (175 mg (25,000 U lipase, 22,500 U amylase 1,250 U protease))		100	🖌 F	Panzytrat	
Cap pancreatin 300 mg (amylase 18,000 Ph Eur U, lipase 25,000 Ph Eur U, total protease 1,000 Ph Eur U)		100	√ (Creon 25000	
Modified release granules pancreatin 60.12 mg (amylase 3,600 Ph Eur U, lipase 5,000 Ph Eur U, protease 200 Ph	1				
Eur U)		20 g OF	· √ (Creon Micro	
URSODEOXYCHOLIC ACID - Special Authority see SA1739 be	elow – Retail pharma	су			
Cap 250 mg		100	✓ I	Jrsosan	
■ SA1739 Special Authority for Subsidy					

1/39 Special Authority for Subsidy

Initial application — (Alagille syndrome or progressive familial intrahepatic cholestasis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either:

- 1 Patient has been diagnosed with Alagille syndrome; or
- 2 Patient has progressive familial intrahepatic cholestasis.

Initial application — (Chronic severe drug induced cholestatic liver injury) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic severe drug induced cholestatic liver injury; and
- 2 Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults; and
- 3 Treatment with ursodeoxycholic acid may prevent hospital admission or reduce duration of stay.

Initial application — (Primary biliary cholangitis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Primary biliary cholangitis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and
- 2 Patient not requiring a liver transplant (bilirubin > 100 umol/l; decompensated cirrhosis).

Initial application - (Pregnancy) from any relevant practitioner. Approvals valid for 6 months where the patient diagnosed with cholestasis of pregnancy.

Initial application — (Haematological Transplant) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient at risk of veno-occlusive disease or has hepatic impairment and is undergoing conditioning treatment prior to allogenic stem cell or bone marrow transplantation; and
- 2 Treatment for up to 13 weeks.

Initial application --- (Total parenteral nutrition induced cholestasis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

- Both:
 - 1 Paediatric patient has developed abnormal liver function as indicated on testing which is likely to be induced by Total Parenteral Nutrition (TPN); and
 - 2 Liver function has not improved with modifying the TPN composition.

Renewal — (Chronic severe drug induced cholestatic liver injury) from any relevant practitioner. Approvals valid for 6

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

months where the patient continues to benefit from treatment.

Renewal — (Pregnancy/Primary biliary cholangitis) from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (Total parenteral nutrition induced cholestasis) from any relevant practitioner. Approvals valid for 6 months where the paediatric patient continues to require TPN and who is benefiting from treatment, defined as a sustained improvement in bilirubin levels.

Note: Ursodeoxycholic acid is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 100 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transplant centre. Treatment failure -- doubling of serum bilirubin levels, absence of a significant decrease in ALP or ALT and AST, development of varices, ascites or encephalopathy, marked worsening of pruritus or fatigue, histological progression by two stages, or to cirrhosis, need for transplantation.

Laxatives

Bulk-forming Agents

ISPAGHULA (PSYLLIUM) HUSK – Only on a prescription * Powder for oral soln	6.00	250 g OP	✓ Macro Organic Psyllium Husk
	12.20	500 g OP	✓ <u>Konsyl-D</u>
MUCILAGINOUS LAXATIVES WITH STIMULANTS			
* Dry		500 g OP	Newsersel Dive
	(17.32) 2.41	200 g OP	Normacol Plus
	(8.72)	200 g Oi	Normacol Plus
Faecal Softeners			
DOCUSATE SODIUM – Only on a prescription			
* Tab 50 mg		100	Coloxyl
* Tab 120 mg DOCUSATE SODIUM WITH SENNOSIDES	3.13	100	✓ <u>Coloxyl</u>
* Tab 50 mg with sennosides 8 mg	4.20	200	✓ Laxsol
POLOXAMER – Only on a prescription Not funded for use in the ear.			
* Oral drops 10%	3.98	30 ml OP	✓ Coloxyl
Opioid Receptor Antagonists - Peripheral			
METHYLNALTREXONE BROMIDE - Special Authority see SA169 Inj 12 mg per 0.6 ml vial		ail pharmacy 1	✓ Relistor

 Relistor 	1	Inj 12 mg per 0.6 ml vial
 Relistor 	7	246.00

➡SA1691 Special Authority for Subsidy

Initial application — (Opioid induced constipation) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 The patient is receiving palliative care; and
- 2 Either:
 - 2.1 Oral and rectal treatments for opioid induced constipation are ineffective; or
 - 2.2 Oral and rectal treatments for opioid induced constipation are unable to be tolerated.

	Subsidy (Manufacturer's Price \$) Per	Fully Subsidised	
Osmotic Laxatives	\$	Fei		Manulacturer
GLYCEROL				
₭ Suppos 3.6 g – Only on a prescription	9.25	20	1	PSM
ACTULOSE – Only on a prescription				
Oral liq 10 g per 15 ml	3.33	500 ml	1	Laevolac
ACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BIO Powder for oral soln 13.125 g with potassium chloride 46.6 m		SODIU	M CHLOF	RIDE
sodium bicarbonate 178.5 mg and sodium chloride 350.7		30	1	Molaxole
SODIUM ACID PHOSPHATE – Only on a prescription				
Enema 16% with sodium phosphate 8%	2.50	1	1	Fleet Phosphate Enema
ODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE	- Only on a prescr	ription		
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml,				
5 ml		50	1	Micolette
Ctimulant Lavativas				
Stimulant Laxatives				
SISACODYL – Only on a prescription				
 Tab 5 mg 	5.80	200		Pharmacy Health
	5.99			Lax-Tab
Suppos 10 mg	3.69	10	-	Lax-Suppositories
Lax-Tab Tab 5 mg to be delisted 1 June 2022)				
ENNA – Only on a prescription	o / -	400		
 Tab, standardised 		100		Constrat
	(8.21) 0.43	20		Senokot
	(2.06)	20		Senokot
ODIUM PICOSULFATE – Special Authority see SA2053 below	· · · ·			
Oral soln 7.5 mg per ml		30 ml O	Р 🖌	Dulcolax SP Drop
CA20E2 Created Authority for Suboidy				Daisolar of Brop

⇒SA2053 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 The patient is a child with problematic constipation despite an adequate trial of other oral pharmacotherapies including macrogol where practicable; and
- 2 The patient would otherwise require a high-volume bowel cleansing preparation or hospital admission.

Renewal from any relevant practitioner. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application only from a metabolic physician. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

1 The patient is aged up to 24 months at the time of initial application and has been diagnosed with infantile Pompe disease;

continued...

26

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

and

- 2 Any of the following:
 - 2.1 Diagnosis confirmed by documented deficiency of acid alpha-glucosidase by prenatal diagnosis using chorionic villus biopsies and/or cultured amniotic cells; or
 - 2.2 Documented deficiency of acid alpha-glucosidase, and urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides; or
 - 2.3 Documented deficiency of acid alpha-glucosidase, and documented molecular genetic testing indicating a disease-causing mutation in the acid alpha-glucosidase gene (GAA gene); or
 - 2.4 Documented urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides, and molecular genetic testing indicating a disease-causing mutation in the GAA gene; and
- 3 Patient has not required long-term invasive ventilation for respiratory failure prior to starting enzyme replacement therapy (ERT); and
- 4 Patient does not have another life-threatening or severe disease where the prognosis is unlikely to be influenced by ERT or might be reasonably expected to compromise a response to ERT; and
- 5 Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks.

Renewal only from a metabolic physician. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The treatment remains appropriate for the patient and the patient is benefiting from treatment; and
- 2 Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks; and
- 3 Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates; and
- 4 Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by ERT; and
- 5 Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT; and
- 6 There is no evidence of life threatening progression of respiratory disease as evidenced by the needed for > 14 days of invasive ventilation; and
- 7 There is no evidence of new or progressive cardiomyopathy.

ARGININE – Special Authority see SA2042 below – Retail pharmacy

Tab 1,000 mg	CBS	90	 Clinicians
Cap 500 mg	CBS	50	 Solgar
Powder		400 g	 Biomed

► SA2042 Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 6 months where patient has a suspected inborn error of metabolism that may respond to arginine supplementation.

Renewal only from a metabolic physician. Approvals valid for 24 months for applications meeting the following criteria: Both:

- 1 The patient has a confirmed diagnosis of an inborn error of metabolism that responds to arginine supplementation; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

BETAINE – Special Authority see SA1987 below – Retail pharmacy

 Cystadane

► SA1987 Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient has a confirmed diagnosis of homocystinuria; and
- 2 Any of the following:

AThree months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

(M	Subsidy	l	ully	Brand or
	anufacturer's Price)	Subsid	ised	Generic
·	\$	Per	✓	Manufacturer

continued...

- 2.1 A cystathionine beta-synthase (CBS) deficiency; or
- 2.2 A 5,10-methylene-tetrahydrofolate reductase (MTHFR) deficiency; or
- 2.3 A disorder of intracellular cobalamin metabolism; and

3 An appropriate homocysteine level has not been achieved despite a sufficient trial of appropriate vitamin supplementation. **Renewal** only from a metabolic physician. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

COENZYME Q10 - Special Authority see SA2039 below	 Retail pharmacy 		
Cap 120 mg	CBS	30	 Solgar
Cap 160 mg	CBS	60	Go Healthy

⇒SA2039 Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 6 months where patient has a suspected inborn error of metabolism that may respond to coenzyme Q10 supplementation.

Renewal only from a metabolic physician. Approvals valid for 24 months for applications meeting the following criteria: Both:

- 1 The patient has a confirmed diagnosis of an inborn error of metabolism that responds to coenzyme Q10 supplementation; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

GALSULFASE – Special Authority see SA1988 below – Retail pharmacy

Inj 1 mg per ml, 5 ml vial	Naglazyme
----------------------------	-----------

⇒SA1988 Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 12 months for applications meeting the following criteria: Both:

- 1 The patient has been diagnosed with mucopolysaccharidosis VI; and
- 2 Either:
 - 2.1 Diagnosis confirmed by demonstration of N-acetyl-galactosamine-4-sulfatase (arylsulfatase B) deficiency by either enzyme activity assay in leukocytes or skin fibroblasts; or
 - 2.2 Detection of two disease causing mutations and patient has a sibling who is known to have mucopolysaccharidosis VI.

Renewal only from a metabolic physician. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The treatment remains appropriate for the patient and the patient is benefiting from treatment; and
- 2 Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates; and
- 3 Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by Enzyme Replacement Therapy (ERT); and
- 4 Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT.

IDURSULFASE – Special Authority see SA1623 below – Retail pharmacy

Inj 2 mg per ml, 3 ml vial4,60	18.30	 Elaprase
--------------------------------	-------	------------------------------

⇒SA1623 Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 24 weeks for applications meeting the following criteria: All of the following:

- 1 The patient has been diagnosed with Hunter Syndrome (mucopolysaccharidosis II); and
- 2 Either:
 - 2.1 Diagnosis confirmed by demonstration of iduronate 2-sulfatase deficiency in white blood cells by either enzyme

	Subsidy (Manufacturer's Price \$) Per	Fully Subsidised	Brand or Generic Manufacturer
 continued assay in cultured skin fibroblasts; or 2.2 Detection of a disease causing mutation in the idu. 3 Patient is going to proceed with a haematopoietic stem c idursulfase would be bridging treatment to transplant; and 4 Patient has not required long-term invasive ventilation for 	ell transplant (HSCT) d	withir	n the next 3 n	
 (ERT); and Idursulfase to be administered for a total of 24 weeks (eq greater than 0.5 mg/kg every week. 	uivalent to 12 weeks	pre- a	and 12 weeks	s post-HSCT) at doses no
LARONIDASE – Special Authority see SA1695 below – Retail p Inj 100 U per ml, 5 ml vial	1,335.16	1 annlir		Idurazyme
All of the following: 1 The patient has been diagnosed with Hurler Syndrome (r 2 Either:				ng the following chicha.
 2.1 Diagnosis confirmed by demonstration of alpha-L- assay in cultured skin fibroblasts; or 2.2 Detection of two disease causing mutations in the to have Hurler syndrome; and 		-		
 3 Patient is going to proceed with a haematopoietic stem c laronidase would be bridging treatment to transplant; and 4 Patient has not required long-term invasive ventilation for (ERT); and 5 Laronidase to be administered for a total of 24 weeks (ec than 100 units/kg every week. 	l r respiratory failure pr	ior to	starting Enzy	me Replacement Therapy
LEVOCARNITINE – Special Authority see SA2040 below – Ret Tab 500 mg Cap 250 mg Cap 500 mg Oral lig 500 mg per 10 ml	CBS CBS CBS	30 30 60 300 n	✓ S ✓ B	olgar olgar alance alance
 ⇒SA2040 Special Authority for Subsidy Initial application only from a metabolic physician. Approvals of metabolism that may respond to carnitine supplementation. Renewal only from a metabolic physician. Approvals valid for 2 Both: 	4 months for applicat	ions n	neeting the fo	ollowing criteria:
 The patient has a confirmed diagnosis of an inborn error The treatment remains appropriate and the patient is ber RIBOFLAVIN – Special Authority see SA2041 below – Retail pt 	nefiting from treatmen		is to carnitine	e supplementation, and
Tab 100 mg Cap 100 mg	CBS	100 100		country Life olgar
► SA2041 Special Authority for Subsidy Initial application only from a metabolic physician or neurologis inborn error of metabolism that may respond to riboflavin supple Renewal only from a metabolic physician or neurologist. Appro- criteria: Both:	mentation.			

1 The patient has a confirmed diagnosis of an inborn error of metabolism that responds to riboflavin supplementation; and

2 The treatment remains appropriate and the patient is benefiting from treatment.

	Subsidy (Manufacturer's Price		Fully sidised	Brand or Generic
	\$	Per	1	Manufacturer
SAPROPTERIN DIHYDROCHLORIDE – Special Authority se	ee SA1989 below – Re	tail pharmad		
Tab soluble 100 mg		30 OP	✓ K	luvan
SA1989 Special Authority for Subsidy				
nitial application only from a metabolic physician. Approva	Is valid for 1 month for	applications	meetin	g the following criteria:
1 Patient has phenylketonuria (PKU) and is pregnant or	actively planning to be	oomo progn	ant: and	4
2 Treatment with sapropterin is required to support man	JI 0	1 0	,	
3 Sapropterin to be administered at doses no greater that				
4 Sapropterin to be used alone or in combination with P	KU dietary managemer	nt; and		
5 Total treatment duration with sapropterin will not exceed becoming pregnant) and treatment will be stopped after		pregnancy (include	s time for planning and
Renewal only from a metabolic physician or any relevant practice		endation of	a meta	bolic physician.
Approvals valid for 12 months for applications meeting the fol All of the following:	lowing criteria:			
1 Either:				
1.1 Following the initial one-month approval, the pa of sapropterin with a clinically appropriate redu				
pregnancy; or				
 On subsequent renewal applications, the patient sapropterin and maintained adequate phenylal 				
2 Any of the following:				
2.1 Patient continues to be pregnant and treatment				
2.2 Patient is actively planning a pregnancy and th2.3 Treatment with sapropterin is required for a sec during pregnancy; and				
3 Sapropterin to be administered at doses no greater that	an a total daily dose of	20 mg/kg; a	Ind	
4 Sapropterin to be used alone or in combination with Pl				
5 Total treatment duration with sapropterin will not excee becoming pregnant) and treatment will be stopped after		pregnancy (include	s time for planning and
SODIUM BENZOATE – Special Authority see SA1599 below	•			
Soln 100 mg per ml		100 ml	🗸 A	mzoate S29
■SA1599 Special Authority for Subsidy				
nitial application only from a metabolic physician. Approva	ls valid for 12 months v	where the pa	atient ha	is a diagnosis of a urea
ycle disorder.				
Renewal only from a metabolic physician. Approvals valid fo	r 12 months where the	treatment re	emains	appropriate and the
patient is benefiting from treatment.	00 kalan Datallakan			
SODIUM PHENYLBUTYRATE – Special Authority see SA19		macy 174 g OP	. / D	heburane
Grans 483 mg per g	2,010.00	174 y OF	• •	liebulaile
SA1990 Special Authority for Subsidy nitial application only from a metabolic physician. Approva	le valid for 12 monthe v	whore the pa	tiont ha	e a diagnosis of a urea
cycle disorder involving a deficiency of carbamylphosphate sy				
synthetase.		loouloullyn		giinitoodoonidto
Renewal only from a metabolic physician. Approvals valid fo patient is benefiting from treatment.	r 12 months where the	treatment re	emains	appropriate and the
AURINE - Special Authority see SA2043 on the next page	 Retail pharmacy 			
Cap 500 mg	CBS	50		olgar
Cap 1,000 mg	CBS	90	🗸 L	ife Extension
Powder	e	300 g		ife Extension

30

Subsidy (Manufacturer's Price)	Ful Subsidise	d Generic	
 \$	Per •	Manufacturer	

⇒SA2043 Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 6 months where patient has a suspected specific mitochondrial disorder that may respond taurine supplementation.

Renewal only from a metabolic physician. Approvals valid for 24 months for applications meeting the following criteria: Both:

- 1 The patient has confirmed diagnosis of a specific mitochondrial disorder which responds to taurine supplementation; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Gaucher's Disease

⇒SA1880 Special Authority for Subsidy

Special Authority approved by the Gaucher Treatment Panel

Notes: Application details may be obtained from Pharmac's website <u>schedule.pharmac.govt.nz/SAForms</u> or:

The Co-ordinator, Gaucher Treatment Panel	Phone: 04 460 4990
Pharmac PO Box 10 254	Facsimile: 04 916 7571
Wellington	Email: gaucherpanel@pharmac.govt.nz

Completed application forms must be sent to the coordinator for the Gaucher Treatment Panel and will be considered by the Gaucher Treatment Panel at the next practicable opportunity.

Notification of the Gaucher Treatment Panel's decision will be sent to the patient, the applying clinician and the patient's GP (if specified).

Access Criteria

6)

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- The patient has a diagnosis of symptomatic type 1 or type 3* Gaucher disease confirmed by the demonstration of specific deficiency of glucocerebrosidase in leukocytes or cultured skin fibroblasts, and genotypic analysis; and
- 2) Patient does not have another life-threatening or severe disease where the prognosis is unlikely to be influenced by taliglucerase alfa or might be reasonably expected to compromise a response to therapy with taliglucerase alfa; and
- Taliglucerase alfa is to be administered at a dose no greater than 30 unit/kg every other week rounded to the nearest whole vial (200 units), unless otherwise agreed by Pharmac; and
- 4) Supporting clinical information including test reports, MRI whole body STIR, haematological data, and other relevant investigations, are submitted to the Gaucher Panel for assessment; and
- 5) Any of the following:
 - Patient has haematological complications such as haemoglobin less than 95 g/l, symptomatic anaemia, thrombocytopenia; at least two episodes of severely symptomatic splenic infarcts confirmed with imagery; or massive symptomatic splenomegaly; or
 - 2) Patient has skeletal complications such as acute bone crisis requiring hospitalisation or major pain management strategies; radiological MRI Evidence of incipient destruction of any major joint (e.g. hips or shoulder); spontaneous fractures or vertebral collapse; chronic bone pain not controlled by other pharmaceuticals; or
 - 3) Patient has significant liver dysfunction or hepatomegaly attributable to Gaucher disease; or
 - Patient has reduced vital capacity from clinically significant or progressive pulmonary disease due to Gaucher disease; or
 - 5) Patient is a child and has experienced growth failure with significant decrease in percentile linear growth over a 6-12 month period.

*Unapproved indication

Renewal from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Subsidy (Manufactured Drive)		Fully	Brand or
(Manufacturer's Price) \$	Per	Subsidised	Generic Manufacturer

continued...

All of the following:

- 1) Patient has demonstrated a symptomatic improvement or no deterioration in the main symptom for which therapy was initiated; and
- Patient has demonstrated a clinically objective improvement or no deterioration in haemoglobin levels, platelet counts and liver and spleen size; and
- 3) Radiological (MRI) signs of bone activity performed at two years since initiation of treatment, and three yearly thereafter, demonstrate no deterioration shown by the MRI, compared with MRI taken immediately prior to commencement of therapy or adjusted dose; and
- 4) Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates; and
- 5) Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT; and
- 6) Patient is compliant with regular treatment and taliglucerase alfa is to be administered at a dose no greater than 30 unit/kg every other week rounded to the nearest whole vial (200 units), unless otherwise agreed by Pharmac; and
- Supporting clinical information including test reports, MRI whole body STIR, haematological data, and other relevant investigations are submitted to the Gaucher Panel for assessment as required.

Mouth and Throat

Agents Used in Mouth Ulceration

ENZYDAMINE HYDROCHLORIDE			
Soln 0.15% – Higher subsidy of \$20.31 per 500 ml with			
Endorsement		500 ml	
	(20.31)		Difflam
Additional subsidy by endorsement for a patient who ha prescription is endorsed accordingly.	as oral mucositis a	as a result of tr	eatment for cancer, and the
ARMELLOSE SODIUM WITH GELATIN AND PECTIN			
Paste		56 g OP	Stomahesive
	4.55	15 g OP	••••••
	(7.90)		Orabase
	1.52	5 g OP	
	(3.60)	- 3 -	Orabase
Powder	· · · ·	28 g OP	
	(10.95)		Stomahesive
HOLINE SALICYLATE WITH CETALKONIUM CHLOBIDE	()		
	0.06	15 g OP	
Adhesive gel 8.7% with cetalkonium chloride 0.01%	2.06 (6.00)	15 y OF	Bonjela
	(0.00)		Dorijela
RIAMCINOLONE ACETONIDE			<i></i>
Paste 0.1%	5.33	5 g OP	 Kenalog in Orabase
Oropharyngeal Anti-infectives			
MPHOTERICIN B			
Lozenges 10 mg	5.86	20	 Fungilin
ICONAZOLE			-
Oral gel 20 mg per g	4 74	40 g OP	Decozol
		40 y O1	- 0600201
YSTATIN Oral lig 100,000 u per ml	4 70	24 ml OP	 Nilstat

	Subsidy		Fully	Brand or	
(Ma	anufacturer's Price) \$	Per	Subsidised	Generic Manufacturer	
	Ŧ				
Vitamins					
Vitamin B					
IYDROXOCOBALAMIN					
Inj 1 mg per ml, 1 ml ampoule – Up to 6 inj available on a PSO	1.89	3	-	leo-B12 /ita-B12	
	3.15	5	√ ł	lydroxocobalamin Mercury Pharma	
YRIDOXINE HYDROCHLORIDE				-	
a) No more than 100 mg per dose					
 b) Only on a prescription Fab 25 mg - No patient co-payment payable 	0.70	00		litemin BC 05	
Tab 25 mg – No patient co-payment payable Tab 50 mg		90 500		/ <u>itamin B6 25</u> Apo-Pyridoxine	
	23.45			Pyridoxine	
				multichem	
Apo-Pyridoxine Tab 50 mg to be delisted 1 May 2022)					
HIAMINE HYDROCHLORIDE – Only on a prescription	=				
K Tab 50 mg	7.09	100	✓ 1	Max Health	
ITAMIN B COMPLEX ≰ Tab, strong, BPC	7 15	500		Bplex	
•		500	•	phex	
Vitamin C					
SCORBIC ACID					
a) No more than 100 mg per dose					
 b) Only on a prescription ✤ Tab 100 mg 	0 00	500	10	Cvite	
		500	• •	<u>vite</u>	
Vitamin D					
LFACALCIDOL					
K Cap 0.25 mcg		100		Dne-Alpha	
 K Cap 1 mcg K Oral drops 2 mcg per ml 		100 0 ml C		Dne-Alpha Dne-Alpha	
ALCITRIOL		0 1111 0			
K Cap 0.25 mcg	7.95	100	✓ (Calcitriol-AFT	
 Cap 0.5 mcg 		100	-	Calcitriol-AFT	
COLECALCIFEROL					
Cap 1.25 mg (50,000 iu) – Maximum of 12 cap per prescription		12	_	<u>/it.D3</u>	
Oral liq 188 mcg per ml (7,500 iu per ml)	9.00 4	.8 ml C)P 🖌 F	Puria	
Multivitamin Preparations					
IULTIVITAMIN RENAL – Special Authority see SA1546 on the next	page – Retail pl	narma	су		
				Clinicians Renal Vit	

	Subsidy	·	Fully	Brand or
	(Manufacturer's Pr \$	ice) Subs Per	sidised ✓	Generic Manufacturer
SA1546 Special Authority for Subsidy itial application from any relevant practitioner. Approvals valid	without further r	enewal unless	s notified	I for applications meetin
e following criteria: ither:				
 The patient has chronic kidney disease and is receiving eith The patient has chronic kidney disease grade 5, defined as 15 ml/min/1.73 m² body surface area (BSA). 				
IULTIVITAMINS – Special Authority see SA1036 below – Retail		200 g OP	✓ P	aediatric Seravit
SA1036 Special Authority for Subsidy		0		
itial application from any relevant practitioner. Approvals valid born errors of metabolism.	without further r	enewal unless	s notified	I where the patient has
enewal from any relevant practitioner. Approvals valid without for oproval for multivitamins.	urther renewal u	nless notified	where p	atient has had a previou
ITAMINS ← Tab (BPC cap strength)	11.45	1,000	✓ <u>м</u>	vite
Cap (fat soluble vitamins A, D, E, K) – Special Authority see SA1720 below – Retail pharmacy	23.40	60	🗸 V	itabdeck
SA1720 Special Authority for Subsidy				
nitial application from any relevant practitioner. Approvals valid	without further r	enewal unless	s notified	d for applications meetir
e following criteria: ny of the following:				
1 Patient has cystic fibrosis with pancreatic insufficiency; or				
2 Patient is an infant or child with liver disease or short gut sy	vndrome; or			
3 Patient has severe malabsorption syndrome.	, .			
Minerals				
millerais				
Calcium				
	0.00	050	()	-1-1 T-1 500
 Tab 1.25 g (500 mg elemental) Tab eff 1.25 g (500 mg elemental) – Subsidy by endorsemental 		250 76		alci-Tab 500 acit ^{\$29}
Subsidy by endorsement – Only when prescribed for paer considered unsuitable.				
ALCIUM GLUCONATE				
 Inj 10%, 10 ml ampoule 	32.00	10	✓ M	ax Health - Hameln S29
	64.00	20	🗸 M	ax Health S29
	0 1100			
ALCIUM LACTATE GLUCONATE WITH CALCIUM CARBONAT				
ALCIUM LACTATE GLUCONATE WITH CALCIUM CARBONAT Tab eff 2.94 g with calcium carbonate 0.3 g (500 mg elementa	E	20		alcium-Sandoz

Subsidy by endorsement – Only when prescribed for paediatric patients (< 5 years) where calcium carbonate oral liquid is considered unsuitable.

34

	Subsidy (Manufacturer's Price) \$	Subsi Per	Fully dised	Brand or Generic Manufacturer
Fluoride				
SODIUM FLUORIDE * Tab 1.1 mg (0.5 mg elemental)	8.64	100	✓ P:	SM
lodine				
POTASSIUM IODATE * Tab 253 mcg (150 mcg elemental iodine)	4.58	90	✓ <u>N</u>	euroTabs
Iron				
FERROUS FUMARATE * Tab 200 mg (65 mg elemental) Ferro-tab to be Principal Supply on 1 May 2022	3.04	100	✔ Fe	erro-tab
FERROUS FUMARATE WITH FOLIC ACID * Tab 310 mg (100 mg elemental) with folic acid 350 mcg	4.68	60	✓ Fe	erro-F-Tabs
FERROUS SULFATE * Tab long-acting 325 mg (105 mg elemental) * Oral liq 30 mg (6 mg elemental) per 1 ml		30 500 ml		errograd erodan
IRON (AS FERRIC CARBOXYMALTOSE) – Special Authority se Inj 50 mg per ml, 10 ml vial		letail pharm 1	-	erinject

⇒SA1840 Special Authority for Subsidy

Initial application — (serum ferritin less than or equal to 20 mcg/L) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria: Both:

- 1 Patient has been diagnosed with iron-deficiency anaemia with a serum ferritin level of less than or equal to 20 mcg/L; and
- 2 Any of the following:
 - 2.1 Patient has been compliant with oral iron treatment and treatment has proven ineffective; or
 - 2.2 Treatment with oral iron has resulted in dose-limiting intolerance; or
 - 2.3 Rapid correction of anaemia is required.

Renewal — (serum ferritin less than or equal to 20 mcg/L) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Both:

1 Patient continues to have iron-deficiency anaemia with a serum ferritin level of less than or equal to 20 mcg/L; and

2 A re-trial with oral iron is clinically inappropriate.

Initial application — (iron deficiency anaemia) only from an internal medicine physician, obstetrician, gynaecologist, anaesthetist or medical practitioner on the recommendation of a internal medicine physician, obstetrician, gynaecologist or anaesthetist. Approvals valid for 3 months for applications meeting the following criteria: Both:

- 1 Patient has been diagnosed with iron-deficiency anaemia; and
- 2 Any of the following:
 - 2.1 Patient has been compliant with oral iron treatment and treatment has proven ineffective; or
 - 2.2 Treatment with oral iron has resulted in dose-limiting intolerance; or
 - 2.3 Patient has symptomatic heart failure, chronic kidney disease stage 3 or more or active inflammatory bowel disease and a trial of oral iron is unlikely to be effective; or
 - 2.4 Rapid correction of anaemia is required.

Renewal — (iron deficiency anaemia) only from an internal medicine physician, obstetrician, gynaecologist, anaesthetist or

continued...

AThree months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price \$	e) Subs Per	Fully idised	Brand or Generic Manufacturer
 continued medical practitioner on the recommendation of a internal medicin Approvals valid for 3 months for applications meeting the followin Both: Patient continues to have iron-deficiency anaemia; and A re-trial with oral iron is clinically inappropriate. IRON POLYMALTOSE Inj 50 mg per ml, 2 ml ampoule 	g criteria:	ician, gynae 5	Ū	t or anaesthetist. errosig
Magnesium				
MAGNESIUM HYDROXIDE Suspension 8%		355 ml	√ P	hillips Milk of Magnesia ⁸²⁹
MAGNESIUM SULPHATE * Inj 2 mmol per ml, 5 ml ampoule	25.53	10	✓ <u>N</u>	lartindale
Zinc				
ZINC SULPHATE * Cap 137.4 mg (50 mg elemental)	11.00	100	✓ <u>z</u>	incaps_

Subsidised

Per

Fully

Subsidy (Manufacturer's Price) \$ Brand or Generic Manufacturer

Antianaemics

Hypoplastic and Haemolytic

➡SA1775 Special Authority for Subsidy

Initial application — (chronic renal failure) from any specialist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Patient in chronic renal failure; and
- 2 Haemoglobin is less than or equal to 100g/L; and
- 3 Any of the following:
 - 3.1 Both:
 - 3.1.1 Patient does not have diabetes mellitus; and
 - 3.1.2 Glomerular filtration rate is less than or equal to 30ml/min; or

3.2 Both:

- 3.2.1 Patient has diabetes mellitus; and
- 3.2.2 Glomerular filtration rate is less than or equal to 45ml/min; or
- 3.3 Patient is on haemodialysis or peritoneal dialysis.

Note: Epoetin alfa is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy. Initial application — (myelodysplasia) from any specialist. Approvals valid for 2 months for applications meeting the following

criteria:

All of the following:

- 1 Patient has a confirmed diagnosis of myelodysplasia (MDS)*; and
- 2 Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent; and
- 3 Patient has very low, low or intermediate risk MDS based on the WHO classification based prognostic scoring system for myelodysplastic syndrome (WPSS); and
- 4 Other causes of anaemia such as B12 and folate deficiency have been excluded; and
- 5 Patient has a serum epoetin level of < 500 IU/L; and
- 6 The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

Note: Indication marked with * is an unapproved indication

Renewal — (chronic renal failure) from any specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Note: Epoetin alfa is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy.

Renewal — (myelodysplasia) from any specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient's transfusion requirement continues to be reduced with erythropoietin treatment; and
- 2 Transformation to acute myeloid leukaemia has not occurred; and
- 3 The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

Note: Indication marked with * is an unapproved indication

	Subsidy (Manufacturer's Price \$) Sub Per	Fully sidised	Brand or Generic Manufacturer
EPOETIN ALFA - Special Authority see SA1775 on the previ	ous page – Retail phar	macv		
Wastage claimable	ouo pugo inotan pitat			
Inj 1,000 iu in 0.5 ml, syringe		6	🖌 E	Binocrit
Inj 2,000 iu in 1 ml, syringe		6	🗸 E	Binocrit
Inj 3,000 iu in 0.3 ml, syringe		6	🗸 E	Binocrit
Inj 4,000 iu in 0.4 ml, syringe		6	🗸 🗸	Binocrit
Inj 5,000 iu in 0.5 ml, syringe		6	🗸 🗸	Binocrit
Inj 6,000 iu in 0.6 ml, syringe	145.00	6	🗸 E	Binocrit
Inj 8,000 iu in 0.8 ml, syringe	175.00	6	✓ E	Binocrit
Inj 10,000 iu in 1 ml, syringe		6	✓ <u>E</u>	Binocrit
Inj 40,000 iu in 1 ml, syringe		1	✓ <u>E</u>	Binocrit
Megaloblastic				
FOLIC ACID				
Tab 0.8 mg	21.84	1,000		Apo-Folic Acid
-	26.60		✓ F	olic Acid multichem
* Tab 5 mg – Brand switch fee payable (Pharmacode 2621	940) -			
see page 239 for details	5.82	100	✓ <u>F</u>	Folic Acid Mylan
Oral liq 50 mcg per ml		25 ml OP	🖌 E	Biomed
(Apo-Folic Acid Tab 0.8 mg to be delisted 1 May 2022)				

Antifibrinolytics, Haemostatics and Local Sclerosants

EFTRENONACOG ALFA [RECOMBINANT FACTOR IX] - [Xpharm]

For patients with haemophilia B receiving prophylaxis treatment. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management group.

Inj 250 iu vial	612.50	1	Alprolix
Inj 500 iu vial	1,225.00	1	 Alprolix
Inj 1,000 iu vial	2,450.00	1	 Alprolix
Inj 2,000 iu vial	4,900.00	1	 Alprolix
Inj 3,000 iu vial	7,350.00	1	 Alprolix
ELTROMBOPAG - Special Authority see SA1743 below - Retail	pharmacy		
Wastage claimable			
Tab 25 mg	1,550.00	28	Revolade
Tab 50 mg	3,100.00	28	Revolade

⇒SA1743 Special Authority for Subsidy

Initial application — (idiopathic thrombocytopenic purpura - post-splenectomy) only from a haematologist. Approvals valid for 6 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has had a splenectomy; and
- 2 Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab); and
- 3 Any of the following:
 - 3.1 Patient has a platelet count of 20,000 to 30,000 platelets per microlitre and has evidence of significant mucocutaneous bleeding; or
 - 3.2 Patient has a platelet count of less than or equal to 20,000 platelets per microlitre and has evidence of active bleeding; or

continued...

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🗸	Manufacturer	

continued...

3.3 Patient has a platelet count of less than or equal to 10,000 platelets per microlitre.

Initial application — (idiopathic thrombocytopenic purpura - preparation for splenectomy) only from a haematologist. Approvals valid for 6 weeks where the patient requires eltrombopag treatment as preparation for splenectomy.

Initial application — (idiopathic thrombocytopenic purpura contraindicated to splenectomy) only from a haematologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a significant and well-documented contraindication to splenectomy for clinical reasons; and
- 2 Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab); and
- 3 Either:
 - 3.1 Patient has immune thrombocytopenic purpura* with a platelet count of less than or equal to 20,000 platelets per microliter; or
 - 3.2 Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding.

Initial application — (severe aplastic anaemia) only from a haematologist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Two immunosuppressive therapies have been trialled and failed after therapy of at least 3 months duration; and
- 2 Either:
 - 2.1 Patient has severe aplastic anaemia with a platelet count of less than or equal to 20,000 platelets per microliter; or
 - 2.2 Patient has severe aplastic anaemia with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding.

Renewal — (idiopathic thrombocytopenic purpura - post-splenectomy) only from a haematologist. Approvals valid for 12 months where the patient has obtained a response (see Note) from treatment during the initial approval or subsequent renewal periods and further treatment is required.

Note: Response to treatment is defined as a platelet count of > 30,000 platelets per microlitre.

Renewal — (idiopathic thrombocytopenic purpura contraindicated to splenectomy) only from a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient's significant contraindication to splenectomy remains; and
- 2 The patient has obtained a response from treatment during the initial approval period; and
- 3 Patient has maintained a platelet count of at least 50,000 platelets per microlitre on treatment; and
- 4 Further treatment with eltrombopag is required to maintain response.

Renewal — (severe aplastic anaemia) only from a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has obtained a response from treatment of at least 20,000 platelets per microlitre above baseline during the initial approval period; and
- 2 Platelet transfusion independence for a minimum of 8 weeks during the initial approval period.

EMICIZUMAB – [Xpharm] – Special Authority see SA1969 on the next page

Inj 30 mg in 1 ml vial		1	🗸 Hemlibra
Inj 60 mg in 0.4 ml vial		1	 Hemlibra
Inj 105 mg in 0.7 ml vial		1	 Hemlibra
Inj 150 mg in 1 ml vial	,	1	 Hemlibra

Subsidy	Su	Fully	Brand or
(Manufacturer's Price)		bsidised	Generic
\$	Per	1	Manufacturer

⇒SA1969 Special Authority for Subsidy

Initial application only from a haematologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Patient has severe congenital haemophilia A and history of bleeding and bypassing agent usage within the last six months; and
- 2 Either:
 - 2.1 Patient has had greater than or equal to 6 documented and treated spontaneous bleeds within the last 6 months if on an on-demand bypassing agent regimen; or
 - 2.2 Patient has had greater than or equal to 2 documented and treated spontaneous bleeds within the last 6 months if on a bypassing agent prophylaxis regimen; and
- 3 Patient has a high-titre inhibitor to Factor VIII (greater than or equal to 5 Bethesda units per ml) which has persisted for six months or more; and
- 4 There is no immediate plan for major surgery within the next 12 months; and
- 5 Either:
 - 5.1 Patient has failed immune tolerance induction (ITI) after an initial period of 12 months; or
 - 5.2 The Haemophilia Treaters Group considers the patient is not a suitable candidate for ITI; and
- 6 Treatment is to be administered at a maximum dose of 3 mg/kg weekly for 4 weeks followed by the equivalent of 1.5 mg/kg weekly.

Renewal only from a haematologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Patient has had no more than two spontaneous and clinically significant treated bleeds after the end of the loading dose period (i.e. after the first four weeks of treatment until the end of the 24-week treatment period); and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

EPTACOG ALFA [RECOMBINANT FACTOR VIIA] - [Xpharm]

For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group. Rare Clinical Circumstances Brand of bypassing agent for > 14 days predicted use. Access to funded treatment for > 14 days predicted use is by named patient application to the Haemophilia Treaters Group, subject to access criteria.

Inj 1 mg syringe	1,178.30	1	NovoSeven RT
Inj 2 mg syringe	2,356.60	1	NovoSeven RT
Inj 5 mg syringe	5,891.50	1	NovoSeven RT
Inj 8 mg syringe		1	NovoSeven RT
ing o my synnge	9,420.40	1	 NovoSeven ni

FACTOR EIGHT INHIBITOR BYPASSING FRACTION - [Xpharm]

For patients with haemophilia. Preferred Brand of bypassing agent for > 14 days predicted use. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

Inj 500 U		1	🗸 FEIBA NF
Inj 1,000 U	2,630.00	1	🖌 FEIBA NF
Inj 2,500 U	6,575.00	1	🖌 FEIBA NF

MOROCTOCOG ALFA [RECOMBINANT FACTOR VIII] - [Xpharm]

For patients with haemophilia. Rare Clinical Circumstances Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group, subject to criteria.

Inj 250 iu prefilled syringe	.50 1	🗸 Xyntha
Inj 500 iu prefilled syringe575		🗸 Xyntha
Inj 1,000 iu prefilled syringe1,150		 Xyntha
Inj 2,000 iu prefilled syringe		 Xyntha
Inj 3,000 iu prefilled syringe		🗸 Xyntha

	Subsidy (Manufacturaria Driac)	_	Fully	Brand or
	(Manufacturer's Price) \$	Per Su	bsidised	Generic Manufacturer
		1.01	-	Manulaotaron
IONACOG GAMMA, [RECOMBINANT FACTOR IX] – [Xpl For patients with haemophilia. Access to funded treatm		omonhili	a Troate	re Group in conjunction
with the National Haemophilia Management Group.	lent is managed by the ha	aemophin	a meate	
Inj 500 iu vial	435.00	1	~ 1	RIXUBIS
Inj 1,000 iu vial		1	-	RIXUBIS
Inj 2,000 iu vial		1	-	RIXUBIS
Inj 3,000 iu vial		1	 I 	RIXUBIS
OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (ADVATI	E) – [Xpharm]			
For patients with haemophilia. Preferred Brand of short		or VIII. A	ccess to	funded treatment is
managed by the Haemophilia Treaters Group in conjunc				
Inj 250 iu vial		1		Advate
Inj 500 iu vial		1	 I 	Advate
Inj 1,000 iu vial		1	 I 	Advate
lnj 1,500 iu vial	,	1		Advate
Inj 2,000 iu vial		1	-	Advate
Inj 3,000 iu vial		1		Advate
OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (KOGEN				
For patients with haemophilia. Rare Clinical Circumstar				
treatment is managed by the Haemophilia Treaters Gro	up in conjunction with the	National	Haemop	philia Management Group
subject to criteria.				
Inj 250 iu vial		1		Kogenate FS
Inj 500 iu vial		1		Kogenate FS
Inj 1,000 iu vial		1		Kogenate FS
Inj 2,000 iu vial		1		Kogenate FS
Inj 3,000 iu vial	2,850.00	1	✓	Kogenate FS
RURIOCTOCOG ALFA PEGOL [RECOMBINANT FACTOR	VIII] – [Xpharm]			
For patients with haemophilia A receiving prophylaxis tr	eatment. Access to funde	ed treatm	ent is ma	anaged by the Haamonhi
Treaters Group in conjunction with the National Usama				anaged by the nachtoph
Treaters Group in conjunction with the National Haemor	philia Management group			
Inj 250 iu vial	bhilia Management group	1	•	Adynovate
Inj 250 iu vial Inj 500 iu vial	bhilia Management group 300.00 600.00	1 1	 I I 	Adynovate Adynovate
Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial	bhilia Management group 	1 1 1	5 5 5	Adynovate Adynovate Adynovate
Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 2,000 iu vial	bhilia Management group 	1 1	5 5 5	Adynovate Adynovate
Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 2,000 iu vial SODIUM TETRADECYL SULPHATE	bilia Management group 	1 1 1 1	5 5 5	Adynovate Adynovate Adynovate
Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 2,000 iu vial SODIUM TETRADECYL SULPHATE	billia Management group 	1 1 1		Adynovate Adynovate Adynovate Adynovate
Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial	bilia Management group 	1 1 1 1		Adynovate Adynovate Adynovate
Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 2,000 iu vial SODIUM TETRADECYL SULPHATE Inj 3% 2 ml TRANEXAMIC ACID	billia Management group 	1 1 1 1		Adynovate Adynovate Adynovate Adynovate
Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 2,000 iu vial SODIUM TETRADECYL SULPHATE Inj 3% 2 ml	billia Management group 	1 1 1 1		Adynovate Adynovate Adynovate Adynovate
Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 2,000 iu vial SODIUM TETRADECYL SULPHATE	billia Management group 	1 1 1 1		Adynovate Adynovate Adynovate Adynovate
Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 2,000 iu vial SODIUM TETRADECYL SULPHATE k Inj 3% 2 ml RANEXAMIC ACID Tab 500 mg Vitamin K	billia Management group 	1 1 1 1		Adynovate Adynovate Adynovate Adynovate
Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 2,000 iu vial SODIUM TETRADECYL SULPHATE Inj 3% 2 ml 'RANEXAMIC ACID Tab 500 mg Vitamin K PHYTOMENADIONE	billia Management group 	1 1 1 1		Adynovate Adynovate Adynovate Adynovate Fibro-vein <u>Mercury Pharma</u>
Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 2,000 iu vial SODIUM TETRADECYL SULPHATE k Inj 3% 2 ml RANEXAMIC ACID Tab 500 mg Vitamin K PHYTOMENADIONE Inj 2 mg per 0.2 ml – Up to 5 inj available on a PSO	billia Management group 	1 1 1 1		Adynovate Adynovate Adynovate Adynovate Fibro-vein Mercury Pharma Konakion MM
Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 2,000 iu vial SODIUM TETRADECYL SULPHATE Inj 3% 2 ml RANEXAMIC ACID Tab 500 mg Vitamin K PHYTOMENADIONE	billia Management group 	1 1 1 5 60		Adynovate Adynovate Adynovate Adynovate Fibro-vein <u>Mercury Pharma</u>
Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 2,000 iu vial SODIUM TETRADECYL SULPHATE k Inj 3% 2 ml RANEXAMIC ACID Tab 500 mg Vitamin K PHYTOMENADIONE Inj 2 mg per 0.2 ml – Up to 5 inj available on a PSO	billia Management group 	1 1 1 5 60		Adynovate Adynovate Adynovate Adynovate Fibro-vein Mercury Pharma Konakion MM
Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 2,000 iu vial SODIUM TETRADECYL SULPHATE k Inj 3% 2 ml RANEXAMIC ACID Tab 500 mg Vitamin K PHYTOMENADIONE Inj 2 mg per 0.2 ml – Up to 5 inj available on a PSO Inj 10 mg per ml, 1 ml – Up to 5 inj available on a PSO Antithrombotic Agents	billia Management group 	1 1 1 5 60		Adynovate Adynovate Adynovate Adynovate Fibro-vein Mercury Pharma Konakion MM
Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 2,000 iu vial SODIUM TETRADECYL SULPHATE k Inj 3% 2 ml TRANEXAMIC ACID Tab 500 mg Vitamin K PHYTOMENADIONE Inj 2 mg per 0.2 ml – Up to 5 inj available on a PSO Inj 10 mg per ml, 1 ml – Up to 5 inj available on a PSO Antithrombotic Agents Antiplatelet Agents	billia Management group 	1 1 1 5 60		Adynovate Adynovate Adynovate Adynovate Fibro-vein Mercury Pharma Konakion MM
Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 2,000 iu vial SODIUM TETRADECYL SULPHATE k Inj 3% 2 ml RANEXAMIC ACID Tab 500 mg Vitamin K PHYTOMENADIONE Inj 2 mg per 0.2 ml – Up to 5 inj available on a PSO Inj 10 mg per ml, 1 ml – Up to 5 inj available on a PSO Antithrombotic Agents	billia Management group 	1 1 1 5 60		Adynovate Adynovate Adynovate Adynovate Fibro-vein Mercury Pharma Konakion MM

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
CLOPIDOGREL * Tab 75 mg	4.60	84	✓ <u>c</u>	lopidogrel Multichem
DIPYRIDAMOLE * Tab long-acting 150 mg		60	✓ <u>P</u>	ytazen SR
TICAGRELOR – Special Authority see SA1955 below – Retail pha * Tab 90 mg		56	✔ В	rilinta

⇒SA1955 Special Authority for Subsidy

Initial application — (acute coronary syndrome) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient has recently (within the last 60 days) been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome; and
- 2 Fibrinolytic therapy has not been given in the last 24 hours and is not planned.

Initial application — (thrombosis prevention neurological stenting) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 Patient has had a neurological stenting procedure* in the last 60 days; or
 - 1.2 Patient is about to have a neurological stenting procedure performed*; and

2 Either:

- 2.1 Patient has demonstrated clopidogrel resistance using the P2Y12 (VerifyNow) assay or another appropriate platelet function assay and requires antiplatelet treatment with ticagrelor; or
- 2.2 Either:
 - 2.2.1 Clopidogrel resistance has been demonstrated by the occurrence of a new cerebral ischemic event; or
 - 2.2.2 Clopidogrel resistance has been demonstrated by the occurrence of transient ischemic attack symptoms referable to the stent.

Initial application — (Percutaneous coronary intervention with stent deployment) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has undergone percutaneous coronary intervention; and
- 2 Patient has had a stent deployed in the previous 4 weeks; and
- 3 Patient is clopidogrel-allergic**.

Initial application — (Stent thrombosis) from any relevant practitioner. Approvals valid without further renewal unless notified where patient has experienced cardiac stent thrombosis whilst on clopidogrel.

Renewal — (subsequent acute coronary syndrome) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient has recently (within the last 60 days) been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome; and
- 2 Fibrinolytic therapy has not been given in the last 24 hours and is not planned.

Renewal — (thrombosis prevention neurological stenting) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient is continuing to benefit from treatment; and
- 2 Treatment continues to be clinically appropriate.

Renewal - (Percutaneous coronary intervention with stent deployment) from any relevant practitioner. Approvals valid for

continued...

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🗸	Manufacturer	

continued...

6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has undergone percutaneous coronary intervention; and
- 2 Patient has had a stent deployed in the previous 4 weeks; and
- 3 Patient is clopidogrel-allergic**.

Notes: indications marked with * are unapproved indications.

Note: ** Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment.

Heparin and Antagonist Preparations

ENOXAPARIN SODIUM – Special Authority see SA1646 below – Retail pharmacy

Inj 20 mg in 0.2 ml syringe	 10	Clexane
Inj 40 mg in 0.4 ml syringe	 10	 Clexane
Inj 60 mg in 0.6 ml syringe	10	 Clexane
Inj 80 mg in 0.8 ml syringe	10	 Clexane
Inj 100 mg in 1 ml syringe	10	 Clexane
Inj 120 mg in 0.8 ml syringe	10	 Clexane Forte
Inj 150 mg in 1 ml syringe	10	 Clexane Forte

⇒SA1646 Special Authority for Subsidy

Initial application — (Pregnancy, Malignancy or Haemodialysis) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 Low molecular weight heparin treatment is required during a patients pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy; or
- 3 For the prevention of thrombus formation in the extra-corporeal circulation during haemodialysis.

Initial application — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria: Any of the following:

Any of the following:

- 1 For the short-term treatment of venous thromboembolism prior to establishing a therapeutic level of oral anti-coagulant treatment; or
- 2 For the prophylaxis and treatment of venous thromboembolism in high risk surgery; or
- 3 To enable cessation/re-establishment of existing oral anticoagulant treatment pre/post surgery; or
- 4 For the prophylaxis and treatment of venous thromboembolism in Acute Coronary Syndrome surgical intervention; or
- 5 To be used in association with cardioversion of atrial fibrillation.

Renewal — (Pregnancy, Malignancy or Haemodialysis) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 Low molecular weight heparin treatment is required during a patient's pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy; or
- 3 For the prevention of thrombus formation in the extra-corporeal circulation during haemodialysis.

Renewal — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month where low molecular weight heparin treatment or prophylaxis is required for a second or subsequent event (surgery, ACS, cardioversion, or prior to oral anti-coagulation).

	Subsidy (Manufacturer's Price)		Fully Subsidised	
	(Manulactuler 31 lice) \$	Per		Manufacturer
HEPARIN SODIUM				
Inj 1,000 iu per ml, 5 ml ampoule		50	1	Pfizer
Inj 5,000 iu per ml, 1 ml		5	1	DBL Heparin
				Sodium S29
	70.33		1	Hospira
Inj 5,000 iu per ml, 5 ml ampoule		50	1	Pfizer
Inj 25,000 iu per ml, 0.2 ml	19.00	5	✓	Hospira
	42.40		1	Heparin DBL S29
	482.20	50	1	Heparin DBL S29
HEPARINISED SALINE				
Inj 10 iu per ml, 5 ml	65 48	50	1	Pfizer
		00		1 11201
Oral Anticoagulants				
DABIGATRAN				
Cap 75 mg - No more than 2 cap per day		60	1	Pradaxa
Cap 110 mg		60	1	Pradaxa
Cap 150 mg		60	1	Pradaxa
RIVAROXABAN				
Tab 10 mg - No more than 1 tab per day		30	1	Xarelto
Tab 15 mg – Up to 14 tab available on a PSO		28	1	Xarelto
Tab 20 mg		28	✓	Xarelto
WARFARIN SODIUM				
Note: Marevan and Coumadin are not interchangeable.				
* Tab 1 mg	3.46	50	1	Coumadin
-	6.46	100	✓	Marevan
* Tab 2 mg	4.31	50		Coumadin
* Tab 3 mg	10.03	100		Marevan
* Tab 5 mg		50		Coumadin
	11.48	100	1	Marevan

Blood Colony-stimulating Factors

FILGRASTIM - Special Authority see SA1259 below - Retail ph	narmacy		
Inj 300 mcg per 0.5 ml prefilled syringe		10	✓ <u>Nivestim</u>
Inj 480 mcg per 0.5 ml prefilled syringe	148.58	10	✓ Nivestim

SA1259 Special Authority for Subsidy

Initial application only from a relevant specialist, vocationally registered general practitioner or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk greater than or equal to 20%*): or
- 2 Peripheral blood stem cell mobilisation in patients undergoing haematological transplantation; or
- 3 Peripheral blood stem cell mobilisation or bone marrow donation from healthy donors for transplantation; or
- 4 Treatment of severe chronic neutropenia (ANC < 0.5 ×10⁹/L); or
- 5 Treatment of drug-induced prolonged neutropenia (ANC < 0.5×10^{9} /L).

Note: *Febrile neutropenia risk greater than or equal to 20% after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines.

PEGFILGRASTIM - Special Authority see SA1912 on the next page - Retail pharmacy

✓ Neulastim

44

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	1	Manufacturer

➡SA1912 Special Authority for Subsidy

Initial application only from a relevant specialist, vocationally registered general practitioner or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified where used for prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk greater than or equal to 5%*). Note: *Febrile neutropenia risk greater than or equal to 5% after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines.

Fluids and Electrolytes

Intravenous Administration

GLUCOSE [DEXTROSE]		
 Inj 50%, 10 ml ampoule – Up to 5 inj available on a PSO		 ✓ <u>Biomed</u> ✓ Biomed
	0 1	• Biomed
POTASSIUM CHLORIDE		
* Inj 75 mg per ml, 10 ml65.0	0 50	 Juno
SODIUM BICARBONATE		
Inj 8.4%, 50 ml21.4	0 1	 Biomed
a) Up to 5 inj available on a PSO		
b) Not in combination		
Inj 8.4%, 100 ml21.9	5 1	 Biomed
a) Up to 5 inj available on a PSO		
b) Not in combination		
SODIUM CHLORIDE		
Not funded for use as a nasal drop. Not funded for nebuliser use excep	t when used in conji	unction with an antibiotic intended
for nebuliser use.		_
Inj 0.9%, bag – Up to 2000 ml available on a PSO1.2		✓ Baxter
1.2	,	✓ Baxter
Only if prescribed on a prescription for renal dialysis, maternity or p	ost-natal care in the	home of the patient, or on a PSO
for emergency use. (500 ml and 1,000 ml packs)	~ -	
Inj 23.4% (4 mmol/ml), 20 ml ampoule		 Biomed
For Sodium chloride oral liquid formulation refer Standard Formulae		Freeering Kehi
Inj 0.9%, 5 ml ampoule – Up to 5 inj available on a PSO2.8		 ✓ <u>Fresenius Kabi</u> ✓ Fresenius Kabi
Inj 0.9%, 10 ml ampoule – Up to 5 inj available on a PSO	0 50	

Inj 0.9%, 20 ml ampoule......5.00 TOTAL PARENTERAL NUTRITION (TPN) InfusionCBS

1) On a prescription or Practitioner's Supply Order only when on the same form as an injection listed in the Pharmaceutical Schedule requiring a solvent or diluent; or

20

1 OP

2) On a bulk supply order: or

WATER

- 3) When used in the extemporaneous compounding of eve drops; or
- 4) When used for the dilution of sodium chloride soln 7% for cystic fibrosis patients only.

Inj 10 ml ampoule – Up to 5 inj available on a PSO	50	 Pfizer
Inj 20 ml ampoule – Up to 5 inj available on a PSO	20	 Fresenius Kabi
		/ Marthlada and

🗸 Multichem

Fresenius Kabi

TPN

	Subsidy (Manufacturer's F \$	Price) Subsi Per	Fully Brand or idised Generic ✓ Manufacturer
Oral Administration			
CALCIUM POLYSTYRENE SULPHONATE Powder	169.85	300 g OP	 Calcium Resonium
COMPOUND ELECTROLYTES Powder for oral soln – Up to 5 sach available on a PSO	9.77	50	✓ Electral
COMPOUND ELECTROLYTES WITH GLUCOSE [DEXTROSE] Soln with electrolytes (2 × 500 ml)	6.55	1,000 ml OP	 Pedialyte - Bubblegum
PHOSPHORUS Tab eff 500 mg (16 mmol)		100	Phosphate Phebra
POTASSIUM CHLORIDE * Tab eff 548 mg (14 m eq) with chloride 285 mg (8 m eq)		60	
* Tab long-acting 600 mg (8 mmol)	(11.85)	200	Chlorvescent Span-K
SODIUM BICARBONATE Cap 840 mg	8.52	100	✓ Sodibic
SODIUM POLYSTYRENE SULPHONATE			✓ Sodibic
Powder		454 g OP	 Resonium-A

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Alpha-Adrenoceptor Blockers				
Alpha Adrenoceptor Blockers				
DOXAZOSIN ¥ Tab 2 mg	17.35	500		Apo-Doxazosin Doxazosin Clinect
* Tab 4 mg	20.94	500	1	Apo-Doxazosin Doxazosin Clinect
(Apo-Doxazosin Tab 2 mg to be delisted 1 September 2022) (Apo-Doxazosin Tab 4 mg to be delisted 1 September 2022) PHENOXYBENZAMINE HYDROCHLORIDE				
* Cap 10 mg		30	1	BNM S29
	216.67	100	1	Dibenzyline S29
PRAZOSIN ₩ Tab 1 mg	5.53	100		Apo-Prazosin Arrotex-Prazosin S29 S29
* Tab 2 mg	7.00	100		Apo-Prazosin Arrotex-Prazosin S29 S29
₩ Tab 5 mg	11.70	100		Apo-Prazosin Arrotex-Prazosin S29 S29

(Apo-Prazosin Tab 1 mg to be delisted 1 May 2022) (Apo-Prazosin Tab 2 mg to be delisted 1 May 2022) (Apo-Prazosin Tab 5 mg to be delisted 1 May 2022)

Agents Affecting the Renin-Angiotensin System

ACE Inhibitors

CAPTOPRIL			
 * Oral liq 5 mg per ml Oral liquid restricted to children under 12 year 		95 ml OP	 Capoten
CILAZAPRIL – Subsidy by endorsement			
Subsidy by endorsement – Subsidised for patient: endorsed accordingly. Pharmacists may annotate dispensing of cilazapril.			
* Tab 0.5 mg	2.09	90	✓ Zapril
* Tab 2.5 mg	4.80	90	 Zapril
Tab 5 mg	8.35	90	✓ Zapril
ENALAPRIL MALEATE			
* Tab 5 mg		100	 Acetec
* Tab 10 mg	2.02	100	✓ Acetec
* Tab 20 mg		100	✓ Acetec
LISINOPRIL			
* Tab 5 mg		90	 Ethics Lisinopril
* Tab 10 mg		90	 Ethics Lisinopril
* Tab 20 mg		90	 Ethics Lisinopril

AThree months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Sub: Per	Fully Brand or sidised Generic ✓ Manufacturer
PERINDOPRIL Tab 2 mg Tab 4 mg QUINAPRIL		30 30	✓ <u>Coversyl</u> ✓ <u>Coversyl</u>
Tab 5 mg Tab 10 mg Tab 20 mg	5.18	90 90 90	 <u>Arrow-Quinapril 5</u> <u>Arrow-Quinapril 10</u> <u>Arrow-Quinapril 20</u>
ACE Inhibitors with Diuretics			
QUINAPRIL WITH HYDROCHLOROTHIAZIDE Tab 10 mg with hydrochlorothiazide 12.5 mg Accuretic 10 to be Principal Supply on 1 March 2022 * Tab 20 mg with hydrochlorothiazide 12.5 mg Accuretic 20 to be Principal Supply on 1 March 2022 (Accuretic Tab 10 mg with hydrochlorothiazide 12.5 mg to be delivered)	4.10 5.25	28 30 30	 Accuretic Accuretic 10 Accuretic 20
Angiotensin II Antagonists			
CANDESARTAN CILEXETIL * Tab 4 mg * Tab 8 mg * Tab 16 mg * Tab 32 mg LOSARTAN POTASSIUM	2.28 3.31 5.26	90 90 90 90	 <u>Candestar</u> <u>Candestar</u> <u>Candestar</u> <u>Candestar</u> <u>Candestar</u>
Tab 12.5 mg Tab 25 mg Tab 50 mg Tab 100 mg	1.84 2.25	84 84 84 84	 <u>Losartan Actavis</u> <u>Losartan Actavis</u> <u>Losartan Actavis</u> <u>Losartan Actavis</u>
Angiotensin II Antagonists with Diuretics			
LOSARTAN POTASSIUM WITH HYDROCHLOROTHIAZIDE Tab 50 mg with hydrochlorothiazide 12.5 mg	15.25	30	 Arrow-Losartan & Hydrochlorothiazide

Angiotensin II Antagonists with Neprilysin Inhibitors

 SACUBITRIL WITH VALSARTAN – Special Authority see SA1905 below – Retail pharmacy

 Note: Due to the angiotensin II receptor blocking activity of sacubitril with valsartan it should not be co-administered with an ACE inhibitor or another ARB.

 Tab 24.3 mg with valsartan 25.7 mg

 Tab 48.6 mg with valsartan 51.4 mg

 190.00
 56

 ✓ Entresto 24/26

 Tab 97.2 mg with valsartan 102.8 mg

 190.00
 56

 ✓ Entresto 49/51

 Tab 97.2 mg with valsartan 102.8 mg

➡SA1905 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

1 Patient has heart failure; and

continued...

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Subs	sidised	Generic	
\$	Per	~	Manufacturer	

continued...

- 2 Any of the following:
 - 2.1 Patient is in NYHA/WHO functional class II; or
 - 2.2 Patient is in NYHA/WHO functional class III; or
 - 2.3 Patient is in NYHA/WHO functional class IV; and

3 Either:

- 3.1 Patient has a documented left ventricular ejection fraction (LVEF) of less than or equal to 35%; or
- 3.2 An ECHO is not reasonably practical, and in the opinion of the treating practitioner the patient would benefit from treatment; and
- 4 Patient is receiving concomitant optimal standard chronic heart failure treatments.

Renewal from any relevant practitioner. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Antiarrhythmics

For lignocaine hydrochloride refer to NERVOUS SYSTEM, Anaest	hetics, Local, pa	age 119	
AMIODARONE HYDROCHLORIDE			
▲ Tab 100 mg	3.80	30	Aratac
▲ Tab 200 mg	5.25	30	✓ Aratac
Inj 50 mg per ml, 3 ml ampoule – Up to 10 inj available on a PSO	16.37	10	✓ Max Health
ATROPINE SULPHATE			
* Inj 600 mcg per ml, 1 ml ampoule - Up to 5 inj available on a			
PSO	15.09	10	 Martindale
DIGOXIN			<u></u>
 Tab 62.5 mcg – Up to 30 tab available on a PSO 	7 00	240	 Lanoxin PG
 * Tab 02.5 mcg – Up to 30 tab available on a PSO * Tab 250 mcg – Up to 30 tab available on a PSO 		240	✓ Lanoxin
* Oral lig 50 mcg per ml		60 ml	✓ Lanoxin
		00 111	✓ Lanoxin Paediatric
			Elixir S29
			Lanoxin S29 S29
DISOPYRAMIDE PHOSPHATE			
▲ Cap 100 mg	23.87	100	 Rythmodan
FLECAINIDE ACETATE			
▲ Tab 50 mg		60	 Flecainide BNM
▲ Cap long-acting 100 mg		90	✓ Flecainide
			Controlled Release Teva
▲ Cap long-acting 200 mg	61.06	90	✓ Flecainide
	01.00	30	<u>Controlled</u> Release Teva
Inj 10 mg per ml, 15 ml ampoule	100.00	5	 Tambocor
MEXILETINE HYDROCHLORIDE		-	
	160.00	100	Tava coo
▲ Cap 150 mg		100	Teva S29
▲ Cap 250 mg	202.00	100	Teva S29
PROPAFENONE HYDROCHLORIDE			
▲ Tab 150 mg	40.90	50	 Rytmonorm

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

	(Manufacturer's Price)		Subsidised	Generic	
	\$	Per	1	Manufacturer	
Antihypotensives					
MIDODRINE - Special Authority see SA1474 below - Retail pha	irmacy				
Tab 2.5 mg		100	🖌 G	utron	
Tab 5 mg	79.00	100	🗸 G	utron	
➡SA1474 Special Authority for Subsidy					

Subsidy

Fully

Brand or

Initial application from any relevant practitioner. Approvals valid for 2 years where patient has disabling orthostatic hypotension not due to drugs.

Note: Treatment should be started with small doses and titrated upwards as necessary. Hypertension should be avoided, and the usual target is a standing systolic blood pressure of 90 mm Hg.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Beta-Adrenoceptor Blockers

Beta Adrenoceptor Blockers

ATENOLOL			• · · · · · · · · ·
* Tab 50 mg	9.33	500	Mylan Atenolol
* Tab 100 mg	14.20	500	 Mylan Atenolol
* Oral liq 25 mg per 5 ml	21.25	300 ml OP	 Atenolol AFT
			 Atenolol AFT
			S29 S29
	38.20		 Essential
			Generics S29
Restricted to children under 12 years of age.			
BISOPROLOL FUMARATE			
* Tab 2.5 mg		90	Bisoprolol Mylan
* Tab 5 mg	2.55	90	 Bisoprolol Mylan
* Tab 10 mg	3.62	90	 Bisoprolol Mylan
CARVEDILOL			
* Tab 6.25 mg		60	 Carvedilol Sandoz
* Tab 12.5 mg		60	 Carvedilol Sandoz
* Tab 25 mg		60	 Carvedilol Sandoz
LABETALOL			
* Tab 100 mg		100	 Trandate
* Tab 200 mg		100	 Trandate
* Inj 5 mg per ml, 20 ml ampoule		5	
j s i i i i	(88.60)		Trandate
* inj 5 mg per ml, 20 ml vial	(/	1	
	(48.20)		Alvogen S29
METOPROLOL SUCCINATE			
* Tab long-acting 23.75 mg	1.45	30	 Betaloc CR
* Tab long-acting 47.5 mg		30	 Betaloc CR
* Tab long-acting 95 mg		30	 Betaloc CR
* Tab long-acting 190 mg		30	 Betaloc CR
5 6 6			

	Subsidy (Manufacturer's Price)		Fully Subsidised	
	(Manulacturer's Frice)	Per	Subsidised	Manufacturer
METOPROLOL TARTRATE				
Tab 50 mg	5.66	100	1	Apo-Metoprolol
				IPCA-Metoprolol
IPCA-Metoprolol to be Sole Supply on 1 March 2022				·
Tab 100 mg	7.55	60	✓	Apo-Metoprolol
			1	IPCA-Metoprolol
IPCA-Metoprolol to be Sole Supply on 1 March 2022				
* Tab long-acting 200 mg	23.40	28		Slow-Lopresor
* Inj 1 mg per ml, 5 ml vial		5	✓	Metoprolol IV Mylan
(Apo-Metoprolol Tab 50 mg to be delisted 1 March 2022)				
(Apo-Metoprolol Tab 100 mg to be delisted 1 March 2022)				
NADOLOL				
Tab 40 mg		100	1	Apo-Nadolol
	19.19			Nadolol BNM S29
Nadolol BNM to be Sole Supply on 1 March 2022	10110			
Tab 80 mg	26.43	100	1	Apo-Nadolol
	30.39			Nadolol BNM S29
Nadolol BNM to be Sole Supply on 1 March 2022	00.00		•	
(Apo-Nadolol Tab 40 mg to be delisted 1 March 2022)				
(Apo-Nadolol Tab 80 mg to be delisted 1 March 2022)				
PINDOLOL – Subsidy by endorsement				a contato concentrato de
Subsidy by endorsement – Subsidised for patients who we				
endorsed accordingly. Pharmacists may annotate the pre	scription as endorsed w	nere	there exist	s a record of prior
dispensing of pindolol. * Tab 5 mg	10.00	100		Apo-Pindolol
		100		Apo-Pindolol
 * Tab 10 mg * Tab 15 mg 		100		Apo-Pindolol
5		100	•	Apo-Filluoloi
(Apo-Pindolol Tab 5 mg to be delisted 1 May 2022)				
(Apo-Pindolol Tab 10 mg to be delisted 1 May 2022) (Apo-Pindolol Tab 15 mg to be delisted 1 May 2022)				
PROPRANOLOL				
Tab 10 mg		100		Apo-Propranolol
	704		✓	Drofate
Drofate to be Sole Supply on 1 March 2022	7.04			Diolate
Tab 40 mg	5.72	100		Apo-Propranolol
, , , , , , , , , , , , , , , , , , ,	5.72 8.75	100		
IPCA-Propranolol to be Sole Supply on 1 March 2022	5.72 8.75		1	Apo-Propranolol IPCA-Propranolol
IPCA-Propranolol to be Sole Supply on 1 March 2022 * Cap long-acting 160 mg	5.72 8.75 	100 100	1	Apo-Propranolol
IPCA-Propranolol to be Sole Supply on 1 March 2022 Cap long-acting 160 mg Oral liq 4 mg per ml – Special Authority see SA1327 belo	5.72 8.75 	100	, ,	Apo-Propranolol IPCA-Propranolol Cardinol LA
IPCA-Propranolol to be Sole Supply on 1 March 2022 * Cap long-acting 160 mg	5.72 8.75 		, ,	Apo-Propranolol IPCA-Propranolol

(Apo-Propranolol Tab 10 mg to be delisted 1 March 2022) (Apo-Propranolol Tab 40 mg to be delisted 1 March 2022)

➡SA1327 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy		Fully	Brand or
(Manufacturer's Price)	Subsid	dised	Generic
\$	Per	✓	Manufacturer

continued...

- 1 For the treatment of a child under 12 years with an haemangioma causing functional impairment (not for cosmetic reasons only); or
- 2 For the treatment of a child under 12 years with cardiac arrthymias or congenital cardiac abnormalities.
- Renewal from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 For the treatment of a child under 12 years with an haemangioma causing functional impairment (not for cosmetic reasons only); or
- 2 For the treatment of a child under 12 years with cardiac arrthymias or congenital cardiac abnormalities.

SOTALOL	
---------	--

*	Tab 80 mg3	2.58	500	 Mylan
	Tab 160 mg1		100	 Mylan

Calcium Channel Blockers

Dihydropyridine Calcium Channel Blockers

٨N	ILODIPINE		
*	Tab 2.5 mg1.08	90	✓ <u>Vasorex</u>
*	Tab 5 mg0.96	90	✓ <u>Vasorex</u>
*	Tab 10 mg1.19	90	✓ <u>Vasorex</u>
FE	LODIPINE		
*	Tab long-acting 2.5 mg1.45	30	 Plendil ER
*	Tab long-acting 5 mg4.07	90	Felo 5 ER
*	Tab long-acting 10 mg4.32	90	✓ Felo 10 ER
NI	EDIPINE		
*	Tab long-acting 10 mg18.80	56	 Tensipine MR10 S29
*	Tab long-acting 20 mg9.12	50	🗸 Mylan (12 hr
			release) S29
	17.72	100	✓ Nyefax Retard
*	Tab long-acting 30 mg4.78	14	 Mylan Italy (24 hr
			release) \$29
	34.10	100	✓ Mylan (24 hr
			release) \$29
*	Tab long-acting 60 mg52.81	100	✓ Mylan (24 hr
•		100	release) \$29
C	ther Calcium Channel Blockers		
DII	TIAZEM HYDROCHLORIDE		
	Cap extended-release 120 mg44.40	100	 Accord S29
*	Cap long-acting 120 mg	500	 Apo-Diltiazem CD
*	Cap long-acting 180 mg7.00 Cardizem CD to be Sole Supply on 1 March 2022	30	 Cardizem CD
*	Cap long-acting 240 mg	30	 Cardizem CD

PERHEXILINE MALEATE

100

Pexsig

	Subsidy		Fully	
	(Manufacturer's Price) \$	Per	Subsidised	I Generic Manufacturer
/ERAPAMIL HYDROCHLORIDE	Ψ	1.01	-	manulaotaron
* Tab 40 mg	7.01	100	1	Isoptin
★ Tab 80 mg		100		Isoptin
 Tab long-acting 120 mg 		100		Isoptin Retard S29
		100		Isoptin SR
* Tab long-acting 240 mg		30		Isoptin SR
 Inj 2.5 mg per ml, 2 ml ampoule – Up to 5 inj available on a 				
PSO		5	1	Isoptin
				•
Centrally-Acting Agents				
CLONIDINE * Patch 2.5 mg, 100 mcg per day – Only on a prescription	10.24	4		Mylan
 Patch 2.5 mg, 100 mcg per day – Only on a prescription Patch 5 mg, 200 mcg per day – Only on a prescription 		4 4		<u>Mylan</u> Mylan
 Patch 5.5 mg, 300 mcg per day – Only on a prescription 		4		Mylan
		7	•	wyian
CLONIDINE HYDROCHLORIDE * Tab 25 mcg	0.75	112		Clonidine BNM
* Tab 25 mcg	8.75 36.50	112		Clonidine Teva
卷 Tab 150 mcg		100		Catapres
 Ini 150 mcg per ml, 1 ml ampoule 		10		Medsurge
/ETHYLDOPA		10	-	mououngo
* Tab 250 mg	15 10	100	1	Methyldopa Mylan
* Tab 250 mg	52.85	500		Methyldopa Mylan
	52.05	500	•	S29 S29
				02J CE
Diuretics				
Lean Dismetiae				
Loop Diuretics				
BUMETANIDE				
* Tab 1 mg	4.91	30	1	Burinex S29 S29
Ŭ	16.36	100	1	Burinex
Inj 500 mcg per ml, 4 ml vial	7.95	5	1	Burinex
UROSEMIDE [FRUSEMIDE]				
Tab 40 mg – Up to 30 tab available on a PSO	7.24	1,000	1	Apo-Furosemide
	8.00	,		IPCA-Frusemide
IPCA-Frusemide to be Sole Supply on 1 March 2022				
₭ Tab 500 mg	25.00	50		Urex Forte
	89.48		1	Furosemid-
				Ratiopharm S29
	169.96	100		Furosemid-
	103.90	100		
				Ratiopharm S29
✤ Oral liq 10 mg per ml		0 ml C	P 🗸	Lasix
 Inj 10 mg per ml, 25 ml ampoule 		6		Lasix
Inj 10 mg per ml, 2 ml ampoule – Up to 5 inj available on a F	SO 1.15	5		Furosemide-Baxter
Apo-Furosemide Tab 40 mg to be delisted 1 March 2022)				

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

	Subsidy		Fully	Brand or
	(Manufacturer's Pri		idised	Generic
	\$	Per		Manufacturer
Potassium Sparing Diuretics				
AMILORIDE HYDROCHLORIDE				
Oral liq 1 mg per ml		25 ml OP	🗸 I	Biomed
EPLERENONE - Special Authority see SA1728 below - Retail pl	harmacy			
Tab 25 mg	•	30	1	nspra
Tab 50 mg		30		nspra
► SA1728 Special Authority for Subsidy				
Initial application from any relevant practitioner. Approvals valid the following criteria: Both:	without further re	enewal unless	notifie	ed for applications meeting
 Patient has heart failure with ejection fraction less than 40^o Either: 	%; and			
2.1 Patient is intolerant to optimal dosing of spironolact	one; or			
2.2 Patient has experienced a clinically significant adve	rse effect while o	n optimal dos	ing of	spironolactone.
METOLAZONE			-	
Tab 5 mg	CDC	4		Matalanana 600
Tab 5 mg		1		Metolazone S29
		50	• 4	Zaroxolyn S29
SPIRONOLACTONE				
* Tab 25 mg		100		Spiractin
* Tab 100 mg		100		Spiractin
Oral liq 5 mg per ml		25 ml OP	✓ [Biomed
Potassium Sparing Combination Diuretics				
AMILORIDE HYDROCHLORIDE WITH FUROSEMIDE * Tab 5 mg with furosemide 40 mg	8.63	28	√ I	Frumil
AMILORIDE HYDROCHLORIDE WITH HYDROCHLOROTHIAZI				
* Tab 5 mg with hydrochlorothiazide 50 mg		50	v 1	Moduretic
Thiazide and Related Diuretics				
BENDROFLUMETHIAZIDE [BENDROFLUAZIDE]				
* Tab 2.5 mg – Up to 150 tab available on a PSO	20.00	500	\[Arrow-
				Bendrofluazide
May be even lied on a DCO for records other than among				
May be supplied on a PSO for reasons other than emerge	-	500		A ## 0.17
* Tab 5 mg		500	• [Arrow- Bendrofluazide
				Dentronuaziae
CHLOROTHIAZIDE				
Oral liq 50 mg per ml		25 ml OP	/ I	Biomed
CHLORTALIDONE [CHLORTHALIDONE]	2 00	20		arotop con
Tab 25 mg	3.90 6.50	30 50		groton §29) Hygroton
	0.00	50	Ϋ́	iyyioton
INDAPAMIDE	10.15	00		News Take
* Tab 2.5 mg		90		<u>Dapa-Tabs</u>
	11.61	100	¥ 1	Nylan Jadanamida ang
				Indapamide S29

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Lipid-Modifying Agents				
Fibrates				
BEZAFIBRATE k Tab 200 mgk Tab long-acting 400 mg		90 30		<u>Bezalip</u> Bezalip Retard
Other Lipid-Modifying Agents				
CIPIMOX ≰ Cap 250 mg	21.56	30		Dibetam Dibetam S29 S29
Resins				
COLESTIPOL HYDROCHLORIDE Grans for oral liq 5 g		30	√ (Colestid
HMG CoA Reductase Inhibitors (Statins)				
TORVASTATIN ₭ Tab 10 mg	9.24 14.92	500 500 500 500	✓ <u> </u> ✓ <u> </u>	<u>.orstat</u> .orstat .orstat .orstat
RAVASTATIN ∉ Tab 20 mg ∉ Tab 40 mg	2.11	28 28	✓ <u>F</u>	Pravastatin Mylan Pravastatin Mylan
OSUVASTATIN – Special Authority see SA2093 below – Retail Tab 5 mg		30	🗸 F	Rosuvastatin Viatris
Rosuvastatin Viatris to be Sole Supply on 1 May 2022 Tab 10 mg Rosuvastatin Viatris to be Sole Supply on 1 May 2022	2.42	30	🗸 F	Rosuvastatin Viatris
Tab 20 mg Rosuvastatin Viatris to be Sole Supply on 1 May 2022	3.92	30	-	Rosuvastatin Viatris
Tab 40 mg Rosuvastatin Viatris to be Sole Supply on 1 May 2022	5.28	30	✓ F	Rosuvastatin Viatris

► SA2093 Special Authority for Subsidy

Initial application — (cardiovascular disease risk) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either:

1 Both:

- 1.1 Patient is considered to be at risk of cardiovascular disease; and
- 1.2 Patient is Māori or any Pacific ethnicity; or

2 Both:

- 2.1 Patient has a calculated risk of cardiovascular disease of at least 15% over 5 years; and
- 2.2 LDL cholesterol has not reduced to less than 1.8 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin.

continued...

Subsidy	F	ully	Brand or	
(Manufacturer's Price)	Subsidis	sed	Generic	
\$	Per	✓	Manufacturer	

continued...

Initial application — (familial hypercholesterolemia) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has familial hypercholesterolemia (defined as a Dutch Lipid Criteria score greater than or equal to 6); and
- 2 LDL cholesterol has not reduced to less than 1.8 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin.

Initial application — (established cardiovascular disease) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both:

- 1 Any of the following:
 - 1.1 Patient has proven coronary artery disease (CAD); or
 - 1.2 Patient has proven peripheral artery disease (PAD); or
 - 1.3 Patient has experienced an ischaemic stroke; and
- 2 LDL cholesterol has not reduced to less than 1.4 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin.

Initial application — (recurrent major cardiovascular events) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has experienced a recurrent major cardiovascular event (defined as myocardial infarction, ischaemic stroke, coronary revascularisation, hospitalisation for unstable angina) in the last 2 years; and
- 2 LDL cholesterol has not reduced to less than 1.0 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin.

SIMVASTATIN

*	Tab 10 mg1.23	90	🗸 Simvastatin Mylan
	Tab 20 mg2.03	90	 Simvastatin Mylan
	Tab 40 mg	90	 Simvastatin Mylan
	Tab 80 mg	90	 Simvastatin Mylan

Selective Cholesterol Absorption Inhibitors

EZETIMIBE - Special Authority see SA1045 below - Retail p	harmacy	
* Tab 10 mg		 Ezetimibe Sandoz

⇒SA1045 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
- 3 Any of the following:
 - 3.1 The patient has rhabdomyolysis (defined as muscle aches and creatine kinase more than 10 × normal) when treated with one statin; or
 - 3.2 The patient is intolerant to both simvastatin and atorvastatin; or
 - 3.3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

Notes: A patient who has failed to reduce their LDL cholesterol to < 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapies.

Other treatment options including fibrates, resins and nicotinic acid should be considered after failure of statin therapy.

If a patient's LDL cholesterol cannot be calculated because the triglyceride level is too high then a repeat test should be

continued...

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🗸	Manufacturer	

continued...

performed and if the LDL cholesterol again cannot be calculated then it can be considered that the LDL cholesterol is greater than 2.0 mmol/litre.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

EZETIMIBE WITH SIMVASTATIN - Special Authority see SA1046 below - Retail pharmacy

Tab 10 mg with simvastatin 10 mg	 30	 Zimybe
Tab 10 mg with simvastatin 20 mg	30	 Zimybe
Tab 10 mg with simvastatin 40 mg	30	 Zimybe
Tab 10 mg with simvastatin 80 mg	30	 Zimybe

➡SA1046 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 year; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
- 3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

Notes: A patient who has failed to reduce their LDL cholesterol to less than or equal to 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapies.

Other treatment options including fibrates, resins and nicotinic acid should be considered after failure of statin therapy. If a patient's LDL cholesterol cannot be calculated because the triglyceride level is too high then a repeat test should be performed and if the LDL cholesterol again cannot be calculated then it can be considered that the LDL cholesterol is greater than 2.0 mmol/litre.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Nitrates

GLYCERYL TRINITRATE

*	Oral pump spray, 400 mcg per dose – Up to 250 dose		
	available on a PSO6.09	250 dose OP	 Nitrolingual Pump Spray
*	Patch 25 mg, 5 mg per day 15.73	30	 Nitroderm TTS
	Patch 50 mg, 10 mg per day 18.62	30	 Nitroderm TTS
ISC	SORBIDE MONONITRATE		
*	Tab 20 mg	100	Ismo 20
*	Tab long-acting 40 mg8.20	30	 Ismo 40 Retard
*	Tab long-acting 60 mg9.25	90	✓ Duride
S	vmpathomimetics		

ADRENALINE

Inj 1 in 1,000, 1 ml ampoule – Up to 5 inj available on a PSO4.98	5	 Aspen Adrenaline
10.76		 DBL Adrenaline
Inj 1 in 10,000, 10 ml ampoule – Up to 5 inj available on a PSO27.00	5	 Hospira
49.00	10	 Aspen Adrenaline

Vasodilators HYDRALAZINE HYDROCHLORIDE * Tab 25 mg – Special Authority see SA1321 below – Retail pharmacy	(Manufacturer's Price) \$	Per	Subsidised	Generic Manufacturer
HYDRALAZINE HYDROCHLORIDE * Tab 25 mg – Special Authority see SA1321 below – Retail	CBS			
HYDRALAZINE HYDROCHLORIDE * Tab 25 mg – Special Authority see SA1321 below – Retail	CBS			
* Tab 25 mg – Special Authority see SA1321 below – Retail	CBS			
5 1 5	CBS			
pnarmacy				Understander -
		1		Hydralazine
		56		Onelink S29
		84		AMDIPHARM \$29
W In: 00 man amagula	05.00	100		Onelink S29
 Inj 20 mg ampoule SA1321 Special Authority for Subsidy 		5	•	Apresoline
Initial application from any relevant practitioner. Approvals valid the following criteria: Either: 1 For the treatment of refractory hypertension; or 2 For the treatment of heart failure in combination with a nitr inhibitors and/or angiotensin receptor blockers.				
MINOXIDIL				
▲ Tab 10 mg	70.00	100	1	Loniten
-		100	•	Lonnen
NICORANDIL ▲ Tab 10 mg	25.57	60	1	Ikorel
▲ Tab 20 mg		60		Ikorel
PAPAVERINE HYDROCHLORIDE				
 Inj 12 mg per ml, 10 ml ampoule 	217.90	5	1	Hospira
PENTOXIFYLLINE [OXPENTIFYLLINE]		•		
Tab 400 mg	42.26	50	1	Trental 400
		00	-	
Endothelin Receptor Antagonists				
AMBRISENTAN – Special Authority see SA1702 below – Retail	oharmacy			
Tab 5 mg		30	1	Ambrisentan Mylan
Tab 10 mg	1,550.00	30	1	Ambrisentan Mylan
SA1702 Special Authority for Subsidy Special Authority approved by the Pulmonary Arterial Hypertensic Notes: Application details may be obtained from Pharmac's webs The Coordinator, PAH Panel		c.govi	i.nz/SAFo	r <u>ms</u> or:
Pharmac, PO Box 10-254, WELLINGTON				
Tel: (04) 916 7561, Fax: (04) 974 4858, Email: <u>PAH@pharmac</u>	.govt.nz			
BOSENTAN – Special Authority see SA1991 below – Retail phan	,			
Tab 62.5 mg	119.85	60	~	Bosentan Dr
				Reddy's
Tab 125 mg	119.85	60	1	Bosentan Dr
SA1991 Special Authority for Subsidy				Reddy's

SA1991 Special Authority for Subsidy

Initial application only from a respiratory specialist, cardiologist or medical practitioner on the recommendation of a respiratory physician or cardiologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

continued...

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

- continued...
 - 1 Patient has pulmonary arterial hypertension (PAH)*; and
 - 2 PAH is in Group 1, 4 or 5 of the WHO (Venice) clinical classifications; and
 - 3 PAH is at NYHA/WHO functional class II, III, or IV; and
 - 4 Any of the following:
 - 4.1 Both:
 - 4.1.1 Bosentan is to be used as PAH monotherapy; and
 - 4.1.2 Either:
 - 4.1.2.1 Patient is intolerant or contraindicated to sildenafil; or
 - 4.1.2.2 Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease; or
 - 4.2 Both:
 - 4.2.1 Bosentan is to be used as PAH dual therapy; and
 - 4.2.2 Either:
 - 4.2.2.1 Patient has tried a PAH monotherapy for at least three months and failed to respond; or
 - 4.2.2.2 Patient deteriorated while on a PAH monotherapy; or
 - 4.3 Both:
 - 4.3.1 Bosentan is to be used as PAH triple therapy; and
 - 4.3.2 Any of the following:
 - 4.3.2.1 Patient is on the lung transplant list; or
 - 4.3.2.2 Patient is presenting acutely with idiopathic pulmonary arterial hypertension (IPAH) in New York Heart Association/World Health Organization (NYHA/WHO) Functional Class IV; or
 - 4.3.2.3 Patient is deteriorating rapidly to NYHA/WHO Functional Class IV who may be lung transplant recipients in the future, if their disease is stabilised; or
 - 4.3.2.4 Patient has PAH associated with the scleroderma spectrum of diseases (APAHSSD) who have no major morbidities and are deteriorating despite combination therapy.

Renewal only from a respiratory specialist, cardiologist or medical practitioner on the recommendation of a respiratory physician or cardiologist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following:

- 1 Both:
 - 1.1 Bosentan is to be used as PAH monotherapy; and
 - 1.2 Patient is stable or has improved while on bosentan; or
 - 2 Both:
 - 2.1 Bosentan is to be used as PAH dual therapy; and
 - 2.2 Patient has tried a PAH monotherapy for at least three months and either failed to respond or later deteriorated; or Both:
 - 3 Both:
 - 3.1 Bosentan is to be used as PAH triple therapy; and
 - 3.2 Any of the following:
 - 3.2.1 Patient is on the lung transplant list; or
 - 3.2.2 Patient is presenting acutely with idiopathic pulmonary arterial hypertension (IPAH) in New York Heart Association/World Health Organization (NYHA/WHO) Functional Class IV; or
 - 3.2.3 Patient is deteriorating rapidly to NYHA/WHO Functional Class IV who may be lung transplant recipients in the future, if their disease is stabilised; or
 - 3.2.4 Patient has PAH associated with the scleroderma spectrum of diseases (APAHSSD) who have no major morbidities and are deteriorating despite combination therapy.

Phosphodiesterase Type 5 Inhibitors

SILDENAFIL - Special Authority see SA1992 on the next page - F	Retail pharmacy		
Tab 25 mg	0.85	4	 Vedafil
Tab 50 mg	1.70	4	✓ Vedafil
Tab 100 mg		12	✓ Vedafil

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy		Fully	Brand or	
(Manufacturer's Price)	5	Subsidised	Generic	
\$	Per	1	Manufacturer	

⇒SA1992 Special Authority for Subsidy

Initial application — (Raynaud's Phenomenon*) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has Raynaud's Phenomenon*; and
- 2 Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene); and
- 3 Patient is following lifestyle management (avoidance of cold exposure, sufficient protection, smoking cessation support, avoidance of sympathomimetic drugs); and
- 4 Patient is being treated with calcium channel blockers and nitrates (or these are contraindicated/not tolerated).

Initial application — (Pulmonary arterial hypertension*) only from a respiratory specialist, cardiologist or medical practitioner on the recommendation of a respiratory specialist or cardiologist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH)*; and
- 2 Any of the following:
 - 2.1 PAH is in Group 1 of the WHO (Venice) clinical classifications; or
 - 2.2 PAH is in Group 4 of the WHO (Venice) clinical classifications; or
 - 2.3 PAH is in Group 5 of the WHO (Venice) clinical classifications; and
- 3 Any of the following:
 - 3.1 PAH is in NYHA/WHO functional class II; or
 - 3.2 PAH is in NYHA/WHO functional class III; or
 - 3.3 PAH is in NYHA/WHO functional class IV; and
- 4 Either:
 - 4.1 All of the following:
 - 4.1.1 Patient has a pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and 4.1.2 Either:
 - 4.1.2.1 Patient has a mean pulmonary artery pressure (PAPm) > 25 mmHg; or
 - 4.1.2.2 Patient is peri Fontan repair; and
 - 4.1.3 Patient has a pulmonary vascular resistance (PVR) of at least 3 Wood Units or at least 240 International Units (dyn s cm-5); or
 - 4.2 Testing for PCWP, PAPm, or PVR cannot be performed due to the patient's young age.

Note: Indications marked with * are unapproved indications.

Initial application — (erectile dysfunction due to spinal cord injury) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

60

- 1 Patient has a documented history of traumatic or non-traumatic spinal cord injury; and
- 2 Patient has erectile dysfunction secondary to spinal cord injury requiring pharmacological treatment.

Renewal — (erectile dysfunction due to spinal cord injury) from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Prostacyclin Analogues

EPOPROSTENOL - Special Authority see SA1696 on the next page	– Retail pha	rmacy	
Inj 500 mcg vial	36.61	1	🗸 Veletri
Inj 1.5 mg vial	73.21	1	 Veletri

	Subsidy (Manufacturer's Price)	S Per	Fully Subsidised	Brand or Generic Manufacturer	
	Ψ	1 61		Manulaciurei	
■SA1696 Special Authority for Subsidy Special Authority approved by the Pulmonary Arterial Hypertensi Notes: Application details may be obtained from Pharmac's web The Coordinator, PAH Panel Pharmac, PO Box 10-254, WELLINGTON Tel: (04) 916 7561, Fax: (04) 974 4858, Email: <u>PAH@pharmac</u> ILOPROST – Special Authority see SA1705 below – Retail phar	osite <u>schedule.pharma</u> c.govt.nz	<u>c.govt.</u>	nz/SAForm	<u>ıs</u> or:	
Nebuliser soln 10 mcg per ml, 2 ml		30	✓ <u>v</u>	entavis	
► SA1705 Special Authority for Subsidy Special Authority approved by the Pulmonary Arterial Hypertensi Notes: Application details may be obtained from Pharmac's web The Coordinator, PAH Panel Pharmac, PO Box 10-254, WELLINGTON	osite <u>schedule.pharma</u>	<u>c.govt.</u>	nz/SAForm	<u>15</u> or:	

Tel: (04) 916 7561, Fax: (04) 974 4858, Email: PAH@pharmac.govt.nz

	Subsidy (Manufacturer's Pric \$	ce) Subs Per	Fully sidised	Brand or Generic Manufacturer
Antiacne Preparations				
For systemic antibacterials, refer to INFECTIONS, Antibacteria ADAPALENE a) Maximum of 30 g per prescription b) Only on a prescription Crm 0.1%		30 g OP 30 g OP	✓ Di ✓ Di	
ISOTRETINOIN – Special Authority see SA2023 below – Reta Cap 5 mg Oratane to be Principal Supply on 1 March 2022		60	🗸 Or	ratane
Cap 10 mg Oratane to be Principal Supply on 1 March 2022	18.75	120	🗸 Or	ratane
Cap 20 mg Oratane to be Principal Supply on 1 March 2022	26.73	120	✔ Or	ratane

⇒SA2023 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following:

- 1 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
- 2 Applicant has an up to date knowledge of the safety issues around isotretinoin and is competent to prescribe isotretinoin; and
- 3 Either:
 - 3.1 Patient is of child bearing potential and the possibility of pregnancy has been excluded prior to commencement of treatment and patient has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and that they must not become pregnant during treatment and for a period of one month after the completion of treatment; or
 - 3.2 Patient is not of child bearing potential.

Note: Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body.

Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Either:

- 1 Patient is of child bearing potential and the possibility of pregnancy has been excluded prior to commencement of treatment and patient has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and that they must not become pregnant during treatment and for a period of one month after the completion of treatment; or
- 2 Patient is not of child bearing potential.

Note: Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body.

TRETINOIN

Crm 0.5 mg per g – Maximum of 50 g per prescription 15.57	50 g OP	ReTrieve
---	---------	----------

Antibacterials Topical

For systemic antibacterials, refer to INFECTIONS, Antibacterials, page 90		
HYDROGEN PEROXIDE		
* Crm 1%8.56	10 g OP	 Crystaderm
	15 g OP	 Crystaderm

	Subsidy (Manufacturer's F	Price) Subs	Fully Brand sidised Gener	
	\$	Per		acturer
MUPIROCIN				
Oint 2%	6.60 (11.50)	15 g OP	Bactroba	n
a) Only on a prescriptionb) Not in combination				
SODIUM FUSIDATE [FUSIDIC ACID]				
Crm 2%	1.59	5 g OP	 Foban 	
a) Maximum of 5 g per prescriptionb) Only on a prescription				
c) Not in combination				
Oint 2%	1.59	5 g OP	 Foban 	
a) Maximum of 5 g per prescriptionb) Only on a prescriptionc) Not in combination				
SULFADIAZINE SILVER				
Crm 1%	10.80	50 g OP	🗸 Flamaziı	ne
 a) Up to 250 g available on a PSO b) Not in combination 				
Antifungals Topical				
For systemic antifungals, refer to INFECTIONS, Antifungals, p	900 97			
AMOROLFINE	age 97			
a) Only on a prescription				
b) Not in combination				
Nail soln 5%	14.93	5 ml OP	✓ MycoNa	il
CICLOPIROX OLAMINE				
a) Only on a prescription				
b) Not in combination				
Nail-soln 8%	5.72	7 ml OP	Apo-Cic	lopirox
(Apo-Ciclopirox Nail-soln 8% to be delisted 1 May 2022)				
CLOTRIMAZOLE * Crm 1%	0.77	00 ~ OD	 Clomazo 	.1
	0.77	20 g OP		И
a) Only on a prescriptionb) Not in combination				
* Soln 1%	4.36	20 ml OP		
	(7.55)		Canester	ו
a) Only on a prescription				
b) Not in combination				
ECONAZOLE NITRATE				
Crm 1%		20 g OP	Deview	
a) Only on a proceription	(7.48)		Pevaryl	
a) Only on a prescriptionb) Not in combination				
Foaming soln 1%, 10 ml sachets	9.89	3		
	(17.23)	-	Pevaryl	
 a) Only on a prescription b) Not in combination 	. ,		2	

DERMATOLOGICALS

DERMATOLOGICALS

	Subsidy (Manufacturer's Pri	ce) Sub	Fully Brand or sidised Generic
	\$	Per	 Manufacturer
MICONAZOLE NITRATE			
* Crm 2%	0.81	15 g OP	✓ Multichem
a) Only on a prescription			
b) Not in combination	4.00		
* Lotn 2%	(10.03)	30 ml OP	Daktarin
a) Only on a prescription	(10.00)		Daktann
b) Not in combination			
* Tinct 2%	4.36	30 ml OP	
	(12.10)		Daktarin
a) Only on a prescription			
b) Not in combination			
Antipruritic Preparations			
CALAMINE			
a) Only on a prescription			
b) Not in combination Crm, aqueous, BP	1 09	100 g	✓ Calamine-AFT
Cilli, aqueous, DF	1.26	100 g	 ✓ calanine-APT ✓ healthE Calamine
	1.20		Aqueous Cream
			BP
Calamine-AFT to be Principal Supply on 1 May 2022			
(healthE Calamine Aqueous Cream BP Crm, aqueous, BP to be	delisted 1 May 20.	22)	
CROTAMITON			
a) Only on a prescription			
b) Not in combination Crm 10%	2.00	20 a OB	✓ Itch-Soothe
		20 g OP	Iteli+Sootile
MENTHOL – Only in combination	the Table 10		Dista
 Only in combination with a dermatological base or prop With or without other dermatological galenicals. 	prietary Topical Co	rticosteriod -	- Plain
Crystals	6.92	25 g	✓ MidWest
• ;•	29.60	100 g	✓ MidWest

Corticosteroids Topical

For systemic corticosteroids, refer to CORTICOSTEROIDS AND RELATED AGENTS, page 80

Corticosteroids - Plain

BETAMETHASONE DIPROPIONATE			
Crm 0.05%	2.96	15 g OP	 Diprosone
	36.00	50 g OP	 Diprosone
Oint 0.05%	2.96	15 g OP	 Diprosone
	36.00	50 g OP	✓ Diprosone
Oint 0.05% in propylene glycol base	4.33	30 g OP	 Diprosone OV
BETAMETHASONE VALERATE			
* Crm 0.1%	4.53	50 g OP	 Beta Cream
* Oint 0.1%	5.84	50 g OP	 Beta Ointment
* Lotn 0.1%		50 ml OP	 Betnovate
Betnovate to be Principal Supply on 1 March 2022			

fully subsidised

Principal Supply

DERMATOLOGICALS

	Subsidy		Fully	Brand or
	(Manufacturer's F	Price) Subs	Fully idised	
	\$	Per	√	Manufacturer
CLOBETASOL PROPIONATE				
* Crm 0.05%		30 g OP	1	Dermol
* Oint 0.05%		30 g OP		Dermol
CLOBETASONE BUTYRATE				
Crm 0.05%	5 38	30 g OP		
0111 0.05 /6	(10.00)	50 g OI		Eumovate
	(10.00)			Luniovale
HYDROCORTISONE	0.70	100 - 00		I had was a with a sure
* Crm 1% – Only on a prescription	3.70	100 g OP	•	Hydrocortisone
		500		(<u>PSM)</u>
	17.15	500 g	•	Hydrocortisone
				(<u>PSM)</u>
* Powder – Only in combination		25 g		ABM
Up to 5% in a dermatological base (not proprietary Topic	al Corticosterioo	I – Plain) with o	or with	out other dermatological
galenicals				
HYDROCORTISONE AND PARAFFIN LIQUID AND LANOLIN				
Lotn 1% with paraffin liquid 15.9% and lanolin 0.6% - Only o	n			
a prescription	10.57	250 ml	1	DP Lotn HC
HYDROCORTISONE BUTYRATE				
Lipocream 0.1%		100 g OP	1	Locoid Lipocream
Oint 0.1%		100 g OP		Locoid
Milky emul 0.1%		100 ml OP		Locoid Crelo
METHYLPREDNISOLONE ACEPONATE				
Crm 0.1%	4.46	15 g OP	1	Advantan
Oint 0.1%		15 g OP		Advantan
	4.40	15 9 01	•	Auvantan
	1.05	15 - 00		Flagon Alashal Free
Crm 0.1%	1.95 3.10	15 g OP		Elocon Alcohol Free
Oint 0.1%	••••	50 g OP		Elocon Alcohol Free Elocon
UIIIL U. I %	2.90	15 g OP 50 g OP		Elocon
Lotn 0.1%		30 ml OP		Elocon
	4.50	30 III OF	•	LIOCOT
TRIAMCINOLONE ACETONIDE		400 00		
Crm 0.02%		100 g OP		Aristocort
Oint 0.02%	6.35	100 g OP	•	Aristocort
Corticosteroids - Combination				
Controsteroids - Combination				
BETAMETHASONE VALERATE WITH SODIUM FUSIDATE [FUS	SIDIC ACID]			
Crm 0.1% with sodium fusidate (fusidic acid) 2%	3.49	15 g OP		
	(10.45)			Fucicort
 Maximum of 15 g per prescription 				
b) Only on a prescription				
HYDROCORTISONE WITH MICONAZOLE - Only on a prescrip	tion			
* Crm 1% with miconazole nitrate 2%		15 g OP	1	Micreme H
		0	-	
HYDROCORTISONE WITH NATAMYCIN AND NEOMYCIN – O				Dimefueert
Crm 1% with natamycin 1% and neomycin sulphate 0.5%		15 g OP		Pimafucort Pimafucort
Oint 1% with natamycin 1% and neomycin sulphate 0.5%		15 g OP		rinalucort
(Pimafucort Crm 1% with natamycin 1% and neomycin sulphate 0	.5% IO DE GEllSt	eu 1 may 2022,	/	

*Three months or six months, as applicable, dispensed all-at-once

AThree months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's \$	Price) Subsi Per	Fully Brand or dised Generic ✔ Manufacturer
TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMY	CIN AND NYSTA	TIN	
Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 r and gramicidin 250 mcg per g – Only on a prescription		15 g OP	Viaderm KC
Barrier Creams and Emollients			
Barrier Creams			
DIMETHICONE			
* Crm 5% pump bottle		500 ml OP	✓ <u>healthE</u> <u>Dimethicone 5%</u>
* Crm 10% pump bottle	4.52	500 ml OP	 healthE Dimethicone 10%
ZINC AND CASTOR OIL * Oint	1 65	500 a	✓ Boucher
	4.05	500 g	• Boucher
Emollients			
AQUEOUS CREAM * Crm	1 70	E00 ~	
₩ CIII		500 g	 GEM Aqueous Cream
	1.92		 Basic AquaCream Boucher
GEM Aqueous Cream to be Principal Supply on 1 April (Basic AquaCream Crm to be delisted 1 April 2022) (Boucher Crm to be delisted 1 April 2022) (Medco Crm to be delisted 1 April 2022)	2022		✓ Medco
CETOMACROGOL			
* Crm BP		500 g	 Cetomacrogol-AFT
Cetomacrogol-AFT to be Principal Supply on 1 May 20 (healthE Crm BP to be delisted 1 May 2022)	2.48 22		✓ healthE
CETOMACROGOL WITH GLYCEROL Crm 90% with glycerol 10%	2.35	500 ml OP	
			Boucher
			 ✓ <u>Boucher</u> ✓ Pharmacy Health Sorbolene with Glycerin
	3.10	1,000 ml OP	 Pharmacy Health
EMULSIFYING OINTMENT	3.10	,	 Pharmacy Health Sorbolene with Glycerin Boucher
EMULSIFYING OINTMENT	3.10	1,000 ml OP 500 g	 Pharmacy Health Sorbolene with Glycerin
EMULSIFYING OINTMENT * Oint BP DIL IN WATER EMULSION	3.10 3.40	,	 Pharmacy Health Sorbolene with Glycerin Boucher Emulsifying
EMULSIFYING OINTMENT * Oint BP DIL IN WATER EMULSION	3.10 3.40 2.19	500 g	 Pharmacy Health Sorbolene with Glycerin <u>Boucher</u> <u>Emulsifying</u> <u>Ointment ADE</u> O/W Fatty Emulsion

(\$29) Unapproved medicine supplied under Section 29 Sole Subsidised Supply

DERMATOLOGICALS

	Subsidy		Fully Brand or
	(Manufacturer's P \$	rice) Subs Per	idised Generic Manufacturer
WOOL FAT WITH MINERAL OIL – Only on a prescription			
* Lotn hydrous 3% with mineral oil	5.60 (11.95)	1,000 ml	DP Lotion
	(11.95)	250 ml OP	
	(4.53)		DP Lotion
	5.60	1,000 ml	
	(20.53) (23.91)		Alpha-Keri Lotion BK Lotion
	1.40	250 ml OP	Bit Louisin
	(7.73)		BK Lotion
Other Dermatological Bases			
PARAFFIN			
White soft – Only in combination		450 g	✓ <u>healthE</u>
Only in combination with a dermatological galenical or	19.99 as a diluent for a r	2,500 g proprietary Topi	✓ <u>healthE</u> cal Corticosteroid – Plain
Only in combination with a dermatological galenical of			
Minor Skin Infections			
POVIDONE IODINE			
Oint 10%	7.40	65 g OP	 Betadine
a) Maximum of 130 g per prescription			
b) Only on a prescription Antiseptic Solution 10%	4 15	100 ml	✓ Riodine
Riodine to be Principal Supply on 1 March 2022		100 111	
Antiseptic soln 10%	3.83	15 ml	✓ Riodine
	5.40	500 ml	 Riodine
Skin preparation, povidone iodine 10% with 30% alcohol		100 ml	Betadine Skin Prep
Skin preparation, povidone iodine 10% with 70% alcohol	(3.48) 1.63	100 ml	Detautile Skill Flep
	(7.78)	100 111	Pfizer
Parasiticidal Preparations			
DIMETHICONE			
* Lotn 4%	4.98	200 ml OP	✓ healthE
			Dimethicone 4% Lotion
IVERMECTIN - Special Authority see SA1225 on the next page			
Tab 3 mg – Up to 100 tab available on a PSO		4	 Stromectol
 PSO for institutional use only. Must be endorsed a valid Special Authority for patient of that institut hypermedia available on PSO provided the PSO in 	ion.		·

- 2) Ivermectin available on BSO provided the BSO includes a valid Special Authority for a patient of the institution.
- For the purposes of subsidy of ivermectin, institution means age related residential care facilities, disability care facilities or prisons.

Subsidy (Manufacturer's Price)	Subsi	Fully	Brand or Generic
\$	Per	1	Manufacturer

⇒SA1225 Special Authority for Subsidy

Initial application — (Scables) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Both:

- 1 Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical microbiologist; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 The patient is in the community; and
 - 2.1.2 Any of the following:
 - 2.1.2.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
 - 2.1.2.2 The community patient is physically or mentally unable to comply with the application instructions of topical therapy; or
 - 2.1.2.3 The patient has previously tried and failed to clear infestation using topical therapy; or
 - 2.2 All of the following:
 - 2.2.1 The Patient is a resident in an institution; and
 - 2.2.2 All residents of the institution with scabies or at risk of carriage are to be treated for scabies concurrently; and
 - 2.2.3 Any of the following:
 - 2.2.3.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
 - 2.2.3.2 The patient is physically or mentally unable to comply with the application instructions of topical therapy; or
 - 2.2.3.3 Previous topical therapy has been tried and failed to clear the infestation.

Note: Ivermectin is no more effective than topical therapy for treatment of standard scabies infestation.

Initial application — (Other parasitic infections) only from an infectious disease specialist, clinical microbiologist or dermatologist. Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:

- 1 Filaricides; or
- 2 Cutaneous larva migrans (creeping eruption); or
- 3 Strongyloidiasis.

Renewal — (Scabies) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria: Both:

- 1 Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical microbiologist; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 The patient is in the community; and
 - 2.1.2 Any of the following:
 - 2.1.2.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
 - 2.1.2.2 The community patient is physically or mentally unable to comply with the application instructions of topical therapy; or
 - 2.1.2.3 The patient has previously tried and failed to clear infestation using topical therapy; or
 - 2.2 All of the following:
 - 2.2.1 The Patient is a resident in an institution; and
 - 2.2.2 All residents of the institution with scabies or at risk of carriage are to be treated for scabies concurrently; and
 - 2.2.3 Any of the following:

DERMATOLOGICALS

continued...

- 2.2.3.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
- 2.2.3.2 The patient is physically or mentally unable to comply with the application instructions of topical therapy; or
- 2.2.3.3 Previous topical therapy has been tried and failed to clear the infestation.

Note: Ivermectin is no more effective than topical therapy for treatment of standard scabies infestation.

Renewal — (Other parasitic infections) only from an infectious disease specialist, clinical microbiologist or dermatologist. Approvals valid for 1 month for applications meeting the following criteria: Any of the following:

- 1 Filaricides; or
- 2 Cutaneous larva migrans (creeping eruption); or
- 3 Strongyloidiasis.

PERMETHRIN

Crm 5%5.75	30 g OP	✓ Lyderm
Lotn 5%	30 ml OP	 <u>A-Scabies</u>

Psoriasis and Eczema Preparations

ACITRETIN – Special Authority see SA2024 below – Retail pharmacy			
Cap 10 mg	6	60 .	Novatretin
Cap 25 mg	6	60 •	Novatretin

⇒SA2024 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following:

- 1 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
- 2 Applicant has an up to date knowledge of the safety issues around acitretin and is competent to prescribe acitretin; and
- 3 Either:
 - 3.1 Patient is of child bearing potential and the possibility of pregnancy has been excluded prior to commencement of treatment and patient has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and that they must not become pregnant during treatment and for a period of three years after the completion of treatment; or
 - 3.2 Patient is not of child bearing potential.

Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Either:

- 1 Patient is of child bearing potential and the possibility of pregnancy has been excluded prior to commencement of treatment and patient has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and that they must not become pregnant during treatment and for a period of three years after the completion of treatment; or
- 2 Patient is not of child bearing potential.

BETAMETHASONE DIPROPIONATE WITH CALCIPOTRIOL

Foam spray 500 mcg with calcipotriol 50 mcg per g	59.95	60 g OP	 Enstilar
Gel 500 mcg with calcipotriol 50 mcg per g		60 g OP	 Daivobet
Oint 500 mcg with calcipotriol 50 mcg per g	15.90	30 g OP	 Daivobet
CALCIPOTRIOL			
Oint 50 mcg per g	40.00	120 g OP	 Daivonex

DERMATOLOGICALS

	Fully	Brand or
/	sidised	Generic
Per		Manufacturer
000 ml		Midure et
200 ml	_	<u>Midwest</u>
ry Topical C	JOILICOS	steriod – Plain
75 g OP		
-	E	Egopsoryl TA
30 g OP		
	E	Egopsoryl TA
		0
25 g OP		Coco-Scalp Coco-Scalp
40 g OP	• (Coco-Scalp
n per 12 we	oke	
15 g OP		Elidel
	=	
, cataracts,	glauco	dermatitis, rosacea, ma, or raised intraocular
prescriptio 500 ml		Pinetarsol
250 g		Midwest PSM
Corticoster	-	ain or collodion flexible
100 g		Vidwest
Corticoster	oid – Pl	ain
	_	
30 g OP	✓ Z	Zematop
ption per 1	2 weeks	S.
	Ū	otion per 12 week

 Subsidy (Manufacturer's Price)	Fu Subsidis	· · · ·	
 \$	Per	 Manufacturer 	

⇒SA2074 Special Authority for Subsidy

Initial application only from a dermatologist, paediatrician or any relevant practitioner on the recommendation of a dermatologist, paediatrician, . Approvals valid without further renewal unless notified for applications meeting the following criteria: Both:

- 1 Patient has atopic dermatitis on the face; and
- 2 Patient has at least one of the following contraindications to topical corticosteroids: periorificial dermatitis, rosacea, documented epidermal atrophy or documented allergy to topical corticosteroids.

Scalp Preparations		
BETAMETHASONE VALERATE		
* Scalp app 0.1%	100 ml OP	 Beta Scalp
CLOBETASOL PROPIONATE		4 - -
* Scalp app 0.05%	30 ml OP	✓ <u>Dermol</u>
HYDROCORTISONE BUTYRATE		4
Scalp lotn 0.1%	100 ml OP	Locoid
KETOCONAZOLE Shampoo 2%	100 ml OP	✓ Sebizole
Shanpoo 2%	TOO MI OP	✓ <u>Sebizole</u> ✓ Sebizole
a) Maximum of 100 ml per prescription		
b) Only on a prescription		
Sunscreens		
SUNSCREENS, PROPRIETARY – Subsidy by endorsement		
Only if prescribed for a patient with severe photosensitivity secondary to a	defined clinical co	ndition and the prescription is
endorsed accordingly.		··· · · · · ·
Lotn,	200 g OP	✓ Marine Blue Lotion SPF 50+
		<u>3FF 30+</u>
Wart Preparations		
Ear activitie and propagations refer to DCODIASIS AND ECZEMA DEEDADAT		
For salicylic acid preparations refer to PSORIASIS AND ECZEMA PREPARAT IMIQUIMOD	IONS, page 69	
Crm 5%, 250 mg sachet	24	✓ Perrigo
PODOPHYLLOTOXIN	24	• Tenigo
Soln 0.5%	3.5 ml OP	 Condyline
a) Maximum of 3.5 ml per prescription		oonayinto
b) Only on a prescription		
Other Skin Preparations		
Antineoplastics		
FLUOROURACIL SODIUM		
Crm 5%	20 g OP	✓ Efudix

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy	Fully Subsidised		Brand or
(Manufacturer's Price)			Generic
 \$	Per	1	Manufacturer

		Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
С	ontraceptives - Non-hormonal				
С	ondoms				
റ	NDOMS				
	49 mm – Up to 144 dev available on a PSO		144	 Image: A second s	Moments
	53 mm		10		Moments
		11.64	144		Moments
	a) Maximum of 60 dev per prescription				
	b) Up to 60 dev available on a PSO				
*	53 mm, 0.05 mm thickness	0.95	10	✓	Moments
		11.42	144	 Image: A second s	Moments
	a) Up to 60 dev available on a PSO				
	b) Maximum of 60 dev per prescription				
ŧ	53 mm, chocolate, brown	0.95	10	 Image: A second s	Moments
		11.64	144		Moments
	a) Up to 60 dev available on a PSO				
	b) Maximum of 60 dev per prescription				
*	53 mm, strawberry, red	0.95	10	✓	Moments
		11.64	144	✓]	Moments
	a) Up to 60 dev available on a PSO				
	b) Maximum of 60 dev per prescription				
ŧ	56 mm	0.97	10	✓	Moments
		11.64	144	✓]	Moments
	a) Maximum of 60 dev per prescription				
	b) Up to 60 dev available on a PSO				
ŧ	56 mm, 0.05 mm thickness	1.30	12	 Image: A second s	Gold Knight
		15.57	144	1	Gold Knight
	a) Up to 60 dev available on a PSO				
	b) Maximum of 60 dev per prescription				
ŧ	56 mm, 0.05mm thickness (bulk pack)	14.61	144	1	Gold Knight
	a) Maximum of 60 dev per prescription			-	
	b) Up to 60 dev available on a PSO				
ŧ	56 mm, 0.08 mm thickness	0.97	10	✓	Moments
		11.64	144		Moments
	a) Up to 60 dev available on a PSO			-	
	b) Maximum of 60 dev per prescription				
ŧ	56 mm, 0.08 mm thickness, red	0.97	10	✓	Moments
		11.64	144		Moments
	a) Up to 60 dev available on a PSO			-	
	b) Maximum of 60 dev per prescription				
ŧ	56 mm, chocolate	1.30	12	1	Gold Knight
		15.57	144		Gold Knight
	a) Up to 60 dev available on a PSO			-	<u>v</u>
	b) Maximum of 60 dev per prescription				
ŧ	56 mm, strawberry	1.30	12	 Image: A second s	Gold Knight
	·	15.57	144		Gold Knight
	a) Up to 60 dev available on a PSO			-	
	b) Maximum of 60 dev per prescription				
ŧ	60 mm		12	1	Gold Knight XL
		14.87	144		Shield XL
		17.02			Gold Knight XL

Three anon Maximum Map de las part as or information if endorsed "certified exemption" by the prescriber or pharmacist. ★Three anon Maximum of SR day have a state and the second all at once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
 # 60 mm (bulk pack) a) Maximum of 60 dev per prescription b) Up to 60 dev available on a PSO 	14.87	144	1	<u>Gold Knight XL</u>
Contraceptive Devices				
INTRA-UTERINE DEVICE a) Up to 40 dev available on a PSO b) Only on a PSO				
* IÚD 29.1 mm length × 23.2 mm width		1	✓	Choice TT380 Short
* IUD 33.6 mm length × 29.9 mm width		1	~	Choice TT380 Standard
* IUD 35.5 mm length × 19.6 mm width	15.50	1	1	Choice Load 375
Contraceptives - Hormonal				

Combined Oral Contraceptives

■ SA0500 Special Authority for Alternate Subsidy

Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

- 1 Fither:
 - 1.1 Patient is on a Social Welfare benefit: or
 - 1.2 Patient has an income no greater than the benefit; and
- 2 Has tried at least one of the fully funded options and has been unable to tolerate it.

Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

- 1 Patient is on a Social Welfare benefit: or
- 2 Patient has an income no greater than the benefit.

Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon.

The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999.

Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either:

- on a Social Welfare benefit: or
- have an income no greater than the benefit.

The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED

ETHINYLOESTRADIOL WITH DESOGESTREL

* Tab 20 mcg with desogestrel 150 mcg and 7 inert tab - Up to 84 tab

o a	vailable on a	PSO	 00.0

84

✓ Mercilon 28

	Subsidy (Manufacturer's Price)		Fully Subsidised	
	\$	Per		Manufacturer
ETHINYLOESTRADIOL WITH LEVONORGESTREL				
* Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets -	-			
Up to 112 tab available on a PSO	2.18	84	✓	Microgynon 20 ED
	6.45	112	✓	Femme-Tab ED
* Tab 50 mcg with levonorgestrel 125 mcg and 7 inert tab - U	p			
to 84 tab available on a PSO		84	1	Microgynon 50 ED
* Tab 30 mcg with levonorgestrel 150 mcg	6.62	63		
	(16.50)			Microgynon 30
a) Higher subsidy of \$15.00 per 63 tab with Special Auth	nority see SA0500 on	the	previous p	age
b) Up to 63 tab available on a PSO				Č.
* Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets	_			
Up to 112 tab available on a PSO		84	1	Levlen ED
	6.45	112	1	Femme-Tab ED
(Microgynon 50 ED Tab 50 mcg with levonorgestrel 125 mcg and	7 inert tab to be delis	sted	1 March 20	022)
ETHINYLOESTRADIOL WITH NORETHISTERONE				,
Tab 35 mcg with norethisterone 1 mg and 7 inert tab – Up to				
84 tab available on a PSO		84	1	Brevinor 1/28
Tab 35 mcg with norethisterone 500 mcg and 7 inert tab – U		07	•	Dictilion 1/20
to 84 tab available on a PSO		84	1	Norimin
		04	•	
Bragastagon only Contragentives				

Progestogen-only Contraceptives

⇒SA0500 Special Authority for Alternate Subsidy

Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

1 Either:

- 1.1 Patient is on a Social Welfare benefit; or
- 1.2 Patient has an income no greater than the benefit; and
- 2 Has tried at least one of the fully funded options and has been unable to tolerate it.

Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

1 Patient is on a Social Welfare benefit; or

2 Patient has an income no greater than the benefit.

Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon.

The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999.

Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either:

- on a Social Welfare benefit; or
- have an income no greater than the benefit.

The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED

*	Tab 30 mcg – Up to 84 tab available on a PSO	.16.50 22.00	84 112	 ✓ <u>Microlut</u> ✓ <u>Microlut</u>
*	Subdermal implant (2 × 75 mg rods) – Up to 3 pack available on a PSO	106.92	1	✓ Jadelle

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
MEDROXYPROGESTERONE ACETATE Inj 150 mg per ml, 1 ml syringe – Up to 5 inj available on a P	SO7.98	1	√ [Depo-Provera
NORETHISTERONE Tab 350 mcg – Up to 84 tab available on a PSO Noriday 28 to be Principal Supply on 1 March 2022	12.25	84	• •	Noriday 28
Emergency Contraceptives				
LEVONORGESTREL * Tab 1.5 mg a) Maximum of 2 tab per prescription b) Up to 5 tob available on a PSO	4.95	1	√ F	Postinor-1

b) Up to 5 tab available on a PSO

c) Note: Direct Provision by a pharmacist permitted under the provisions in Part I of Section A.

d) Postinor-1 to be Sole Supply on 1 March 2022

Antiandrogen Oral Contraceptives

Prescribers may code prescriptions "contraceptive" (code "O") when used as indicated for contraception. The period of supply and prescription charge will be as per other contraceptives, as follows:

- \$5.00 prescription charge (patient co-payment) will apply.
- prescription may be written for up to six months supply.

Prescriptions coded in any other way are subject to the non contraceptive prescription charges, and the non-contraceptive period of supply. ie. Prescriptions may be written for up to three months supply.

CYPROTERONE ACETATE WITH ETHINYLOESTRADIOL

 * Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tabs – Up to 168 tab available on a PSO	168	✓ <u>Ginet</u>
Gynaecological Anti-infectives		
ACETIC ACID WITH HYDROXYQUINOLINE AND RICINOLEIC ACID Jelly with glacial acetic acid 0.94%, hydroxyquinoline sulphate 0.025%, glycerol 5% and ricinoleic acid 0.75% with applicator8.43 (24.00)	100 g OP	Aci-Jel
CLOTRIMAZOLE * Vaginal crm 1% with applicators2.50 * Vaginal crm 2% with applicators	35 g OP 20 g OP	✓ <u>Clomazol</u> ✓ <u>Clomazol</u>
MICONAZOLE NITRATE * Vaginal crm 2% with applicator6.89 NYSTATIN	40 g OP	✓ <u>Micreme</u>
Vaginal crm 100,000 u per 5 g with applicator(s)4.00	75 g OP	✓ <u>Nilstat</u>
Myometrial and Vaginal Hormone Preparations		
ERGOMETRINE MALEATE		
Inj 500 mcg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	5	 DBL Ergometrine
* Crm 1 mg per g with applicator	15 g OP	✓ <u>Ovestin</u>

76

Pessaries 500 mcg......6.86

Ovestin

	Subsidy		Fully Brand or
	(Manufacturer's Price \$	e) Subsi Per	dised Generic Manufacturer
DXYTOCIN – Up to 5 inj available on a PSO Inj 5 iu per ml, 1 ml ampoule Inj 10 iu per ml, 1 ml ampoule	4.98	5 5	✓ Oxytocin BNM✓ Oxytocin BNM
DXYTOCIN WITH ERGOMETRINE MALEATE – Up to 5 inj avai Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml		5	✓ Syntometrine
Pregnancy Tests - hCG Urine PREGNANCY TESTS - HCG URINE a) Up to 200 test available on a PSO b) Only on a PSO Cassette		0 test OP	 ✓ David One Step Cassette Pregnancy Test ✓ Smith BioMed Rapid Pregnancy Test
Urinary Agents			
or urinary tract Infections refer to INFECTIONS, Antibacterials,	page 108		
5-Alpha Reductase Inhibitors			
 INASTERIDE – Special Authority see SA0928 below – Retail p Tab 5 mg SA0928 Special Authority for Subsidy nitial application from any relevant practitioner. Approvals validate following criteria: 	4.81	100 ewal unless	✓ <u>Ricit</u> notified for applications meeting
Both: 1 Patient has symptomatic benign prostatic hyperplasia; and 2 Either:	d		
2.1 The patient is intolerant of non-selective alpha blog2.2 Symptoms are not adequately controlled with non-Note: Patients with enlarged prostates are the appropriate candi	selective alpha bloc	kers.	
Alpha-1A Adrenoreceptor Blockers			
AMSULOSIN HYDROCHLORIDE – Special Authority see SA1 Cap 400 mcg		100	✓ <u>Tamsulosin-Rex</u> notified for applications meetir
 Patient has symptomatic benign prostatic hyperplasia; and The patient is intolerant of non-selective alpha blockers or 		licated.	

2 The patient is intolerant of non-selective alpha blockers or these are contraindicated.

	Subsidy (Manufacturer's I \$	Price) Subs Per	Fully Brand or idised Generic ✓ Manufacturer
Other Urinary Agents			
OXYBUTYNIN – Subsidy by endorsement Subsidy by endorsement – Subsidised for patients who were endorsed accordingly. Pharmacists may annotate the prescr dispensing of oxybutynin.	taking oxybutyr iption as endors	nin prior to 1 Jur sed where there	e 2021 and the prescription is exists a record of prior
* Tab 5 mg	5.42	100	 Alchemy Oxybutynin ^{\$29}
	11.70	500	✓ Apo-Oxybutynin
* Oral liq 5 mg per 5 ml		473 ml	✓ Apo-Oxybutynin
(Apo-Oxybutynin Tab 5 mg to be delisted 1 May 2022) (Apo-Oxybutynin Oral liq 5 mg per 5 ml to be delisted 1 May 2022			
POTASSIUM CITRATE			
Oral liq 3 mmol per ml – Special Authority see SA1083 below Retail pharmacy		200 ml OP	✓ Biomed
⇒SA1083 Special Authority for Subsidy			
Initial application from any relevant practitioner. Approvals valid Both: 1 The patient has recurrent calcium oxalate urolithiasis; and			meeting the following criteria:
2 The patient has had more than two renal calculi in the two			
Renewal from any relevant practitioner. Approvals valid for 2 year benefitting from the treatment.	ars where the tr	eatment remain	s appropriate and the patient is
SODIUM CITRO-TARTRATE			_
* Grans eff 4 g sachets	2.22	28	✓ <u>Ural</u>
SOLIFENACIN SUCCINATE			_
Tab 5 mg		30	Solifenacin Mylan
Tab 10 mg	3.72	30	 Solifenacin Mylan
Detection of Substances in Urine			
ORTHO-TOLIDINE			
* Compound diagnostic sticks	7.50 (8.25)	50 test OP	Hemastix
TETRABROMOPHENOL			
* Blue diagnostic strips	7.02 (13.92)	100 test OP	Albustix
Obstetric Preparations			
Antiprogesterones			
MIFEPRISTONE			
Tab 200 mg	60.00	1	 Mifegyne
	180.00	3	 Mifegyne
 a) Up to 15 tab available on a PSO b) Only on a PSO 			

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	
Calcium Homeostasis				
CALCITONIN				
* Inj 100 iu per ml, 1 ml ampoule	121.00	5	1	Miacalcic
CINACALCET - Special Authority see SA1618 below - Retail ph	narmacv			
Tab 30 mg – Wastage claimable		28	✓	Cinacalet Devatis
	210.30		✓	Sensipar
Cinacalet Devatis to be Principal Supply on 1 April 2022				
Tab 60 mg – Wastage claimable		28	✓	Cinacalet Devatis
Cinacalet Devatis to be Principal Supply on 1 April 2022				
(Sensipar Tab 30 mg to be delisted 1 April 2022)				
SA1618 Special Authority for Subsidy				
Initial application only from a nephrologist or endocrinologist. A	pprovals valid for 6 m	onth	s for applic	cations meeting the
following criteria:				
Either:				
1 All of the following:				
1.1 The patient has been diagnosed with a parathyroid				
1.2 The patient has persistent hypercalcaemia (serum	0			/ / /
first-line treatments including sodium thiosulfate (w 1.3 The patient is symptomatic; or	mere appropriate) and	i Dist	nosprioria	les, and
2 All of the following:			امريم المراقع	
2.1 The patient has been diagnosed with calciphylaxis	,			
 The patient has symptomatic (e.g. painful skin ulc 3 mmol/L); and 	ers) hypercalcaemia (seru	n caicium	greater man of equal to
2.3 The patient's condition has not responded to previo	ous first-line treatmen	ts inc	ludina hier	hosphonates and sodium
thiosulfate.			adding bio	
Renewal only from a nephrologist or endocrinologist. Approvals	valid without further r	enew	al unless i	notified for applications

meeting the following criteria:

Both:

- 1 The patient's serum calcium level has fallen to < 3mmol/L; and
- 2 The patient has experienced clinically significant symptom improvement.

Note: This does not include parathyroid adenomas unless these have become malignant.

ZOLEDRONIC ACID

Inj 4 mg per 5 ml, vial - Special Authority see SA203	1 below –		
Retail pharmacy		1	Zoledronic acid
			Mylan

⇒SA2031 Special Authority for Subsidy

Initial application — (bone metastases) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Patient has hypercalcaemia of malignancy; or
- 2 Both:
 - 2.1 Patient has bone metastases or involvement; and
 - 2.2 Patient has severe bone pain resistant to standard first-line treatments; or

3 Both:

- 3.1 Patient has bone metastases or involvement; and
- 3.2 Patient is at risk of skeletal-related events pathological fracture, spinal cord compression, radiation to bone or

continued...

Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	✓	Manufacturer

continued...

surgery to bone.

Initial application — (early breast cancer) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Treatment to be used as adjuvant therapy for early breast cancer; and
- 2 Patient has been amenorrhoeic for 12 months or greater, either naturally or induced, with endocrine levels consistent with a postmenopausal state; and
- 3 Treatment to be administered at a minimum interval of 6-monthly for a maximum of 2 years.

Corticosteroids and Related Agents for Systemic Use BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHASONE ACETATE * Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml 19.20 5 (36.96)Celestone Chronodose DEXAMETHASONE * Tab 0.5 mg – Up to 60 tab available on a PSO......1.50 30 Dexmethsone * Tab 4 mg – Up to 30 tab available on a PSO......2.65 Dexmethsone 30 1 25 ml OP Biomed DEXAMETHASONE PHOSPHATE Dexamethasone phosphate injection will not be funded for oral use. * Inj 4 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO9.25 10 Dexamethasone Phosphate Panpharma * Inj 4 mg per ml, 2 ml ampoule - Up to 5 inj available on a PSO 16.37 10 Dexamethasone Phosphate Panpharma FLUDROCORTISONE ACETATE ✓ Florinef 100 HYDROCORTISONE Tab 5 mg8.10 Douglas 100 * ✓ Douglas 100 1 Solu-Cortef a) Up to 5 inj available on a PSO b) Only on a PSO METHYLPREDNISOLONF Medrol 100 ✓ Medrol 20 METHYLPREDNISOLONE (AS SODIUM SUCCINATE) ✓ Solu-Medrol-Act-1 O-Vial ✓ Solu-Medrol-Act-1 O-Vial ✓ Solu-Medrol-Act-1 O-Vial 1 ✓ Solu-Medrol

	(Manufacturer's Price		Subsidised	l Generic
	\$	Per	 ✓ 	Manufacturer
METHYLPREDNISOLONE ACETATE				
Inj 40 mg per ml, 1 ml vial		5	1	Depo-Medrol
PREDNISOLONE				
 Oral liq 5 mg per ml – Up to 30 ml available on a PSO Restricted to children under 12 years of age. 	6.00	30 ml OF	• ✓	Redipred
PREDNISONE			_	
* Tab 1 mg		500		Apo-Prednisone
₭ Tab 2.5 mg	21.04	500		Prednisone Clinect Apo-Prednisone
r Tab 2.5 mg		500		Prednisone Clinect
✤ Tab 5 mg – Up to 30 tab available on a PSO		500		Apo-Prednisone
			1	Prednisone Clinect
* Tab 20 mg – Up to 30 tab available on a PSO	50.51	500		Apo-Prednisone Prednisone Clinect
Apo-Prednisone Tab 1 mg to be delisted 1 November 2022) Apo-Prednisone Tab 2.5 mg to be delisted 1 November 2022) Apo-Prednisone Tab 5 mg to be delisted 1 November 2022) Apo-Prednisone Tab 20 mg to be delisted 1 November 2022)				
TETRACOSACTRIN				
Inj 250 mcg per ml, 1 ml ampoule		1	1	UK Synacthen S29
				AU Synacthen
				Synacthen
Inj 1 mg per ml, 1 ml ampoule	690.00	1		Synacthen Depot Synacthene Retard S29
FRIAMCINOLONE ACETONIDE				
Inj 10 mg per ml, 1 ml ampoule		5		Kenacort-A 10
Inj 40 mg per ml, 1 ml ampoule	51.10	5	1	Kenacort-A 40
Sex Hormones Non Contraceptive				
Androgen Agonists and Antagonists				
CYPROTERONE ACETATE				
Tab 50 mg		50		Siterone
Tab 100 mg		50	v	Siterone
ESTOSTERONE				
Patch 5 mg per day	90.00	30	v	Androderm
ESTOSTERONE CIPIONATE				
Inj 100 mg per ml, 10 ml vial		1	/	Depo-Testosterone
TESTOSTERONE ESTERS			_	
Inj 250 mg per ml, 1 ml		1	/	Sustanon Ampoules
TESTOSTERONE UNDECANOATE			-	
Cap 40 mg – Subsidy by endorsement		60		Andriol Testocaps
Subsidy by endorsement – subsidised for patients who w				
 November 2021 and the prescription is endorsed accor where there exists a record of prior dispensing of testoste 				
where there exists a record of prior dispensing of lestoste	crone undecandale	1 cap	0	Reandron 1000

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price \$	ce) Subs Per	Fully sidised	Brand or Generic Manufacturer
Hormone Replacement Therapy - Systemic Prescribing Guideline HRT should be taken at the lowest dose for the shortest period	of time necessary to	o control sym	ntome	Patients should be
reviewed 6 monthly in line with the updated NZGG "Evidence-ba March 2004".				
Oestrogens				
OESTRADIOL – See prescribing guideline above * Tab 1 mg	4.12	28 OP		
* Tab 2 mg	(11.10) 4.12 (11.10)	28 OP		strofem
Patch 25 mcg per day		8	✓ E: ✓ E:	stradot stradiol TDP Mylan S29
a) No more than 2 patch per weekb) Only on a prescription				,
Patch 50 mcg per day	7.04 9.22	8	✓ Es	stradot 50 mcg stradiol TDP Mylan ^{S29}
 a) No more than 2 patch per week b) Only on a prescription 	7.01	0		-tur de t
Patch 75 mcg per day	10.60	8	🖌 Es	stradot stradiol TDP Mylan S29
 a) No more than 2 patch per week b) Only on a prescription 	7.01	8	. E	stradot
Patch 100 mcg per day a) No more than 2 patch per week b) Only on a prescription		0	• E	Siradot
(Estradiol TDP Mylan 529 Patch 25 mcg per day to be delisted	•			
(Estradiol TDP Mylan S29 Patch 50 mcg per day to be delisted (Estradiol TDP Mylan S29 Patch 75 mcg per day to be delisted	. ,			
OESTRADIOL VALERATE – See prescribing guideline above * Tab 1 mg * Tab 2 mg		84 84		rogynova rogynova
OESTROGENS – See prescribing guideline above * Conjugated, equine tab 300 mcg		28	• 11	ogynova
Conjugated, equine tab 625 mcg	(17.50)	28	Pi	remarin
	(17.50)		Pi	remarin
Progestogens				
MEDROXYPROGESTERONE ACETATE – See prescribing gu * Tab 2.5 mg	4.69	30 100		rovera
* Tab 5 mg * Tab 10 mg		100 30		rovera

	Subsidy (Manufacturer's Price \$) Per	Fully Subsidised	Brand or Generic Manufacturer
Progestogen and Oestrogen Combined Prepara	tions			
DESTRADIOL WITH NORETHISTERONE – See prescribing gu	ideline on the previo	us pag	е	
K Tab 1 mg with 0.5 mg norethisterone acetate	5.40	28 OP		
	(18.10)			Kliovance
Fab 2 mg with 1 mg norethisterone acetate		28 OP		
	(18.10)			Kliogest
← Tab 2 mg with 1 mg norethisterone acetate (10), and 2 mg				
oestradiol tab (12) and 1 mg oestradiol tab (6)		28 OP		- .
	(18.10)			Trisequens
Other Oestrogen Preparations				
THINYLOESTRADIOL				
← Tab 10 mcg		100	1	NZ Medical and
				Scientific
ESTRIOL				
F Tab 2 mg	7.00	30	1	Ovestin
·				<u></u>
Other Progestogen Preparations				
EVONORGESTREL				
 Intra-uterine device 52 mg 		1	1	Mirena
 Intra-uterine device 13.5 mg 		1		Jaydess
Tab 100 mg	116 15	100	1	Provera HD
5		100	•	
ORETHISTERONE ← Tab 5 mg – Up to 30 tab available on a PSO	F 40	30		Primolut N
		30	•	
ROGESTERONE				
Cap 100 mg – Special Authority see SA1609 below – Retail				
pharmacy		30	~	Utrogestan
SA1609 Special Authority for Subsidy				
nitial application only from an obstetrician or gynaecologist. Ap	oprovals valid for 12	month	s for appli	cations meeting the
Illowing criteria:				
oth:				
1 For the prevention of pre-term labour*; and				
2 Either:				
2.1 The patient has a short cervix on ultrasound (defin		5 to 28	weeks); o	
2.2 The patient has a history of pre-term birth at less the				
enewal only from an obstetrician or gynaecologist. Approvals w	alid for 12 months f	or appl	cations m	eeting the following criter
Il of the following:				
 For the prevention of pre-term labour*: and 				

- 1 For the prevention of pre-term labour*; and
- 2 Treatment is required for second or subsequent pregnancy; and
- 3 Either:
 - 3.1 The patient has a short cervix on ultrasound (defined as < 25 mm at 16 to 28 weeks); or
 - 3.2 The patient has a history of pre-term birth at less than 28 weeks.

Note: Indications marked with * are unapproved indications.

	Subsidy (Manufacturer's Price)		Fully Subsidised	
	(Manulacturer's Flice) \$	Per		
Thyroid and Antithyroid Agents				
CARBIMAZOLE				
* Tab 5 mg	10.80	100	1	Neo-Mercazole
LEVOTHYROXINE				
* Tab 25 mcg	5.55	90	✓	Synthroid
* Tab 50 mcg	1.71	28	1	Mercury Pharma
	5.79	90		Synthroid
	64.28	1,000		Eltroxin
₭ Tab 100 mcg		28		Mercury Pharma
	6.01	90	-	Synthroid
	66.78	1,000	v	Eltroxin
PROPYLTHIOURACIL – Special Authority see SA1199 below – Propylthiouracil is not recommended for patients under the a treatments are contraindicated.		s the p	patient is p	pregnant and other
Tab 50 mg	35.00	100	✓	PTU \$29
SA1199 Special Authority for Subsidy				
nitial application from any relevant practitioner. Approvals vali	d for 2 years for appli	icatior	is meeting	the following criteria:
Both:			-	-
1 The patient has hyperthyroidism; and				
2 The patient is intolerant of carbimazole or carbimazole is	contraindicated.			
Renewal from any relevant practitioner. Approvals valid for 2 ye benefitting from the treatment.	ars where the treatme	ent re	mains app	propriate and the patient is

Trophic Hormones

Growth Hormones

SOMATROPIN (C	MNITROPE) - Special Authority see SA2032 below - Retai	il pharmacy	
* Inj 5 mg cartr	dge69.75	1	 Omnitrope
* Inj 10 mg car	ridge	1	 Omnitrope
* Inj 15 mg car	ridge139.50	1	 Omnitrope

⇒SA2032 Special Authority for Subsidy

Initial application — (growth hormone deficiency in children) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria: Fither:

- 1 Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient sequelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH < 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose < 2 mmol/l using a laboratory device); or</p>
- 2 All of the following:
 - 2.1 Height velocity < 25th percentile for age adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985); and</p>
 - 2.2 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
 - 2.3 Peak growth hormone value of < 5.0 mcg per litre in response to two different growth hormone stimulation tests. In children who are 5 years or older, GH testing with sex steroid priming is required; and</p>
 - 2.4 If the patient has been treated for a malignancy, they should be disease free for at least one year based upon follow-up laboratory and radiological imaging appropriate for the malignancy, unless there are strong medical

continued...

Subsidy		Fully	Brand or
(Manufacturer's Price)	S	ubsidised	Generic
\$	Per	✓	Manufacturer

continued...

reasons why this is either not necessary or appropriate; and

2.5 Appropriate imaging of the pituitary gland has been obtained.

Renewal — (growth hormone deficiency in children) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 2 Height velocity is greater than or equal to 25th percentile for age (adjusted for bone age/pubertal status if appropriate) while on growth hormone treatment, as calculated over six months using the standards of Tanner and Davis (1985); and
- 3 Height velocity is greater than or equal to 2.0 cm per year, as calculated over 6 months; and
- 4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone treatment has occurred: and
- 5 No malignancy has developed since starting growth hormone.

Initial application — (Turner syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the followina:

- 1 The patient has a post-natal genotype confirming Turner Syndrome; and
- 2 Height velocity is < 25th percentile over 6-12 months using the standards of Tanner and Davies (1985); and
- 3 A current bone age is < 14 years.

Renewal — (Turner syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Height velocity is greater than or equal to 50th percentile for age (while on growth hormone calculated over 6 to 12 months using the Ranke's Turner Syndrome growth velocity charts); and
- 2 Height velocity is greater than or equal to 2 cm per year, calculated over six months; and
- 3 A current bone age is 14 years or under; and
- 4 No serious adverse effect that the specialist considers is likely to be attributable to growth hormone treatment has occurred: and
- 5 No malignancy has developed since starting growth hormone.

Initial application — (short stature without growth hormone deficiency) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria: All of the followina:

- 1 The patient's height is more than 3 standard deviations below the mean for age or for bone age if there is marked growth acceleration or delay; and
- 2 Height velocity is < 25th percentile for age (adjusted for bone age/pubertal status if appropriate), as calculated over 6 to 12 months using the standards of Tanner and Davies(1985); and
- 3 A current bone age is < 14 years or under (female patients) or < 16 years (male patients); and
- 4 The patient does not have severe chronic disease (including malignancy or recognized severe skeletal dysplasia) and is not receiving medications known to impair height velocity.

Renewal — (short stature without growth hormone deficiency) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

- All of the following:
 - 1 Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
 - 2 Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
 - 3 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
 - 4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred.

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Subs	idised	Generic	
\$	Per	~	Manufacturer	

continued...

Initial application — (short stature due to chronic renal insufficiency) only from a paediatric endocrinologist, endocrinologist or renal physician on the recommendation of a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient's height is more than 2 standard deviations below the mean; and
- 2 Height velocity is < 25th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 3 A current bone age is to 14 years or under (female patients) or to 16 years or under (male patients); and
- 4 The patient is metabolically stable, has no evidence of metabolic bone disease and absence of any other severe chronic disease; and
- 5 The patient is under the supervision of a specialist with expertise in renal medicine; and
- 6 Either:
 - 6.1 The patient has a GFR less than or equal to 30 ml/min/1.73m² as measured by the Schwartz method (Height(cm)/plasma creatinine (umol/l) × 40 = corrected GFR (ml/min/1.73m² in a child who may or may not be receiving dialysis; or
 - 6.2 The patient has received a renal transplant and has received < 5mg/ m²/day of prednisone or equivalent for at least 6 months..

Renewal — (short stature due to chronic renal insufficiency) only from a paediatric endocrinologist, endocrinologist or renal physician on the recommendation of a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
- 3 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone has occurred; and
- 5 No malignancy has developed after growth hormone therapy was commenced; and
- 6 The patient has not experienced significant biochemical or metabolic deterioration confirmed by diagnostic results; and
- 7 The patient has not received renal transplantation since starting growth hormone treatment; and
- 8 If the patient requires transplantation, growth hormone prescription should cease before transplantation and a new application should be made after transplantation based on the above criteria.

Initial application — (Prader-Willi syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a diagnosis of Prader-Willi syndrome that has been confirmed by genetic testing or clinical scoring criteria; and
- 2 The patient is aged six months or older; and
- 3 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
- 4 Sleep studies or overnight eximetry have been performed and there is no obstructive sleep disorder requiring treatment, or if an obstructive sleep disorder is found, it has been adequately treated under the care of a paediatric respiratory physician and/or ENT surgeon; and
- 5 Either:
 - 5.1 Both:
 - 5.1.1 The patient is aged two years or older; and
 - 5.1.2 There is no evidence of type II diabetes or uncontrolled obesity defined by BMI that has increased by greater than or equal to 0.5 standard deviations in the preceding 12 months; or
 - 5.2 The patient is aged between six months and two years and a thorough upper airway assessment is planned to be

Subsidy (Manufacture's Pric	e)	Fully Subsidised	Brand or Generic	
\$	Per	✓	Manufacturer	

continued...

undertaken prior to treatment commencement and at six to 12 weeks following treatment initiation.

Renewal — (Prader-Willi syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
- 3 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed after growth hormone therapy was commenced; and
- 6 The patient has not developed type I diabetes or uncontrolled obesity as defined by BMI that has increased by greater than or equal to 0.5 standard deviations in the preceding 12 months.

Initial application — (adults and adolescents) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a medical condition that is known to cause growth hormone deficiency (e.g. surgical removal of the pituitary for treatment of a pituitary tumour); and
- 2 The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses; and
- 3 The patient has severe growth hormone deficiency (see notes); and
- 4 The patient's serum IGF-I is more than 1 standard deviation below the mean for age and sex; and
- 5 The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDA®).

Notes: For the purposes of adults and adolescents, severe growth hormone deficiency is defined as a peak serum growth hormone level of less than or equal to 3 mcg per litre during an adequately performed insulin tolerance test (ITT) or glucagon stimulation test.

Patients with one or more additional anterior pituitary hormone deficiencies and a known structural pituitary lesion only require one test. Patients with isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak serum growth hormone level of less than or equal to 0.4 mcg per litre.

The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until the serum IGF-I is within 1 standard deviation of the mean normal value for age and sex; and

Dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.

At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement doses of corticosteroid and levothyroxine.

Renewal — (adults and adolescents) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

Any of the following:

- 1 All of the following:
 - 1.1 The patient has been treated with somatropin for < 12 months; and
 - 1.2 There has been an improvement in Quality of Life defined as a reduction of at least 8 points on the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA®) score from baseline; and
 - 1.3 Serum IGF-I levels have been increased within ±1SD of the mean of the normal range for age and sex; and
 - 1.4 The dose of somatropin has not exceeded 0.7 mg per day for male patients, or 1 mg per day for female patients; or
- 2 All of the following:
 - 2.1 The patient has been treated with somatropin for more than 12 months; and
 - 2.2 The patient has not had a deterioration in Quality of Life defined as a 6 point or greater increase from their lowest QoL-AGHDA® score on treatment (other than due to obvious external factors such as external stressors); and

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

 Subsidy (Manufacturer's Price)	Sub	Fully	Brand or Generic
 (Manulacturer's Frice) \$	Per	/siuiseu	Manufacturer

continued...

- 2.3 Serum IGF-I levels have continued to be maintained within ±1SD of the mean of the normal range for age and sex (other than for obvious external factors); and
- 2.4 The dose of somatropin has not exceeded 0.7 mg per day for male patients or 1 mg per day for female patients; or
- 3 All of the following:
 - 3.1 The patient has had a Special Authority approval for somatropin for childhood deficiency in children and no longer meets the renewal criteria under this indication; and
 - 3.2 The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses; and
 - 3.3 The patient has severe growth hormone deficiency (see notes); and
 - 3.4 The patient's serum IGF-I is more than 1 standard deviation below the mean for age and sex; and
 - 3.5 The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDA®).

Notes: For the purposes of adults and adolescents, severe growth hormone deficiency is defined as a peak serum growth hormone level of less than or equal to 3 mcg per litre during an adequately performed insulin tolerance test (ITT) or glucagon stimulation test.

Patients with one or more additional anterior pituitary hormone deficiencies and a known structural pituitary lesion only require one test. Patients with isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak serum growth hormone level of less than or equal to 0.4 mcg per litre.

The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until the serum IGF-I is within 1 standard deviation of the mean normal value for age and sex; and

Dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.

At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement doses of corticosteroid and levothyroxine.

GnRH Analogues

GOSERELIN

Implant 3.6 mg, syringe	65.68	1	🖌 Teva
Implant 10.8 mg, syringe	122.37	1	✓ Teva

LEUPRORELIN

Additional subsidy by endorsement where the patient is a child or adolescent and is unable to tolerate administration of goserelin and the prescription is endorsed accordingly.

5 I I I 5,			
Inj 3.75 mg prefilled dual chamber syringe – Higher subsidy of			
\$221.60 per 1 inj with Endorsement	66.48	1	
	(221.60)		Lucrin Depot 1-month
Inj 11.25 mg prefilled dual chamber syringe – Higher subsidy			
of \$591.68 per 1 inj with Endorsement	177.50	1	
	(591.68)		Lucrin Depot 3-month

Vasopressin Agonists DESMOPRESSIN 30 Minirin Melt DESMOPRESSIN ACETATE ✓ Minirin 30 Tab 200 mcg......54.45 30 ✓ Minirin 6 ml OP ✓ Desmopressin-PH&T ✓ Minirin 10

	Subsidy (Manufacturer's Price) \$	Sub Per	Fully sidised	Brand or Generic Manufacturer
Other Endocrine Agents				
CABERGOLINE				
Tab 0.5 mg – Maximum of 2 tab per prescription; can be				
waived by Special Authority see SA2070 below	3.75	2	🗸 D	lostinex
	15.20	8	🗸 D	lostinex
► SA2070 Special Authority for Waiver of Rule				
Initial application from any relevant practitioner. Approvals vali	d without further rene	wal unles	s notifie	d for applications meeting
the following criteria:				
Any of the following:				
1 Hyperprolactinemia; or				
2 Acromegaly*; or				
3 Inhibition of lactation.				
Renewal — (for patients who have previously been funded upractitioner. Approvals valid without further renewal unless notifivation has expired and the treatment remains appropriate and the Note: Indication marked with * is an unapproved indication.	ed where the patient	has previ	ously he	
CLOMIFENE CITRATE				
Tab 50 mg	29.84	10	✓ N	Iylan Clomiphen ^{©29}
METYRAPONE				
Cap 250 mg		50	✓ <u>N</u>	letopirone

	Subsidy (Manufacturer's Price \$) Su Per	Fully bsidised	Brand or Generic Manufacturer
Anthelmintics				
ALBENDAZOLE - Special Authority see SA1318 below - Retail	pharmacy			
Tab 400 mg		60	✓ E	skazole S29
SA1318 Special Authority for Subsidy Initial application only from an infectious disease specialist or c	linical microbiologist	. Approva	als valid f	or 6 months where the
patient has hydatids.	-			
Renewal only from an infectious disease specialist or clinical mic remains appropriate and the patient is benefitting from the treatm		als valid f	or 6 mon	ths where the treatment
MEBENDAZOLE – Only on a prescription				
Tab 100 mg		6	✓ <u>v</u>	ermox
Oral liq 100 mg per 5 ml	2.18 (7.53)	15 ml	v	'ermox
PRAZIQUANTEL	(1.00)			
Tab 600 mg		8	🗸 E	liltricide
Antibacterials				
 a) For topical antibacterials, refer to DERMATOLOGICALS, pag b) For anti-infective eye preparations, refer to SENSORY ORGA 				
	110, page 204			
Cephalosporins and Cephamycins				
CEFACLOR MONOHYDRATE Cap 250 mg	04 70	100	./ 5	anbaxy-Cefaclor
Cap 250 mg	24.70	100		anbaxy-Cefaclor S29 S29
Grans for oral liq 125 mg per 5 ml – Wastage claimable	3.53	100 ml		anbaxy-Cefaclor anbaxy-Cefaclor S29 ^{S29}
CEFALEXIN				
Cap 250 mg Cap 500 mg		20 20		ephalexin ABM Ephalexin ABM
Grans for oral liq 25 mg per ml – Wastage claimable		100 ml		efalexin Sandoz
Grans for oral liq 50 mg per ml - Wastage claimable		100 ml	✓ 0	efalexin Sandoz
CEFAZOLIN – Subsidy by endorsement Only if prescribed for dialysis or cellulitis in accordance with accordingly.	a DHB approved pro	otocol and	the pres	cription is endorsed
Inj 500 mg vial		5	✓ <u>A</u>	FT
Inj 1 g vial		5	A A	<u>IFT</u>
CEFTRIAXONE – Subsidy by endorsement				
 a) Up to 10 inj available on a PSO b) Subsidised only if prescribed for a dialysis or cystic fibros pelvic inflammatory disease, or the treatment of suspecte endorsed accordingly. 				
Inj 500 mg vial		1		eftriaxone-AFT
Inj 1 g vial		5	✓ [eftriaxone-AFT
CEFUROXIME AXETIL – Subsidy by endorsement Only if prescribed for prophylaxis of endocarditis and the pre	scription is endorse	d accordir	nalv.	
Tab 250 mg		50		innat
	Con Unonprov			

fully subsidised
 Principal Supply

90

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

	Subsidy (Manufacturer's Price) \$	Su Per	Fully ubsidised	Brand or Generic Manufacturer
Macrolides				

► SA1683 Special Authority for Waiver of Rule

Initial application — (bronchiolitis obliterans syndrome, cystic fibrosis and atypical Mycobacterium infections) only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following:

- 1 Patient has received a lung transplant, stem cell transplant, or bone marrow transplant and requires treatment for bronchiolitis obliterans syndrome*; or
- 2 Patient has received a lung transplant and requires prophylaxis for bronchiolitis obliterans syndrome*; or
- 3 Patient has cystic fibrosis and has chronic infection with Pseudomonas aeruginosa or Pseudomonas-related gram negative organisms*; or
- 4 Patient has an atypical Mycobacterium infection.

Note: Indications marked with * are unapproved indications.

Initial application — (non-cystic fibrosis bronchiectasis*) only from a respiratory specialist or paediatrician. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 For prophylaxis of exacerbations of non-cystic fibrosis bronchiectasis*; and
- 2 Patient is aged 18 and under; and
- 3 Either:
 - 3.1 Patient has had 3 or more exacerbations of their bronchiectasis, within a 12 month period; or
 - 3.2 Patient has had 3 acute admissions to hospital for treatment of infective respiratory exacerbations within a 12 month period.

Note: Indications marked with * are unapproved indications.

Renewal — (non-cystic fibrosis bronchiectasis*) only from a respiratory specialist or paediatrician. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has completed 12 months of azithromycin treatment for non-cystic fibrosis bronchiectasis; and
- 2 Following initial 12 months of treatment, the patient has not received any further azithromycin treatment for non-cystic fibrosis bronchiectasis for a further 12 months, unless considered clinically inappropriate to stop treatment; and
- 3 The patient will not receive more than a total of 24 months' azithromycin cumulative treatment (see note).

The patient must not have had more than 1 prior approval.

Note: No further renewals will be subsidised. A maximum of 24 months of azithromycin treatment for non-cystic fibrosis bronchiectasis will be subsidised. Indications marked with * are unapproved indications

CLARITHROMYCIN - Maximum of 500 mg per prescription; of	can be waived by Spe	ecial Authorit	ty see SA1857 below
Tab 250 mg	8.53	14	 Klacid
Grans for oral liq 250 mg per 5 ml - Wastage claimable		50 ml	✓ Klacid

► SA1857 Special Authority for Waiver of Rule

Initial application — (Mycobacterial infections) only from a respiratory specialist, infectious disease specialist or paediatrician. Approvals valid for 2 years for applications meeting the following criteria: Either:

Subs		ully Bran	nd or
(Manufactur	rer's Price) Subsidi	sed Gen	eric
\$	Per	 Man 	ufacturer

continued...

1 Atypical mycobacterial infection; or

2 Mycobacterium tuberculosis infection where there is drug-resistance or intolerance to standard pharmaceutical agents.

Initial application — (Helicobacter pylori eradication) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Both:

1 For the eradication of helicobacter pylori in a patient unable to swallow tablets; and

2 For use only in combination with omeprazole and amoxicillin as part of a triple therapy regimen.

Initial application — (Prophylaxis of infective endocarditis) from any relevant practitioner. Approvals valid for 3 months where prophylaxis of infective endocarditis associated with surgical or dental procedures if amoxicillin is contra-indicated. Renewal — (Mycobacterial infections) only from a respiratory specialist, infectious disease specialist or paediatrician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

ERYTHROMYCIN (AS LACTOBIONATE) Inj 1 g vial		1	 Erythrocin IV
ERYTHROMYCIN ETHYL SUCCINATE			
Tab 400 mg		100	 E-Mycin
a) Up to 20 tab available on a PSO			,
b) Up to 2 x the maximum PSO guantity for RFPP			
Grans for oral liq 200 mg per 5 ml	5.00	100 ml	 E-Mycin
a) Up to 300 ml available on a PSO			
b) Up to 2 x the maximum PSO quantity for RFPP			
c) Wastage claimable			
Grans for oral liq 400 mg per 5 ml	6.77	100 ml	 E-Mycin
a) Up to 200 ml available on a PSO			
b) Wastage claimable			
ERYTHROMYCIN STEARATE			
Tab 250 mg – Up to 30 tab available on a PSO		100	
Teh 500 mm	(22.29)	100	ERA
Tab 500 mg	29.90 (44.58)	100	ERA
(EPA Tab 250 mg to be delicted 1 April 2022)	(44.50)		LNA
(ERA Tab 250 mg to be delisted 1 April 2022) (ERA Tab 500 mg to be delisted 1 September 2022)			
· · · · · ·			
	0.00	10	✓ Rulide D
Tab disp 50 mg Restricted to children under 12 years of age.	0.29	10	
Tab 150 mg	8 28	50	 Arrow-
	0.20	00	Roxithromycin
			<u></u>
Tab 300 mg		50	✓ Arrow-
			Roxithromycin

	Subsidy (Manufacturer's Price \$	e) Subs Per	Fully idised	Brand or Generic Manufacturer
Penicillins				
AMOXICILLIN Cap 250 mg a) Up to 30 cap available on a PSO	22.50	500	✓ <u>A</u>	lphamox
 b) Up to 10 x the maximum PSO quantity for RFPP Cap 500 mg a) Up to 30 cap available on a PSO b) Up to 10 x the maximum PSO quantity for RFPP 		500	✓ <u>A</u>	<u>Iphamox</u>
Grans for oral liq 125 mg per 5 ml a) Up to 200 ml available on a PSO b) Wastage claimable	1.40	100 ml	✓ <u>A</u>	Iphamox 125
Grans for oral liq 250 mg per 5 ml a) Up to 300 ml available on a PSO b) Up to 10 x the maximum PSO quantity for RFPP c) Wastage claimable	1.73	100 ml	✓ <u>A</u>	Iphamox 250
Inj 250 mg vial		10		piamox
Inj 500 mg vial Inj 1 g vial – Up to 5 inj available on a PSO		10 10		piamox piamox
AMOXICILLIN WITH CLAVULANIC ACID Tab 500 mg with clavulanic acid 125 mg – Up to 30 tab		10		
available on a PSO		10	✓ <u>C</u>	uram Duo 500/125
Grans for oral liq amoxicillin 25 mg with clavulanic acid 6.25 per ml a) Up to 200 ml available on a PSO b) Wastage claimable		100 ml	✓ A	ugmentin
Grans for oral liq amoxicillin 50 mg with clavulanic acid 12.5 per ml – Up to 200 ml available on a PSO		00 ml OP	✓ c	Curam
BENZATHINE BENZYLPENICILLIN				
Inj 900 mg (1.2 million units) in 2.3 ml syringe – Up to 5 inj available on a PSO		10	✔ В	Bicillin LA
BENZYLPENICILLIN SODIUM [PENICILLIN G] Inj 600 mg (1 million units) vial – Up to 5 inj available on a P	SO 11.09	10	✓ <u>s</u>	andoz

	Subsidy (Manufacturer's Price		Fully Brand or osidised Generic	
	\$	Per	 Manufacturer 	
LUCLOXACILLIN				
Cap 250 mg – Up to 30 cap available on a PSO		250	 Flucloxacillin-AF1 Staphlex 	Γ
Flucloxacillin-AFT to be Principal Supply on 1 May 2022				
Cap 500 mg – Up to 30 cap available on a PSO		500	 Flucloxacillin-AFT Staphlex 	Γ
Flucloxacillin-AFT to be Principal Supply on 1 May 2022				
Grans for oral liq 25 mg per ml	3.29	100 ml	✓ <u>AFT</u>	
a) Up to 200 ml available on a PSOb) Wastage claimable				
Grans for oral liq 50 mg per ml	3.68	100 ml	✓ <u>AFT</u>	
a) Up to 200 ml available on a PSOb) Wastage claimable				
Inj 250 mg vial		10	 Flucloxin 	
Inj 500 mg vial		10	 Flucloxin 	
Inj 1 g vial – Up to 5 inj available on a PSO	5.70	5	✓ Flucil	
Staphlex Cap 250 mg to be delisted 1 May 2022) Staphlex Cap 500 mg to be delisted 1 May 2022)				
PHENOXYMETHYLPENICILLIN (PENICILLIN V)				
Cap 250 mg - Up to 30 cap available on a PSO		50	 Cilicaine VK 	
Cap 500 mg		50	 Cilicaine VK 	
a) Up to 20 cap available on a PSO				
b) Up to 2 x the maximum PSO quantity for RFPP				
Grans for oral liq 125 mg per 5 ml	2.99	100 ml	🗸 AFT	
a) Up to 200 ml available on a PSOb) Wastage claimable				
Grans for oral liq 250 mg per 5 ml	3.99	100 ml	✓ <u>AFT</u>	
 a) Up to 300 ml available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP b) We show the involve 				
c) Wastage claimable				
PROCAINE PENICILLIN				
Inj 1.5 g in 3.4 ml syringe – Up to 5 inj available on a PSO		5	 Cilicaine 	
Tetracyclines				
OXYCYCLINE				
K Tab 100 mg – Up to 30 tab available on a PSO	64.43	500	 Doxine 	
INOCYCLINE HYDROCHLORIDE				
Tab 50 mg – Additional subsidy by Special Authority see				
SA1355 below – Retail pharmacy	5.79	60		
	(12.05)		Mino-tabs	
⊱ Cap 100 mg		100		
	(52.04)		Minomycin	
SA1355 Special Authority for Manufacturers Price	. ,		•	
Special Automy for Manufacturers Price itial application from any relevant practitioner. Approvals vali osacea.	d without further ren	ewal unles	as notified where the patien	nt has
ETRACYCLINE - Special Authority see SA1332 on the next pa	age – Retail pharma	су		
Tab 250 mg		28	✓ Accord S29	
		20		

	Subsidy (Manufacturer's Price) \$	Sul Per	Fully bsidised	Brand or Generic Manufacturer
SA1332 Special Authority for Subsidy nitial application from any relevant practitioner. Approvals va toth:	lid for 3 months for app	lications	meeting	the following criteria:
 For the eradication of helicobacter pylori following unsuc For use only in combination with bismuth as part of a qu 			ate first-li	ine therapy; and
Other Antibiotics				
or topical antibiotics, refer to DERMATOLOGICALS, page 62				
CIPROFLOXACIN Recommended for patients with any of the following: i) microbiologically confirmed and clinically significant p ii) prostatitis; or iii) pyelonephritis; or	seudomonas infection;	or		
iv) gonorrhoea.				
Tab 250 mg – Up to 5 tab available on a PSO	2.42	28		ipflox
Tab 500 mg – Up to 5 tab available on a PSO Tab 750 mg		28 28		ipflox ipflox
CLINDAMYCIN				
Cap hydrochloride 150 mg Inj phosphate 150 mg per ml, 4 ml ampoule		24 10		elacin C Valacin C
OLISTIN SULPHOMETHATE - Retail pharmacy-Specialist -				
Only if prescribed for dialysis or cystic fibrosis patient and t Inj 150 mg		sed acc		olistin-Link
AENTAMICIN SULPHATE		I	• •	
Inj 10 mg per ml, 1 ml ampoule – Subsidy by endorsement		5	✓ D	BL Gentamicin
Only if prescribed for a dialysis or cystic fibrosis patien endorsed accordingly.		tract inf	ection ar	nd the prescription is
Inj 10 mg per ml, 2 ml ampoule - Subsidy by endorsement	91.00	5	🗸 M	ockhardt S29
	182.00	10		eligent S29
Only if prescribed for a dialysis or cystic fibrosis patien endorsed accordingly.	t or complicated urinary	tract inf	ection ar	nd the prescription is
Inj 40 mg per ml, 2 ml ampoule - Subsidy by endorsement		10		fizer
Only if prescribed for a dialysis or cystic fibrosis patien endorsed accordingly.	87.50 t or complicated urinary	50 tract inf	-	fizer ad the prescription is
IOXIFLOXACIN - Special Authority see SA1740 below - Reta	ail pharmacy			
No patient co-payment payable				
Tab 400 mg		5	✓ <u>A</u>	velox

Initial application — (Tuberculosis) only from a respiratory specialist or infectious disease specialist. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

1 Both:

1.1 Active tuberculosis*; and

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 1.2 Any of the following:
 - 1.2.1 Documented resistance to one or more first-line medications; or
 - 1.2.2 Suspected resistance to one or more first-line medications (tuberculosis assumed to be contracted in an area with known resistance), as part of regimen containing other second-line agents; or
 - 1.2.3 Impaired visual acuity (considered to preclude ethambutol use); or
 - 1.2.4 Significant pre-existing liver disease or hepatotoxicity from tuberculosis medications; or
 - 1.2.5 Significant documented intolerance and/or side effects following a reasonable trial of first-line medications; or
- 2 Mycobacterium avium-intracellulare complex not responding to other therapy or where such therapy is contraindicated.*; or
- 3 Patient is under five years of age and has had close contact with a confirmed multi-drug resistant tuberculosis case.
- Note: Indications marked with * are unapproved indications.

Renewal only from a respiratory specialist or infectious disease specialist. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Mycoplasma genitalium) only from a sexual health specialist or Practitioner on the recommendation of a sexual health specialist. Approvals valid for 1 month for applications meeting the following criteria: All of the following:

- 1 Has nucleic acid amplification test (NAAT) confirmed Mycoplasma genitalium* and is symptomatic; and
- 2 Either:
 - 2.1 Has tried and failed to clear infection using azithromycin; or
 - 2.2 Has laboratory confirmed azithromycin resistance; and
- 3 Treatment is only for 7 days.

Initial application — (Penetrating eye injury) only from an ophthalmologist. Approvals valid for 1 month where the patient requires prophylaxis following a penetrating eye injury and treatment is for 5 days only.

Note: Indications marked with * are unapproved indications.

PAROMOMYCIN - Special Authority see SA1689 below - Retail pharmacy

⇒SA1689 Special Authority for Subsidy

Initial application only from an infectious disease specialist, clinical microbiologist or gastroenterologist. Approvals valid for 1 month for applications meeting the following criteria:

Either:

1 Patient has confirmed cryptosporidium infection; or

2 For the eradication of Entamoeba histolyica carriage.

Renewal only from an infectious disease specialist, clinical microbiologist or gastroenterologist. Approvals valid for 1 month for applications meeting the following criteria:

Either:

- 1 Patient has confirmed cryptosporidium infection; or
- 2 For the eradication of Entamoeba histolyica carriage.

PYRIMETHAMINE - Special Authority see SA1328 below - Retail pharmacy

➡SA1328 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 For the treatment of toxoplasmosis in patients with HIV for a period of 3 months; or
- 2 For pregnant patients for the term of the pregnancy; or
- 3 For infants with congenital toxoplasmosis until 12 months of age.

SODIUM FUSIDATE [FUSIDIC ACID]

Tab 250 mg67.85 36

Fucidin

fully subsidised
 Principal Supply

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

	Subsidy (Manufacturer's Price \$) Per	Fully Subsidised	Generic
SULFADIAZINE SODIUM – Special Authority see SA1331 below	– Retail pharmacy			
Tab 500 mg	543.20	56	~	Wockhardt S29
SA1331 Special Authority for Subsidy				
Initial application from any relevant practitioner. Approvals valid	I without further ren	ewal u	inless notif	ied for applications meeting
the following criteria:				
Any of the following:				
 For the treatment of toxoplasmosis in patients with HIV for For pregnant patients for the term of the pregnancy; or 	a period of 3 month	ns; or		
3 For infants with congenital toxoplasmosis until 12 months	ofage			
	er ager			
Inj 40 mg per ml, 2 ml vial – Subsidy by endorsement	18 50	5	1	Tobramycin Mylan
Only if prescribed for dialysis or cystic fibrosis patient and		-		
Solution for inhalation 60 mg per ml, 5 ml – Subsidy by				<u>9</u> -)
endorsement		56 do	se 🗸	Tobramycin BNM
a) Wastage claimable				
b) Only if prescribed for a cystic fibrosis patient and the 	prescription is endo	rsed a	accordingly	
TRIMETHOPRIM				
 Tab 300 mg – Up to 30 tab available on a PSO 		50	✓	TMP
TRIMETHOPRIM WITH SULPHAMETHOXAZOLE [CO-TRIMOX/	AZOLE]			
* Tab trimethoprim 80 mg and sulphamethoxazole 400 mg - U				
to 30 tab available on a PSO		500	~	Trisul
* Oral liq 8 mg sulphamethoxazole 40 mg per ml – Up to 200 r				- ·
available on a PSO	2.97	100 n	ni 🗸	Deprim
VANCOMYCIN – Subsidy by endorsement	www.hudeude.ef.e.ed			ater ant of Olasteidium
Only if prescribed for a dialysis or cystic fibrosis patient or for difficile following metronidazole failure and the prescription is			is of for the	eatment of Clostridium
Inj 500 mg vial		уу. 1	1	Mylan
	2.00			<u></u>
Antifungals				
a) For topical antifungals refer to DERMATOLOGICALS, page 63	3			
b) For topical antifungals refer to GENITO URINARY, page 76				
FLUCONAZOLE	0.75	00		Mulan
Cap 50 mg Cap 150 mg		28 1		<u>Mylan</u> Mylan
Cap 200 mg		28		Mylan
Powder for oral suspension 10 mg per ml – Special Authority				<u>,</u>
see SA1359 below – Retail pharmacy		35 m	l 🗸	Diflucan
Wastage claimable				
SA1359 Special Authority for Subsidy				

Initial application — (Systemic candidiasis) from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:

Both:

- 1 Patient requires prophylaxis for, or treatment of systemic candidiasis; and
- 2 Patient is unable to swallow capsules.

Initial application - (Immunocompromised) from any relevant practitioner. Approvals valid for 6 months for applications

	Subsidy (Manufacturer's F \$	Price) Sub Per	Fully Brand or osidised Generic Manufacturer
continued meeting the following criteria: All of the following:			
 Patient is immunocompromised; and Patient is at moderate to high risk of invasive fungal infec Patient is unable to swallow capsules. 	tion; and		
Renewal — (Systemic candidiasis) from any relevant practitio ollowing criteria: Both:	ner. Approvals v	valid for 6 wee	ks for applications meeting the
 Patient requires prophylaxis for, or treatment of systemic Patient is unable to swallow capsules. 	candidiasis; and		
Renewal — (Immunocompromised) from any relevant practitio following criteria: All of the following:	oner. Approvals	valid for 6 mo	nths for applications meeting th
 Patient remains immunocompromised; and Patient remains at moderate to high risk of invasive funga Patient is unable to swallow capsules. 	al infection; and		
TRACONAZOLE			
Cap 100 mg		15	✓ <u>Itrazole</u>
Oral liq 10 mg per ml – Special Authority see SA1322 below Retail pharmacy		150 ml OP	✓ Sporanox
SA1322 Special Authority for Subsidy Initial application only from an infectious disease specialist, clin practitioner on the recommendation of a infectious disease physi valid for 6 months where the patient has a congenital immune de Renewal from any relevant practitioner. Approvals valid for 6 mo benefitting from the treatment.	ician, clinical mic eficiency.	robiologist or o	clinical immunologist. Approva
KETOCONAZOLE Tab 200 mg – PCT	CRS	30	Link Healthcare S29
Tab 200 Hig - FCT		30	 Nizoral S29
		100	✓ Strides Shasun S29
NYSTATIN		100	
	14 16	50	
Tab 500,000 u	(17.09)		Nilstat
-	(17.09)	50	Nilstat
Tab 500,000 u	(17.09) 12.81 (15.47)	50	
Tab 500,000 u Cap 500,000 u POSACONAZOLE – Special Authority see SA1285 below – Ret Tab modified-release 100 mg	(17.09) 12.81 (15.47) ail pharmacy 869.86	24	Nilstat ✔ Noxafil
Tab 500,000 u Cap 500,000 u POSACONAZOLE – Special Authority see SA1285 below – Ret Tab modified-release 100 mg Oral liq 40 mg per ml	(17.09) 12.81 (15.47) ail pharmacy 869.86		Nilstat
Tab 500,000 u Cap 500,000 u POSACONAZOLE – Special Authority see SA1285 below – Ret Tab modified-release 100 mg	(17.09) 12.81 (15.47) ail pharmacy 	24 105 ml OP	Nilstat ✓ Noxafil ✓ Noxafil

- 1 Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation chemotherapy; or
- 2 Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppressive

continued...

(Mar	Subsidy nufacturer's Price)	Subsid	-ully ised	Brand or Generic
·	\$	Per	1	Manufacturer

continued...

therapy*.

Renewal only from a haematologist or infectious disease specialist. Approvals valid for 6 weeks for applications meeting the following criteria:

Either:

- 1 Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation therapy; or
- 2 Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppression* and requires on going posaconazole treatment.

Note: * Graft versus host disease (GVHD) on significant immunosuppression is defined as acute GVHD, grade II to IV, or extensive chronic GVHD, or if they were being treated with intensive immunosuppressive therapy consisting of either high-dose corticosteroids (1 mg or greater per kilogram of body weight per day for patients with acute GVHD or 0.8 mg or greater per kilogram every other day for patients with chronic GVHD), antithymocyte globulin, or a combination of two or more immunosuppressive agents or types of treatment.

TERBINAFINE

* Tab 250 mg	8.15	84	 Deolate
VORICONAZOLE - Special Authority see SA1273 below - Retail	l pharmacy		
Tab 50 mg		56	 Vttack
Tab 200 mg		56	 Vttack
Powder for oral suspension 40 mg per ml – Wastage			
claimable	1,437.00	70 ml	 Vfend

➡SA1273 Special Authority for Subsidy

Initial application — (invasive fungal infection) only from a haematologist, infectious disease specialist or clinical microbiologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient is immunocompromised; and
- 2 Applicant is part of a multidisciplinary team including an infectious disease specialist; and
- 3 Any of the following:
 - 3.1 Patient has proven or probable invasive aspergillus infection; or
 - 3.2 Patient has possible invasive aspergillus infection; or
 - 3.3 Patient has fluconazole resistant candidiasis; or
 - 3.4 Patient has mould strain such as Fusarium spp. and Scedosporium spp.

Renewal — (invasive fungal infection) only from a haematologist, infectious disease specialist or clinical microbiologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient is immunocompromised; and
- 2 Applicant is part of a multidisciplinary team including an infectious disease specialist; and
- 3 Any of the following:
 - 3.1 Patient continues to require treatment for proven or probable invasive aspergillus infection; or
 - 3.2 Patient continues to require treatment for possible invasive aspergillus infection; or
 - 3.3 Patient has fluconazole resistant candidiasis; or
 - 3.4 Patient has mould strain such as Fusarium spp. and Scedosporium spp.

Antimalarials

PRIMAQUINE – Special Authority see SA1684 on the next page – Retail pharmacy Tab 15 mg400.00

Sanofi
 Primaguine S29

Subsidy		Fully	Brand or
(Manufacturer's Price		Subsidised	Generic
\$	Per		Manufacturer

⇒SA1684 Special Authority for Subsidy

Initial application only from an infectious disease specialist or clinical microbiologist. Approvals valid for 1 month for applications meeting the following criteria:

Both:

- 1 The patient has vivax or ovale malaria; and
- 2 Primaquine is to be given for a maximum of 21 days.

Renewal only from an infectious disease specialist or clinical microbiologist. Approvals valid for 1 month for applications meeting the following criteria:

Both:

- 1 The patient has relapsed vivax or ovale malaria; and
- 2 Primaquine is to be given for a maximum of 21 days.

Antitrichomonal Agents		
METRONIDAZOLE Tab 200 mg – Up to 30 tab available on a PSO	250 21 100 ml 10	✓ <u>Metrogyl</u> ✓ <u>Metrogyl</u> ✓ Flagyl-S ✓ Flagyl
ORNIDAZOLE Tab 500 mg	10	✓ <u>Arrow-Ornidazole</u>
Antituberculotics and Antileprotics		
Note: There is no co-payment charge for all pharmaceuticals listed in the Antitub immigration status.	erculotics and	Antileprotics group regardless of
CLOFAZIMINE – Betail pharmacy-Specialist		

CLOFAZIMINE – Retail pharmacy-Specialist

- a) No patient co-payment payable
- b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or dermatologist.

a) No patient co-payment payable

b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or dermatologist

Tab 25 mg	.268.50	100	 Dapsone
Tab 100 mg	.329.50	100	 Dapsone

ETHAMBUTOL HYDROCHLORIDE - Retail pharmacy-Specialist

a) No patient co-payment payable

Tab 100 mg	85.73	100	 EMB Fatol \$29
Tab 400 mg	49.34	56	 Myambutol S29

	Cubaidu		E.ully	Drand ar
	Subsidy (Manufacturer's Price)		Fully Subsidised	Brand or Generic
	\$	Per	1	Manufacturer
ISONIAZID – Retail pharmacy-Specialist				
a) No patient co-payment payable				
b) Prescriptions must be written by, or on the recommendati microbiologist, dermatologist or public health physician	on of, an internal me	dicine	physician	, paediatrician, clinical
* Tab 100 mg		100	1	PSM
ISONIAZID WITH RIFAMPICIN – Retail pharmacy-Specialist				
 a) No patient co-payment payable b) Prescriptions must be written by, or on the recommendati microbiologist, dermatologist or public health physician 				
* Tab 100 mg with rifampicin 150 mg		100		Rifinah Bifinah
* Tab 150 mg with rifampicin 300 mg	179.13	100	•	Rifinah
PARA-AMINO SALICYLIC ACID – Retail pharmacy-Specialist				
 a) No patient co-payment payable b) Prescriptions must be written by, or on the recommendati respiratory physician 				
Grans for oral liq 4 g sachet		30	<i>•</i>	Paser S29
PROTIONAMIDE – Retail pharmacy-Specialist				
 a) No patient co-payment payable b) Prescriptions must be written by, or on the recommendati respiratory physician 				-
Tab 250 mg		100	~	Peteha S29
PYRAZINAMIDE – Retail pharmacy-Specialist				
 a) No patient co-payment payable b) Prescriptions must be written by, or on the recommendati respiratory physician 	on of, an infectious d	isease	e physiciai	n, clinical microbiologist or
* Tab 500 mg		100	✓	AFT-Pyrazinamide
RIFABUTIN – Retail pharmacy-Specialist				
 a) No patient co-payment payable b) Prescriptions must be written by, or on the recommendati gastroenterologist 				
* Cap 150 mg		30	~	Mycobutin
RIFAMPICIN – Subsidy by endorsement				
 a) No patient co-payment payable b) For confirmed recurrent Staphylococcus aureus infection antimicrobial based on susceptibilities and the prescriptio Retail pharmacy - Specialist. Specialist must be an interr paediatrician, or public health physician. 	n is endorsed accord nal medicine physicia	ingly; n, clini	can be wa ical microl	vived by endorsement - biologist, dermatologist,
* Cap 150 mg		100		<u>Rifadin</u>
* Cap 300 mg * Oral lig 100 mg per 5 ml		100 60 ml		<u>Rifadin</u> Rifadin
	12.00	00 111	·	niiduili
Antivirals				
For eye preparations refer to Eye Preparations, Anti-Infective Pre	parations, page 234			
Hepatitis B Treatment				
ENTECAVIR				
* Tab 0.5 mg		30	1	Entecavir Sandoz

Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

itioner on the reco ion of hepatitis B. rs where used for atment of HIV is ir page 105	the treatme	✓ Z n of a re ent or pre	Manufacturer Letiam Leffix levant specialist. evention of hepatitis B s of up to 4 subsidised
	240 ml OP ommendation	✓ Z n of a re ent or pre	levant specialist. evention of hepatitis B
270.00 itioner on the reco ion of hepatitis B. rs where used for atment of HIV is ir page 105	240 ml OP ommendation	✓ Z n of a re ent or pre	levant specialist. evention of hepatitis B
itioner on the reco ion of hepatitis B. rs where used for atment of HIV is ir page 105	ommendation the treatme	n of a re nt or pre	levant specialist. evention of hepatitis B
ion of hepatitis B. rs where used for atment of HIV is ir page 105	the treatme	ent or pre	evention of hepatitis B
ion of hepatitis B. rs where used for atment of HIV is ir page 105	the treatme	ent or pre	evention of hepatitis B
ion of hepatitis B. rs where used for atment of HIV is ir page 105	the treatme	ent or pre	evention of hepatitis B
atment of HIV is ir page 105			
page 105	ncluded in th	ne count	of up to 4 subsidised
page 105	ncluded in th	ne count	of up to 4 subsidised
	30	🗸 Т	enofovir Disoproxil
			Teva
1.60	25	🗸 L	.ovir
	56	✓ L	.ovir
5.98	35	✓ L	.ovir
6.50	30	🗸 V	/aclovir
	30	🗸 V	/aclovir
		_	
	60	🗸 V	alganciclovir
		-	Mylan

⇒SA1993 Special Authority for Subsidy

Initial application — (transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 3 months where the patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis.

Renewal — (transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valganciclovir therapy for CMV prophylaxis; and
- 1.2 Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin; or
- 2 Both:
 - 2.1 Patient has received pulse methylprednisolone for acute rejection and requires further valganciclovir therapy for CMV prophylaxis; and
 - 2.2 Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following pulse methylprednisolone.

Initial application — (cytomegalovirus prophylaxis following anti-thymocyte globulin) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both:

- 1 Patient has undergone a solid organ transplant and received valganciclovir under Special Authority more than 2 years ago (27 months); and
- 2 Patient has received anti-thymocyte globulin and requires valganciclovir for CMV prophylaxis.

Renewal — (cytomegalovirus prophylaxis following anti-thymocyte globulin) only from a relevant specialist. Approvals valid for 3 months where the patient has received a further course of anti-thymocyte globulin and requires valganciclovir for CMV prophylaxis.

Subsidy	ę	Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	1	Manufacturer

continued...

Initial application — (Lung transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

1 Patient has undergone a lung transplant; and

2 Either:

- 2.1 The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or
- 2.2 The recipient is cytomegalovirus positive; and

3 Patient has a high risk of CMV disease.

Initial application — (Cytomegalovirus in immunocompromised patients) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient is immunocompromised; and
- 2 Any of the following:
 - 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
 - 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
 - 2.3 Patient has cytomegalovirus retinitis.

Renewal — (Cytomegalovirus in immunocompromised patients) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient is immunocompromised; and
- 2 Any of the following:
 - 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
 - 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
 - 2.3 Patient has cytomegalovirus retinitis.

Note: for the purpose of this Special Authority "immunocompromised" includes transplant recipients, patients with immunosuppressive diseases (e.g. HIV) or those receiving immunosuppressive treatment for other conditions.

Hepatitis C Treatment

GLECAPREVIR WITH PIBRENTASVIR – [Xpharm] Note the supply of treatment is via Pharmac's approved direct website https://pharmac.govt.nz/maviret	t distribution supp	ly. Further de	tails can be found on Pharmac's
Tab 100 mg with pibrentasvir 40 mg	24,750.00	84 OP	 Maviret
LEDIPASVIR WITH SOFOSBUVIR – [Xpharm] – Special Authori No patient co-payment payable Tab 90 mg with sofosbuvir 400 mg		low 28	🖌 Harvoni
■SA1605 Special Authority for Subsidy Special Authority approved by the Hepatitis C Treatment Panel (H Notes: By application to the Hepatitis C Treatment Panel (HepCT Applications will be considered by HepCTP and approved subject Application details may be obtained from Pharmac's website <u>http:</u> The Coordinator, Hepatitis C Treatment Panel Pharmac, PO Box 10-254, WELLINGTON Tel: (04) 460 4990, Email: <u>hepcpanel@pharmac.govt.nz</u>	HepCTP) TP). to confirmation of	eligibility.	

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	✓	Manufacturer

30

✓ Teva

HIV Prophylaxis and Treatment

EMTRICITABINE WITH TENOFOVIR DISOPROXIL - Subsidy by endorsement: can be waived by Special Authority see SA1994

below Endorsement for treatment of HIV: Prescription is deemed to be endorsed if emtricitabine with tenofovir disoproxil is co-prescribed with another antiretroviral subsidised under Special Authority SA1651 and the prescription is annotated accordingly by the Pharmacist or endorsed by the prescriber.

Note: Emtricitabine with tenofovir disoproxil prescribed under endorsement for the treatment of HIV is included in the count of up to 4 subsidised antiretrovirals, and counts as two antiretroviral medications, for the purposes of Special Authority SA1651, page 105 There is an approval process to become a named specialist to prescribe antiretroviral therapy in New Zealand. Further information is available on the Pharmac website.

Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a

SA1994 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following:

- 1 Applicant has an up to date knowledge of the safety issues and is competent to prescribe pre-exposure prophylaxis (refer to local health pathways or https://ashm.org.au/HIV/PrEP/ for training materials); and
- 2 Patient has undergone testing for HIV, syphilis and Hep B if not immune and a full STI screen in the previous two weeks; and
- 3 Patient has had renal function testing (creatinine, phosphate and urine protein/creatinine ratio) within the last 3 months and is not contraindicated for treatment: and
- 4 Patient has received advice regarding the reduction of risk of HIV and sexually transmitted infections and how to reduce those risks: and
- 5 Patient has tested HIV negative and is not at risk of HIV seroconversion; and
- 6 Fither:
 - 6.1 All of the following:
 - 6.1.1 Patient is male or transgender; and
 - 6.1.2 Patient has sex with men: and
 - 6.1.3 Patient is likely to have multiple episodes of condomless anal intercourse in the next 3 months; and
 - 6.1.4 Any of the following:
 - 6.1.4.1 Patient has had at least one episode of condomless receptive anal intercourse with one or more casual male partners in the last 3 months; or
 - 6.1.4.2 A diagnosis of rectal chlamydia, rectal gonorrhoea, or infectious syphilis within the last 3 months; or
 - 6.1.4.3 Patient has used methamphetamine in the last three months; or
 - 6.2 All of the following:

fully subsidised

Principal Supply

- 6.2.1 Patient has a regular partner who has HIV infection; and
- 6.2.2 Partner is either not on treatment or has a detectable viral load; and
- 6.2.3 Condoms have not been consistently used.

Renewal from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following:

- 1 Applicant has an up to date knowledge of the safety issues and is competent to prescribe pre-exposure prophylaxis (refer to local health pathways or https://ashm.org.au/HIV/PrEP/ for training materials); and
- 2 Patient has undergone testing for HIV, syphilis and Hep B if not immune and a full STI screen in the previous two weeks; and
- 3 Patient has had renal function testing (creatinine, phosphate and urine protein/creatinine ratio) within the last 12 months and is not contraindicated for treatment: and
- 4 Patient has received advice regarding the reduction of risk of HIV and sexually transmitted infections and how to reduce

S	Subsidy	Fully	Brand or
(Manufa	acturer's Price) Subsid	lised	Generic
	\$ Per	1	Manufacturer

continued...

those risks; and

- 5 Patient has tested HIV negative and is not at risk of HIV seroconversion; and
- 6 Either:
 - 6.1 All of the following:
 - 6.1.1 Patient is male or transgender; and
 - 6.1.2 Patient has sex with men; and
 - 6.1.3 Patient is likely to have multiple episodes of condomless anal intercourse in the next 3 months; and
 - 6.1.4 Any of the following:
 - 6.1.4.1 Patient has had at least one episode of condomless receptive anal intercourse with one or more casual male partners in the last 3 months; or
 - 6.1.4.2 A diagnosis of rectal chlamydia, rectal gonorrhoea, or infectious syphilis within the last 3 months; or
 - 6.1.4.3 Patient has used methamphetamine in the last three months; or
 - 6.2 All of the following:
 - 6.2.1 Patient has a regular partner who has HIV infection; and
 - 6.2.2 Partner is either not on treatment or has a detectable viral load; and
 - 6.2.3 Condoms have not been consistently used.

Antiretrovirals

⇒SA1651 Special Authority for Subsidy

Initial application — (Confirmed HIV) only from a named specialist. Approvals valid without further renewal unless notified where the patient has confirmed HIV infection.

Notes: Tenofovir disoproxil prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals. Subsidies apply for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (Confirmed HIV) only from a named specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Prevention of maternal transmission) only from a named specialist. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

Notes: Tenofovir disoproxil prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals. Subsidies apply for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Some antiretrovirals are unapproved or contraindicated for this indication. Practitioners prescribing these medications should exercise their own skill, judgement, expertise and discretion, and make their own prescribing decisions with respect to the use of a Pharmaceutical for an indication for which it is not approved or contraindicated.

Initial application — (post-exposure prophylaxis following non-occupational exposure to HIV) only from a named specialist. Approvals valid for 4 weeks for applications meeting the following criteria: Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
- 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Notes: Tenofovir disoproxil prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals. Subsidies apply for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (second or subsequent post-exposure prophylaxis) only from a named specialist. Approvals valid for 4 weeks for applications meeting the following criteria:

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Initial application — (Percutaneous exposure) only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive.

Notes: Tenofovir disoproxil prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals. Subsidies apply for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (Second or subsequent percutaneous exposure) only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive.

Non-nucleosides Reverse Transcriptase Inhibitors

EFAVIRENZ - Special Authority see SA1651 on the previo	ous page – Retail pharr	nacy	
Tab 200 mg		90	 Stocrin
Tab 600 mg	63.38	30	 Stocrin
ETRAVIRINE - Special Authority see SA1651 on the prev	ious page – Retail phar	macy	
Tab 200 mg	770.00	60	 Intelence
NEVIRAPINE - Special Authority see SA1651 on the prev	ious page – Retail phar	macy	
Tab 200 mg		60	 Nevirapine
			<u>Alphapharm</u>
Oral suspension 10 mg per ml	203.55	240 ml	 Viramune
			Suspension

Nucleosides Reverse Transcriptase Inhibitors

ABACAVIR SULPHATE – Special Authority see SA1651 on the previous page – Retail pharmacy					
Tab 300 mg		60	 Ziagen 		
Oral liq 20 mg per ml	256.31	240 ml OP	 Ziagen 		
ABACAVIR SULPHATE WITH LAMIVUDINE – Special Authorit Note: abacavir with lamivudine (combination tablets) counts anti-retroviral Special Authority.	s as two anti-retro		ns for the purposes of the		
Tab 600 mg with lamivudine 300 mg	63.00	30	 Kivexa 		

	Cubaint		Eully	Brand or	
	Subsidy (Manufacturer's		Fully	Generic	
	(Manulacturers	Price) Subsi Per	uiseu V	Manufacturer	
EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPROXIL – Special Authority see SA1651 on page 105 – Retail					
pharmacy Note: Efavirenz with emtricitabine and tenofovir disoproxil c	ounte as throa	anti-retroviral me	dication	as for the nurnoses of the	
anti-retroviral Special Authority			lication		
	vil				
Tab 600 mg with emtricitabine 200 mg and tenofovir disopro 245 mg (300 mg as a maleate)		30	. N	lylan	
3 (3)			• <u>IV</u>	iyiali	
EMTRICITABINE - Special Authority see SA1651 on page 105					
Cap 200 mg		30	✓ <u>E</u>	mtriva	
LAMIVUDINE - Special Authority see SA1651 on page 105 - Re	etail pharmacy				
Tab 150 mg		60	✓ <u>L</u>	amivudine	
				Alphapharm	
Oral liq 10 mg per ml	102.50	240 ml OP	🗸 3	TC	
ZIDOVUDINE [AZT] - Special Authority see SA1651 on page 10	05 – Retail pha	rmacv			
Cap 100 mg		100	✓ R	etrovir	
Oral lig 10 mg per ml		200 ml OP	🗸 R	etrovir	
ZIDOVUDINE [AZT] WITH LAMIVUDINE - Special Authority see		ago 105 - Rotail r	harma		
Note: zidovudine [AZT] with lamivudine (combination tablets		•		•	
the anti-retroviral Special Authority.	b) courses tw		euicali	ons for the purposes of	
Tab 300 mg with lamivudine 150 mg	33.00	60	ν Δ	lphapharm	
		00	• ~		
Protease Inhibitors					
ATAZANAVIR SULPHATE - Special Authority see SA1651 on p	age 105 – Ret	ail pharmacy			
Cap 150 mg	•	60	✓ T	eva	
Cap 200 mg		60	✓ T	eva	
DARUNAVIR - Special Authority see SA1651 on page 105 - Re	tail pharmacy				
Tab 400 mg		60	✓ D	arunavir Mylan	
Tab 600 mg		60		arunavir Mylan	
LOPINAVIR WITH RITONAVIR – Special Authority see SA1651			=	<u></u>	
, , ,		- netali pharmacy			
Tab 100 mg with ritonavir 25 mg – Brand switch fee payable		<u> </u>		a nin a sin (Dita na sin	
(Pharmacode 2621959) - see page 239 for details		60	ΨL	opinavir/Ritonavir	
Tob 000 ma with ritenavir E0 ma Brand awiteb fee neveble				<u>Mylan</u>	
Tab 200 mg with ritonavir 50 mg – Brand switch fee payable		120		oningvir/Ditengvir	
(Pharmacode 2621959) - see page 239 for details		120	• •	opinavir/Ritonavir Mylan	
Oral lig 80 mg with ritanguir 90 mg nor ml	705.00	200 ml OD		aletra	
Oral liq 80 mg with ritonavir 20 mg per ml		300 ml OP	♥ K	aletta	
RITONAVIR – Special Authority see SA1651 on page 105 – Ret					
Tab 100 mg	43.31	30	✓ <u>N</u>	orvir	
Strand Transfer Inhibitors					
DOLUTEGRAVIR - Special Authority see SA1651 on page 105	 Retail pharm 	acy			
Tab 50 mg	1,090.00	30	🗸 Т	ivicay	
RALTEGRAVIR POTASSIUM - Special Authority see SA1651 c		Retail pharmacy		-	
Tab 400 mg	1 0	60	🖌 İs	entress	
Tab 600 mg	,	60		entress HD	
·					

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy		Fully	Brand or
(Manufacturer's Price)	5	Subsidised	Generic
`\$	Per	1	Manufacturer

Immune Modulators

Guidelines for the use of interferon in the treatment of hepatitis C:

Physicians considering treatment of patients with hepatitis C should discuss cases with a gastroenterologist or an infectious disease physician. All subjects undergoing treatment require careful monitoring for side effects. Patients should be otherwise fit.

Hepatocellular carcinoma should be excluded by ultrasound examination and alpha-fetoprotein level.

Criteria for Treatment

- 1) Diagnosis
 - Anti-HCV positive on at least two occasions with a positive PCR for HCV-RNA and preferably confirmed by a supplementary RIBA test; or
 - · PCR-RNA positive for HCV on at least 2 occasions if antibody negative; or
 - Anti-HCV positive on at least two occasions with a positive supplementary RIBA test with a negative PCR for HCV RNA but with a liver biopsy consistent with 2(b) following.

Exclusion Criteria

- 1) Autoimmune liver disease. (Interferon may exacerbate autoimmune liver disease as well as other autoimmune diseases such as thyroid disease).
- 2) Pregnancy.
- 3) Neutropenia (< 2.0×10^9) and/or thrombocytopenia.
- 4) Continuing alcohol abuse and/or continuing intravenous drug users.

Dosage

The current recommended dosage is 3 million units of interferon alfa-2a or interferon alfa-2b administered subcutaneously 3 times a week for 52 weeks (twelve months)

Exit Criteria

The patient's response to interferon treatment should be reviewed at either three or four months. Interferon treatment should be discontinued in patients who do not show a substantial reduction (50%) in their mean pre-treatment ALT level at this stage.

PEGYLATED INTERFERON ALFA-2A - Special Authority see SA2034 below - Retail pharmacy

- a) See prescribing guideline above
- b) Note: Pharmac will consider funding ribavirin for the small group of patients who have a clinical need for ribavirin and meet Special Authority criteria. Please contact the Hepatitis C Coordinator at Pharmac on 0800-023-588 option 4.
 b) 190 mag partilled primes

⇒SA2034 Special Authority for Subsidy

Initial application — (chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver transplant) from any specialist. Approvals valid for 18 months for applications meeting the following criteria: Both:

- 1 Any of the following:
 - 1.1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or
 - 1.2 Patient has chronic hepatitis C and is co-infected with HIV; or
 - 1.3 Patient has chronic hepatitis C genotype 2 or 3 and has received a liver transplant; and
- 2 Maximum of 48 weeks therapy.

Notes:

- Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.
- Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less than 50IU/ml) AND Baseline serum HCV RNA is less than 400,000IU/ml

Renewal — (Chronic hepatitis C - genotype 1 infection) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

INFECTIONS - AGENTS FOR SYSTEMIC USE

(M	Subsidy Ianufacturer's Price)	Subsi	Fully dised	Brand or Generic
	\$	Per	1	Manufacturer

continued...

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has had previous treatment with pegylated interferon and ribavirin; and
- 3 Either:

3.1 Patient has responder relapsed; or

- 3.2 Patient was a partial responder; and
- 4 Patient is to be treated in combination with boceprevir; and
- 5 Maximum of 48 weeks therapy.

Initial application - (Chronic Hepatitis C - genotype 1 infection treatment more than 4 years prior) only from a

gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has had previous treatment with pegylated interferon and ribavirin; and
- 3 Any of the following:
 - 3.1 Patient has responder relapsed; or
 - 3.2 Patient was a partial responder; or
 - 3.3 Patient received interferon treatment prior to 2004; and
- 4 Patient is to be treated in combination with boceprevir; and
- 5 Maximum of 48 weeks therapy.

Initial application — (chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV) from any specialist. Approvals valid for 12 months for applications meeting the following criteria: Both:

- 1 Patient has chronic hepatitis C, genotype 2 or 3 infection; and
- 2 Maximum of 6 months therapy.

Initial application — (Hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 2 Patient is Hepatitis B treatment-naive; and
- 3 ALT > 2 times Upper Limit of Normal; and
- 4 HBV DNA < 10 log10 IU/ml; and
- 5 Either:
 - 5.1 HBeAg positive; or
 - 5.2 serum HBV DNA greater than or equal to 2,000 units/ml and significant fibrosis (Metavir Stage F2 or greater or moderate fibrosis); and
- 6 Compensated liver disease; and
- 7 No continuing alcohol abuse or intravenous drug use; and
- 8 Not co-infected with HCV, HIV or HDV; and
- 9 Neither ALT nor AST > 10 times upper limit of normal; and
- 10 No history of hypersensitivity or contraindications to pegylated interferon; and
- 11 Maximum of 48 weeks therapy.

Initial application — (myeloproliferative disorder or cutaneous T cell lymphoma) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Any of the following:

- 1 Patient has a cutaneous T cell lymphoma*; or
- 2 All of the following:

AThree months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

INFECTIONS - AGENTS FOR SYSTEMIC USE

Subsidy		Fully	Brand or
(Manufacturer's Price)	Su	ubsidised	Generic
\$	Per	1	Manufacturer

continued...

- 2.1 Patient has a myeloproliferative disorder*; and
- 2.2 Patient is intolerant of hydroxyurea; and
- 2.3 Treatment with anagrelide and busulfan is not clinically appropriate; or
- 3 Both:
 - 3.1 Patient has a myeloproliferative disorder; and
 - 3.2 Patient is pregnant, planning pregnancy or lactating.

Renewal — (myeloproliferative disorder or cutaneous T cell lymphoma) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and patient is benefitting from treatment; and
- 3 Either:
 - 3.1 Patient has a cutaneous T cell lymphoma*; or
 - 3.2 Both:
 - 3.2.1 Patient has a myeloproliferative disorder*; and
 - 3.2.2 Either:
 - 3.2.2.1 Remains intolerant of hydroxyurea and treatment with anagrelide and busulfan remains clinically inappropriate; or
 - 3.2.2.2 Patient is pregnant, planning pregnancy or lactating.

Notes: Indications marked with * are unapproved indications.

- Approved dose is 180 mcg once weekly.
- The recommended dose of Pegylated Interferon alfa-2a is 180 mcg once weekly.
- In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Pegylated Interferon-alfa 2a dose should be reduced to 135 mcg once weekly.
- In patients with neutropaenia and thrombocytopaenia, dose should be reduced in accordance with the datasheet guidelines.
- Pegylated Interferon-alfa 2a is not approved for use in children.

Initial application — (post-allogenic bone marrow transplant) from any relevant practitioner. Approvals valid for 3 months where patient has received an allogeneic bone marrow transplant* and has evidence of disease relapse.

Renewal — (post-allogenic bone marrow transplant) from any relevant practitioner. Approvals valid for 3 months where patient is responding and ongoing treatment remains appropriate.

Note: Indications marked with * are unapproved indications.

Urinary Tract Infections

METHENAMINE (HEXAMINE) HIPPURATE		
* Tab 1 g	100	 Hiprex
NITROFURANTOIN		
* Tab 50 mg - Up to 30 tab available on a PSO	100	 Nifuran
* Tab 100 mg	100	 Nifuran
* Cap modified-release 100 mg - Wastage claimable		✓ Macrobid
NORFLOXACIN		
Tab 400 mg – Subsidy by endorsement135.00	100	 Arrow-Norfloxad

(Manufacturer's Price) Subaidisad Generic Anticholinesterases NEOSTIGMINE METILSULFATE Inj 2.5 mg per mi, 1 mi ampoule 19.60 10 ✓ Max Health Max Health to be Principal Supply on 1 March 2022 98.00 50 ✓ AstraZeneca (AttaZeneca Inj 2.5 mg per mi, 1 mi ampoule to be delisted 1 March 2022) (AstraZeneca Inj 2.5 mg per mi, 1 mi ampoule to be delisted 1 March 2022) PYRIDOSTIGMINE BROMDE 45.79 100 ✓ Mestimon Non-Steroidal Anti-Infianmatory Drugs 20 ✓ Voltaren D DICLOFENAC SODUUM 150 20 ✓ Voltaren D * Tab 50 mg depersible 150 20 ✓ Voltaren Sandoz * Tab biong-acting 75 mg 198 50 ✓ Diciofenae Sandoz * Tab biong-acting 75 mg 198 50 ✓ Voltaren D * Tab biong-acting 75 mg 20.41 0 ✓ Voltaren Sandoz * Tab biong-acting 100 mg 22.80 500 ✓ Apo-Dicio SR * Tab biong-acting 75 mg 20.41 0 ✓ Voltaren * Suppos 125 mg 24.41 10 ✓ Voltaren		Subsidy		Fully Brand or
Anticholinesterases NEOSTIGMINE METILSULFATE 19.60 10 ✓ Juno I hard and Sast 19.25 mg per ml, 1 ml anpoule Max Health to be Principal Supply on 1 March 2020 98.00 50 ✓ Max Health KastaZeneca Inj 2.5 mg per ml, 1 ml anpoule to be delisted 1 March 2022) (AstraZeneca inj 2.5 mg per ml, 1 ml anpoule to be delisted 1 March 2022) VRIDOSTIGMINE BROMIDE ▲ Tab 60 mg .45.79 100 ✓ Mestinon Non-Steroidal Anti-Inflammatory Drugs .150 20 ✓ Voltaren 9 DICLOFENAC SODIUM .199 50 ✓ Diclofenac Sandoz * Tab EC 50 mg .199 50 ✓ Voltaren 9R * Tab EC 50 mg .198 500 ✓ Apo-Diclo SR * Tab EC 50 mg .22.80 .500 ✓ Apo-Diclo SR * Tab EC 50 mg .24 10 ✓ Voltaren 9R * Suppos 125 mg .24 10 ✓ Voltaren 9R * Suppos 25 mg .24 10 ✓ Voltaren 18R * Suppos 100 mg .010 .22.10 ✓ Voltaren 10 * Suppos 100 mg .010 .22.20 10.00				
NECSTIGMINE METILSULFATE 19,25 mg per ml, 1 ml ampoule		\$	Per	 Manufacturer
NECSTIGMINE METILSULFATE 19,25 mg per ml, 1 ml ampoule				
Inj 2.5 mg per ml, 1 ml ampoule	Anticholinesterases			
Inj 2.5 mg per ml, 1 ml ampoule	NEOSTIGMINE METILSULEATE			
33.81 ✓ Max Health 98.00 50 ✓ AstraZeneca 98.00 50 ✓ Mestineca 98.00 50 ✓ Mestineca AstraZeneca Inj 2.5 mg per ml, 1 ml ampoule to be delisted 1 March 2022) PYRIDOSTICMINE BROMIDE A Tab 50 mg .45.79 100 ✓ Mestinon Non-Steroidal Anti-Inflammatory Drugs .150 20 ✓ Voltaren D DicLOFENAC SODIUM .199 50 ✓ Diclofenac Sandoz ✓ Voltaren D * Tab 50 mg .190 50 ✓ Voltaren D ✓ Voltaren SR * Tab long-acting 100 mg .22.61 500 ✓ Apo-Diclo SR * Tab long-acting 100 mg .204 10 ✓ Voltaren * Suppos 50 mg - Up to 10 supp available on a PSO .422 10 ✓ Voltaren * Suppos 50 mg - Up to 10 sup available on a PSO .422 10 ✓ Voltaren *		10.60	10	
98.00 50 ✓ AstraZeneca Max Health to be Principal Supply on 1 March 2022 (Juno IIII) 2.5 mg per ml, 1 ml ampoule to be delisted 1 March 2022) (AstraZeneca III) 2.5 mg per ml, 1 ml ampoule to be delisted 1 March 2022) PYRIDOSTIGMINE BROMIDE Tab 60 mg 45.79 100 ✓ Mestinon Non-Steroidal Anti-Infilammatory Drugs Diclofenac Sandoz ✓ Voltaren D Variance So DolluM 1.99 50 ✓ Diclofenac Sandoz * Tab EC 25 mg 1.99 50 ✓ Voltaren D * Tab EC 50 mg 1.99 50 ✓ Diclofenac Sandoz * Tab EC 50 mg 1.99 50 ✓ Diclofenac Sandoz * Tab EC 50 mg			10	
Max Health to be Principal Supply on 1 March 2022 (Juno ﷺ Inj 2.5 mg per ml, 1 ml ampoule to be delisted 1 March 2022) PYRIDOSTIGMINE BROMIDE ▲ Tab 60 mg .45.79 100 ✓ Mestinon Non-Steroidal Anti-Inflammatory Drugs DICLOFENAC SODIUM .199 * Tab 50 mg .150 20 CLOFENAC SODIUM .199 * Tab 50 mg .150 * Tab 50 mg .960 * Tab 10 ng-acting 75 mg .198 50 ✓ Diclofenac Sandoz * Tab 10 ng-acting 100 mg .22.80 50 ✓ Apo-Diclo SR * Tab 10 ng-acting 100 mg .22.41 10 Z spep rml, 3 ml ampoule – Up to 5 inj available on a PSO .42.21 * Suppos 12.5 mg .244 10 Z spep rml, 3 ml ampoule – Up to 5 inj available on a PSO .42.21 * Suppos 100 mg .700 10 ✓ Voltaren * Suppos 50 mg .04 to 10 supp available on a PSO .244 10 ✓ Voltaren * Suppos 100 mg .700 10 ✓ Voltaren Yoltaren * Suppos 50 SR Tab long-acting 75 mg to be delisted 1 May 2022) 1000 ✓ Relieve <t< td=""><td></td><td></td><td>50</td><td></td></t<>			50	
(Juno ﷺ Inj 2.5 mg per ml, 1 ml ampoule to be delisted 1 March 2022) (AstraZeneca Inj 2.5 mg per ml, 1 ml ampoule to be delisted 1 March 2022) PYRIDOSTIGMINE BROMIDE	Max Health to be Principal Supply on 1 March 2022	30.00	50	• Astrazeneca
(AstraZeneca inj 2.5 mg per ml, 1 ml ampoule to be delisted 1 March 2022) PYRIDOSTIGMINE BROMIDE ▲ Tab 60 mg		h 2022)		
PYRIDOSTIGMINE BROMIDE 45.79 100 ✓ Mestinon Non-Steroidal Anti-Inflammatory Drugs DICLOFENAC SODIUM 1.99 50 ✓ Diclofenac Sandoz * Tab 50 mg dispersible 1.50 20 ✓ Voltaren D * Tab 50 mg dispersible 1.50 20 ✓ Voltaren D * Tab 10 ng-acting 75 mg 19.60 100 ✓ Voltaren SR 22.80 500 ✓ Apo-Diclo SR * * Suppos 25 mg 2.24 10 ✓ Voltaren * Suppos 125 mg 2.04 10 ✓ Voltaren * Suppos 125 mg 2.04 10 ✓ Voltaren * Suppos 100 mg - To to supp available on a PSO 4.22 10 ✓ Voltaren * Suppos 100 mg - Qto to 10 supp available on a PSO 4.22 10 ✓ Voltaren * Suppos 100 mg - Qto to 10 supp available on a PSO 3.05 30 > Entlere * Tab bong-acting 75 mg to be delisted 1 May 2022) (Apo-Diclo SR Tab long-acting 100 mg to be delisted 1 May 2022) IBUPROFEN * Tab bong-acting 200 mg 12.07 28 > Drulen SR * Oral lag 200 mg per ml 2.01 2.0		,		
▲ Tab 60 mg		10112022)		
Non-Steroidal Anti-Inflammatory Drugs DICLOFEINAC SODIUM * Tab EC 25 mg 1.99 50 ✓ Diclofenac Sandoz * Tab EC 50 mg 1.99 50 ✓ Voltaren D * Tab EC 50 mg 1.99 50 ✓ Voltaren D * Tab EC 50 mg 1.99 50 ✓ Diclofenac Sandoz * Tab Long-acting 75 mg 1.90 10 ✓ Voltaren SR * Tab long-acting 100 mg 22.80 500 ✓ Apo-Diclo SR * Inj 25 mg per ml, 3 ml ampoule – Up to 5 inj available on a PSO 13.20 5 ✓ Voltaren * Suppos 12.5 mg 2.04 10 ✓ Voltaren * * Suppos 50 mg – Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren * Suppos 100 mg 2.44 10 ✓ Voltaren * * Suppos 100 mg – acting 75 mg to be delisted 1 May 2022) (Apo-Diclo SR Tab long-acting 100 mg to be delisted 1 May 2022) (Apo-Diclo SR Tab long-acting 100 mg to be delisted 1 May 2022) IBUPROFEN * Ethics * Ethics * Tab long-acting 200 mg 1.000 ✓ Ethics * Ethics * Ethics Ethors to		45 70	100	Maatinan
DICLOFENAC SODIUM ** Tab EC 25 mg 1.99 50 ✓ Diclofenac Sandoz ** Tab 50 mg dispersible 1.50 20 ✓ Voltaren D ** Tab C 50 mg 1.99 50 ✓ Diclofenac Sandoz ** Tab long-acting 75 mg 19.60 100 ✓ Voltaren SR ** Tab long-acting 75 mg 28.00 ✓ Apo-Diclo SR ** Tab long-acting 75 mg 20.41 ✓ Voltaren ** Suppos 12.5 mg 20.41 ✓ Voltaren ** Suppos 50 mg Up to 10 supp available on a PSO 4.22 .42.44 10 ✓ Voltaren ** Suppos 50 mg Up to 10 supp available on a PSO 4.22 .42.10 ✓ Voltaren ** Suppos 100 mg .7.00 10 ✓ Voltaren ** Suppos 100 mg .06 delisted 1 May 2022) (Apo-Diclo SR Tab long-acting 75 mg to be delisted 1 May 2022) (Apo-Diclo SR Tab long-acting 75 mg to be delisted 1 May 2022) Ethics Ethics BUPPOFEN * Tab long-acting 800 mg 3.05 30 ✓ Brufen SR ** Caal long-acting 200 mg 1 April 2022 KETOPROFEN ✓ Oruvail SR Ethics Ethics <	▲ 1 ab 60 mg		100	✓ <u>Mestinon</u>
DICLOFENAC SODIUM ** Tab EC 25 mg 1.99 50 ✓ Diclofenac Sandoz ** Tab 50 mg dispersible 1.50 20 ✓ Voltaren D ** Tab C 50 mg 1.99 50 ✓ Diclofenac Sandoz ** Tab long-acting 75 mg 19.60 100 ✓ Voltaren SR ** Tab long-acting 75 mg 28.00 ✓ Apo-Diclo SR ** Tab long-acting 75 mg 20.41 ✓ Voltaren ** Suppos 12.5 mg 20.41 ✓ Voltaren ** Suppos 50 mg Up to 10 supp available on a PSO 4.22 .42.44 10 ✓ Voltaren ** Suppos 50 mg Up to 10 supp available on a PSO 4.22 .42.10 ✓ Voltaren ** Suppos 100 mg .7.00 10 ✓ Voltaren ** Suppos 100 mg .06 delisted 1 May 2022) (Apo-Diclo SR Tab long-acting 75 mg to be delisted 1 May 2022) (Apo-Diclo SR Tab long-acting 75 mg to be delisted 1 May 2022) Ethics Ethics BUPPOFEN * Tab long-acting 800 mg 3.05 30 ✓ Brufen SR ** Caal long-acting 200 mg 1 April 2022 KETOPROFEN ✓ Oruvail SR Ethics Ethics <	Non-Storoidal Anti-Inflammatory Druge			
** Tab EC 25 mg 1.99 50 ✓ Diclofenac Sandoz ** Tab 50 mg dispersible 1.50 20 ✓ Voltaren D ** Tab EC 50 mg 1.99 50 ✓ Voltaren D ** Tab long-acting 75 mg 1.90 50 ✓ Voltaren SR 22.80 500 ✓ Apo-Diclo SR ** Tab long-acting 100 mg 22.515 500 ✓ Apo-Diclo SR ** Suppos 12.5 mg 2.04 10 ✓ Voltaren ** Suppos 50 mg - Up to 10 supp available on a PSO 1.20 5 ✓ Voltaren ** Suppos 50 mg - Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren ** Suppos 50 mg - Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren ** Suppos 100 mg 7.00 10 ✓ Voltaren Voltaren ** Suppos 100 mg 2.04 1,000 ✓ Voltaren Voltaren ** Tab long-acting 75 mg to be delisted 1 May 2022) (Apo-Diclo SR Tab long-acting 100 mg to be delisted 1 May 2022) Elburce Zo0 ml ✓ Ethics IBUPROFEN ** Tab 200 mg 1.00 ✓ Relieve ✓ Oruvail SR ✓ Ethics KETOPROFEN ** Cap long-acting 200 mg	Non-Steroidar Anti-Innanimatory Drugs			
** Tab EC 25 mg 1.99 50 ✓ Diclofenac Sandoz ** Tab 50 mg dispersible 1.50 20 ✓ Voltaren D ** Tab EC 50 mg 1.99 50 ✓ Voltaren D ** Tab long-acting 75 mg 1.90 50 ✓ Voltaren SR 22.80 500 ✓ Apo-Diclo SR ** Tab long-acting 100 mg 22.515 500 ✓ Apo-Diclo SR ** Suppos 12.5 mg 2.04 10 ✓ Voltaren ** Suppos 50 mg - Up to 10 supp available on a PSO 1.20 5 ✓ Voltaren ** Suppos 50 mg - Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren ** Suppos 50 mg - Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren ** Suppos 100 mg 7.00 10 ✓ Voltaren Voltaren ** Suppos 100 mg 2.04 1,000 ✓ Voltaren Voltaren ** Tab long-acting 75 mg to be delisted 1 May 2022) (Apo-Diclo SR Tab long-acting 100 mg to be delisted 1 May 2022) Elburce Zo0 ml ✓ Ethics IBUPROFEN ** Tab 200 mg 1.00 ✓ Relieve ✓ Oruvail SR ✓ Ethics KETOPROFEN ** Cap long-acting 200 mg	DICLOFENAC SODIUM			
** Tab 50 mg dispersible 1.50 20 ✓ Voltaren D ** Tab EC 50 mg 19.9 50 ✓ Diclofenac Sandoz ** Tab long-acting 75 mg 19.60 100 ✓ Voltaren SR ** Tab long-acting 100 mg 22.80 500 ✓ Apo-Dicio SR ** Tab long-acting 100 mg 22.80 500 ✓ Apo-Dicio SR ** Inj 25 mg per ml, 31 ml ampoule – Up to 5 inj available on a PSO 13.20 5 ✓ Voltaren ** Suppos 12.5 mg 2.04 10 ✓ Voltaren × ** Suppos 50 mg -Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren ** Suppos 50 mg -Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren ** Suppos 50 mg -Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren ** Suppos 50 mg -Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren ** Suppos 50 mg -Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren ** Suppos 10.5 R Tab long-acting 100 mg to be delisted 1 May 2022) IBUPROFEN * Ethics Ethics ** Tab 200 mg 10.01 Apo-Dicio SR		1.99	50	 Diclofenac Sandoz
** Tab EC 50 mg. .199 50 ✓ Diclofenac Sandoz ** Tab long-acting 75 mg. .19.60 100 ✓ Voltaren SR 22.80 500 ✓ Apo-Diclo SR ** Tab long-acting 100 mg. .25.15 500 ✓ Apo-Diclo SR ** Suppos 25 mg .2.04 10 ✓ Voltaren ** Suppos 50 mg -Up to 10 supp available on a PSO .4.22 10 ✓ Voltaren ** Suppos 50 mg -Up to 10 supp available on a PSO .4.22 10 ✓ Voltaren ** Suppos 100 mg. .0.1 May 2022) IBUPROFEN * Voltaren * Voltaren ** Tab long-acting 800 mg. .21.40 1,000 * Relieve * Ethics ** Tab 200 mg. .21.40 1,000 * Ethics * Ethics Ethics to be Principal Supply on 1 April 2022 KETOPROFEN * Oral Iig 200 mg. * Oral 12.07 28 * Oruvail SR </td <td></td> <td></td> <td>20</td> <td></td>			20	
22.80 500 ✓ Apo-Diclo SR ** Tab long-acting 100 mg. 25.15 500 ✓ Apo-Diclo SR ** Inj 25 mg per ml, 3 ml ampoule – Up to 5 inj available on a PSO13.20 5 ✓ Voltaren ** Suppos 12.5 mg. 2.04 10 ✓ Voltaren ** Suppos 25 mg. 2.04 10 ✓ Voltaren ** Suppos 50 mg. -Up to 10 supp available on a PSO4.22 10 ✓ Voltaren ** Suppos 50 mg. -Up to 10 supp available on a PSO4.22 10 ✓ Voltaren ** Suppos 100 mg. -Up to 10 supp available on a PSO4.22 10 ✓ Voltaren (Apo-Diclo SR Tab long-acting 75 mg to be delisted 1 May 2022) (Apo-Diclo SR Tab long-acting 100 mg to be delisted 1 May 2022) IBUPROFEN ** Tab 200 mg. 21.40 1,000 ✓ Relieve ** Tab 200 mg. 2.140 1,000 ✓ Butien SR 200 ml ✓ Ethics Ethics to be Principal Supply on 1 April 2022 200 ml ✓ Ethics 200 ml ✓ Ethics KETOPROFEN * Cap long-acting 200 mg. 12.07 28 ✓ Oruvail SR MEFENAMIC ACID * 28.71 250 Ponstan 0.50			50	 Diclofenac Sandoz
** Tab long-acting 100 mg	* Tab long-acting 75 mg	19.60	100	 Voltaren SR
** Inj 25 mg per ml, 3 ml ampoule – Up to 5 inj available on a PSO13.20 5 ✓ Voltaren ** Suppos 25 mg			500	 Apo-Diclo SR
** Suppos 12.5 mg 2.04 10 ✓ Voltaren ** Suppos 25 mg 2.44 10 ✓ Voltaren ** Suppos 50 mg -Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren ** Suppos 100 mg -Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren ** Suppos 100 mg -Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren ** Suppos 100 mg -Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren ** Suppos 100 mg -Tito ong-acting 75 mg to be delisted 1 May 2022) 10 ✓ Voltaren (Apo-Diclo SR Tab long-acting 100 mg to be delisted 1 May 2022) IBUPROFEN * Tab long-acting 800 mg 21.40 1,000 ✓ Relieve ** Tab long-acting 800 mg .2.25 200 ml ✓ Ethics Ethics Ethics to principal Supply on 1 April 2022 KETOPROFEN * Cap long-acting 200 mg 12.07 28 ✓ Oruvail SR MEFENAMIC ACID	* Tab long-acting 100 mg	25.15	500	 Apo-Diclo SR
** Suppos 25 mg 2.44 10 ✓ Voltaren ** Suppos 50 mg - Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren ** Suppos 100 mg - Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren ** Suppos 100 mg - Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren ** Suppos 25 Tab long-acting 75 mg to be delisted 1 May 2022) 10 ✓ Voltaren ✓ Voltaren (Apo-Diclo SR Tab long-acting 100 mg to be delisted 1 May 2022) IBUPROFEN * * Tab long-acting 800 mg 21.40 1,000 ✓ Relieve ** Tab long-acting 800 mg .21.40 1,000 ✓ Relieve * Ethics Ethics to be Principal Supply on 1 April 2022 KETOPROFEN * Cap long-acting 200 mg 12.07 28 ✓ Oruvail SR MEFENAMIC ACID * (9.16) Ponstan 0.50 20 (5.60) Ponstan 0.50 20 (5.60) Ponstan 0.50 20 * Nofiam 500 * Naprosyn SR 750 * Naprosyn SR 750 * Naprosyn SR 750	* Inj 25 mg per ml, 3 ml ampoule – Up to 5 inj available on a P	SO 13.20	5	 Voltaren
** Suppos 50 mg - Up to 10 supp available on a PSO			10	 Voltaren
** Suppos 100 mg 7.00 10 ✓ Voltaren (Apo-Diclo SR Tab long-acting 75 mg to be delisted 1 May 2022) (Apo-Diclo SR Tab long-acting 100 mg to be delisted 1 May 2022) IBUPROFEN ** Tab 200 mg 21.40 1,000 ✓ Relieve ** Tab 200 mg .21.40 1,000 ✓ Relieve ** Tab 200 mg .21.40 1,000 ✓ Relieve ** Tab long-acting 800 mg .21.40 1,000 ✓ Relieve ** Tab long-acting 800 mg .21.40 1,000 ✓ Relieve ** Tab long-acting 200 mg .2.25 200 ml ✓ Ethics KETOPROFEN * Cap long-acting 200 mg .12.07 28 ✓ Oruvail SR MEFENAMIC ACID * Cap 250 mg .125 50 0.50 20 ** Tab 250 mg .28.71 .250 ✓ Noflam 250 ✓ Noflam 500 ** Tab 100 mg-acting 1 g .8.62 28 ✓ Noflam 500 ✓ Noflam 500 ** Tab long-acting 1 g .8.62 28 ✓ Naprosyn SR 750 ✓ Maprosyn SR 750 * Tab				
(Apo-Diclo SR Tab long-acting 75 mg to be delisted 1 May 2022) (Apo-Diclo SR Tab long-acting 100 mg to be delisted 1 May 2022) IBUPROFEN * Tab 200 mg				
(<i>Apo-Diclo SR Tab long-acting 100 mg to be delisted 1 May 2022</i>) IBUPROFEN * Tab 200 mg		7.00	10	Voltaren
IBUPROFEN * Tab 200 mg 21.40 1,000 ✓ Relieve * Tab long-acting 800 mg 3.05 30 ✓ Brufen SR * Oral liq 20 mg per ml 2.25 200 ml ✓ Ethics Ethics to be Principal Supply on 1 April 2022 200 ml ✓ Ethics KETOPROFEN * Cap long-acting 200 mg 12.07 28 ✓ Oruvail SR MEFENAMIC ACID 1.25 50 900 ml Ponstan 0.50 20 0 050 20 (5.60) Ponstan 0.50 20 * Tab 500 mg 28.71 250 ✓ Moflam 500 * Tab long-acting 750 mg 8.62 <td< td=""><td></td><td></td><td></td><td></td></td<>				
* Tab 200 mg 21.40 1,000 ✓ Relieve * Tab long-acting 800 mg 3.05 30 ✓ Brufen SR * Oral liq 20 mg per ml 2.25 200 ml ✓ Ethics Ethics to be Principal Supply on 1 April 2022 200 ml ✓ Ethics KETOPROFEN * Cap long-acting 200 mg 12.07 28 ✓ Oruvail SR MEFENAMIC ACID * 1.25 50 900 ml Ponstan 0.50 20 (5.60) Ponstan 0.50 20 NAPROXEN * Tab 250 mg 28.71 250 ✓ Noflam 250 * Tab 500 mg 28.71 250 ✓ Noflam 500 × Naprosyn SR 750 * Tab long-acting 750 mg 6.47 28 ✓ Naprosyn SR 750 × Naprosyn SR 750 * Tab long-acting 1 g 8.62 28 ✓ Maprosyn SR 1000 SULINDAC * Yaprosyn SR 1000 * Tab 100 mg 9.57 56 ✓ Mylan sa Yaprosyn SR 1000 SULINDAC * Tab 20 mg 9.15 100 ✓ Tilcotil	(Apo-Diclo SR Tab long-acting 100 mg to be delisted 1 May 2022)		
** Tab long-acting 800 mg				
* Oral liq 20 mg per ml 2.25 200 ml ✓ Ethics Ethics to be Principal Supply on 1 April 2022 XETOPROFEN ✓ Oruvail SR * Cap long-acting 200 mg 12.07 28 ✓ Oruvail SR MEFENAMIC ACID 1.25 50 900 ml ✓ Denstan 0.50 20 10.50 20 900 ml ✓ Noflam 250 NAPROXEN 1.25 500 ✓ Noflam 250 ✓ Noflam 500 * Tab 250 mg 28.71 250 ✓ Noflam 500 * Tab long-acting 750 mg 6.47 28 ✓ Naprosyn SR 750 * Tab long-acting 1 g 8.62 28 ✓ Naprosyn SR 750 SULINDAC 9.57 56 ✓ Mylan 520 * Tab 20 mg 9.15 100 ✓ Tilcotil			1,000	Relieve
Ethics to be Principal Supply on 1 April 2022 KETOPROFEN * Cap long-acting 200 mg 12.07 28 ✓ Oruvail SR MEFENAMIC ACID 1.25 50 900 * Cap 250 mg (9.16) Ponstan 0.50 20 20 900 (5.60) Ponstan 900 NAPROXEN 28.71 250 ✓ Noflam 250 * Tab 250 mg 28.71 250 ✓ Noflam 500 * Tab long-acting 750 mg 6.47 28 ✓ Naprosyn SR 750 * Tab long-acting 1 g 8.62 28 ✓ Naprosyn SR 750 SULINDAC 9.57 56 ✓ Mylan 520 * Tab 100 mg 9.57 56 ✓ Mylan 520 * Tab 20 mg 9.15 100 ✓ Tilcotil				
KETOPROFEN ** Cap long-acting 200 mg MEFENAMIC ACID ** Cap 250 mg (9.16) 0.50 (9.16) 0.50 (5.60) Ponstan 0.50 ** Tab 250 mg ** Tab 500 mg ** Tab 500 mg ** Tab 500 mg ** Tab long-acting 750 mg 6.47 28 * Tab long-acting 1 g 8.62 28 * Tab long-acting 1 g 8.62 ** Tab 100 mg 9.57 56 * Mylan \$20 ** Tab 20 mg ** Tab		2.25	200 m	Ethics
* Cap long-acting 200 mg 12.07 28 ✓ Oruvail SR MEFENAMIC ACID 1.25 50 * Cap 250 mg 1.25 50 (9.16) Ponstan 0.50 20 (5.60) Ponstan NAPROXEN 32.69 500 ✓ Noflam 250 * Tab 250 mg 28.71 250 ✓ Noflam 500 * Tab long-acting 750 mg 6.47 28 ✓ Naprosyn SR 750 * Tab long-acting 1 g 8.62 28 ✓ Naprosyn SR 1000 SULINDAC * * Tab 100 mg 9.57 56 ✓ Mylan \$29 * Tab 20 mg 9.15 100 ✓ Tilcotil 100 ✓ Tilcotil	Ethics to be Principal Supply on 1 April 2022			
MEFENAMIC ACID * Cap 250 mg. 1.25 50 (9.16) Ponstan 0.50 20 (5.60) Ponstan NAPROXEN * Tab 250 mg. 28.71 250 * Tab 500 mg. 28.71 250 * * Tab long-acting 750 mg. 6.47 28 * Naprosyn SR 750 * Tab long-acting 1 g. 8.62 28 * Naprosyn SR 750 SULINDAC * Tab 100 mg. 9.57 56 * Mylan \$29 TENOXICAM * Tab 20 mg. 9.15 100 * Tilcotil	KETOPROFEN			
* Cap 250 mg	* Cap long-acting 200 mg	12.07	28	 Oruvail SR
(9.16) Ponstan 0.50 20 (5.60) Ponstan NAPROXEN * * Tab 250 mg	MEFENAMIC ACID			
(9.16) Ponstan 0.50 20 (5.60) Ponstan NAPROXEN * * Tab 250 mg	* Cap 250 mg	1.25	50	
(5.60) Ponstan NAPROXEN * Tab 250 mg 32.69 500 ✓ Noflam 250 * Tab 500 mg 28.71 250 ✓ Noflam 500 * Tab long-acting 750 mg 6.47 28 ✓ Naprosyn SR 750 * Tab long-acting 1 g 8.62 28 ✓ Naprosyn SR 1000 SULINDAC * 750 56 ✓ Mylan \$29 TENOXICAM * 7100 ✓ Tilcotil		(Ponstan
NAPROXEN ** Tab 250 mg 32.69 500 ✓ Noflam 250 ** Tab 500 mg 28.71 250 ✓ Noflam 500 ** Tab long-acting 750 mg 6.47 28 ✓ Naprosyn SR 750 ** Tab long-acting 1 g 8.62 28 ✓ Naprosyn SR 1000 SULINDAC 9.57 56 ✓ Mylan \$29 ** Tab 100 mg 9.15 100 ✓ Tilcotil		0.50	20	
* Tab 250 mg 32.69 500 ✓ Noflam 250 * Tab 500 mg 28.71 250 ✓ Noflam 500 * Tab long-acting 750 mg 6.47 28 ✓ Naprosyn SR 750 * Tab long-acting 1 g 8.62 28 ✓ Naprosyn SR 1000 SULINDAC * 7ab 100 mg 9.57 56 ✓ Mylan \$29 * Tab 20 mg 9.15 100 ✓ Tilcotil		(5.60)		Ponstan
* Tab 250 mg 32.69 500 ✓ Noflam 250 * Tab 500 mg 28.71 250 ✓ Noflam 500 * Tab long-acting 750 mg 6.47 28 ✓ Naprosyn SR 750 * Tab long-acting 1 g 8.62 28 ✓ Naprosyn SR 1000 SULINDAC * 7ab 100 mg 9.57 56 ✓ Mylan \$29 * Tab 20 mg 9.15 100 ✓ Tilcotil	NAPROXEN			
* Tab 500 mg 28.71 250 ✓ Noflam 500 * Tab long-acting 750 mg 6.47 28 ✓ Naprosyn SR 750 * Tab long-acting 1 g 8.62 28 ✓ Naprosyn SR 1000 SULINDAC 9.57 56 ✓ Mylan \$29 * Tab 100 mg 9.15 100 ✓ Tilcotil			500	 Noflam 250
* Tab long-acting 750 mg		~~ ~ /		1
* Tab long-acting 1 g				
* Tab 100 mg	* Tab long-acting 1 g	8.62	28	Naprosyn SR 1000
* Tab 100 mg	SULINDAC			
TENOXICAM * Tab 20 mg		9.57	56	V Mylan S29
* Tab 20 mg	0		00	- mynan -
•		0.15	100	- Tilootil
m 111 ∠ 111y viai	•			
	か 111j とv 111y viai		I	

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy		Full	
	(Manufacturer's Price \$) Per	Subsidise	d Generic Manufacturer
	•			manadotaron
NSAIDs Other				
ELECOXIB				_
Cap 100 mg		60		Celecoxib Pfizer
Cap 200 mg	2.30 3.30	30		Celebrex
	5.50		•	Celecoxib Filzer
Topical Products for Joint and Muscular Pain				
APSAICIN				
Crm 0.025% - Special Authority see SA1289 below - Retail				
pharmacy	9.75	45 g Ol	⊳ √	Zostrix
SA1289 Special Authority for Subsidy				
nitial application from any relevant practitioner. Approvals valid				
steoarthritis that is not responsive to paracetamol and oral non-	steroidal anti-inflamr	natorie	s are cor	traindicated.
Antirheumatoid Agents				
YDROXYCHLOROQUINE – Subsidy by endorsement				
Subsidised only if prescribed for rheumatoid arthritis, system		,	,	
suppression, relevant dermatological conditions (cutaneous f	•			
mucosal ulceration)*, sarcoidosis (pulmonary and non-pulmo				
Pharmacists may annotate the prescription as endorsed whe			orior disp	ensing of
hydroxychloroquine. Note: Indication marked with a * is an				Diamanil
★ Tab 200 mg	8.78	100	v	Plaquenil
EFLUNOMIDE Tab 10 mg	6.00	20		´ Arava
Tab 10 mg Tab 20 mg		30 30		Arava Arava
8	0.00	50	•	Alava
'ENICILLAMINE Tab 125 mg	67 23	100	1	D-Penamine
Tab 250 mg		100		D-Penamine
· ~				2
Drugs Affecting Bone Metabolism				
Alendronate for Osteoporosis				
•				
ALENDRONATE SODIUM	0.44	4		Facamay
₭ Tab 70 mg	2.44	4	•	<u>Fosamax</u>
ALENDRONATE SODIUM WITH COLECALCIFEROL	4 54			
* Tab 70 mg with colecalciferol 5,600 iu	1.51	4	•	Fosamax Plus
Other Treatments				
ENOSUMAB – Special Authority see SA1777 below – Retail ph				
Inj 60 mg prefilled syringe		1	✓	Prolia
SA1777 Special Authority for Subsidy				
nitial application from any relevant practitioner. Approvals valid	d without further ren	ewal ur	nless noti	fied for applications meet
he following criteria:				

the following criteria:

Subsidy		Fully	Brand or	
(Manufacturer's Price)	e) Subsidi		Generic	
\$	Per	1	Manufacturer	

continued...

All of the following:

- 1 The patient has severe, established osteoporosis; and
- 2 Either:
 - 2.1 The patient is female and postmenopausal; or
 - 2.2 The patient is male or non-binary; and
- 3 Any of the following:
 - 3.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note); or
 - 3.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons; or
 - 3.3 History of two significant osteoporotic fractures demonstrated radiologically; or
 - 3.4 Documented T-Score less than or equal to -3.0 (see Note); or
 - 3.5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
 - 3.6 Patient has had a Special Authority approval for alendronate (Underlying cause Osteoporosis) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and
- 4 Zoledronic acid is contraindicated because the patient's creatinine clearance is less than 35 mL/min; and
- 5 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes); and
- 6 The patient must not receive concomitant treatment with any other funded antiresorptive agent for this condition or teriparatide.

Notes:

- a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable
- b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for treatment with denosumab
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less
- d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body
- e) Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: risedronate sodium tab 35 mg once weekly; alendronate sodium tab 70 mg or tab 70 mg with cholecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy

PAMIDRONATE DISODIUM

Inj 3 mg per ml, 10 ml vial	27.53	1	Pamisol
Inj 6 mg per ml, 10 ml vial	74.67	1	Pamisol
Inj 9 mg per ml, 10 ml vial		1	 Pamisol
RALOXIFENE HYDROCHLORIDE - Special Authority see SA177	9 on the next page	– Retail	pharmacy
* Tab 60 mg	53.76	28	 Evista

*Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price)	Ful Subsidise		
\$	Per •	 Manufacturer 	

⇒SA1779 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Notes); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score less than or equal to -3.0 (see Notes); or
- 5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Notes); or
- 6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause Osteoporosis) or has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) prior to 1 February 2019.

Notes:

- BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for raloxifene funding.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

RISEDRONATE SODIUM

Tab 35 mg3.	10 4	4	 Risedronate Sandoz
TERIPARATIDE - Special Authority see SA1139 below - Retail pharmacy			
Inj 250 mcg per ml, 2.4 ml	00	1	 Forteo

SA1139 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 18 months for applications meeting the following criteria: All of the following:

- 1 The patient has severe, established osteoporosis; and
- 2 The patient has a documented T-score less than or equal to -3.0 (see Notes); and
- 3 The patient has had two or more fractures due to minimal trauma; and
- 4 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes).

Notes:

- a) The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable
- b) Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: alendronate sodium tab 70 mg or tab 70 mg with colecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily;

continued...

zoledronic acid 5 mg per year. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy.

- c) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.
- d) A maximum of 18 months of treatment (18 cartridges) will be subsidised.

ZOLEDRONIC ACID

100 ml OP 🖌 🖌 Aclasta

⇒SA1780 Special Authority for Subsidy

Initial application — (Paget's disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Paget's disease; and
- 2 Any of the following:
 - 2.1 Bone or articular pain; or
 - 2.2 Bone deformity; or
 - 2.3 Bone, articular or neurological complications; or
 - 2.4 Asymptomatic disease, but risk of complications; or
 - 2.5 Preparation for orthopaedic surgery; and
- 3 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Initial application — (Underlying cause - Osteoporosis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note); or
 - 1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
 - 1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
 - 1.4 Documented T-Score less than or equal to -3.0 (see Note); or
 - 1.5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
 - 1.6 Patient has had a Special Authority approval for alendronate (Underlying cause Osteoporosis) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and
- 2 The patient will not be prescribed more than 5 mg of zoledronic acid in a 12-month period.

Initial application — (Underlying cause - glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The patient is receiving systemic glucocorticosteroid therapy (greater than or equal to 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
- 2 Any of the following:
 - 2.1 The patient has documented BMD greater than or equal to 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -1.5) (see Note); or

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Su	ubsidised	Generic	
\$	Per	✓	Manufacturer	

- 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
- 2.3 The patient has had a Special Authority approval for alendronate (Underlying cause glucocorticosteroid therapy) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and
- 3 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Renewal — (Paget's disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 The patient has relapsed (based on increases in serum alkaline phosphatase); or
 - 1.2 The patient's serum alkaline phosphatase has not normalised following previous treatment with zoledronic acid; or
 - 1.3 Symptomatic disease (prescriber determined); and
- 2 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

The patient must not have had more than 1 prior approval in the last 12 months.

Renewal — (Underlying cause was, and remains, glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The patient is continuing systemic glucocorticosteriod therapy (greater than or equal to 5 mg per day prednisone equivalents); and
- 2 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.
- The patient must not have had more than 1 prior approval in the last 12 months.

Renewal — (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause - osteoporosis' criteria) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both:

- 1 Any of the following:
 - 1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note); or
 - 1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
 - 1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
 - 1.4 Documented T-Score less than or equal to -3.0 (see Note); or
 - 1.5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
 - 1.6 The patient has had a Special Authority approval for alendronate (Underlying was glucocorticosteroid therapy but patient now meets the 'Underlying cause Osteoporosis' criteria) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and
- 2 The patient will not be prescribed more than 5 mg of zoledronic acid in a 12-month period.

Notes:

- a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below

Subsidy		Fully	Brand or
(Manufacturer's Price)	Subsi	dised	Generic
 \$	Per	1	Manufacturer

continued...

-2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.

d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Hyperuricaemia and Antigout

ALLOPURINOL

* Tab 100 mg		500	DP-Allopurinol
* Tab 300 mg		500	✓ DP-Allopurinol
BENZBROMARONE - Special Authority see SA1963	below – Retail pharmacy		
Tab 50 mg		100	✓ Narcaricin mite S29
Tab 100 mg		30	Desuric S29
			 Urinorm S29
	45.00	100	 Benzbromaron AL
			100 S29

⇒SA1963 Special Authority for Subsidy

Renewal from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefitting from the treatment; and
- 2 There is no evidence of liver toxicity and patient is continuing to receive regular (at least every three months) liver function tests.

COLCHICINE

* Tab 500 mcg	10.06	100	 Colgout
FEBUXOSTAT - Special Authority see SA2054 below - Retail	l pharmacy		
Brand switch fee payable (Pharmacode 2621967) - see pa	ge 239 for details		
Tab 80 mg		28	 Febuxostat
			multichem
Tab 120 mg		28	 Febuxostat
-			multichem

► SA2054 Special Authority for Subsidy

Initial application — (Gout) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has been diagnosed with gout; and
- 2 Any of the following:
 - 2.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
 - 2.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
 - 2.3 The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note); or
 - 2.4 The patient has previously had an initial Special Authority approval for benzbromarone for treatment of gout...

Subsidy	F	ully	Brand or
(Manufacturer's Price)	Subsid	ised	Generic
\$	Per	✓	Manufacturer

Initial application - (Tumour lysis syndrome) only from a haematologist or oncologist. Approvals valid for 6 weeks for applications meeting the following criteria:

Both:

1 Patient is scheduled to receive cancer therapy carrying an intermediate or high risk of tumour lysis syndrome; and

2 Patient has a documented history of allopurinol intolerance.

Tab 100 mg20.76

Renewal - (Gout) from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefitting from treatment.

treatment remains appropriate and the patient is benefitting from treatment.

Note: In chronic renal insufficiency, particularly when the glomerular filtration rate is 30 ml/minute or less, probenecid may not be effective. The efficacy and safety of febuxostat have not been fully evaluated in patients with severe renal impairment (creatinine clearance less than 30 ml/minute). No dosage adjustment of febuxostat is necessary in patients with mild or moderate renal impairment. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

	OBENECID Tab 500 mg	55.00	100	✓ Probenecid-AFT
N	luscle Relaxants			
BA	CLOFEN			
*	Tab 10 mg	4.20	100	 Pacifen
	Inj 0.05 mg per ml, 1 ml ampoule - Subsidy by endorsement	11.55	1	 Lioresal Intrathecal
	Subsidised only for use in a programmable pump in patien caused intolerable side effects and the prescription is endo			ents have been ineffective or have
	Inj 2 mg per ml, 5 ml ampoule - Subsidy by endorsement	306.82	5	 Medsurge
	Subsidised only for use in a programmable pump in patien caused intolerable side effects and the prescription is endo			ents have been ineffective or have
DA	NTROLENE			
	Cap 25 mg	97.50	100	 Dantrium
				 Dantrium S29 S29
	Cap 50 mg	77.00	100	 Dantrium

ORPHENADRINE CITRATE

100

Norflex

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Agents for Parkinsonism and Related Disorders				
Dopamine Agonists and Related Agents				
MANTADINE HYDROCHLORIDE	22.24			
Cap 100 mg		60	v :	Symmetrel
	50 50	-		
Inj 10 mg per ml, 2 ml ampoule Inj 10 mg per ml, 5 ml ampoule		5 5		<u>Movapo</u> Movapo
ROMOCRIPTINE MESYLATE – Subsidy by endorsement	121.04	5	• !	novapo
Subsidy by endorsement – Subsidised for patients who were t prescription is endorsed accordingly. Pharmacists may annot prior dispensing of bromocriptine mesylate.	ate the prescription	as er	dorsed whe	ere there exists a record
• Tab 2.5 mg	11.70 32.08	30 100		Parlodel ©29 Apo-Bromocriptine
Parlodel ⁶²³⁹ Tab 2.5 mg to be delisted 1 September 2022) Apo-Bromocriptine Tab 2.5 mg to be delisted 1 March 2022) NTACAPONE				
Tab 200 mg		100	✓ (Comtan
	22.00		✓ I	Entapone
Comtan to be Principal Supply on 1 April 2022 Entapone Tab 200 mg to be delisted 1 April 2022)				
EVODOPA WITH BENSERAZIDE				
Tab dispersible 50 mg with benserazide 12.5 mg		100		Madopar Rapid
Cap 50 mg with benserazide 12.5 mg		100		Madopar 62.5
Cap 100 mg with benserazide 25 mg		100		Madopar 125
Cap long-acting 100 mg with benserazide 25 mg		100	-	Madopar HBS
Cap 200 mg with benserazide 50 mg		100	• 1	Madopar 250
EVODOPA WITH CARBIDOPA	01.11	100		Sinemet
Tab 100 mg with carbidopa 25 mg Tab long-acting 200 mg with carbidopa 50 mg		100	-	Sinemet CR
Tab 250 mg with carbidopa 25 mg		100		Sinemet
RAMIPEXOLE HYDROCHLORIDE			-	
Tab 0.25 mg		100	 Image: A second s	Ramipex
Tab 1 mg		100	-	Ramipex
ASAGILINE			-	
• Tab 1 mg		30	 Image: A second s	Azilect S29
OPINIROLE HYDROCHLORIDE			-	
Tab 0.25 mg		84	 I 	Ropin
······································	3.39	100	-	Nylan S29
Tab 1 mg		84	-	Ropin
<u> </u>	4.70	100	-	Mylan S29
Tab 2 mg	5.48	84	✓	Ropin

	0.1.11			
	Subsidy		Fully	
	(Manufacturer's Price) \$	Per	Subsidised	Generic Manufacturer
	Ψ	1.01	•	Manufacturer
SELEGILINE HYDROCHLORIDE – Subsidy by endorsement Subsidy by endorsement – Subsidised for patients who were prescription is endorsed accordingly. Pharmacists may anno prior dispensing of selegiline hydrochloride.				
 * Tab 5 mg 		100	1	Apo-Selegiline
	48.00		1	S29 S29 Eldepryl S29
(Apo-Selegiline S29 S29 Tab 5 mg to be delisted 1 April 2022)				
TOLCAPONE				
▲ Tab 100 mg		100	~	Tasmar
Anticholinergics				
BENZATROPINE MESYLATE				
Tab 2 mg	9.59	60	1	Benztrop
Inj 1 mg per ml, 2 ml	95.00	5	✓	Phebra
a) Up to 10 inj available on a PSO				
b) Only on a PSO				
PROCYCLIDINE HYDROCHLORIDE	7.40			<i>v</i>
Tab 5 mg		100	•	Kemadrin
Agents for Essential Tremor, Chorea and Relate	ed Disorders			
RILUZOLE - Special Authority see SA1403 below - Retail pharr	nacy			
Wastage claimable				
Tab 50 mg		56	•	Rilutek
SA1403 Special Authority for Subsidy Initial application only from a neurologist or respiratory specialis following criteria: All of the following:	t. Approvals valid fo	or 6 m	onths for a	pplications meeting the
 The patient has amyotrophic lateral sclerosis with disease The patient has at least 60 percent of predicted forced vita The patient has not undergone a tracheostomy; and The patient has not experienced respiratory failure; and Any of the following: 				e initial application; and
5.1 The patient is ambulatory; or				
5.2 The patient is able to use upper limbs; or				
5.3 The patient is able to swallow.				
Renewal from any relevant practitioner. Approvals valid for 18 m	onths for application	s mee	eting the fo	llowing criteria:
All of the following:				
1 The patient has not undergone a tracheostomy; and				
2 The patient has not experienced respiratory failure; and				
3 Any of the following:				
3.1 The patient is ambulatory; or				
3.2 The patient is able to use upper limbs; or3.3 The patient is able to swallow.				
TETRABENAZINE				
Tab 25 mg	91 10	112	1	Motetis
		112		mototio

	Subsidy (Manufacturer's Price \$) Per	Fully Subsidised	Brand or Generic Manufacturer
Anaesthetics				
Local				
IDOCAINE [LIGNOCAINE] Gel 2%, tube – Subsidy by endorsement a) Up to 150 ml available on a PSO	14.50	30 m	 Image: A second sec second second sec	Xylocaine 2% Jelly
 b) Subsidised only if prescribed for urethral or cervical Gel 2%, 11 ml urethral syringe – Subsidy by endorsement 		ie pres 10		endorsed accordingly. Instillagel Lido
 a) Up to 5 each available on a PSO b) Subsidised only if prescribed for urethral, cervical or accordingly. 	rectal administration	and th	ne prescript	tion is endorsed
IDOCAINE [LIGNOCAINE] HYDROCHLORIDE Oral (gel) soln 2% Inj 1%, 5 ml ampoule – Up to 25 inj available on a PSO		200 m 25 50		Mucosoothe Lidocaine-Baxter
Inj 2%, 5 ml ampoule – Up to 5 inj available on a PSO Inj 1%, 20 ml ampoule – Up to 5 inj available on a PSO	12.00	25 5	•	Xylocaine <u>Lidocaine-Baxter</u>
Inj 1%, 20 mI vial – Up to 5 inj available on a PSO Inj 2%, 20 mI vial – Up to 5 inj available on a PSO		5 5	1	Xylocaine <u>Lidocaine-Claris</u> Lidocaine-Baxter Lidocaine-Claris
Lidocaine-Claris Inj 2%, 20 ml vial to be delisted 1 June 2022) IDOCAINE [LIGNOCAINE] WITH CHLORHEXIDINE Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringes –			-	
Subsidy by endorsement a) Up to 5 each available on a PSO b) Subsidised only if prescribed for urethral or cervical	103.32	10 ie pres		Pfizer endorsed accordingly.
Topical Local Anaesthetics				
SA0906 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valic condition requiring frequent injections or venepuncture. Renewal from any relevant practitioner. Approvals valid for 2 yes benefiting from treatment.				
LIDOCAINE [LIGNOCAINE] – Special Authority see SA0906 ab Crm 4%	5.40	cy 5 g Ol 30 g O		LMX4 LMX4
IDOCAINE [LIGNOCAINE] WITH PRILOCAINE - Special Auth	ority see SA0906 ab	ove –	Retail phar	macy

LIDOCAINE [LIGNOCAINE] WITH PRILOCAINE - Special Authors	ority see SA0906	above – Reta	il pharmacy
Crm 2.5% with prilocaine 2.5%		30 g OP	🖌 EMLA
Crm 2.5% with prilocaine 2.5% (5 g tubes)	45.00	5	🖌 EMLA

Analgesics

For Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, page 111

Non-opioid Analgesics

ASPIRIN

* Tab dispersible 300 mg – Up to 30 tab available on a PSO......4.50 100 🖌 Ethics Aspirin

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

	Subsidy		Fully Brand or
	(Manufacturer's Pi \$	rice) Subs Per	sidised Generic Manufacturer
	Ψ	1 61	• Manulacturer
APSAICIN – Subsidy by endorsement Subsidised only if prescribed for post-herpetic neuralgia of	r diabatia paripharal	nouronathy a	nd the prescription is opdersed
accordingly.	ulabelic periprieral	neuropairiy a	nu lite prescription is endorsed
Crm 0.075%		45 g OP	 Zostrix HP
	15.83	57 g OP	 Rugby Capsaicin Topical Cream S29
EFOPAM HYDROCHLORIDE			
Tab 30 mg	23.40	90	 Acupan
ARACETAMOL			
Tab 500 mg - blister pack		1,000	Pacimol
 a) Maximum of 300 tab per prescription; can be waive b) Up to 30 tab available on a PSO c) 	ed by endorsement		
 Subsidy by endorsement for higher quantities regular daily dosing for one month or greater annotate the prescription as endorsed where Maximum of 100 tab per dispensing for non- (for non-endorsed patients), then dispense in Tab 500 mg - bottle pack – Maximum of 300 tab per 	, and the prescription dispensing history endorsed patients.	n is annotated supports a lon If quantities pr	d accordingly. Pharmacists may ig-term condition. rescribed for more than 100 tab
prescription; can be waived by endorsement	17 92	1.000	 Noumed
		,	Paracetamol
 Subsidy by endorsement for higher quantities is daily dosing for one month or greater, and the pi prescription as endorsed where dispensing histo Maximum of 100 tab per dispensing for non-end non-endorsed patients), then dispense in repeat 	available for patient rescription is annota ry supports a long-t orsed patients. If q	s with long ter ted according erm condition uantities preso	Paracetamol rm conditions who require regul ly. Pharmacists may annotate to pribed for more than 100 tabs (fr
 Subsidy by endorsement for higher quantities is daily dosing for one month or greater, and the p prescription as endorsed where dispensing histo Maximum of 100 tab per dispensing for non-end non-endorsed patients), then dispense in repeat Oral liq 120 mg per 5 ml Up to 200 ml available on a PSO 	available for patient rescription is annota ry supports a long-t orsed patients. If qu dispensings not exc	s with long ter ted according erm condition uantities preso	Paracetamol rm conditions who require regul ly. Pharmacists may annotate to pribed for more than 100 tabs (fr
 Subsidy by endorsement for higher quantities is daily dosing for one month or greater, and the p prescription as endorsed where dispensing histo Maximum of 100 tab per dispensing for non-end non-endorsed patients), then dispense in repeat Oral liq 120 mg per 5 ml 	available for patient rescription is annota ory supports a long-t orsed patients. If q dispensings not ex 	s with long ten ted according erm condition uantities preso ceeding 100 ta	Paracetamol rm conditions who require regul ly. Pharmacists may annotate bribed for more than 100 tabs (for ab per dispensing. Paracare Paracare Double
 Subsidy by endorsement for higher quantities is daily dosing for one month or greater, and the p prescription as endorsed where dispensing histo Maximum of 100 tab per dispensing for non-end non-endorsed patients), then dispense in repeat Oral liq 120 mg per 5 ml Wot in combination Oral liq 250 mg per 5 ml 	available for patient rescription is annota ory supports a long-t orsed patients. If q dispensings not ex 	s with long ter ted according erm condition uantities preso ceeding 100 ta 1,000 ml	Paracetamol rm conditions who require regul ly. Pharmacists may annotate bribed for more than 100 tabs (for ab per dispensing.
 Subsidy by endorsement for higher quantities is daily dosing for one month or greater, and the p prescription as endorsed where dispensing histo Maximum of 100 tab per dispensing for non-end non-endorsed patients), then dispense in repeat Oral liq 120 mg per 5 ml a) Up to 200 ml available on a PSO b) Not in combination Oral liq 250 mg per 5 ml a) Up to 100 ml available on a PSO 	available for patient rescription is annota ory supports a long-t orsed patients. If q dispensings not ex 	s with long ter ted according erm condition uantities preso ceeding 100 ta 1,000 ml	Paracetamol rm conditions who require regul ly. Pharmacists may annotate bribed for more than 100 tabs (for ab per dispensing. Paracare Paracare Double
 Subsidy by endorsement for higher quantities is daily dosing for one month or greater, and the p prescription as endorsed where dispensing histo Maximum of 100 tab per dispensing for non-end non-endorsed patients), then dispense in repeat Oral liq 120 mg per 5 mla) Up to 200 ml available on a PSO b) Not in combination Oral liq 250 mg per 5 mla) Up to 100 ml available on a PSO b) Not in combination Oral liq 250 mg per 5 mla) 	available for patient rescription is annota ry supports a long-t orsed patients. If q dispensings not ex 5.45	s with long ter ted according erm condition uantities preso ceeding 100 ta 1,000 ml	Paracetamol rm conditions who require regul ly. Pharmacists may annotate to bribed for more than 100 tabs (for ab per dispensing. Paracare Paracare Double
 Subsidy by endorsement for higher quantities is daily dosing for one month or greater, and the p prescription as endorsed where dispensing histo Maximum of 100 tab per dispensing for non-end non-endorsed patients), then dispense in repeat Oral liq 120 mg per 5 ml a) Up to 200 ml available on a PSO b) Not in combination Oral liq 250 mg per 5 ml a) Up to 100 ml available on a PSO 	available for patient rescription is annota ry supports a long-t orsed patients. If q dispensings not ex 5.45 	s with long ter ted according erm condition uantities preso ceeding 100 ta 1,000 ml 1,000 ml	Paracetamol rm conditions who require regul ly. Pharmacists may annotate t pribed for more than 100 tabs (for ab per dispensing. Paracare Paracare Strength
 Subsidy by endorsement for higher quantities is daily dosing for one month or greater, and the p prescription as endorsed where dispensing histo Maximum of 100 tab per dispensing for non-end non-endorsed patients), then dispense in repeat Oral liq 120 mg per 5 mla) Up to 200 ml available on a PSO b) Not in combination Oral liq 250 mg per 5 mla) Up to 100 ml available on a PSO b) Not in combination Suppos 125 mga) 	available for patient rescription is annota ry supports a long-t orsed patients. If q dispensings not ex 5.45 6.25 	s with long ter ted according erm condition uantities press ceeding 100 ta 1,000 ml 1,000 ml 1,000 ml	Paracetamol The paracetamol Th
 Subsidy by endorsement for higher quantities is daily dosing for one month or greater, and the p prescription as endorsed where dispensing histo Maximum of 100 tab per dispensing for non-end non-endorsed patients), then dispense in repeat Oral liq 120 mg per 5 ml a) Up to 200 ml available on a PSO b) Not in combination Oral liq 250 mg per 5 ml a) Up to 100 ml available on a PSO b) Not in combination Suppos 125 mg Suppos 250 mg 	available for patient rescription is annota ry supports a long-t orsed patients. If q dispensings not ex 5.45 6.25 	s with long ter ted according erm condition uantities press ceeding 100 ta 1,000 ml 1,000 ml 1,000 ml 10 10	Paracetamol rm conditions who require regul ly. Pharmacists may annotate t sribed for more than 100 tabs (for ab per dispensing. ✓ Paracare ✓ Paracare Double <u>Strength</u> ✓ Gacet ✓ Gacet
 Subsidy by endorsement for higher quantities is daily dosing for one month or greater, and the p prescription as endorsed where dispensing histo Maximum of 100 tab per dispensing for non-end non-endorsed patients), then dispense in repeat Oral liq 120 mg per 5 ml	available for patient rescription is annota ry supports a long-t orsed patients. If q dispensings not exc 	s with long ter ted according erm condition uantities preso ceeding 100 ta 1,000 ml 1,000 ml 10 10 50	Paracetamol rm conditions who require regul ly. Pharmacists may annotate t sribed for more than 100 tabs (for ab per dispensing. ✓ Paracare ✓ Paracare Double <u>Strength</u> ✓ Gacet ✓ Gacet
 Subsidy by endorsement for higher quantities is daily dosing for one month or greater, and the p prescription as endorsed where dispensing histo Maximum of 100 tab per dispensing for non-end non-endorsed patients), then dispense in repeat Oral liq 120 mg per 5 ml a) Up to 200 ml available on a PSO b) Not in combination Oral liq 250 mg per 5 ml a) Up to 100 ml available on a PSO b) Not in combination Suppos 125 mg Suppos 250 mg Suppos 500 mg 	available for patient rescription is annota ry supports a long-t orsed patients. If q dispensings not exc 	s with long ter ted according erm condition uantities preso ceeding 100 ta 1,000 ml 1,000 ml 10 10 50	Paracetamol rm conditions who require regula ly. Pharmacists may annotate t sribed for more than 100 tabs (for ab per dispensing. Paracare Paracare Paracare Double Strength Gacet Gacet Gacet
 Subsidy by endorsement for higher quantities is daily dosing for one month or greater, and the p prescription as endorsed where dispensing histo Maximum of 100 tab per dispensing for non-end non-endorsed patients), then dispense in repeat Oral liq 120 mg per 5 ml a) Up to 200 ml available on a PSO b) Not in combination Oral liq 250 mg per 5 ml a) Up to 100 ml available on a PSO b) Not in combination Suppos 125 mg Suppos 250 mg Suppos 500 mg Opioid Analgesics ODEINE PHOSPHATE – Safety medicine; prescriber may d Tab 15 mg Tab 30 mg 	available for patient rescription is annota ory supports a long-t orsed patients. If q dispensings not exc 	s with long ter ted according erm condition uantities preso ceeding 100 te 1,000 ml 1,000 ml 10 10 50	Paracetamol The paracetamol The conditions who require regulity. Pharmacists may annotate the pribed for more than 100 tabs (for ab per dispensing. Paracare Paracare Paracare Paracare Paracare Strength Gacet Gacet Gacet Gacet PSM PSM
 Subsidy by endorsement for higher quantities is daily dosing for one month or greater, and the p prescription as endorsed where dispensing histo Maximum of 100 tab per dispensing for non-end non-endorsed patients), then dispense in repeat Oral liq 120 mg per 5 ml a) Up to 200 ml available on a PSO b) Not in combination Oral liq 250 mg per 5 ml a) Up to 100 ml available on a PSO b) Not in combination Suppos 125 mg Suppos 500 mg Suppos 500 mg Opioid Analgesics ODEINE PHOSPHATE – Safety medicine; prescriber may d Tab 15 mg 	available for patient rescription is annota ory supports a long-t orsed patients. If q dispensings not exc 	s with long ter ted according erm condition uantities preso ceeding 100 ta 1,000 ml 1,000 ml 10 10 50	Paracetamol The paracetamol The conditions who require regulity. Pharmacists may annotate the pribed for more than 100 tabs (for ab per dispensing. Paracare Paracare Paracare Paracare Paracare Strength Gacet Gacet Gacet Fight
 Subsidy by endorsement for higher quantities is daily dosing for one month or greater, and the p prescription as endorsed where dispensing histo Maximum of 100 tab per dispensing for non-end non-endorsed patients), then dispense in repeat Oral liq 120 mg per 5 ml a) Up to 200 ml available on a PSO b) Not in combination Oral liq 250 mg per 5 ml a) Up to 100 ml available on a PSO b) Not in combination Suppos 125 mg Suppos 250 mg Suppos 500 mg Opioid Analgesics ODEINE PHOSPHATE – Safety medicine; prescriber may d Tab 15 mg Tab 30 mg 	available for patient rescription is annota ory supports a long-t orsed patients. If q dispensings not exc 	s with long ter ted according erm condition uantities preso ceeding 100 te 1,000 ml 1,000 ml 10 10 50	Paracetamol The paracetamol The conditions who require regul IV. Pharmacists may annotate The period of the period

	Subsidy		Fully	Brand or
	(Manufacturer's Price)	_	Subsidised	
	\$	Per		Manufacturer
FENTANYL				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing fre	equency			
Inj 50 mcg per ml, 2 ml ampoule		10	✓	Boucher and Muir
Boucher and Muir to be Principal Supply on 1 April 2022				
Inj 50 mcg per ml, 10 ml ampoule	9.41	10	✓	Boucher and Muir
Boucher and Muir to be Principal Supply on 1 April 2022				
Patch 12.5 mcg per hour	6.99	5	✓	Fentanyl Sandoz
Patch 25 mcg per hour	7.99	5	✓	Fentanyl Sandoz
Patch 50 mcg per hour	9.49	5	✓	Fentanyl Sandoz
Patch 75 mcg per hour	17.99	5	✓	Fentanyl Sandoz
Patch 100 mcg per hour		5	1	Fentanyl Sandoz
METHADONE HYDROCHLORIDE				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing fre	eauencv			
d) Extemporaneously compounded methadone will only be r		e of th	ne cheape	st form available
(methadone powder, not methadone tablets).				
e) For methadone hydrochloride oral liquid refer Standard F	ormulae, page 241			
Tab 5 mg		10	1	Methatabs
Oral lig 2 mg per ml	6.40 2	200 m	nl 🖌	Biodone
Oral lig 5 mg per ml	6.40 2	200 m	nl 🖌	Biodone Forte
Oral lig 10 mg per ml	7.50 2	200 m	nl 🖌	Biodone Extra Forte
Inj 10 mg per ml, 1 ml	61.00	10		AFT
MORPHINE HYDROCHLORIDE				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing free	equency			
Oral lig 1 mg per ml		200 m	nl 🗸	RA-Morph
Oral lig 2 mg per ml		200 m		RA-Morph
Oral lig 5 mg per ml		200 m		Ordine S29
				RA-Morph
Oral lig 10 mg per ml	27.74	200 m		Ordine S29
		.00 11		RA-Morph
			v	na-worph

(Subsidy Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
MORPHINE SULPHATE				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing freq	uency			
Tab immediate-release 10 mg		10	1	Sevredol
Tab immediate-release 20 mg		10	✓ :	Sevredol
Cap long-acting 10 mg	2.05	10	✓	m-Eslon
Cap long-acting 30 mg	3.00	10	✓ 1	m-Eslon
Cap long-acting 60 mg	6.12	10	✓ 1	m-Eslon
Cap long-acting 100 mg	7.13	10	✓ 1	m-Eslon
Inj 5 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSC)6.99	5	✓ 1	DBL Morphine Sulphate
Inj 10 mg per ml, 1 ml ampoule – Up to 5 inj available on a PS	O5.61	5	√	DBL Morphine Sulphate
Inj 15 mg per ml, 1 ml ampoule – Up to 5 inj available on a PS	O7.08	5	√	DBL Morphine Sulphate
Inj 30 mg per ml, 1 ml ampoule $-$ Up to 5 inj available on a PS	07.28	5	√	DBL Morphine Sulphate

	Subsidy (Manufacturer's Price)) 9	Fully Subsidised	
	\$	Per	 ✓ 	Manufacturer
(YCODONE HYDROCHLORIDE				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing	frequency			
Tab controlled-release 5 mg	2.69	20	✓	Oxycodone Sandoz
-	3.01	28	✓	Oxycodone Sandoz
				S29 S29
Tab controlled-release 10 mg	2.69	20	✓	Oxycodone Sandoz
-	3.23	30	✓	Oxycodone Sandoz
				S29 S29
	5.38	50	1	Oxycodone Sandoz
				S29 S29
	10.75	100	1	Oxycodone Sandoz
	10.70	100	-	S29 S29
	11.50	28		OxyContin
Tab controlled release 20 mg		28 20		Oxycodone Sandoz
Tab controlled-release 20 mg	5.38	20 50		Oxycodone Sandoz
	5.50	50	•	S29 S29
	10.75	100		
	10.75	100	v	Oxycodone Sandoz
				S29 S29
T	13.25	28		OxyContin
Tab controlled-release 40 mg		20		Oxycodone Sandoz
Tab controlled-release 80 mg		20		Oxycodone Sandoz
Cap immediate-release 5 mg		20		OxyNorm
Cap immediate-release 10 mg		20 20		OxyNorm OxyNorm
Cap immediate-release 20 mg Oral liq 5 mg per 5 ml		20 250 ml		OxyNorm OxyNorm
Inj 10 mg per ml, 1 ml ampoule		200 mi 5		Hameln
	7.28	5		OxyNorm
Inj 10 mg per ml, 2 ml ampoule		5		Hameln
	14.36	0		OxyNorm
Inj 50 mg per ml, 1 ml ampoule		5		Hameln
	30.60	Ũ		OxyNorm
cycodone Sandoz S29 S29 Tab controlled-release 5 mg to		22)		•
kycodone Sandoz S29 (22) Tab controlled release 5 mg k		'		
vycodone Sandoz S29 (22) Tab controlled-release 10 mg		,		
cycodone Sandoz S29 S29 Tab controlled-release 10 mg)22)		
cyContin Tab controlled-release 10 mg to be delisted 1 Jun	,			
cycodone Sandoz S29 S29 Tab controlled-release 20 mg		'		
cycodone Sandoz S29 S29 Tab controlled-release 20 mg)22)		
kyContin Tab controlled-release 20 mg to be delisted 1 Jun				
xyNorm Inj 10 mg per ml, 1 ml ampoule to be delisted 1 Jul willerm Ini 10 mg per ml, 2 ml ampoule to be delisted 1 Jul				
xyNorm Inj 10 mg per ml, 2 ml ampoule to be delisted 1 Jul willerm Inj 50 mg por ml, 1 ml ampoule to be delisted 1 Jul				
xyNorm Inj 50 mg per ml, 1 ml ampoule to be delisted 1 Jul	. ,			
RACETAMOL WITH CODEINE – Safety medicine; prescri		•	•	
Tab paracetamol 500 mg with codeine phosphate 8 mg		1,000	<i>✓</i>	Paracetamol +
				Codeine (Relieve)

	Subsidy		Fully	
	(Manufacturer's Price) \$	Per	Subsidised	Generic Manufacturer
PETHIDINE HYDROCHLORIDE	_			
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing fr	equency			
Tab 50 mg		10	1	PSM
Inj 50 mg per ml, 1 ml ampoule – Up to 5 inj available on a l	PSO29.88	5	1	DBL Pethidine
		_		Hydrochloride
Inj 50 mg per ml, 2 ml ampoule – Up to 5 inj available on a l	PSO 30.72	5	~	DBL Pethidine Hydrochloride
RAMADOL HYDROCHLORIDE				
Tab sustained-release 100 mg	1.52	20	1	Tramal SR 100
Tab sustained-release 150 mg	2.10	20	1	Tramal SR 150
Tab sustained-release 200 mg		20		Tramal SR 200
Cap 50 mg	2.80	100	/	Arrow-Tramadol
Antidepressants				
Cyclic and Related Agents				
MITRIPTYLINE - Safety medicine; prescriber may determine of	dispensing frequency			
Tab 10 mg		100	1	Arrow-Amitriptyline
Tab 25 mg	1.51	100	✓	Arrow-Amitriptyline
Tab 50 mg	2.51	100	1	Arrow-Amitriptyline
CLOMIPRAMINE HYDROCHLORIDE				
a) Brand switch fee payable (Pharmacode 2630915) - see	page 239 for details			
b) Safety medicine; prescriber may determine dispensing fr				
Tab 10 mg	10.17	30		Clomipramine Teva
Tab 25 mg	11.99	30	✓	Clomipramine Teva
OSULEPIN [DOTHIEPIN] HYDROCHLORIDE – Subsidy by er	ndorsement			
a) Safety medicine; prescriber may determine dispensing fr	equency			
b) Subsidy by endorsement - Subsidised for patients who v	were taking dosulepin	[doth	iepin] hydr	ochloride prior to 1 June
2019 and the prescription is endorsed accordingly. Phar	rmacists may annotate	the	prescriptio	n as endorsed where the
aviete a record of prior disponsing of docularin (dathionin				
exists a record of prior dispensing of dosulepin [dothiepir				
Tab 75 mg		30		Dosulepin Mylan
		30 50		Dosulepin
Tab 75 mg Cap 25 mg		50	1	Dosulepin Mylan S29
Tab 75 mg Cap 25 mg	r may determine dispe	50 nsing	✓ g frequenc	Dosulepin Mylan ^(S29)
Tab 75 mg Cap 25 mg		50 nsing 50	g frequency	Dosulepin Mylan S29 / Tofranil
Tab 75 mg Cap 25 mg VIPRAMINE HYDROCHLORIDE – Safety medicine; prescriber Tab 10 mg		50 nsing 50 100	g frequency	Dosulepin Mylan S29 / Tofranil Tofranil
Tab 75 mg Cap 25 mg VIPRAMINE HYDROCHLORIDE – Safety medicine; prescriber Tab 10 mg Tab 25 mg		50 nsing 50 100 50	g frequence	Dosulepin Mylan 🖘 / Tofranil Tofranil Tofranil
Tab 75 mg Cap 25 mg VIPRAMINE HYDROCHLORIDE – Safety medicine; prescriber Tab 10 mg Tab 25 mg IORTRIPTYLINE HYDROCHLORIDE – Safety medicine; presc		50 nsing 50 100 50 dispe	g frequency	Dosulepin Mylan 2000 / Tofranil Tofranil Tofranil Jency
Tab 75 mg Cap 25 mg MIPRAMINE HYDROCHLORIDE – Safety medicine; prescriber Tab 10 mg Tab 25 mg IORTRIPTYLINE HYDROCHLORIDE – Safety medicine; presc Tab 10 mg		50 nsing 50 100 50 dispe 100	g frequency	Dosulepin Mylan 529 / Tofranil Tofranil Jency Norpress
Tab 75 mg Cap 25 mg MIPRAMINE HYDROCHLORIDE – Safety medicine; prescriber Tab 10 mg Tab 25 mg IORTRIPTYLINE HYDROCHLORIDE – Safety medicine; presc		50 nsing 50 100 50 dispe	g frequency	Dosulepin Mylan 7 Tofranil Tofranil Tofranil Jency
Tab 75 mg Cap 25 mg VIPRAMINE HYDROCHLORIDE – Safety medicine; prescriber Tab 10 mg Tab 25 mg IORTRIPTYLINE HYDROCHLORIDE – Safety medicine; presc Tab 10 mg Tab 25 mg Monoamine-Oxidase Inhibitors (MAOIs) - Non S	3.85 7.83 r may determine dispe 5.48 10.96 8.80 criber may determine c 2.44 5.98	50 nsing 50 100 50 dispe 100	g frequency	Dosulepin Mylan 529 / Tofranil Tofranil Jency Norpress
Tab 75 mg Cap 25 mg VIIPRAMINE HYDROCHLORIDE – Safety medicine; prescriber Tab 10 mg IORTRIPTYLINE HYDROCHLORIDE – Safety medicine; presc Tab 10 mg Tab 25 mg Tab 25 mg Monoamine-Oxidase Inhibitors (MAOIs) - Non S RANYLCYPROMINE SULPHATE	3.85 7.83 r may determine dispe 5.48 10.96 8.80 criber may determine c 2.44 5.98 Selective	50 nsing 50 100 50 Jispe 100 180	g frequency	Dosulepin Mylan ^{S29} / Tofranil Tofranil Jency <u>Norpress</u> <u>Norpress</u>
Tab 75 mg Cap 25 mg VIPRAMINE HYDROCHLORIDE – Safety medicine; prescriber Tab 10 mg Tab 25 mg IORTRIPTYLINE HYDROCHLORIDE – Safety medicine; presc Tab 10 mg Tab 25 mg Monoamine-Oxidase Inhibitors (MAOIs) - Non S	3.85 	50 nsing 50 100 50 Jispe 100 180	g frequency	Dosulepin Mylan ^{\$29} / Tofranil Tofranil iency <u>Norpress</u> <u>Norpress</u>
Tab 75 mg Cap 25 mg MIPRAMINE HYDROCHLORIDE – Safety medicine; prescriber Tab 10 mg IORTRIPTYLINE HYDROCHLORIDE – Safety medicine; presc Tab 10 mg Tab 25 mg Monoamine-Oxidase Inhibitors (MAOIs) - Non S RANYLCYPROMINE SULPHATE	3.85 	50 nsing 50 100 50 dispe 100 180 28 50	g frequency	Dosulepin Mylan ^{\$29} / Tofranil Tofranil Iency <u>Norpress</u> Norpress Parnate \$29 \$29 Parnate
Tab 75 mg Cap 25 mg MIPRAMINE HYDROCHLORIDE – Safety medicine; prescriber Tab 10 mg IORTRIPTYLINE HYDROCHLORIDE – Safety medicine; presc Tab 10 mg Tab 25 mg Monoamine-Oxidase Inhibitors (MAOIs) - Non S RANYLCYPROMINE SULPHATE	3.85 	50 nsing 50 100 50 Jispe 100 180	g frequency	Dosulepin Mylan ^{\$29} / Tofranil Tofranil iency <u>Norpress</u> <u>Norpress</u>

	Subsidy (Manufacturer's Price)		Fully	Brand or Generic
	\$	Per		Manufacturer
Monoamine-Oxidase Type A Inhibitors				
MOCLOBEMIDE * Tab 150 mg * Tab 300 mg		60 60	_	urorix urorix
Selective Serotonin Reuptake Inhibitors				
CITALOPRAM HYDROBROMIDE * Tab 20 mg ESCITALOPRAM	1.91	84	✓ <u>P</u>	SM Citalopram
* Tab 10 mg	1.07	28	✓ <u>E</u>	<u>scitalopram</u> (Ethics)
* Tab 20 mg	1.92	28	✓ <u>E</u>	<u>scitalopram</u> (Ethics)
FLUOXETINE HYDROCHLORIDE * Tab dispersible 20 mg, scored – Subsidy by endorsement Subsidised by endorsement	1.98	30	✔ F	luox
 When prescribed for a patient who cannot swallow accordingly; or When prescribed in a daily dose that is not a multip endorsed. Note: Tablets should be combined with 	le of 20 mg in which o	case the	prescrip	tion is deemed to be
Cap 20 mg	2.91	84	🗸 F	luox
PAROXETINE * Tab 20 mg	3.61	90	✓ <u>L</u>	oxamine
SERTRALINE * Tab 50 mg	0.92	30	-	etrona
* Tab 100 mg	1.61	30	-	etrona AU <u>etrona</u>
Other Antidepressants				
MIRTAZAPINE Tab 30 mg Tab 45 mg		28 28		oumed oumed
VENLAFAXINE * Cap 37.5 mg * Cap 75 mg		84 84		nlafax XR nlafax XR
* Cap 150 mg		84		nlafax XR
Antiepilepsy Drugs				
Agents for Control of Status Epilepticus				
CLONAZEPAM – Safety medicine; prescriber may determine disp Inj 1 mg per ml, 1 ml		5	✔ R	ivotril

A Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price \$	e) Sub Per	Fully sidised	Brand or Generic Manufacturer
DIAZEPAM – Safety medicine; prescriber may determine disper Inj 5 mg per ml, 2 ml ampoule – Subsidy by endorsement a) Up to 5 inj available on a PSO b) Only on a PSO		5	✔ Н	ospira
 c) PSO must be endorsed "not for anaesthetic procedul Rectal tubes 5 mg – Up to 5 tube available on a PSO PHENYTOIN SODIUM 		5	✓ s	tesolid
 Inj 50 mg per ml, 2 ml ampoule – Up to 5 inj available on a F Inj 50 mg per ml, 5 ml ampoule – Up to 5 inj available on a 	PSO 88.63	5	✔ Н	ospira
PSO		5	✔ Н	ospira
Control of Epilepsy				
CARBAMAZEPINE * Tab 200 mg * Tab long-acting 200 mg * Tab 400 mg * Tab long-acting 400 mg * Oral lig 20 mg per ml	16.98 34.58 39.17	100 100 100 100 250 ml	✓ T ✓ T ✓ T	egretol egretol CR egretol egretol CR egretol
CLOBAZAM – Safety medicine; prescriber may determine dispe Tab 10 mg	ensing frequency	50		risium
CLONAZEPAM – Safety medicine; prescriber may determine dis Oral drops 2.5 mg per ml.		10 ml OP	✔ R	ivotril
ETHOSUXIMIDE Cap 250 mg Oral lig 250 mg per 5 ml		100 200 ml		arontin arontin
GABAPENTIN Note: Not subsidised in combination with subsidised pregab	palin			
 Cap 100 mg Cap 300 mg Cap 400 mg 	8.45	100 100 100	✓ <u>N</u>	<u>upentin</u> upentin upentin
LACOSAMIDE - Special Authority see SA1125 below - Retail p	,		_	
 ▲ Tab 50 mg ▲ Tab 100 mg 		14 14 56	🗸 V	impat impat impat
▲ Tab 150 mg		56 14 56	🗸 V	impat impat
▲ Tab 200 mg		56		impat

⇒SA1125 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Both:

- 1 Patient has partial-onset epilepsy; and
- 2 Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note).

Note: "Optimal treatment" is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight and other features affecting the pharmacokinetics of the drug with good evidence of

Subsidy		Fully	Brand or	
(Manufacturer's Price)	5	Subsidised	Generic	
\$	Per	1	Manufacturer	

compliance. Women of childbearing age are not required to have a trial of sodium valproate.

Renewal from any relevant practitioner. Approvals valid for 24 months where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life compared with that prior to starting lacosamide treatment (see Note).

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

LAMOTRIGINE

LAMOTHIGINE			
▲ Tab dispersible 2 mg	55.00	30	 Lamictal
▲ Tab dispersible 5 mg		30	 Lamictal
* Tab dispersible 25 mg	2.76	56	 Logem
* Tab dispersible 50 mg	3.31	56	✓ Logem
* Tab dispersible 100 mg	4.40	56	✓ Logem
LEVETIRACETAM			
Tab 250 mg	4.99	60	 Everet
Tab 500 mg	8.79	60	 Everet
Tab 750 mg		60	 Everet
Tab 1,000 mg		60	 Everet
Oral liq 100 mg per ml		300 ml OP	 Levetiracetam-AFT
PHENOBARBITONE			
For phenobarbitone oral liquid refer Standard Formulae,	bage 241		
* Tab 15 mg		500	✓ PSM
* Tab 30 mg		500	✓ PSM
PHENYTOIN SODIUM			
* Tab 50 mg	75.00	200	 Dilantin Infatab
Cap 30 mg		200	✓ Dilantin
Cap 100 mg		200	✓ Dilantin
* Oral lig 30 mg per 5 ml		500 ml	✓ Dilantin
PREGABALIN			-
Note: Not subsidised in combination with subsidised gab	anentin		
* Cap 25 mg		56	Pregabalin Pfizer
* Cap 75 mg		56	✓ Pregabalin Pfizer
* Cap 150 mg		56	✓ Lyrica
••••••••••••••••••••••••••••••••••••••			 Pregabalin Pfizer
* Cap 300 mg	7.38	56	Pregabalin Pfizer
PRIMIDONE			Ū
* Tab 250 mg	37 35	100	 Apo-Primidone
-		100	· Apo i minuono
SODIUM VALPROATE Tab 100 mg	10.65	100	 Epilim Crushable
0		100	
Tab 200 mg EC			✓ Epilim
Tab 500 mg EC		100	✓ Epilim
* Oral liq 200 mg per 5 ml	20.48	300 ml	 Epilim S/F Liquid Epilim Symp
* Inj 100 mg per ml, 4 ml	41.50	1	 Epilim Syrup Epilim IV
STIRIPENTOL – Special Authority see SA1330 on the next p	•	,	
Cap 250 mg	509.29	60	 Diacomit S29
Powder for oral liq 250 mg sachet		60	 Diacomit S29

Subsidy (Manufacturer's F	Price) S	Fully ubsidised	Brand or Generic	
\$	Per	1	Manufacturer	

⇒SA1330 Special Authority for Subsidy

Initial application only from a paediatric neurologist or Practitioner on the recommendation of a paediatric neurologist. Approvals valid for 6 months for applications meeting the following criteria: Both

- 1 Patient has confirmed diagnosis of Dravet syndrome; and
- 2 Seizures have been inadequately controlled by appropriate courses of sodium valproate, clobazam and at least two of the following: topiramate, levetiracetam, ketogenic diet.

Renewal from any relevant practitioner. Approvals valid without further renewal unless notified where the patient continues to benefit from treatment as measured by reduced seizure frequency from baseline.

TOPIRAMATE

11.07	60	Arrow-Topiramate
		 Topiramate Actavis
26.04		 Topamax
18.81	60	 Arrow-Topiramate
		 Topiramate Actavis
44.26		 Topamax
31.99	60	Arrow-Topiramate
		 Topiramate Actavis
75.25		 Topamax
55.19	60	 Arrow-Topiramate
		 Topiramate Actavis
129.85		 Topamax
20.84	60	 Topamax
	60	 Topamax
nacv		
	100	 Sabril
	18.81 44.26 31.99 75.25 55.19	26.04 60 44.26 60 75.25 60 75.25.19 60 129.85 60 20.84 60 20.94 60

⇒SA2088 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Both:

- 1 Any of the following:
 - 1.1 Patient has infantile spasms; or
 - 1.2 Both:
 - 1.2.1 Patient has epilepsy; and
 - 1.2.2 Either:
 - 1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
 - 1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; or
 - 1.3 Patient has tuberous sclerosis complex; and
- 2 Either:
 - 2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or
 - 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields..

Notes: ``Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

Subsidy		Fully	Brand or
(Manufacturer's Pr	ce)	Subsidised	Generic
\$	Pe	r 🖌	Manufacturer

Renewal from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

1 The patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life; and

- 2 Either:
 - 2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin; or
 - 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields...

Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

Antimigraine Preparations

For Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, page 111

Acute Migraine Treatment

RIZATRIPTAN Tab orodispersible 10 mg SUMATRIPTAN	3.65	30	✓ <u>Rizamelt</u>
Tab 50 mg Tab 100 mg	22.68	90 90	✓ <u>Sumagran</u> ✓ <u>Sumagran</u>
Inj 12 mg per ml, 0.5 ml prefilled pen – Maximum of 10 in prescription		2 OP	✓ Imigran
Prophylaxis of Migraine			
For Beta Adrenoceptor Blockers refer to CARDIOVASCULAR PIZOTIFEN	SYSTEM, page 50		
* Tab 500 mcg	23.21	100	 Sandomigran
Antinausea and Vertigo Agents			
For Antispasmodics refer to ALIMENTARY TRACT, page 8			
APREPITANT - Special Authority see SA0987 below - Retail			
Cap 2 × 80 mg and 1 × 125 mg		3 OP	Emend Tri-Pack
SA0987 Special Authority for Subsidy			
Initial application from any relevant practitioner. Approvals v			
emetogenic chemotherapy and/or anthracycline-based chemo			
Renewal from any relevant practitioner. Approvals valid for 12			dergoing highly emetogenic
chemotherapy and/or anthracycline-based chemotherapy for th	he treatment of malig	inancy.	
BETAHISTINE DIHYDROCHLORIDE	0.00	04	Varaa 16
* Tab 16 mg	3.88 4.62	84 100	 ✓ Vergo 16 ✓ Serc
(Vergo 16 Tab 16 mg to be delisted 1 July 2022)	4.02	100	
Tab 50 mg	0.49	10	 Nausicalm
CYCLIZINE LACTATE			
Inj 50 mg per ml, 1 ml	21.53	10	✓ <u>Hameln</u>

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

(Subsidy Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
DOMPERIDONE				
* Tab 10 mg	2.85	100	✓ <u>F</u>	harmacy Health
HYOSCINE HYDROBROMIDE				
* Inj 400 mcg per ml, 1 ml ampoule	93.00	10	🗸 N	lartindale S29
Patch 1.5 mg – Special Authority see SA1998 below – Retail				
pharmacy	14.11	2	√ 9	Scopoderm TTS
pharmacy	14.11	2	√ 9	Scopoderm TTS

⇒SA1998 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Either:

- 1 Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease where the patient cannot tolerate or does not adequately respond to oral anti-nausea agents; or
- 2 Control of clozapine-induced hypersalivation where trials of at least two other alternative treatments have proven ineffective.

Renewal from any relevant practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.

METOCLOPRAMIDE HYDROCHLORIDE

* Tab 10 mg - Up to 30 tab available on a PSO1.30	100	✓ <u>Metoclopramide</u> <u>Actavis 10</u>
✤ Inj 5 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO9.50	10	✓ Pfizer
ONDANSETRON		
* Tab 4 mg2.68	50	 Onrex
* Tab disp 4 mg – Up to 10 tab available on a PSO0.76	10	✓ Ondansetron ODT-DRLA
* Tab 8 mg4.57	50	 Onrex
* Tab disp 8 mg – Up to 10 tab available on a PSO1.13	10	✓ Ondansetron ODT-DRLA
PROCHLORPERAZINE		
* Tab 3 mg buccal	50	
(30.00)		Buccastem
* Tab 5 mg – Up to 30 tab available on a PSO	250	Nausafix
* Inj 12.5 mg per ml, 1 ml – Up to 5 inj available on a PSO25.81	10	 Stemetil

Antipsychotics

General

AMISULPRIDE – Safety medicine; prescriber may determine di	ispensing frequency	1
Tab 100 mg	5.15	30
·	17.16	100
	17.10	100
Tab 200 mg	14.96	60
Tab 400 mg		60
ARIPIPRAZOLE - Safety medicine; prescriber may determine of	dispensing frequenc	;y
Tab 5 mg		30
Tab 10 mg		30
Tab 15 mg		30
Tab 20 mg	17 50	30
Tab 30 mg	17.50	30

- ✓ <u>Sulprix</u>
 ✓ Amisulpride Mylan S29
 ✓ Sulprix
- ✓ Sulprix
- Aripiprazole Sandoz
 Aripiprazole Sandoz
- Aripiprazole Sandoz
 Aripiprazole Sandoz
- Aripiprazole Sandoz
 Aripiprazole Sandoz
- Aripiprazole Sandoz
- Aripiprazole Sandoz

	Subsidy		Fully	Brand or
	(Manufacturer's Pr		sidised	Generic
	\$	Per	1	Manufacturer
CHLORPROMAZINE HYDROCHLORIDE - Safety medicine; pre	scriber may dete	rmine dispens	sing fr	requency
Tab 10 mg – Up to 30 tab available on a PSO		100	1	Largactil
Tab 25 mg – Up to 30 tab available on a PSO		100	1	Largactil
Tab 100 mg – Up to 30 tab available on a PSO		100		Largactil
Inj 25 mg per ml, 2 ml – Up to 5 inj available on a PSO		10	~	Largactil
CLOZAPINE – Hospital pharmacy [HP4]				
Safety medicine; prescriber may determine dispensing freque	ency			
Tab 25 mg	5.69	50		Clozaril
	6.69			Clopine
	11.36	100		Clozaril
	13.37			Clopine
Tab 50 mg		50		Clopine
	17.33	100		Clopine
Tab 100 mg		50		Clozaril
	17.33	100		Clopine
	29.45	100		Clozaril
	34.65	50	-	Clopine
Tab 200 mg		50		Clopine
Supposed FO management	69.30	100 ml		Clopine
Suspension 50 mg per ml		100 ml		Clopine Versacloz
(Clopine Suspension 50 mg per ml to be delisted 1 April 2022)	67.62		•	Versacioz
	. ,			
HALOPERIDOL – Safety medicine; prescriber may determine dis				0
Tab 500 mcg – Up to 30 tab available on a PSO		100		Serenace
Tab 1.5 mg – Up to 30 tab available on a PSO		100	-	Serenace
Tab 5 mg – Up to 30 tab available on a PSO		50 100	-	Serenace Serenace
Oral liq 2 mg per ml – Up to 200 ml available on a PSO		100 ml		Serenace
Inj 5 mg per ml, 1 ml ampoule – Up to 5 inj available on a PS		100 111		Serenace
			•	Jerenace
LEVOMEPROMAZINE – Safety medicine; prescriber may detern				Nation (Outlas)
Tab 25 mg (33.8 mg as a maleate)		100	-	Nozinan (Swiss)
Tab 25 mg as a maleate Tab 100 mg (135 mg as a maleate)		100 100		<u>Nozinan</u> Nozinan (Swiss)
Tab 100 mg as a maleate		100	-	Nozinan
-				
LEVOMEPROMAZINE HYDROCHLORIDE - Safety medicine; p				
Inj 25 mg per ml, 1 ml ampoule		10	v	Nozinan
LITHIUM CARBONATE - Safety medicine; prescriber may deter				.
Tab long-acting 400 mg		100		Priadel
Cap 250 mg		100	•	Douglas
OLANZAPINE - Safety medicine; prescriber may determine disp			_	
Tab 2.5 mg		28		Zypine
Tab 5 mg		28		Zypine
Tab orodispersible 5 mg		28		Zypine ODT
Tab 10 mg	2.01	28		Zypine Zypine ODT
Tab orodispersible 10 mg		28	~	Zypine ODT
PERICYAZINE - Safety medicine; prescriber may determine disp	• •	•		
Tab 2.5 mg		84		Neulactil
	12.49	100		Neulactil
Tab 10 mg		84		Neulactil
	44.45	100	-	Neulactil

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

	Subsidy	0	Fully	
(Manufacturer's Price) \$	Per	bsidised	Generic Manufacturer
UETIAPINE – Safety medicine; prescriber may determine dispen	sing frequency			
Tab 25 mg	2.15	90	✓	Quetapel
Tab 100 mg		90		Quetapel
Tab 200 mg		90	✓	Quetapel
Tab 300 mg		90		Quetapel
SPERIDONE - Safety medicine; prescriber may determine dispe	ensing frequency			
Tab 0.5 mg		60	✓	Risperidone (Teva)
Tab 1 mg	2.06	60	✓	Risperidone (Teva)
Tab 2 mg	2.29	60	✓	Risperidone (Teva)
Tab 3 mg		60	✓	Risperidone (Teva)
Tab 4 mg		60		Risperidone (Teva)
Oral liq 1 mg per ml		30 ml		Risperon
PRASIDONE - Safety medicine; prescriber may determine dispe	ensing frequency			
Cap 20 mg	• • •	60	✓	Zusdone
Cap 40 mg		60	1	Zusdone
Cap 60 mg		60	1	Zusdone
Cap 80 mg		60	1	Zusdone
UCLOPENTHIXOL HYDROCHLORIDE - Safety medicine; presc				
UCLOPENTHIXOL HYDROCHLORIDE – Safety medicine; presc Tab 10 mg		ie dispen 100		quency Clopixol
Tab 10 mg	31.45	100	· /	
Tab 10 mg	31.45 v determine dispens	100	uency	
Tab 10 mg Depot Injections UPENTHIXOL DECANOATE – Safety medicine; prescriber may	31.45 v determine dispens 13.14	100 sing freq	uency	Ċlopixol
Tab 10 mg Depot Injections UPENTHIXOL DECANOATE – Safety medicine; prescriber may Inj 20 mg per ml, 1 ml – Up to 5 inj available on a PSO	31.45 determine dispens 13.14 20.90	100 sing freq	uency	Člopixol Fluanxol
Tab 10 mg Depot Injections LUPENTHIXOL DECANOATE – Safety medicine; prescriber may Inj 20 mg per ml, 1 ml – Up to 5 inj available on a PSO Inj 20 mg per ml, 2 ml – Up to 5 inj available on a PSO Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO	31.45 v determine dispens 13.14 20.90 40.87	100 sing freq 5 5 5 5	uency	Clopixol Fluanxol Fluanxol
Tab 10 mg Depot Injections LUPENTHIXOL DECANOATE – Safety medicine; prescriber may Inj 20 mg per ml, 1 ml – Up to 5 inj available on a PSO Inj 20 mg per ml, 2 ml – Up to 5 inj available on a PSO	31.45 v determine dispens 13.14 20.90 40.87 determine dispensi	100 sing freq 5 5 5 5	uency	Clopixol Fluanxol Fluanxol
Tab 10 mg Depot Injections LUPENTHIXOL DECANOATE – Safety medicine; prescriber may Inj 20 mg per ml, 1 ml – Up to 5 inj available on a PSO Inj 20 mg per ml, 2 ml – Up to 5 inj available on a PSO Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO ALOPERIDOL DECANOATE – Safety medicine; prescriber may	31.45 v determine dispens 13.14 20.90 40.87 determine dispensi 28.39	100 sing freq 5 5 5 ing frequ	uency uency ency	Clopixol Fluanxol Fluanxol Fluanxol
Tab 10 mg Depot Injections UPENTHIXOL DECANOATE – Safety medicine; prescriber may Inj 20 mg per ml, 1 ml – Up to 5 inj available on a PSO Inj 20 mg per ml, 2 ml – Up to 5 inj available on a PSO Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO ALOPERIDOL DECANOATE – Safety medicine; prescriber may Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO	31.45 v determine dispens 13.14 20.90 40.87 determine dispensi 28.39	100 sing freq 5 5 5 ing frequ 5	uency uency ency	Člopixol Fluanxol Fluanxol Fluanxol Fluanxol Haldol
Tab 10 mg Depot Injections UPENTHIXOL DECANOATE – Safety medicine; prescriber may Inj 20 mg per ml, 1 ml – Up to 5 inj available on a PSO Inj 20 mg per ml, 2 ml – Up to 5 inj available on a PSO Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO ALOPERIDOL DECANOATE – Safety medicine; prescriber may Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO	31.45 v determine dispens 13.14 20.90 40.87 determine dispensi 28.39	100 sing freq 5 5 5 ing frequ 5	uency uency ency	Clopixol Fluanxol Fluanxol Fluanxol Haldol Haldol Concentrate
Tab 10 mg Depot Injections LUPENTHIXOL DECANOATE – Safety medicine; prescriber may Inj 20 mg per ml, 1 ml – Up to 5 inj available on a PSO Inj 20 mg per ml, 2 ml – Up to 5 inj available on a PSO Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO ALOPERIDOL DECANOATE – Safety medicine; prescriber may Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO	31.45 r determine dispension 13.14 20.90 40.87 determine dispension 28.39 	100 sing freq 5 5 5 ing frequ 5	uency uency ency	Clopixol Fluanxol Fluanxol Fluanxol Haldol Haldol Concentrate Haldol
Tab 10 mg Depot Injections LUPENTHIXOL DECANOATE – Safety medicine; prescriber may Inj 20 mg per ml, 1 ml – Up to 5 inj available on a PSO Inj 20 mg per ml, 2 ml – Up to 5 inj available on a PSO Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO ALOPERIDOL DECANOATE – Safety medicine; prescriber may Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO	31.45 r determine dispensi 13.14 20.90 40.87 determine dispensi 28.39 55.90 rmacy	100 sing freq 5 5 5 ing frequ 5	uency uency ency	Clopixol Fluanxol Fluanxol Fluanxol Haldol Haldol Concentrate Haldol
Tab 10 mg Depot Injections LUPENTHIXOL DECANOATE – Safety medicine; prescriber may Inj 20 mg per ml, 1 ml – Up to 5 inj available on a PSO Inj 20 mg per ml, 2 ml – Up to 5 inj available on a PSO Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO ALOPERIDOL DECANOATE – Safety medicine; prescriber may Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO		100 sing freq 5 5 5 ing frequ 5	uency ency	Clopixol Fluanxol Fluanxol Fluanxol Haldol Haldol Concentrate Haldol
Tab 10 mg Depot Injections LUPENTHIXOL DECANOATE – Safety medicine; prescriber may Inj 20 mg per ml, 1 ml – Up to 5 inj available on a PSO Inj 20 mg per ml, 2 ml – Up to 5 inj available on a PSO Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO ALOPERIDOL DECANOATE – Safety medicine; prescriber may Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO LANZAPINE – Special Authority see SA1428 below – Retail phal Safety medicine; prescriber may determine dispensing frequen		sing freq 5 5 5 5 ing frequ 5 5	uency ency v	Clopixol Fluanxol Fluanxol Fluanxol Haldol Haldol Concentrate Haldol Decanoas 529
Tab 10 mg Depot Injections LUPENTHIXOL DECANOATE – Safety medicine; prescriber may Inj 20 mg per ml, 1 ml – Up to 5 inj available on a PSO Inj 20 mg per ml, 2 ml – Up to 5 inj available on a PSO Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO ALOPERIDOL DECANOATE – Safety medicine; prescriber may Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO LANZAPINE – Special Authority see SA1428 below – Retail pha Safety medicine; prescriber may determine dispensing frequen Inj 210 mg vial		100 sing freq 5 5 5 sing frequ 5 5	uency ency v	Clopixol Fluanxol Fluanxol Fluanxol Haldol Haldol Concentrate Haldol Decanoas \$29 Zyprexa Relprevv

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Either:

- 1 The patient has had an initial Special Authority approval for paliperidone depot injection or risperidone depot injection; or
- 2 All of the following:
 - 2.1 The patient has schizophrenia; and
 - 2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - 2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

Renewal from any relevant practitioner. Approvals valid for 12 months where the initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

Note: The patient should be monitored for post-injection syndrome for at least two hours after each injection.

	Subsidy (Manufacturer's Price)	er Per	Fully Subsidised	Brand or Generic Manufacturer
PALIPERIDONE – Special Authority see SA1429 below – Retail		rei		Manulaciurei
Safety medicine; prescriber may determine dispensing freque Inj 25 mg syringe	,	1	~	Invega Sustenna
Inj 50 mg syringe		1		Invega Sustenna
Inj 75 mg syringe		1	✓	Invega Sustenna
Inj 100 mg syringe		1	✓	Invega Sustenna
Inj 150 mg syringe		1	✓	Invega Sustenna

⇒SA1429 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Either:

- 1 The patient has had an initial Special Authority approval for risperidone depot injection or olanzapine depot injection; or
- 2 All of the following:
 - 2.1 The patient has schizophrenia or other psychotic disorder; and
 - 2.2 Has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - 2.3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months.

Renewal from any relevant practitioner. Approvals valid for 12 months where the initiation of paliperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

Note: Paliperidone depot injection should ideally be used as monotherapy (i.e. without concurrent use of any other antipsychotic medication). In some cases, it may be clinically appropriate to attempt to treat a patient with typical antipsychotic agents in depot injectable form before trialling paliperidone depot injection.

RISPERIDONE - Special Authority see SA1427 below - Retail pharmacy

Safety medicine; prescriber may determine dispensing frequency

Inj 25 mg vial	1	 Risperdal Consta
Inj 37.5 mg vial	1	 Risperdal Consta
Inj 50 mg vial	1	 Risperdal Consta

⇒SA1427 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Either:

- 1 The patient has had an initial Special Authority approval for paliperidone depot injection or olanzapine depot injection; or
- 2 All of the following:
 - 2.1 The patient has schizophrenia or other psychotic disorder; and
 - 2.2 Has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - 2.3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months.

Renewal from any relevant practitioner. Approvals valid for 12 months where the initiation of risperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

Note: Risperidone depot injection should ideally be used as monotherapy (i.e. without concurrent use of any other antipsychotic medication). In some cases, it may be clinically appropriate to attempt to treat a patient with typical antipsychotic agents in depot injectable form before trialing risperidone depot injection.

ZUCLOPENTHIXOL DECANOATE - Safety medicine; prescriber may determine dispensing frequency

Inj 200 mg per ml, 1 ml – Up to 5 inj available on a PSO......19.80 5 🖌 Clopixol

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	
Anxiolytics				
BUSPIRONE HYDROCHLORIDE				
* Tab 5 mg		100	1	Buspirone Viatris
-	20.23		~	Orion
Buspirone Viatris to be Principal Supply on 1 May 2022				
* Tab 10 mg		100		Buspirone Viatris
	13.16		~	Orion
Buspirone Viatris to be Principal Supply on 1 May 2022				
(Orion Tab 5 mg to be delisted 1 May 2022) (Orion Tab 10 mg to be delisted 1 May 2022)				
CLONAZEPAM - Safety medicine; prescriber may determine dis	spensing frequency			
Tab 500 mcg		100	1	Paxam
Tab 2 mg	10.78	100	1	Paxam
DIAZEPAM - Safety medicine; prescriber may determine disper	nsing frequency			
Tab 2 mg	61.07	500	1	Arrow-Diazepam
Tab 5 mg	73.60	500	~	Arrow-Diazepam
LORAZEPAM – Safety medicine; prescriber may determine disp	ensing frequency			
Tab 1 mg	0 1 7	250	1	Ativan
Tab 2.5 mg		100	1	Ativan
OXAZEPAM - Safety medicine; prescriber may determine dispe	ensina freauency			
Tab 10 mg	0 1 7	100	1	Ox-Pam
Tab 15 mg	8.53	100	1	Ox-Pam
(Ox-Pam Tab 10 mg to be delisted 1 April 2022)				
(Ox-Pam Tab 15 mg to be delisted 1 April 2022)				

Multiple Sclerosis Treatments

⇒SA2051 Special Authority for Subsidy

Initial application — (Multiple sclerosis) only from a neurologist or general physician. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis must include MRI confirmation; and
- 2 Patients must have Clinically Definite Relapsing multiple sclerosis with or without underlying progression; and
- 3 Patients must have an EDSS score between 0 6.0; and
- 4 Patient has had at least 1 significant relapse of multiple sclerosis in the previous 12 months or 2 significant relapses in the past 24 months; and
- 5 All of the following:
 - 5.1 Each significant relapse must be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the relapse, but the neurologist/physician must be satisfied that the clinical features were characteristic); and
 - 5.2 Each significant relapse is associated with characteristic new symptom(s)/sign(s) or substantially worsening of previously experienced symptoms(s)/sign(s); and
 - 5.3 Each significant relapse has lasted at least one week and has started at least one month after the onset of a previous relapse; and
 - 5.4 Each significant relapse can be distinguished from the effects of general fatigue; and is not associated with a fever (T> 37.5°C); and

 rice)	Fully Subsidised	Brand or Generic	
\$ Per	✓	Manufacturer	

- 5.5 Either:
 - 5.5.1 Each significant relapse is severe enough to change either the EDSS or at least one of the Kurtze Functional System scores by at least 1 point; or
 - 5.5.2 Each significant relapse is a recurrent paroxysmal symptom of multiple sclerosis (tonic seizures/spasms, trigeminal neuralgia, Lhermitte's symptom); and
- 6 Evidence of new inflammatory activity on an MR scan within the past 24 months; and
- 7 Any of the following:
 - 7.1 A sign of that new inflammatory activity is a gadolinium enhancing lesion; or
 - 7.2 A sign of that new inflammatory activity is a lesion showing diffusion restriction; or
 - 7.3 A sign of that new inflammatory is a T2 lesion with associated local swelling; or
 - 7.4 A sign of that new inflammatory activity is a prominent T2 lesion that clearly is responsible for the clinical features of a recent relapse that occurred within the last 2 years; or
 - 7.5 A sign of that new inflammatory activity is new T2 lesions compared with a previous MR scan.

Note: Natalizumab can only be dispensed from a pharmacy registered in the Tysabri Australasian Prescribing Programme operated by the supplier. Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted. **Renewal — (Multiple sclerosis)** only from a neurologist or general physician. Approvals valid for 12 months where patient has had an EDSS score of 0 to 6.0 (inclusive) with or without the use of unilateral or bilateral aids at any time in the last six months (i.e. the patient has walked 100 metres or more with or without aids in the last six months).

Note: Natalizumab can only be dispensed from a pharmacy registered in the Tysabri Australasian Prescribing Programme operated by the supplier. Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.

DIMETHYL FUMARATE - Special Authority see SA2051 on the previous page - Retail pharmacy

a) Wastage claimable b) Note: Treatment on two or more funded multiple sc Cap 120 mg Cap 240 mg		taneously is 14 56	not permitted. ✓ Tecfidera ✓ Tecfidera
FINGOLIMOD – Special Authority see SA2051 on the previ a) Wastage claimable b) Note: Treatment on two or more funded multiple sc Cap 0.5 mg	erosis treatments simul	-	not permitted. ✔ Gilenya
GLATIRAMER ACETATE – Special Authority see SA2051 Note: Treatment on two or more funded multiple sclero Inj 40 mg prefilled syringe	sis treatments simultane		
INTERFERON BETA-1-ALPHA – Special Authority see SA Note: Treatment on two or more funded multiple sclero Inj 6 million iu prefilled syringe Injection 6 million iu per 0.5 ml pen injector	sis treatments simultane		
INTERFERON BETA-1-BETA – Special Authority see SA20 Note: Treatment on two or more funded multiple sclero Inj 8 million iu per 1 ml	sis treatments simultane		
NATALIZUMAB – Special Authority see SA2051 on the pre Note: Treatment on two or more funded multiple sclero Inj 20 mg per ml, 15 ml vial	sis treatments simultane		t permitted. ✔ Tysabri
OCRELIZUMAB – Special Authority see SA2051 on the pre Note: Treatment on two or more funded multiple sclero Inj 30 mg per ml, 10 ml vial	sis treatments simultane		t permitted.

	Subsidy (Manufacturer's Price) \$	Su Per	Fully bsidised	Brand or Generic Manufacturer
FERIFLUNOMIDE - Special Authority see SA2051 on page 1	36 – Retail pharmacy			
a) Wastage claimable				
b) Note: Treatment on two or more funded multiple scler Tab 14 mg		1eously I: 28	•	mitted. Aubagio
Tab 14 mg	059.90	20	• •	lubagio
Sedatives and Hypnotics				
IELATONIN – Special Authority see SA1666 below – Retail	pharmacy			
Tab modified-release 2 mg - No more than 5 tab per day		30		/igisom Sircadin
Vigisom to be Principal Supply on 1 April 2022 Circadin Tab modified-release 2 mg to be delisted 1 April 202	22)			
SA1666 Special Authority for Subsidy				
nitial application only from a psychiatrist, paediatrician, neur ecommendation of a psychiatrist, paediatrician, neurologist or pplications meeting the following criteria: Il of the following:				
 Patient has been diagnosed with persistent and distres (including, but not limited to, autism spectrum disorder Behavioural and environmental approaches have been Funded modified-release melatonin is to be given at do Patient is aged 18 years or under*. 	or attention deficit hype tried and were unsucce	ractivity o	disorder)' are inap	; and
enewal only from a psychiatrist, paediatrician, neurologist, re f a psychiatrist, paediatrician, neurologist or respiratory speci ollowing criteria:				
Il of the following:				
1 Patient is aged 18 years or under*; and				
 Patient has demonstrated clinically meaningful benefit Patient has had a trial of funded modified-release mela recurrence of persistent and distressing insomnia; and 			•	<i>/</i> ··
4 Funded modified-release melatonin is to be given at do	ses no greater than 10	mg per d	ay.	
ote: Indications marked with * are unapproved indications.				
IIDAZOLAM – Safety medicine; prescriber may determine di	1 0 1 7			
Inj 1 mg per ml, 5 ml ampoule		10	✓ N	lidazolam-Baxter
Inj 1 mg per ml, 5 ml plastic ampoule – Up to 10 inj availa on a PSO		10	/ •	fizer
On a PSO for status epilepticus use only. PSO must				
Inj 5 mg per ml, 3 ml ampoule		5		lidazolam-Baxter
Inj 5 mg per ml, 3 ml plastic ampoule – Up to 5 inj availal	ble on			
a PSO		5	-	fizer
On a PSO for status epilepticus use only. PSO must		• •	is use or	ıly.
HENOBARBITONE SODIUM – Special Authority see SA138		•		
Inj 200 mg per ml, 1 ml ampoule		10	 N 	lax Health S29
SA1386 Special Authority for Subsidy itial application from any relevant practitioner. Approvals v the following criteria:	alid without further rene	wal unle	ss notifie	d for applications meetir
Both:				
1 For the treatment of terminal agitation that is unresponse		b		

2 The applicant is part of a multidisciplinary team working in palliative care.

	Subsidy		Fully	Brand or
	(Manufacturer's Price)		Subsidised	
	\$	Per		Manufacturer
TEMAZEPAM – Safety medicine; prescriber may determine disp	pensing frequency			
Tab 10 mg	• • •	25	1	Normison
TRIAZOLAM - Safety medicine; prescriber may determine dispe	ensina freauencv			
Tab 125 mcg	0 1 3	100		
	(9.85)			Hypam
Tab 250 mcg		100		,,
, , , , , , , , , , , , , , , , , , ,	(11.20)			Hypam
ZOPICLONE - Safety medicine; prescriber may determine disp	ensing frequency			
Tab 7.5 mg		500	1	Zopiclone Actavis
Stimulants/ADHD Treatments				
ATOMOXETINE				
Cap 10 mg		28	✓	Generic Partners
	107.03		✓	Strattera
Cap 18 mg		28	✓	Generic Partners
	107.03		✓	Strattera
Cap 25 mg		28	✓	Generic Partners
Cap 40 mg		28	✓	Generic Partners
	107.03		✓	Strattera
Cap 60 mg		28	✓	Generic Partners
Cap 80 mg	56.45	28	✓	Generic Partners
Cap 100 mg	58.48	28	✓	Generic Partners
DEXAMFETAMINE SULFATE - Special Authority see SA1149	<mark>below</mark> – Retail pharma	асу		
a) Only on a controlled drug form				
b) Safety medicine; prescriber may determine dispensing fr	equency			
Tab 5 mg		100	✓	PSM

⇒SA1149 Special Authority for Subsidy

Initial application — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or
 - 3.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

Initial application — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria.

Initial application — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy.

Renewal — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria: Both:

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy		Fully	Brand or
(Manufacturer's Price)	Subs	sidised	Generic
\$	Per	1	Manufacturer

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 Applicant is a paediatrician or psychiatrist; or
 - 2.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

Renewal — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

METHYLPHENIDATE HYDROCHLORIDE - Special Authority see SA1964 below - Retail pharmacy

- a) Only on a controlled drug form
- b) Safety medicine; prescriber may determine dispensing frequency

Tab immediate-release 5 mg		30	✓ Bubifen
Tab immediate-release 10 mg		30	✓ Ritalin
ũ			 Rubifen
Tab extended-release 18 mg	7.75	30	 Methylphenidate ER
			- Teva
Tab immediate-release 20 mg	7.85	30	 Rubifen
Tab sustained-release 20 mg		30	 Rubifen SR
Tab extended-release 27 mg	11.45	30	 Methylphenidate ER
			- Teva
Tab extended-release 36 mg		30	 Methylphenidate ER
			- Teva
Tab extended-release 54 mg		30	 Methylphenidate ER
-			- Teva

⇒SA1964 Special Authority for Subsidy

Initial application — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist, medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing) or nurse practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria: All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or
 - 3.2 Applicant is a medical practitioner or nurse practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

Initial application — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria:

- Both:
 - 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age; and
 - 2 Diagnosed according to DSM-IV or ICD 10 criteria.

Initial application — (Narcolepsy*) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy.

Note: *narcolepsy is not a registered indication for Methylphenidate ER - Teva.

Renewal — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist, medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing) or nurse practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria:

Sul	bsidy F	ully	Brand or
(Manufact	turer's Price) Subsidi	sed	Generic
	\$ Per	✓	Manufacturer

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 Applicant is a paediatrician or psychiatrist; or
 - 2.2 Applicant is a medical practitioner or nurse practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

Renewal — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (Narcolepsy*) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

Note: *narcolepsy is not a registered indication for Methylphenidate ER - Teva.

METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE - Special Authority see SA1965 below - Retail pharmacy

a) Only on a controlled drug form

b) Safety medicine; prescriber may determine dispension	sing frequency		
Tab extended-release 18 mg		30	 Concerta
Tab extended-release 27 mg	65.44	30	 Concerta
Tab extended-release 36 mg	71.93	30	 Concerta
Tab extended-release 54 mg		30	 Concerta
Cap modified-release 10 mg		30	 Ritalin LA
Cap modified-release 20 mg	20.40	30	 Ritalin LA
Cap modified-release 30 mg	25.52	30	 Ritalin LA
Cap modified-release 40 mg		30	 Ritalin LA

⇒SA1965 Special Authority for Subsidy

Initial application only from a paediatrician, psychiatrist, medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing) or nurse practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder); and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or
 - 3.2 Applicant is a medical practitioner or nurse practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing; and

4 Either:

- 4.1 Patient is taking a currently subsidised formulation of methylphenidate hydrochloride (immediate-release or sustained-release) which has not been effective due to significant administration and/or compliance difficulties; or
- 4.2 There is significant concern regarding the risk of diversion or abuse of immediate-release methylphenidate hydrochloride.

Renewal only from a paediatrician, psychiatrist, medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing) or nurse practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria:

Both:

1 The treatment remains appropriate and the patient is benefiting from treatment; and

2 Either:

- 2.1 Applicant is a paediatrician or psychiatrist; or
- 2.2 Applicant is a medical practitioner or nurse practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

	Subsidy (Manufacturer's Price) \$	Subs Per	Fully sidised	Brand or Generic Manufacturer
MODAFINIL – Special Authority see SA1999 below – Retail phar Tab 100 mg	,	60	✓ М	odavigil

Modavigil to be Principal Supply on 1 March 2022

⇒SA1999 Special Authority for Subsidy

Initial application only from a neurologist or respiratory specialist. Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more; and
- 2 Either:
 - 2.1 The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods; or
 - 2.2 The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations; and

3 Either:

- 3.1 An effective dose of a subsidised formulation of methylphenidate or dexamfetamine has been trialled and discontinued because of intolerable side effects; or
- 3.2 Methylphenidate and dexamfetamine are contraindicated.

Renewal only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

Treatments for Dementia

DONEPEZIL HYDROCHLORIDE

* Tab 5 mg * Tab 10 mg	90 90	 <u>Donepezil-Rex</u> Donepezil-Rex
RIVASTIGMINE – Special Authority see SA1488 below – Reta	90	
Patch 4.6 mg per 24 hour	 30	 <u>Rivastigmine Patch</u> <u>BNM 5</u>
Patch 9.5 mg per 24 hour	 30	 <u>Rivastigmine Patch</u> BNM 10

⇒SA1488 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both:

1 The patient has been diagnosed with dementia; and

2 The patient has experienced intolerable nausea and/or vomiting from donepezil tablets.

Renewal from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate; and
- 2 The patient has demonstrated a significant and sustained benefit from treatment.

Subsidy (Manufacturer's Price)	Su	Fully bsidised	Brand or Generic	
`\$	Per	~	Manufacturer	

⇒SA1203 Special Authority for Subsidy

Initial application — (Detoxification) from any medical practitioner. Approvals valid for 1 month for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and
- 3 Applicant works in an opioid treatment service approved by the Ministry of Health...

Initial application — (Maintenance treatment) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient will not be receiving methadone; and
- 3 Patient is currently enrolled in an opioid substitution treatment program in a service approved by the Ministry of Health; and
- 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

Renewal — (Detoxification) from any medical practitioner. Approvals valid for 1 month for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient has previously trialled but failed detoxification with buprenorphine with naloxone with relapse back to opioid use and another attempt is planned; and
- 3 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and
- 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

Renewal — (Maintenance treatment) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient is or has been receiving maintenance therapy with buprenorphine with naloxone (and is not receiving methadone); and
- 2 Patient is currently enrolled in an opioid substitution program in a service approved by the Ministry of Health; and
- 3 Applicant works in an opioid treatment service approved by the Ministry of Health or is a medical practitioner authorised by the service to manage treatment in this patient.

Renewal — (Maintenance treatment where the patient has previously had an initial application for detoxification) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 Patient received but failed detoxification with buprenorphine with naloxone; and
- 2 Maintenance therapy with buprenorphine with naloxone is planned (and patient will not be receiving methadone); and
- 3 Patient is currently enrolled in an opioid substitution program in a service approved by the Ministry of Health; and
- 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

BUPROPION HYDROCHLORIDE

Tab modified-release 150 mg	11.00	30	✓ <u>Zyban</u>		
DISULFIRAM Tab 200 mg		100	 Antabuse 		
NALTREXONE HYDROCHLORIDE – Special Authority see SA1408 on the next page – Retail pharmacy					
Tab 50 mg		30	Naltraccord		

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	

⇒SA1408 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence; and
- 2 Applicant works in or with a community Alcohol and Drug Service contracted to one of the District Health Boards or accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard.

Renewal from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Compliance with the medication (prescriber determined); and
- 2 Any of the following:
 - 2.1 Patient is still unstable and requires further treatment; or
 - 2.2 Patient achieved significant improvement but requires further treatment; or
 - 2.3 Patient is well controlled but requires maintenance therapy.

NICOTINE

a) Nicotine will not be funded in amounts less than 4 weeks of treatment.

b) Note: Direct Provision by a pharmacist permitted under the provisions in	Part I of Sect	ion A.
Patch 7 mg – Up to 28 patch available on a PSO	28	 Habitrol
Patch 7 mg for direct distribution only – [Xpharm]	7	 Habitrol
Patch 14 mg – Up to 28 patch available on a PSO 19.95	28	 Habitrol
Patch 14 mg for direct distribution only - [Xpharm]4.52	7	 Habitrol
Patch 21 mg – Up to 28 patch available on a PSO	28	 Habitrol
Patch 21 mg for direct distribution only - [Xpharm]5.18	7	 Habitrol
Lozenge 1 mg – Up to 216 loz available on a PSO	216	 Habitrol
Lozenge 1 mg for direct distribution only - [Xpharm]	36	 Habitrol
Lozenge 2 mg - Up to 216 loz available on a PSO21.02	216	 Habitrol
Lozenge 2 mg for direct distribution only - [Xpharm]	36	 Habitrol
Gum 2 mg (Fruit) – Up to 384 piece available on a PSO	384	 Habitrol
Gum 2 mg (Fruit) for direct distribution only - [Xpharm]8.64	96	 Habitrol
Gum 2 mg (Mint) – Up to 384 piece available on a PSO	384	 Habitrol
Gum 2 mg (Mint) for direct distribution only - [Xpharm]8.64	96	 Habitrol
Gum 4 mg (Fruit) – Up to 384 piece available on a PSO	384	 Habitrol
Gum 4 mg (Fruit) for direct distribution only - [Xpharm]	96	 Habitrol
Gum 4 mg (Mint) – Up to 384 piece available on a PSO	384	 Habitrol
Gum 4 mg (Mint) for direct distribution only - [Xpharm]	96	 Habitrol

VARENICLINE TARTRATE - Special Authority see SA1845 below - Retail pharmacy

- a) A maximum of 12 weeks' varenicline will be subsidised on each Special Authority approval, including the starter pack
- b) Varenicline will not be funded in amounts less than 4 weeks of treatment.
- c) The 6-month time period in which a patient can receive a funded 12-week course of varenicline tartrate starts from the date the Special Authority is approved.

Tab 0.5 mg × 11 and 1 mg × 42	.16.67	53 OP	~	Varenicline Pfizer
Tab 1 mg	.17.62	56	1	Varenicline Pfizer

➡SA1845 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 5 months for applications meeting the following criteria: All of the following:

1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

- continued...
 - 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
 - 3 Either:
 - 3.1 The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy; or
 - 3.2 The patient has tried but failed to quit smoking using bupropion or nortriptyline; and
 - 4 The patient has not had a Special Authority for varenicline approved in the last 6 months; and
 - 5 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
 - 6 The patient is not pregnant; and
 - 7 The patient will not be prescribed more than 12 weeks' funded varenicline (see note).

Renewal from any relevant practitioner. Approvals valid for 5 months for applications meeting the following criteria:

All of the following:

- 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
- 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
- 3 It has been 6 months since the patient's previous Special Authority was approved; and
- 4 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
- 5 The patient is not pregnant; and
- 6 The patient will not be prescribed more than 12 weeks' funded varenicline (see note).

The patient must not have had an approval in the past 6 months.

Notes: a maximum of 12 weeks' varenicline will be subsidised on each Special Authority approval.

This includes the 4-week 'starter' pack.

	Subsidy (Manufacturer's Price)	Su	Fully	Brand or Generic
	\$	Per	1	Manufacturer
Chemotherapeutic Agents				
Alkylating Agents				
BENDAMUSTINE HYDROCHLORIDE - PCT only - Special	st – Special Authority se	e SA204	6 below	
Inj 25 mg vial		1	🗸 F	Ribomustin
Inj 100 mg vial		1	🗸 F	Ribomustin
Inj 1 mg for ECP		1 mg	🗸 E	Baxter
SA2046 Special Authority for Subsidy		•		
Initial application — (treatment naive CLL) only from a relevant	evant specialist or medic	al practiti	oner on	the recommendation of a
relevant specialist. Approvals valid for 12 months for application				
All of the following:	J	J		

- 1 The patient has Binet stage B or C, or progressive stage A chronic lymphocytic leukaemia requiring treatment; and
- 2 The patient is chemotherapy treatment naive; and
- 3 The patient is unable to tolerate toxicity of full-dose FCR; and
- 4 Patient has ECOG performance status 0-2; and
- 5 Patient has a Cumulative Illness Rating Scale (CIRS) score of < 6; and
- 6 Bendamustine is to be administered at a maximum dose of 100 mg/m² on days 1 and 2 every 4 weeks for a maximum of 6 cycles.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma (SLL). Chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

Initial application — (Indolent, Low-grade lymphomas) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria: All of the following:

- 1 The patient has indolent low grade NHL requiring treatment; and
- 2 Patient has a WHO performance status of 0-2; and
- 3 Either:
 - 3.1 Both:
 - 3.1.1 Patient is treatment naive; and
 - 3.1.2 Bendamustine is to be administered for a maximum of 6 cycles (in combination with rituximab when CD20+); or
 - 3.2 All of the following:
 - 3.2.1 Patient has relapsed refractory disease following prior chemotherapy; and
 - 3.2.2 The patient has not received prior bendamustine therapy; and
 - 3.2.3 Either:

3.2.3.1 Both:

- 3.2.3.1.1 Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+); and
- 3.2.3.1.2 Patient has had a rituximab treatment-free interval of 12 months or more; or
- 3.2.3.2 Bendamustine is to be administered as a monotherapy for a maximum of 6 cycles in rituximab refractory patients.

Renewal — (Indolent, Low-grade lymphomas) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria: Both:

- 1 Patients have not received a bendamustine regimen within the last 12 months; and
- 2 Either:
 - 2.1 Both:

	Subsidy	Fully	Brand or
(Manu	facturer's Price)	Subsidised	Generic
	\$ Per	1	Manufacturer

continued...

- 2.1.1 Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+); and
- 2.1.2 Patient has had a rituximab treatment-free interval of 12 months or more; or
- 2.2 Bendamustine is to be administered as a monotherapy for a maximum of 6 cycles in rituximab refractory patients.

Note: 'indolent, low-grade lymphomas' includes follicular, mantle cell, marginal zone and lymphoplasmacytic/ Waldenstrom's macroglobulinaemia.

Initial application — (Hodgkin's lymphoma*) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has Hodgkin's lymphoma requiring treatment; and
- 2 Patient has a ECOG performance status of 0-2; and
- 3 Patient has received one prior line of chemotherapy; and
- 4 Patient's disease relapsed or was refractory following prior chemotherapy; and
- 5 Bendamustine is to be administered in combination with gemcitabine and vinorelbine (BeGeV) at a maximum dose of no greater than 90 mg/m2 twice per cycle, for a maximum of four cycles.

Note: Indications marked with * are unapproved indications.

BUSULFAN - PCT - Retail pharmacy-Specialist

Tab 2 mg		100	 Myleran
CARBOPLATIN – PCT only – Specialist			
Inj 10 mg per ml, 45 ml vial		1	 DBL Carboplatin
	45.20		 Carboplatin Ebewe
	48.50		 Carbaccord
Inj 1 mg for ECP	0.10	1 mg	 Baxter
CARMUSTINE - PCT only - Specialist			
Inj 100 mg vial		1	BiCNU
,	,		✓ Bicnu Heritage S29
Inj 100 mg for ECP		100 mg OP	✓ Baxter
CHLORAMBUCIL – PCT – Retail pharmacy-Specialist		-	
Tab 2 mg		25	 Leukeran FC
CISPLATIN – PCT only – Specialist			
Inj 1 mg per ml, 50 ml vial		1	 Cisplatin Ebewe
Inj 1 mg per ml, 100 ml vial		1	 Cisplatin Ebewe
	29.66		DBL Cisplatin
Inj 1 mg for ECP	0.31	1 mg	✓ Baxter
CYCLOPHOSPHAMIDE			
Tab 50 mg - PCT - Retail pharmacy-Specialist		50	Cyclonex
Inj 1 g vial – PCT – Retail pharmacy-Specialist		1	 Endoxan
, , , , , , , , , , , , , , , , , , , ,	127.80	6	 Cytoxan
Inj 2 g vial – PCT only – Specialist	71.25	1	 Endoxan
Inj 1 mg for ECP - PCT only - Specialist	0.04	1 mg	 Baxter
IFOSFAMIDE – PCT only – Specialist			
Inj 1 g		1	 Holoxan
lnj 2 g		1	 Holoxan
Inj 1 mg for ECP		1 mg	 Baxter
LOMUSTINE - PCT - Retail pharmacy-Specialist			
Cap 10 mg		20	CeeNU
Cap 40 mg		20	✓ CeeNU

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

(N	Subsidy /anufacturer's Price) \$	Per	Fully Subsidised	Generic
MELPHALAN				
Tab 2 mg – PCT – Retail pharmacy-Specialist	40.70	25	1	Alkeran
Inj 50 mg – PCT only – Specialist	67.80	1	✓	Alkeran
			1	Alkeran S29 S29
OXALIPLATIN – PCT only – Specialist				
Inj 100 mg vial	25.01	1	1	Oxaliplatin Actavis
,				100
	110.00		1	Oxaliplatin Ebewe
Inj 5 mg per ml, 20 ml vial	46.32	1		Oxaliplatin Accord
Inj 1 mg for ECP		1 mg	1	Baxter
THIOTEPA – PCT only – Specialist				
Inj 15 mg vial	CBS	1	1	Bedford S29
, ,			1	Max Health S29
			1	THIO-TEPA S29
				Tepadina S29
Ini 100 ma vial	CDC	1		Max Health S29
Inj 100 mg vial		I		
			•	Tepadina S29
Antimetabolites				
AZACITIDINE - PCT only - Specialist - Special Authority see SA1	467 below			
Inj 100 mg vial		1	1	Azacitidine Dr
		•		Reddy's
	605.00		1	Vidaza
Inj 1 mg for ECP		1 mc		Baxter

⇒SA1467 Special Authority for Subsidy

Initial application only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

- All of the following:
 - 1 Any of the following:
 - 1.1 The patient has International Prognostic Scoring System (IPSS) intermediate-2 or high risk myelodysplastic syndrome; or
 - The patient has chronic myelomonocytic leukaemia (10%-29% marrow blasts without myeloproliferative disorder); or
 - 1.3 The patient has acute myeloid leukaemia with 20-30% blasts and multi-lineage dysplasia, according to World Health Organisation Classification (WHO); and
 - 2 The patient has performance status (WHO/ECOG) grade 0-2; and
 - 3 The patient does not have secondary myelodysplastic syndrome resulting from chemical injury or prior treatment with chemotherapy and/or radiation for other diseases; and
 - 4 The patient has an estimated life expectancy of at least 3 months.

Renewal only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and patient is benefitting from treatment.

Subsid	y	Fully Brand or
(Manufacturer		sidised Generic
\$	Per	 Manufacturer
CALCIUM FOLINATE		
Tab 15 mg – PCT – Retail pharmacy-Specialist114.69	10	 DBL Leucovorin
		Calcium
Inj 3 mg per ml, 1 ml – PCT – Retail pharmacy-Specialist	5	 Hospira
Inj 10 mg per ml, 5 ml vial – PCT – Retail pharmacy-Specialist7.28	1	 Calcium Folinate
		<u>Sandoz</u>
		 Calcium Folinate
		Sandoz S29 S29
Inj 50 mg – PCT – Retail pharmacy-Specialist72.80	10	 Leucovorin
Jee Sterring Photos and Photos an		Pharmacia S29
Inj 10 mg per ml, 10 ml vial – PCT only – Specialist9.49	1	✓ Calcium Folinate
	1	Sandoz
Inj 100 mg – PCT only – Specialist7.33	1	✓ Calcium Folinate
	I	Ebewe
04.00	10	
94.90	10	 Leucovorin
		Pharmacia S29
Inj 300 mg - PCT only - Specialist22.51	1	 Calcium Folinate
		Ebewe
25.14		Leucovorin DBL §29
Inj 10 mg per ml, 35 ml vial – PCT only – Specialist	1	 Calcium Folinate
		Sandoz
		Calcium Folinate
		Sandoz S29 S29
Inj 1 g – PCT only – Specialist67.51	1	 Calcium Folinate
		Ebewe
Inj 10 mg per ml, 100 ml vial – PCT only – Specialist	1	 Calcium Folinate
		Sandoz
Inj 1 mg for ECP – PCT only – Specialist0.06	1 mg	 Baxter
APECITABINE – Retail pharmacy-Specialist		
Tab 150 mg	60	 Capercit
Tab 500 mg	120	✓ Capercit
-		
LADRIBINE – PCT only – Specialist Inj 1 mg per ml, 10 ml749.96	1	 Leustatin
Inj 10 mg for ECP	10 mg OP	✓ Baxter
	TO THE OF	• Daxlei
YTARABINE	-	
Inj 20 mg per ml, 5 ml vial – PCT – Retail pharmacy-Specialist400.00	5	Pfizer
Inj 100 mg per ml, 20 ml vial – PCT – Retail		_
pharmacy-Specialist	1	✓ Pfizer
Inj 1 mg for ECP – PCT only – Specialist0.25	10 mg	 Baxter
Inj 100 mg intrathecal syringe for ECP – PCT only – Specialist80.00	100 mg OP	 Baxter
LUDARABINE PHOSPHATE		
Tab 10 mg - PCT - Retail pharmacy-Specialist412.00	20	 Fludara Oral
Inj 50 mg vial - PCT only - Specialist	5	 Fludarabine Ebewe
Inj 50 mg for ECP – PCT only – Specialist115.29	50 mg OP	 Baxter
LUOROURACIL	-	
Inj 50 mg per ml, 20 ml vial – PCT only – Specialist	1	Fluorouracil Accord
Inj 50 mg per ml, 100 ml vial – PCT only – Specialist	1	 Fluorouracil Accord Fluorouracil Accord
Inj 1 mg for ECP – PCT only – Specialist	100 mg	✓ Pluorouracii Accoru ✓ Baxter
	roomy	- DUALCI

Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy		Fully	Brand or
	(Manufacturer's Price		bsidised	Generic
	\$	Per		Manufacturer
GEMCITABINE HYDROCHLORIDE - PCT only - Specialist				
Inj 1 g, 26.3 ml vial	62.50	1	✓	DBL Gemcitabine
Inj 1 g	15.89	1	~	Gemcitabine Ebewe
Inj 1 mg for ECP	0.02	1 mg	~	Baxter
IRINOTECAN HYDROCHLORIDE - PCT only - Specialist				
Inj 20 mg per ml, 5 ml vial		1	✓	Accord
	71.44		✓	Irinotecan
				Accord S29
			~	Irinotecan Actavis
				100
	100.00		1	Irinotecan-Rex
Inj 1 mg for ECP		1 mg	~	Baxter
(Irinotecan Accord sea Inj 20 mg per ml, 5 ml vial to be delisted		5		
MERCAPTOPURINE	,			
Tab 50 mg – PCT – Retail pharmacy-Specialist	37.00	25	1	Puri-nethol
		20	•	runneului
Oral suspension 20 mg per ml – Retail pharmacy-Specialist		00 ml OP	1	Allmaraan
Special Authority see SA1725 below		UU III UP	•	Allmercap
► SA1725 Special Authority for Subsidy				

⇒SA1725 Special Authority for Subsidy

Initial application only from a paediatric haematologist or paediatric oncologist. Approvals valid for 12 months where the patient requires a total dose of less than one full 50 mg tablet per day.

Renewal only from a paediatric haematologist or paediatric oncologist. Approvals valid for 12 months where patient still requires a total dose of less than one full 50 mg tablet per day.

METHOTREXATE

*	Tab 2.5 mg – PCT – Retail pharmacy-Specialist	90	✓ Trexate
*	Tab 10 mg – PCT – Retail pharmacy-Specialist	90	 Trexate
*	Inj 2.5 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist	5	 Methotrexate DBL
*	Inj 7.5 mg prefilled syringe14.61	1	 Methotrexate Sandoz
*	Inj 10 mg prefilled syringe14.66	1	 Methotrexate Sandoz
*	Inj 15 mg prefilled syringe14.77	1	 Methotrexate Sandoz
*	Inj 20 mg prefilled syringe14.88	1	 Methotrexate Sandoz
*	Inj 25 mg prefilled syringe	1	 Methotrexate Sandoz
*	Inj 30 mg prefilled syringe	1	 Methotrexate Sandoz
*	Inj 25 mg per ml, 2 ml vial – PCT – Retail pharmacy-Specialist30.00	5	 Methotrexate DBL Onco-Vial
*	Inj 25 mg per ml, 20 ml vial – PCT – Retail pharmacy-Specialist45.00	1	 DBL Methotrexate Onco-Vial
* *	Inj 100 mg per ml, 10 ml – PCT – Retail pharmacy-Specialist25.00 Inj 100 mg per ml, 50 ml vial – PCT – Retail	1	 Methotrexate Ebewe
	pharmacy-Specialist	1	 Methotrexate Ebewe
*	Inj 1 mg for ECP – PCT only – Specialist0.06	1 mg	✓ Baxter
*	Inj 5 mg intrathecal syringe for ECP – PCT only – Specialist	5 mg OP	 Baxter

	Subsidy (Manufacturer's Price) \$		Fully Subsidised	
PEMETREXED – PCT only – Specialist – Special Authority see	SA1679 below			
Inj 100 mg vial		1	✓	Juno Pemetrexed
Inj 500 mg vial		1	✓	Juno Pemetrexed
Inj 1 mg for ECP	0.55	1 mg	1	Baxter

➡SA1679 Special Authority for Subsidy

Initial application — (mesothelioma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria: Both:

- 1 Patient has been diagnosed with mesothelioma; and
- 2 Pemetrexed to be administered at a dose of 500 mg/m² every 21 days in combination with cisplatin or carboplatin for a maximum of 6 cycles.

Renewal — (mesothelioma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria: All of the following:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefitting from treatment; and
- 3 Pemetrexed to be administered at a dose of 500mg/m² every 21 days for a maximum of 6 cycles.

Initial application — (non-small cell lung carcinoma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria: Both:

- 1 Patient has locally advanced or metastatic non-squamous non-small cell lung carcinoma; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Patient has chemotherapy-naïve disease; and
 - 2.1.2 Pemetrexed is to be administered at a dose of 500 mg/m² every 21 days in combination with cisplatin or carboplatin for a maximum of 6 cycles; or
 - 2.2 All of the following:
 - 2.2.1 Patient has had first-line treatment with platinum based chemotherapy; and
 - 2.2.2 Patient has not received prior funded treatment with pemetrexed; and
 - 2.2.3 Pemetrexed is to be administered at a dose of 500 mg/m² every 21 days for a maximum of 6 cycles.

Renewal — (non-small cell lung carcinoma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria: All of the following:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefitting from treatment; and
- 3 Pemetrexed is to be administered at a dose of 500mg/m² every 21 days.

THIOGUANINE - PCT - Retail pharmacy-Specialist

Tab 40 mg	25	 Lanvis
Other Cytotoxic Agents		
AMSACRINE – PCT only – Specialist		
Inj 50 mg per ml, 1.5 ml ampoule1,500.00	6	 Amsidine S29
4,736.00		 Amsidine S29
Inj 75 mg1,250.00	5	AmsaLyo S29
ANAGRELIDE HYDROCHLORIDE – PCT – Retail pharmacy-Specialist		
Cap 0.5 mg1,175.87	100	🗸 Agrylin
ARSENIC TRIOXIDE – PCT only – Specialist		
Inj 1 mg per ml, 10 ml vial4,817.00	10	 Phenasen
Inj 10 mg for ECP	10 mg OP	 Baxter

AThree months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

(M	Subsidy lanufacturer's Price \$) Subs Per	Fully idised	
BLEOMYCIN SULPHATE – PCT only – Specialist Inj 15,000 iu, vial	161.01	1	1	DBL Bleomycin Sulfate
Inj 1,000 iu for ECP	12.45	1,000 iu	✓	Baxter
BORTEZOMIB – PCT only – Specialist – Special Authority see SA1 Inj 2.5 mg vial		1	1	Bortezomib Juno S29 S29
Inj 3.5 mg vial	105.00	1	•	Bortezomib Dr Reddy's S29 529 Bortezomib Dr-Reddy's Bortezomib Juno 529
Inj 1 mg for ECP (Bortezomib Juno S29 ⁶²⁹ Inj 2.5 mg vial to be delisted 1 August 2 (Bortezomib Dr Reddy's S29 ⁶²⁹ Inj 3.5 mg vial to be delisted 1 August 2 (Bartezomib Iuro Carl State Index 1 August 2000)	2022) Igust 2022)	1 mg	1	Baxter

(Bortezomib Juno S29 Inj 3.5 mg vial to be delisted 1 August 2022)

► SA1889 Special Authority for Subsidy

Initial application — (multiple myeloma/amyloidosis) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 The patient has symptomatic multiple myeloma; or
- 2 The patient has symptomatic systemic AL amyloidosis *.
- Note: Indications marked with * are unapproved indications.

DACARBAZINE - PCT only - Specialist

Inj 200 mg vial	62.70	1	 DBL Dacarbazine
	580.60	10	 Dacarbazine APP S29
Inj 200 mg for ECP	62.70	200 mg OP	 Baxter
DACTINOMYCIN [ACTINOMYCIN D] - PCT only - Specialis	st		
Inj 0.5 mg vial		1	 Cosmegen
Inj 0.5 mg for ECP		0.5 mg OP	✓ Baxter
DAUNORUBICIN – PCT only – Specialist			
Inj 2 mg per ml, 10 ml	149.50	1	 Pfizer
Inj 20 mg for ECP	149.50	20 mg OP	 Baxter
DOCETAXEL – PCT only – Specialist			
Inj 20 mg		1	 Docetaxel Sandoz
Inj 10 mg per ml, 8 ml vial		1	 DBL Docetaxel
Inj 20 mg per ml, 4 ml vial	26.95	1	 Docetaxel
			Accord S29
Inj 80 mg		1	 Docetaxel Sandoz
Inj 1 mg for ECP	0.65	1 mg	 Baxter

	Subsidy (Manufacturer's Price) \$	Per	Fully Brand or Subsidised Generic ✓ Manufacturer
DOXORUBICIN HYDROCHLORIDE - PCT only - Specialist			
Inj 2 mg per ml, 5 ml vial		1	Doxorubicin Ebewe
Inj 2 mg per ml, 25 ml vial	11.50	1	Doxorubicin Ebewe
	17.00		Arrow-Doxorubicin
Inj 2 mg per ml, 50 ml vial		1	 Doxorubicin Ebewe
Inj 2 mg per ml, 100 ml vial	65.00	1	Arrow-Doxorubicin
	69.99		 Doxorubicin Ebewe
Inj 1 mg for ECP	0.35	1 mg	Sexter
EPIRUBICIN HYDROCHLORIDE - PCT only - Specialist			
Inj 2 mg per ml, 5 ml vial		1	 Epirubicin Ebewe
Inj 2 mg per ml, 25 ml vial		1	 Epirubicin Ebewe
Inj 2 mg per ml, 100 ml vial		1	 Epirubicin Ebewe
Inj 1 mg for ECP	0.50	1 mg	Baxter
ETOPOSIDE		-	
Cap 50 mg – PCT – Retail pharmacy-Specialist	340.73	20	✓ Vepesid
Cap 100 mg – PCT – Retail pharmacy-Specialist		10	✓ Vepesid
Inj 20 mg per ml, 5 ml vial – PCT – Retail pharmacy-Specia		1	✓ Rex Medical
Inj 1 mg for ECP – PCT only – Specialist		1 mg	_
ETOPOSIDE PHOSPHATE – PCT only – Specialist			
Inj 100 mg (of etoposide base)	40.00	1	 Etopophos
Inj 1 mg (of etoposide base) for ECP	0.47	1 mg	•••
HYDROXYUREA [HYDROXYCARBAMIDE] – PCT – Retail pha		1 1119	Duktor
		100	 Devatis
Cap 500 mg	23.02	100	• Devails
DARUBICIN HYDROCHLORIDE			4 - .
Inj 5 mg vial – PCT only – Specialist		1	Zavedos
Inj 10 mg vial – PCT only – Specialist		1	✓ Zavedos
Inj 1 mg for ECP – PCT only – Specialist	21.84	1 mg	Baxter
ENALIDOMIDE – Retail pharmacy-Specialist – Special Author Wastage claimable	ity see SA2047 below		
Cap 5 mg	5,122.76	28	 Revlimid
Cap 10 mg	4,655.25	21	 Revlimid
	6,207.00	28	 Revlimid
Cap 15 mg	5,429.39	21	 Revlimid
	7,239.18	28	 Revlimid
Cap 25 mg	7,627.00	21	 Revlimid

⇒SA2047 Special Authority for Subsidy

Initial application — (Relapsed/refractory disease) only from a haematologist or any relevant practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Patient has relapsed or refractory multiple myeloma with progressive disease; and
- 2 Patient has not previously been treated with lenalidomide; and
- 3 Either:
 - 3.1 Lenalidomide to be used as third line* treatment for multiple myeloma; or
 - 3.2 Both:
 - 3.2.1 Lenalidomide to be used as second line treatment for multiple myeloma; and
 - 3.2.2 The patient has experienced severe (grade 3 or higher), dose limiting, peripheral neuropathy with either bortezomib or thalidomide that precludes further treatment with either of these treatments; and

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy		Fully	Brand or	
(Manufacturer's Price)	S	Subsidised	Generic	
\$	Per	1	Manufacturer	

continued...

4 Lenalidomide to be administered at a maximum dose of 25 mg/day in combination with dexamethasone.

Initial application — (Maintenance following first-line autologous stem cell transplant (SCT)) only from a haematologist or any relevant practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has newly diagnosed symptomatic multiple myeloma and has undergone first-line treatment that included an autologous stem cell transplantation; and
- 2 Patient has at least a stable disease response in the first 100 days after transplantation; and
- 3 Lenalidomide maintenance is to be commenced within 6 months of transplantation; and
- 4 Lenalidomide to be administered at a maximum dose of 15 mg/day.

Renewal — (Relapsed/refractory disease) only from a haematologist or any relevant practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and patient is benefitting from treatment.

Renewal — (Maintenance following first line autologous SCT) only from a haematologist or any relevant practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and patient is benefitting from treatment.

Note: Indication marked with * is an unapproved indication. A line of treatment is considered to comprise either: a) a known therapeutic chemotherapy regimen and supportive treatments or b) a transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments. Prescriptions must be written by a registered prescriber in the lenalidomide risk management programme operated by the supplier.

MESNA

Tab 400 mg – PCT – Retail pharmacy-Specialist	50 50	 ✓ <u>Uromitexan</u> ✓ <u>Uromitexan</u>
Inj 100 mg per ml, 4 ml ampoule – PCT only – Specialist	15	 Uromitexan
Inj 100 mg per ml, 10 ml ampoule – PCT only – Specialist	15	 Uromitexan
Inj 1 mg for ECP – PCT only – Specialist2.96	100 mg	 Baxter
MITOMYCIN C – PCT only – Specialist		
Inj 20 mg vial3,275.00	1	 Omegapharm S29
		✓ Teva
Inj 1 mg for ECP470.75	1 mg	 Baxter
MITOZANTRONE – PCT only – Specialist		
Inj 2 mg per ml, 10 ml vial97.50	1	 Mitozantrone Ebewe
Inj 1 mg for ECP5.51	1 mg	 Baxter
OLAPARIB - Retail pharmacy-Specialist - Special Authority see SA1883 below	w	
Tab 100 mg3,701.00	56	🗸 Lynparza
Tab 150 mg	56	 Lynparza

➡SA1883 Special Authority for Subsidy

Initial application only from a medical oncologist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 Patient has a high-grade serous* epithelial ovarian, fallopian tube, or primary peritoneal cancer; and
- 2 There is documentation confirming pathogenic germline BRCA1 or BRCA2 gene mutation; and

Subsidy		Fully	Brand or	
(Manufacturer's Price	e) S	ubsidised	Generic	
\$	Per	1	Manufacturer	

continued...

- 3 Patient has received at least two lines of previous treatment with platinum-based chemotherapy; and
- 4 Patient has platinum sensitive disease defined as disease progression occurring at least 6 months after the last dose of the penultimate line of platinum-based chemotherapy; and
- 5 Patient's disease must have achieved partial or complete response to treatment with the immediately preceding platinum-based regimen; and
- 6 Patient's disease has not progressed following prior treatment with olaparib; and
- 7 Treatment will be commenced within 8 weeks of the patient's last dose of the immediately preceding platinum-based regimen; and
- 8 Treatment to be administered as maintenance treatment; and
- 9 Treatment not to be administered in combination with other chemotherapy.

Renewal only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Treatment remains clinically appropriate and patient is benefitting from treatment; and
- 2 No evidence of progressive disease; and
- 3 Treatment to be administered as maintenance treatment; and
- 4 Treatment not to be administered in combination with other chemotherapy.

Note: *Note "high-grade serous" includes tumours with high-grade serous features or a high-grade serous component.

PACLITAXEL - PCT only - Specialist

Inj 30 mg		5	Paclitaxel Ebewe
Inj 100 mg		1	Paclitaxel Ebewe
	91.67		Paclitaxel Actavis
Inj 150 mg		1	Paclitaxel Ebewe
	137.50		Anzatax
			Paclitaxel Actavis
Inj 300 mg		1	Paclitaxel Ebewe
	275.00		 Anzatax
			Paclitaxel Actavis
Inj 1 mg for ECP	0.20	1 mg	 Baxter
PEGASPARGASE - PCT only - Special Authority	see SA1979 below		
Inj 750 iu per ml, 5 ml vial		1	Oncaspar LYO \$29

⇒SA1979 Special Authority for Subsidy

Initial application — (Acute lymphoblastic leukaemia) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both:

1 The patient has newly diagnosed acute lymphoblastic leukaemia; and

2 Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol.

Initial application — (Lymphoma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months where the patient has lymphoma requiring L-asparaginase containing protocols (e.g. SMILE).

Renewal — (Acute lymphoblastic leukaemia) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both:

1 The patient has relapsed acute lymphoblastic leukaemia; and

2 Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol.

PENTOSTATIN [DEOXYCOFORMYCIN] – PCT only – Specia	alist		
Inj 10 mg	CBS	1	 Nipent S29
PROCARBAZINE HYDROCHLORIDE - PCT - Retail pharma	cy-Specialist		
Cap 50 mg		50	 Natulan S29

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	
EMOZOLOMIDE - Special Authority see SA1741 below -	Retail pharmacy			
Cap 5 mg	9.13	5	✓	Temaccord
Cap 20 mg		5	✓	Temaccord
	18.30		✓	Apo-Temozolomide
	136.00	14	✓	Accord S29
Cap 100 mg		5	✓	Temaccord
	40.20		✓	Apo-Temozolomide
	532.00	14	✓	Accord S29
Cap 140 mg		5	1	Temaccord
	400.00		1	Amneal S29
Cap 180 mg	620.00	14	✓	Accord S29
Cap 250 mg		5	1	Temaccord
	688.00		1	Amneal S29

⇒SA1741 Special Authority for Subsidy

Initial application — (high grade gliomas) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Patient has newly diagnosed glioblastoma multiforme; or
 - 1.2 Patient has newly diagnosed anaplastic astrocytoma*; and
- 2 Temozolomide is to be (or has been) given concomitantly with radiotherapy; and
- 3 Following concomitant treatment temozolomide is to be used for a maximum of 5 days treatment per cycle, at a maximum dose of 200 mg/m² per day.

Initial application — (neuroendocrine tumours) only from a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with metastatic or unresectable well-differentiated neuroendocrine tumour*; and
- 2 Temozolomide is to be given in combination with capecitabine; and
- 3 Temozolomide is to be used in 28 day treatment cycles for a maximum of 5 days treatment per cycle at a maximum dose of 200 mg/m² per day; and
- 4 Temozolomide to be discontinued at disease progression.

Initial application — (ewing's sarcoma) only from a relevant specialist. Approvals valid for 9 months where the patient has relapsed/refractory Ewing's sarcoma.

Renewal — (high grade gliomas) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 Patient has glioblastoma multiforme; and
 - 1.2 The treatment remains appropriate and the patient is benefitting from treatment; or
- 2 All of the following:
 - 2.1 Patient has anaplastic astrocytoma*; and
 - 2.2 The treatment remains appropriate and the patient is benefitting from treatment; and
 - 2.3 Adjuvant temozolomide is to be used for a maximum of 24 months.

Renewal — (neuroendocrine tumours) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

1 No evidence of disease progression; and

Subsidy		Fully	Brand or
(Manufacturer's Price)	Subs	idised	Generic
\$	Per	1	Manufacturer

continued...

2 The treatment remains appropriate and the patient is benefitting from treatment.

Renewal — (ewing's sarcoma) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

1 No evidence of disease progression; and

2 The treatment remains appropriate and the patient is benefitting from treatment.

Note: Indication marked with a * is an unapproved indication. Temozolomide is not subsidised for the treatment of relapsed high grade glioma.

THALIDOMIDE - Retail pharmacy-Specialist - Special Authority see SA1124 below

Cap 50 mg	378.00	28	 Thalomid
Cap 100 mg	756.00	28	 Thalomid

➡SA1124 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either:

- 1 The patient has multiple myeloma; or
- 2 The patient has systemic AL amyloidosis*.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified where the patient has obtained a response from treatment during the initial approval period.

Notes: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier.

Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen.

Indication marked with * is an unapproved indication.

TRETINOIN

Cap 10 mg – PCT – Retail pharmacy-Specialist	479.50	100	 Vesanoid
VENETOCLAX - Retail pharmacy-Specialist - Special Author	ity see SA1868 belo	w	
Tab 14 × 10 mg, 7 × 50 mg, 21 × 100 mg		42 OP	 Venclexta
Tab 10 mg		14 OP	Venclexta
Tab 50 mg		7 OP	 Venclexta
Tab 100 mg – Wastage claimable	8,209.41	120	 Venclexta

➡SA1868 Special Authority for Subsidy

Initial application — (relapsed/refractory chronic lymphocytic leukaemia) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 7 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic lymphocytic leukaemia requiring treatment; and
- 2 Patient has received at least one prior therapy for chronic lymphocytic leukaemia; and
- 3 Patient has not previously received funded venetoclax; and
- 4 The patient's disease has relapsed within 36 months of previous treatment; and
- 5 Venetoclax to be used in combination with six 28-day cycles of rituximab commencing after the 5-week dose titration schedule with venetoclax; and
- 6 Patient has an ECOG performance status of 0-2.

Renewal — (relapsed/refractory chronic lymphocytic leukaemia) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both:

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Subs	sidised	Generic	
\$	Per	1	Manufacturer	

continued...

- 1 Treatment remains clinically appropriate and the patient is benefitting from and tolerating treatment; and
- 2 Venetoclax is to be discontinued after a maximum of 24 months of treatment following the titration schedule unless earlier discontinuation is required due to disease progression or unacceptable toxicity.

Initial application — (previously untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation*) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has previously untreated chronic lymphocytic leukaemia; and
- 2 There is documentation confirming that patient has 17p deletion by FISH testing or TP53 mutation by sequencing; and
- 3 Patient has an ECOG performance status of 0-2.

Renewal — (previously untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation*) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months where the treatment remains clinically appropriate and the patient is benefitting from and tolerating treatment.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma (SLL)* and B-cell prolymphocytic leukaemia (B-PLL)*. Indications marked with * are Unapproved indications.

١	/INBLASTINE SULPHATE		
	Inj 1 mg per ml, 10 ml vial – PCT – Retail pharmacy-Specialist270.37	5	 Hospira
	Inj 1 mg for ECP – PCT only – Specialist	1 mg	 Baxter
١	INCRISTINE SULPHATE		
	Inj 1 mg per ml, 1 ml vial – PCT – Retail pharmacy-Specialist74.52	5	 DBL Vincristine Sulfate
	Inj 1 mg per ml, 2 ml vial – PCT – Retail pharmacy-Specialist 102.73	5	 DBL Vincristine Sulfate
	Inj 1 mg for ECP – PCT only – Specialist12.60	1 mg	 Baxter
١	/INORELBINE - PCT only - Specialist		
	Inj 10 mg per ml, 1 ml vial	1	 Navelbine
	42.00		 Vinorelbine Ebewe
	Inj 10 mg per ml, 5 ml vial56.00	1	 Navelbine
	210.00		 Vinorelbine Ebewe
	328.65		 Sagent S29
	Inj 1 mg for ECP	1 mg	✓ Baxter
	Inj 50 mg for ECP328.65	50 mg OP	 Baxter (Sagent)

Protein-tyrosine Kinase Inhibitors

ALECTINIB - Retail pharmacy-Specialist - Special Authority	see SA1870 below		
Wastage claimable			
Cap 150 mg	7,935.00	224	 Alecensa

⇒SA1870 Special Authority for Subsidy

Initial application only from a medical oncologist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Patient has locally advanced, or metastatic, unresectable, non-small cell lung cancer; and
- 2 There is documentation confirming that the patient has an ALK tyrosine kinase gene rearrangement using an appropriate ALK test; and
- 3 Patient has an ECOG performance score of 0-2.

158

 Subsidy (Manufacturer's Price)	Fu Subsidis	,	
 \$	Per	 Manufacturer 	

continued...

Renewal only from a medical oncologist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both:

1 No evidence of progressive disease according to RECIST criteria; and

2 The patient is benefitting from and tolerating treatment.

DASATINIB - Special Authority see SA1805 below - Retail pharmacy

Wastage claimable

Tab 20 mg	60	 Sprycel
Tab 50 mg6,214.20	60	 Sprycel
Tab 70 mg7,692.58	60	 Sprycel

⇒SA1805 Special Authority for Subsidy

Initial application only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:

Any of the following:

1 Both:

1.1 The patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis or accelerated phase; and

1.2 Maximum dose of 140 mg/day; or

2 Both:

2.1 The patient has a diagnosis of Philadelphia chromosome-positive acute lymphoid leukaemia (Ph+ ALL); and

2.2 Maximum dose of 140 mg/day; or

3 All of the following:

- 3.1 The patient has a diagnosis of CML in chronic phase; and
- 3.2 Maximum dose of 100 mg/day; and
- 3.3 Any of the following:
 - 3.3.1 Patient has documented treatment failure* with imatinib; or
 - 3.3.2 Patient has experienced treatment-limiting toxicity with imatinib precluding further treatment with imatinib; or
 - 3.3.3 Patient has high-risk chronic-phase CML defined by the Sokal or EURO scoring system; or
 - 3.3.4 Patients is enrolled in the KISS study** and requires dasatinib treatment according to the study protocol.

Renewal only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Lack of treatment failure while on dasatinib*; and
- 2 Dasatinib treatment remains appropriate and the patient is benefiting from treatment; and
- 3 Maximum dasatinib dose of 140 mg/day for accelerated or blast phase CML and Ph+ ALL, and 100 mg/day for chronic phase CML.

Note: *treatment failure for CML as defined by Leukaemia Net Guidelines. **Kinase-Inhibition Study with Sprycel Start-up https://www.cancertrialsnz.ac.nz/kiss/

ERLOTINIB - Retail pharmacy-Specialist - Special Author	ty see SA2000 below

Tab 100 mg		30	 Tarceva
Tab 150 mg	1,146.00	30	 Tarceva

⇒SA2000 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria: All of the following:

1 Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and

Subsic	dy Ful	y Brand or
(Manufacture	r's Price) Subsidise	d Generic
\$	Per	Manufacturer

continued...

- 2 There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase; and
- 3 Either:
 - 3.1 Patient is treatment naive; or
 - 3.2 Both:
 - 3.2.1 The patient has discontinued gefitinib due to intolerance; and
 - 3.2.2 The cancer did not progress while on gefitinib; and
- 4 Erlotinib is to be given for a maximum of 3 months.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months where radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

GEFITINIB - Retail pharmacy-Specialist - Special Authority see SA2001 below

Tab 250 mg 1,700.00 30

► SA2001 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria: All of the following:

- 1 Patient has locally advanced, or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
- 2 Either:
 - 2.1 Patient is treatment naive; or
 - 2.2 Both:
 - 2.2.1 The patient has discontinued erlotinib due to intolerance; and
 - 2.2.2 The cancer did not progress whilst on erlotinib; and
- 3 There is documentation confirming that disease expresses activating mutations of EGFR tyrosine kinase; and
- 4 Gefitinib is to be given for a maximum of 3 months.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months where radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

IMATINIB MESILATE

Note: The Glivec brand of imatinib mesilate (supplied by Novartis) remains fully subsidised under Special Authority for patients with unresectable and/or metastatic malignant GIST only, see SA1460 in Section B of the Pharmaceutical Schedule.

	Tab 100 mg – [Xpharm] – Special Authority see	SA1460		
	below	2,400.00	60	 Glivec
*	Cap 100 mg		60	Imatinib-Rex
	Cap 400 mg		30	Imatinib-Rex

► SA1460 Special Authority for Subsidy

Special Authority approved by the CML/GIST Co-ordinator

Notes: Application details may be obtained from Pharmac's website <u>schedule.pharmac.govt.nz/SAForms</u>, and prescriptions should be sent to:

The CML/GIST Co-ordinator	Phone: (04) 460 4990
Pharmac	Facsimile: (04) 916 7571
PO Box 10 254	Email: cmlgistcoordinator@pharmac.govt.nz
Wellington	

Special Authority criteria for GIST - access by application

Funded for patients:

 a) With a diagnosis (confirmed by an oncologist) of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST).

continued...

Iressa

	Subsidy (Manufacturer's Price)	Subsid	Fully dised	Brand or Generic
	\$	Per	1	Manufacturer
continued				
 b) Maximum dose of 400 mg/day. c) Applications to be made and subsequent prescriptions can d) Initial and subsequent applications are valid for one year. the treatment with imatinib (prescriber determined). 			n adeq	uate clinical response to
LAPATINIB DITOSYLATE – Special Authority see SA2035 below Note – no new patients to be initiated on lapatinib ditosylate.	N – Retail pharmacy			
Tab 250 mg	1,899.00	70	🗸 Т	ykerb
 SA2035 Special Authority for Subsidy Renewal — (metastatic breast cancer) only from a relevant specialist. Approvals valid for 12 months for applications All of the following: The patient has metastatic breast cancer expressing HER and The cancer has not progressed at any time point during the substitution of the special bit of the special	s meeting the followin I-2 IHC 3+ or ISH+ (in ne previous 12 months	g criteria: Icluding FIS	SH or o	ther current technology);
 VILOTINIB – Special Authority see SA1489 below – Retail pharr 	2001			
Wastage claimable	nacy			
Cap 150 mg		120	🗸 Ta	asigna
Cap 200 mg	6,532.00	120	🗸 Ta	asigna
 SA1489 Special Authority for Subsidy Initial application only from a haematologist. Approvals valid fo All of the following: Patient has a diagnosis of chronic myeloid leukaemia (CM 2 Either: 	IL) in blast crisis, acce th imatinib; or with imatinib precludii s. Is for applications me eukaemia Net Guideli benefiting from treatm	elerated phone ng further tr eting the fo ines; and hent; and	ase, or reatme	r in chronic phase; and
Wastage claimable	SEE SA 1094 UN LITE II	eni paye		
Tab 75 mg	,	21		orance
Tab 100 mg		21		orance
Tab 125 mg		21 21		prance
Cap 75 mg Cap 100 mg		21 21		orance orance
Cap 125 mg	,	21		brance
(Ibrance Cap 75 mg to be delisted 1 March 2022) (Ibrance Cap 100 mg to be delisted 1 March 2022)	,			

(Ibrance Cap 125 mg to be delisted 1 March 2022)

Subsidy (Manufacturer's Price)	Sub	Fully osidised	Brand or Generic
\$	Per	1	Manufacturer

⇒SA1894 Special Authority for Subsidy

Initial application only from a medical oncologist or medical practitioner on the recommendation of a Medical oncologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

1 Patient has unresectable locally advanced or metastatic breast cancer; and

- 2 There is documentation confirming disease is hormone-receptor positive and HER2-negative; and
- 3 Patient has an ECOG performance score of 0-2; and

4 Either:

second or subsequent line setting

4.1 Disease has relapsed or progressed during prior endocrine therapy; or

4.2 Both:

- first line setting
- 4.2.1 Patient is amenorrhoeic, either naturally or induced, with endocrine levels consistent with a postmenopausal state; and
- 4.2.2 Either:
 - 4.2.2.1 Patient has not received prior systemic treatment for metastatic disease; or
 - 4.2.2.2 All of the following:
 - 4.2.2.2.1 Patient commenced treatment with palbociclib in combination with an endocrine agent prior to 1 April 2020; and
 - 4.2.2.2.2 Patient has not received prior systemic endocrine treatment for metastatic disease; and
 - 4.2.2.2.3 There is no evidence of progressive disease; and
- 5 Treatment must be used in combination with an endocrine partner.

Renewal only from a medical oncologist or medical practitioner on the recommendation of a Medical oncologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Treatment must be used in combination with an endocrine partner; and
- 2 No evidence of progressive disease; and
- 3 The treatment remains appropriate and the patient is benefitting from treatment.

PAZOPANIB - Special Authority see SA1190 below - Retail pharmacy

Tab 200 mg		30	 Votrient
Tab 400 mg	2,669.40	30	 Votrient

➡SA1190 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: All of the following:

All of the following:

- 1 The patient has metastatic renal cell carcinoma; and
- 2 Any of the following:
 - 2.1 The patient is treatment naive; or
 - 2.2 The patient has only received prior cytokine treatment; or

2.3 Both:

2.3.1 The patient has discontinued sunitinib within 3 months of starting treatment due to intolerance; and

- 2.3.2 The cancer did not progress whilst on sunitinib; and
- 3 The patient has good performance status (WHO/ECOG grade 0-2); and
- 4 The disease is of predominant clear cell histology; and The patient has intermediate or poor prognosis defined as:
- 5 Any of the following:

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or
- 5.2 Haemoglobin level < lower limit of normal; or
- 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
- 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or
- 5.5 Karnofsky performance score of less than or equal to 70; or
- 5.6 2 or more sites of organ metastasis; and
- 6 Pazopanib to be used for a maximum of 3 months.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Notes: Pazopanib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

RUXOLITINIB - Special Authority see SA1890 below - Retail pharmacy

Wastage claimable

Tab 5 mg2,500.00	56	🗸 Jakavi
Tab 10mg	56	🗸 Jakavi
Tab 15 mg	56	🗸 Jakavi
Tab 20 mg5,000.00	56	🗸 Jakavi

⇒SA1890 Special Authority for Subsidy

Initial application only from a haematologist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient has primary myelofibrosis or post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis; and
- 2 Either:
 - 2.1 A classification of risk of intermediate-2 or high-risk myelofibrosis according to either the International Prognostic Scoring System (IPSS), Dynamic International Prognostic Scoring System (DIPSS), or the Age-Adjusted DIPSS; or
 - 2.2 Both:
 - 2.2.1 A classification of risk of intermediate-1 myelofibrosis according to either the International Prognostic Scoring System (IPSS), Dynamic International Prognostic Scoring System (DIPSS), or the Age-Adjusted DIPSS; and
 - 2.2.2 Patient has severe disease-related symptoms that are resistant, refractory or intolerant to available therapy; and
- 3 A maximum dose of 20 mg twice daily is to be given.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 A maximum dose of 20 mg twice daily is to be given.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Generic
SUNITINIB - Special Authority see SA2002 below - Retail pharm	nacy			
Cap 12.5 mg		28	✓	Sunitinib Pfizer
	2,315.38		✓	Sutent
Cap 25 mg	416.77	28	✓	Sunitinib Pfizer
	4,630.77		✓	Sutent
Cap 50 mg	694.62	28	✓	Sunitinib Pfizer
· -	9,261.54		✓	Sutent

(Sutent Cap 12.5 mg to be delisted 1 July 2022) (Sutent Cap 25 mg to be delisted 1 July 2022) (Sutent Cap 50 mg to be delisted 1 July 2022)

⇒SA2002 Special Authority for Subsidy

Initial application — (RCC) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: All of the following:

- 1 The patient has metastatic renal cell carcinoma; and
- 2 Any of the following:
 - 2.1 The patient is treatment naive; or
 - 2.2 The patient has only received prior cytokine treatment; or
 - 2.3 The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval; or
 - 2.4 Both:
 - 2.4.1 The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance; and
 - 2.4.2 The cancer did not progress whilst on pazopanib; and
- 3 The patient has good performance status (WHO/ECOG grade 0-2); and
- 4 The disease is of predominant clear cell histology; and
 - The patient has intermediate or poor prognosis defined as:
- 5 Any of the following:
 - 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or
 - 5.2 Haemoglobin level < lower limit of normal; or
 - 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
 - 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or
 - 5.5 Karnofsky performance score of less than or equal to 70; or
 - 5.6 2 or more sites of organ metastasis; and
- 6 Sunitinib to be used for a maximum of 2 cycles.

Initial application — (GIST) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both:

1 The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST); and

- 2 Either:
 - 2.1 The patient's disease has progressed following treatment with imatinib; or
 - 2.2 The patient has documented treatment-limiting intolerance, or toxicity to, imatinib.

Renewal — (RCC) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Notes: Sunitinib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having

Subsidy		Fully	Brand or
(Manufacturer's Price)	S	ubsidised	Generic
\$	Per	✓	Manufacturer

continued...

1 or 2 of criteria 5.1-5.6

Renewal — (GIST) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

The patient has responded to treatment or has stable disease as determined by Choi's modified CT response evaluation criteria as follows:

- 1 Any of the following:
 - 1.1 The patient has had a complete response (disappearance of all lesions and no new lesions); or
 - 1.2 The patient has had a partial response (a decrease in size of 10% or more or decrease in tumour density in Hounsfield Units (HU) of 15% or more on CT and no new lesions and no obvious progression of non measurable disease); or
 - 1.3 The patient has stable disease (does not meet criteria the two above) and does not have progressive disease and no symptomatic deterioration attributed to tumour progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Note: It is recommended that response to treatment be assessed using Choi's modified CT response evaluation criteria (J Clin Oncol, 2007, 25:1753-1759). Progressive disease is defined as either: an increase in tumour size of 10% or more and not meeting criteria of partial response (PR) by tumour density (HU) on CT; or: new lesions, or new intratumoral nodules, or increase in the size of the existing intratumoral nodules.

Endocrine Therapy

For GnRH ANALOGUES - refer to HORMONE PREPARATIONS, Trophic Hormones, page 84

🗸 Zytiga

► SA2003 Special Authority for Subsidy

Initial application only from a medical oncologist, radiation oncologist, urologist or medical practitioner on the recommendation of a medical oncologist, radiation oncologist or urologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Patient has prostate cancer; and
- 2 Patient has metastases; and
- 3 Patient's disease is castration resistant; and
- 4 Either:
 - 4.1 All of the following:
 - 4.1.1 Patient is symptomatic; and
 - 4.1.2 Patient has disease progression (rising serum PSA) after second line anti-androgen therapy; and
 - 4.1.3 Patient has ECOG performance score of 0-1; and
 - 4.1.4 Patient has not had prior treatment with taxane chemotherapy; or
 - 4.2 All of the following:
 - 4.2.1 Patient's disease has progressed following prior chemotherapy containing a taxane; and
 - 4.2.2 Patient has ECOG performance score of 0-2; and
 - 4.2.3 Patient has not had prior treatment with abiraterone.

Renewal — (abiraterone acetate) only from a medical oncologist, radiation oncologist, urologist or medical practitioner on the recommendation of a medical oncologist, radiation oncologist or urologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Significant decrease in serum PSA from baseline; and

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Generic
 continued 2 No evidence of clinical disease progression; and 3 No initiation of taxane chemotherapy with abiraterone; and 4 The treatment remains appropriate and the patient is beneficial disease. 				
BICALUTAMIDE				
Tab 50 mg	4.21	28	1	Binarex
FLUTAMIDE				
Tab 250 mg	107.55	90	✓	Prostacur S29
	119.50	100	1	Flutamin
FULVESTRANT - Retail pharmacy-Specialist - Special Authorit			-	
Inj 50 mg per ml, 5 ml prefilled syringe	1,068.00	2	~	Faslodex
Initial application only from a medical oncologist or medical pra Approvals valid for 6 months for applications meeting the followin All of the following:		nmen	dation of a	medical oncologist.
 Patient has oestrogen-receptor positive locally advanced Patient has disease progression following prior treatment advanced or metastatic disease; and 	with an aromatase in	hibito	,	ifen for their locally
3 Treatment to be given at a dose of 500 mg monthly follow4 Treatment to be discontinued at disease progression.	ing loading doses; ar	nd		
Renewal only from a medical oncologist or medical practitioner or for 6 months for applications meeting the following criteria: All of the following:	on the recommendation	on of	a medical	oncologist. Approvals valid
 Treatment remains appropriate and patient is benefitting f Treatment to be given at a dose of 500 mg monthly; and There is no evidence of disease progression. 	rom treatment; and			
MEGESTROL ACETATE – Subsidy by endorsement Subsidy by endorsement – Subsidised for patients who were prescription is endorsed accordingly. Pharmacists may anno subsidies accordingly.				

prior dispensing of megestrol acetate.

Tab 160 mg	48.80	30	
-	63.53		

(Megace S29) Tab 160 mg to be delisted 1 February 2023) (Apo-Megestrol Tab 160 mg to be delisted 1 May 2022) Megace S29
Apo-Megestrol

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	
OCTREOTIDE				
Inj 50 mcg per ml, 1 ml vial		5	✓	Octreotide
				MaxRx S29
	56.87		1	DBL Octreotide
Inj 100 mcg per ml, 1 ml vial	40.00	5	✓	DBL Octreotide
Inj 500 mcg per ml, 1 ml vial	145.00	5	1	DBL Octreotide
	222.00		1	Octreotide
				(Sun) S29
Inj 50 mcg per ml, 1 ml ampoule	27.58	5	1	Max Health
	30.64		1	Octreotide GH S29
Inj 100 mcg per ml, 1 ml ampoule	32.71	5	1	Max Health
			1	Octreotide GH S29
Inj 500 mcg per ml, 1 ml ampoule	113.10	5	✓	Max Health
			1	Octreotide GH S29
Detreotide GH \$220 Inj 50 mcg per ml, 1 ml ampoule to be deliste Detreotide GH \$220 Inj 100 mcg per ml, 1 ml ampoule to be deliste Detreotide GH \$220 Inj 500 mcg per ml, 1 ml ampoule to be deliste Detreotide GH \$220 Inj 500 mcg per ml, 1 ml ampoule to be deliste Detreotide GH \$220 Inj 500 mcg per ml, 1 ml ampoule to be deliste CTREOTIDE LONG-ACTING – Special Authority see \$A2072 b	ted 1 June 2022) ted 1 June 2022)	асу		
Inj depot 10 mg prefilled syringe	439.97	1	1	Octreotide Depot Teva
	1,772.50		1	Sandostatin LAR
Octreotide Depot Teva to be Principal Supply on 1 March				
Inj depot 20 mg prefilled syringe	647.03	1	1	Octreotide Depot Teva
	2,358.75		✓	Sandostatin LAR
Octreotide Depot Teva to be Principal Supply on 1 March				
Inj depot 30 mg prefilled syringe	718.55	1	1	Octreotide Depot Teva
	2,951.25		✓	Sandostatin LAR
Octreotide Depot Teva to be Principal Supply on 1 March	2022			
Sandostatin LAR Inj depot 10 mg prefilled syringe to be delisted a Sandostatin LAR Inj depot 20 mg prefilled syringe to be delisted a Sandostatin LAR Inj depot 30 mg prefilled syringe to be delisted a	March 2022)			

► SA2072 Special Authority for Subsidy

Initial application — (Malignant Bowel Obstruction) from any relevant practitioner. Approvals valid for 2 months for applications meeting the following criteria:

All of the following:

- 1 The patient has nausea* and vomiting* due to malignant bowel obstruction*; and
- 2 Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has failed; and
- 3 Octreotide to be given at a maximum dose 1500 mcg daily for up to 4 weeks.

Note: Indications marked with * are unapproved indications.

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

Renewal — (Malignant Bowel Obstruction) from any relevant practitioner. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Acromegaly) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

- Both:
 - 1 The patient has acromegaly; and
 - 2 Any of the following:
 - 2.1 Treatment with surgery, radiotherapy and a dopamine agonist has failed; or
 - 2.2 Treatment with octreotide is for an interim period while awaiting the effects of radiotherapy and a dopamine agonist has failed; or
 - 2.3 The patient is unwilling, or unable, to undergo surgery and/or radiotherapy.

Renewal — (Acromegaly) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

- Both:
 - 1 IGF1 levels have decreased since starting octreotide; and
 - 2 The treatment remains appropriate and the patient is benefiting from treatment.

Note: In patients with Acromegaly octreotide treatment should be discontinued if IGF1 levels have not decreased after 3 months treatment. In patients treated with radiotherapy octreotide treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Octreotide treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following octreotide treatment withdrawal for at least 4 weeks

Initial application — (Other Indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

- Any of the following:
 - 1 VIPomas and Glucagonomas for patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or
 - 2 Both:
 - 2.1 Gastrinoma; and
 - 2.2 Either:
 - 2.2.1 Patient has failed surgery; or
 - 2.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or
 - 3 Both:
 - 3.1 Insulinomas; and
 - 3.2 Surgery is contraindicated or has failed; or
 - 4 For pre-operative control of hypoglycaemia and for maintenance therapy; or
 - 5 Both:
 - 5.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and
 - 5.2 Disabling symptoms not controlled by maximal medical therapy.

Note: The use of octreotide in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will not be funded as a Special Authority item

Renewal — (Other Indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. Initial application — (pre-operative acromegaly) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 Patient has acromegaly; and
- 2 Patient has a large pituitary tumour, greater than 10 mm at its widest; and
- 3 Patient is scheduled to undergo pituitary surgery in the next six months.

	Subsidy (Manufacturer's Price)		Fully Subsidised	
	\$	Per		
TAMOXIFEN CITRATE * Tab 10 mg * Tab 20 mg		60 60		<u>Tamoxifen Sandoz</u> Tamoxifen Sandoz
Aromatase Inhibitors				
ANASTROZOLE * Tab 1 mg	4.55	30		Anatrole
EXEMESTANE * Tab 25 mg LETROZOLE	14.50	30	1	Pfizer Exemestane
* Tab 2.5 mg	5.84	30	1	Letrole
Immunosuppressants				
Cytotoxic Immunosuppressants				
AZATHIOPRINE * Tab 25 mg	7.25	60	1	Azamun
* Tab 20 mg		100		Azamun
* Inj 50 mg vial		1	1	Imuran
MYCOPHENOLATE MOFETIL				
Tab 500 mg		50		Cellcept
Cap 250 mg		100		Cellcept
Powder for oral liq 1 g per 5 ml – Subsidy by endorsement Mycophenolate powder for oral liquid is subsidised only the prescription is endorsed accordingly.		5 ml swal		Cellcept and capsules, and when
Fusion Proteins				
ETANERCEPT – Special Authority see SA2048 below – Retail	pharmacy			
Inj 25 mg.		4	1	Enbrel
Inj 25 mg autoinjector		4	-	Enbrel
Inj 50 mg autoinjector		4		Enbrel
Inj 50 mg prefilled syringe	1,050.00	4	1	Enbrel
■ SA2048 Special Authority for Subsidy Initial application — (adult-onset Still's disease) only from a meeting the following criteria: Either:	rheumatologist. Appr	ovals	valid for 6	months for applications

1 Both:

1.1 Either:

- 1.1.1 The patient has had an initial Special Authority approval for adalimumab for adult-onset Still's disease (AOSD); or
- 1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the HML rules; and

1.2 Either:

- 1.2.1 The patient has experienced intolerable side effects from adalimumab and/or tocilizumab; or
- 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

tocilizumab such that they do not meet the renewal criteria for AOSD; or

- 2 All of the following:
 - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
 - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal anti-inflammatory drugs (NSAIDs) and methotrexate; and
 - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Renewal — (adult-onset Still's disease) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 The patient has a sustained improvement in inflammatory markers and functional status.

Initial application — (ankylosing spondylitis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for ankylosing spondylitis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for ankylosing spondylitis; or
- 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
 - 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
 - 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of a regular exercise regimen for ankylosing spondylitis; and
 - 2.5 Either:
 - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
 - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and
 - 2.6 A Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of initial application.

Average normal chest expansion corrected for age and gender:

18-24 years - Male: 7.0 cm; Female: 5.5 cm 25-34 years - Male: 7.5 cm; Female: 5.5 cm 35-44 years - Male: 6.5 cm; Female: 4.5 cm 45-54 years - Male: 6.0 cm; Female: 5.0 cm 55-64 years - Male: 5.5 cm; Female: 4.0 cm 65-74 years - Male: 4.0 cm; Female: 4.0 cm

Subsidy	F	ully	Brand or
(Manufacturer's Price)	Subsidis	sed	Generic
\$	Per	✓	Manufacturer

continued...

75+ years - Male: 3.0 cm; Female: 2.5 cm

Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Following 12 weeks' initial treatment and for subsequent renewals, treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less; and
- 3 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 4 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initial application — (polyarticular course juvenile idiopathic arthritis) only from a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for polyarticular course juvenile idiopathic arthritis (JIA); and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for polyarticular course JIA; or
- 2 All of the following:
 - 2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.2 Patient has had polyarticular course JIA for 6 months duration or longer; and
 - 2.3 Any of the following:
 - 2.3.1 At least 5 active joints and at least 3 joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.3.2 Moderate or high disease activity (cJADAS10 score of at least 2.5) after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.3.3 Low disease activity (cJADAS10 score between 1.1 and 2.5) after a 6-month trial of methotrexate.

Renewal — (polyarticular course juvenile idiopathic arthritis) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initial application — (oligoarticular course juvenile idiopathic arthritis) only from a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Fither:

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	✓	Manufacturer

continued...

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for oligoarticular course juvenile idiopathic arthritis (JIA); and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for oligoarticular course JIA; or
- 2 All of the following:
 - 2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.2 Patient has had oligoarticular course JIA for 6 months duration or longer; and
 - 2.3 Any of the following:
 - 2.3.1 At least 2 active joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.3.2 Moderate or high disease activity (cJADAS10 score greater than 1.5) with poor prognostic features after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.3.3 High disease activity (cJADAS10 score greater than 4) after a 6-month trial of methotrexate.

Renewal — (oligoarticular course juvenile idiopathic arthritis) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initial application — (psoriatic arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

- Either:
 - 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab or secukinumab for psoriatic arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab or secukinumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab or secukinumab to meet the renewal criteria for adalimumab or secukinumab for psoriatic arthritis; or
 - 2 All of the following:
 - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or

S	Subsidy	Fully	Brand or
(Manufac	cturer's Price) Subsid	dised	Generic
	\$ Per	1	Manufacturer

continued...

- 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2.5 Any of the following:
 - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.
- Renewal (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist.
- Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initial application — (pyoderma gangrenosum) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pyoderma gangrenosum*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporine, azathioprine, or methotrexate) and not received an adequate response; and
- 3 A maximum of 8 doses.
- Note: Indications marked with * are unapproved indications.

Renewal — (pyoderma gangrenosum) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has shown clinical improvement; and
- 2 Patient continues to require treatment; and
- 3 A maximum of 8 doses.

Initial application — (rheumatoid arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for rheumatoid arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for rheumatoid arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and

Subsidy		ully	Brand or
(Manufacturer's Price)	Subsidis	ed	Generic
\$	Per	✓	Manufacturer

continued...

- 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
- 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
- 2.5 Any of the following:
 - 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or
 - 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
 - 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and

2.6 Either:

- 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
- 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2.7 Either:
 - 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Renewal — (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

1 Either:

- 1.1 Applicant is a rheumatologist; or
- 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 3 Either:
 - 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 4 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initial application — (severe chronic plaque psoriasis) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for severe chronic plaque psoriasis; and 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe chronic plaque psoriasis; or

Subsidy	Fu	lly Brand or	
(Manufacturer's Price)	Subsidis	ed Generic	
\$	Per	 Manufacturer 	

continued...

2 All of the following:

- 2.1 Either:
 - 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
- 2.3 A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 2.4 The most recent PASI or DLQI assessment is no more than 1 month old at the time of application.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment. **Renewal — (severe chronic plaque psoriasis)** only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 Applicant is a dermatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a dermatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 2.1.2 Either:
 - 2.1.2.1 Following each prior etanercept treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-treatment baseline value; or
 - 2.1.2.2 Following each prior etanercept treatment course the patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, when compared with the pre-treatment baseline value; or
 - 2.2 Both:
 - 2.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 2.2.2 Either:
 - 2.2.2.1 Following each prior etanercept treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 2.2.2.2 Following each prior etanercept treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-treatment baseline value; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Note: A treatment course is defined as a minimum of 12 weeks of etanercept treatment

Initial application — (undifferentiated spondyloarthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

	Subsidy		Fully	Brand or
(Ma	anufacturer's Price)	Subsid	lised	Generic
	\$	Per	✓	Manufacturer

continued...

All of the following:

- 1 Patient has undifferentiated peripheral spondyloarthritis* with active peripheral joint arthritis in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
- 3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day (or maximum tolerated dose); and
- 4 Patient has tried and not responded to at least three months of leflunomide at a dose of up to 20 mg daily (or maximum tolerated dose); and
- 5 Any of the following:
 - 5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 5.2 Patient has an elevated enythrocyte sedimentation rate (ESR) greater than 25 mm per hour measured no more than one month prior to the date of this application; or
 - 5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Note: Indications marked with * are unapproved indications.

Renewal — (undifferentiated spondyloarthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

1 Either:

- 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and
- 3 Etanercept to be administered at doses no greater than 50 mg dose every 7 days.

Immune Modulators

NTITHYMOCYTE GLOBULIN (EQUINE) – PCT only – S Inj 50 mg per ml, 5 ml		5	🖌 ATGAM
BACILLUS CALMETTE-GUERIN (BCG) VACCINE – PCT Subsidised only for bladder cancer.	only – Specialist		
Inj 2-8 × 100 million CFU		1	OncoTICE
Inj 40 mg per ml, vial		3	✓ SII-Onco-BCG S29
SII-Onco-BCG S29 Inj 40 mg per ml, vial to be delisted			

Monoclonal Antibodies

ADALIMUMAB - Special Authority see SA2049 on the next pa	age – Retail pharmac	у	
Inj 20 mg per 0.4 ml prefilled syringe		2	🗸 Humira
Inj 40 mg per 0.8 ml prefilled pen		2	 HumiraPen
Inj 40 mg per 0.8 ml prefilled syringe		2	🗸 Humira

Subsidy	Fu	Illy Brand or	
(Manufacturer's	Price) Subsidis	ed Generic	
\$	Per	 Manufacturer 	

⇒SA2049 Special Authority for Subsidy

Initial application — (adult-onset Still's disease) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Either

1 Both:

- 1.1 Either:
 - 1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still's disease (AOSD); or
 - 1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the HML rules; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept and/or tocilizumab; or
 - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of etanercept and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or
- 2 All of the following:
 - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
 - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal anti-inflammatory drugs (NSAIDs) and methotrexate; and
 - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Renewal — (adult-onset Still's disease) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 The patient has a sustained improvement in inflammatory markers and functional status.

Initial application — (ankylosing spondylitis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for ankylosing spondylitis; or
- 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis for more than six months; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
 - 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
 - 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of a regular exercise regimen for ankylosing spondylitis; and
 - 2.5 Either:
 - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of

Subsidy	Full	y Brand or	
(Manufacturer's Price)	Subsidise	d Generic	
\$	Per 🗸	Manufacturer	

continued...

- less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
- 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the following average normal values corrected for age and gender (see Notes); and
- 2.6 A Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of initial application.

Average normal chest expansion corrected for age and gender:

- 18-24 years Male: 7.0 cm; Female: 5.5 cm
- 25-34 years Male: 7.5 cm; Female: 5.5 cm
- 35-44 years Male: 6.5 cm; Female: 4.5 cm
- 45-54 years Male: 6.0 cm; Female: 5.0 cm
- 55-64 years Male: 5.5 cm; Female: 4.0 cm
- 65-74 years Male: 4.0 cm; Female: 4.0 cm

75+ years - Male: 3.0 cm; Female: 2.5 cm

Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Following 12 weeks' initial treatment and for subsequent renewals, treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less; and
- 3 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (chronic ocular inflammation) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for infliximab for chronic ocular inflammation; and

1.2 Either:

- 1.2.1 The patient has experienced intolerable side effects from infliximab; or
- 1.2.2 The patient has received insufficient benefit from infliximab to meet the renewal criteria for infliximab for chronic ocular inflammation; or

2 Both:

- 2.1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and
- 2.2 Any of the following:
 - 2.2.1 Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective; or
 - 2.2.2 Patient is under 18 years and treatment with methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or
 - 2.2.3 Patient is under 8 years and treatment with steroids or methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or disease requires control to prevent irreversible vision loss prior to achieving a therapeutic dose of methotrexate.

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

Renewal — (chronic ocular inflammation) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 The patient has had a good clinical response following 12 weeks' initial treatment; or
 - 1.2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
 - 1.3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old; and</p>
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if adalimumab is withdrawn.

Initial application — (Crohn's disease - adults) only from a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has severe active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or
 - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
 - 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
 - 2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate.

Renewal — (Crohn's disease - adults) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 Applicant is a gastroenterologist; or
 - 1.2 Applicant is a Practitioner and confirms that a gastroenterologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Either:
 - 2.1 Either:
 - 2.1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or
 - 2.1.2 CDAI score is 150 or less; or
 - 2.2 Both:
 - 2.2.1 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
 - 2.2.2 Applicant to indicate the reason that CDAI score cannot be assessed; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (Crohn's disease - children) only from a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Paediatric patient has severe active Crohn's disease; and
- 2 Either:

continued...

Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

 Subsidy (Manufacturer's Price)		Fully Subsidised	Brand or Generic	
`\$´´	Per	✓	Manufacturer	

continued...

- 2.1 Patient has a Paediatric Crohn's Disease Activity Index (PCDAI) score of greater than or equal to 30; or
- 2.2 Patient has extensive small intestine disease; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate.

Renewal — (Crohn's disease - children) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 Applicant is a gastroenterologist; or
 - 1.2 Applicant is a Practitioner and confirms that a gastroenterologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Either:
 - 2.1 Either:
 - 2.1.1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on adalimumab; or
 - 2.1.2 PCDAI score is 15 or less; or
 - 2.2 Both:
 - 2.2.1 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed; and
 - 2.2.2 Applicant to indicate the reason that PCDAI score cannot be assessed; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (fistulising Crohn's disease) only from a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Crohn's disease; and
- 2 Either:
 - 2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
 - 2.2 Patient has one or more rectovaginal fistula(e); and
- 3 A Baseline Fistula Assessment has been completed and is no more than 1 month old at the time of application; and
- 4 The patient will be assessed for response to treatment after 4 months' adalimumab treatment (see Note).

Note: A maximum of 4 months' adalimumab will be subsidised on an initial Special Authority approval for fistulising Crohn's disease.

Renewal — (fistulising Crohn's disease) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

1 Either:

- 1.1 Applicant is a gastroenterologist; or
- 1.2 Applicant is a Practitioner and confirms that a gastroenterologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Either:
 - 2.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
 - 2.2 There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain.

Initial application — (hidradenitis suppurativa) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 1 Patient has hidradenitis suppurativa Hurley Stage II or Hurley Stage III lesions in distinct anatomic areas; and
- 2 Patient has tried, but had an inadequate response to at least a 90 day trial of systemic antibiotics or patient has demonstrated intolerance to or has contraindications for systemic antibiotics; and
- 3 The patient has 3 or more active lesions (e.g. inflammatory nodules, abscesses, draining fistulae); and
- 4 The patient has a Dermatology Quality of Life Index of 10 or more and the assessment is no more than 1 month old at time of application; and
- 5 Following the initial loading doses, adalimumab is to be administered at doses no greater than 40mg every 7 days.

Renewal — (hidradenitis suppurativa) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

- All of the following:
 - 1 The patient has a reduction in active lesions (e.g. inflammatory nodules, abscesses, draining fistulae) of 25% or more from baseline; and
 - 2 The patient has a Dermatology Quality of Life Index improvement of 4 or more from baseline; and
 - 3 Adalimumab is to be administered at doses no greater than 40mg every 7 days. Fortnightly dosing has been considered.

Initial application — (polyarticular course juvenile idiopathic arthritis) only from a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for polyarticular course juvenile idiopathic arthritis (JIA); and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for polyarticular course JIA; or
- 2 All of the following:
 - 2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.2 Patient has had polyarticular course JIA for 6 months duration or longer; and
 - 2.3 Any of the following:
 - 2.3.1 At least 5 active joints and at least 3 joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.3.2 Moderate or high disease activity (cJADAS10 score of at least 2.5) after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.3.3 Low disease activity (cJADAS10 score between 1.1 and 2.5) after a 6-month trial of methotrexate.

Renewal — (polyarticular course juvenile idiopathic arthritis) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initial application — (oligoarticular course juvenile idiopathic arthritis) only from a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Subsidy		Fully	Brand or
(Manufacturer's Price)	:	Subsidised	Generic
\$	Per	1	Manufacturer

Fither:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for oligoarticular course juvenile idiopathic arthritis (JIA); and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for oligoarticular course JIA; or
- 2 All of the following:
 - 2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance: and
 - 2.2 Patient has had oligoarticular course JIA for 6 months duration or longer; and
 - 2.3 Any of the following:
 - 2.3.1 At least 2 active joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose): or
 - 2.3.2 Moderate or high disease activity (cJADAS10 score greater than 1.5) with poor prognostic features after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.3.3 High disease activity (cJADAS10 score greater than 4) after a 6-month trial of methotrexate.

Renewal - (oligoarticular course juvenile idiopathic arthritis) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance: and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initial application - (psoriatic arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept or secukinumab for psoriatic arthritis: and 1.2 Either:
 - - 1.2.1 The patient has experienced intolerable side effects from etanercept or secukinumab; or
 - 1.2.2 The patient has received insufficient benefit from etanercept or secukinumab to meet the renewal criteria for etanercept or secukinumab for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer: and
 - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
 \$	Per 🗸	Manufacturer

continued...

- 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2.5 Any of the following:
 - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.
- Renewal (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist.
- Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (pyoderma gangrenosum) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pyoderma gangrenosum*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and
- 3 A maximum of 8 doses.
- Note: Note: Indications marked with * are unapproved indications.

Renewal — (pyoderma gangrenosum) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has shown clinical improvement; and
- 2 Patient continues to require treatment; and
- 3 A maximum of 8 doses.

Initial application — (rheumatoid arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and

(Ma	Subsidy anufacturer's Price)	Subsid	Fully lised	Brand or Generic
· · · · · · · · · · · · · · · · · · ·	\$	Per	1	Manufacturer

continued...

- 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
- 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
- 2.5 Any of the following:
 - 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or
 - 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
 - 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and

2.6 Either:

- 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
- 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2.7 Either:
 - 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Renewal — (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

1 Fither:

- 1.1 Applicant is a rheumatologist; or
- 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 3 Either:
 - 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 4 Either:
 - 4.1 Adalimumab to be administered at doses no greater than 40 mg every 14 days; or
 - 4.2 Patient cannot take concomitant methotrexate and requires doses of adalimumab higher than 40 mg every 14 days to maintain an adequate response.

Initial application — (severe Behcet's disease) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 The patient has severe Behcet's disease that is significantly impacting the patient's quality of life (see Notes); and
- 2 Either:

Subsidy		Fully	Brand or	
(Manufacturer's Price		Subsidised	Generic	
\$	Per	~	Manufacturer	

continued...

- 2.1 The patient has severe ocular, neurological, gastrointestinal, rheumatological, mucocutaneous and/or vasculitic symptoms and has not responded adequately to treatment with infliximab (see Notes); or
- 2.2 The patient has severe ocular, neurological, gastrointestinal, rheumatological, mucocutaneous and/or vasculitic symptoms and has experienced intolerable side effects from treatment with infliximab; and
- 3 The patient is experiencing significant loss of quality of life; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Note: Behcet's disease diagnosed according to the International Study Group for Behcet's disease. Lancet

1990;335(8697):1078-80. Quality of life measured using an appropriate quality of life scale such as that published in Gilworth et al, J Rheumatol. 2004;31:931-7.

Renewal — (severe Behcet's disease) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has had a good clinical response to initial treatment with measurably improved quality of life; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (severe chronic plaque psoriasis) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria: Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for severe chronic plaque psoriasis; or
- 2 All of the following:
 - 2.1 Either:
 - 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
 - 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
 - 2.3 A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
 - 2.4 The most recent PASI or DLQI assessment is no more than 1 month old at the time of application.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment. **Renewal — (severe chronic plaque psoriasis)** only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

- All of the following:
 - 1 Either:
 - 1.1 Applicant is a dermatologist; or

Subsidy	Full	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 1.2 Applicant is a Practitioner and confirms that a dermatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 2.1.2 Either:
 - 2.1.2.1 Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or
 - 2.1.2.2 Following each prior adalimumab treatment course the patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, when compared with the pre-treatment baseline valuee; or
 - 2.2 Both:
 - 2.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 2.2.2 Either:
 - 2.2.2.1 Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 2.2.2.2 Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-adalimumab treatment baseline value; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.
- Note: A treatment course is defined as a minimum of 12 weeks adalimumab treatment

Initial application — (severe ocular inflammation) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for infliximab for severe ocular inflammation; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from infliximab; or
 - 1.2.2 The patient has received insufficient benefit from infliximab to meet the renewal criteria for infliximab for severe ocular inflammation; or
- 2 Both:
 - 2.1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and
 - 2.2 Any of the following:
 - 2.2.1 Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms; or
 - 2.2.2 Patient developed new inflammatory symptoms while receiving high dose steroids; or
 - 2.2.3 Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms.

Renewal — (severe ocular inflammation) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

- Both:
 - 1 Any of the following:
 - 1.1 The patient has had a good clinical response following 3 initial doses; or
 - 1.2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active</p>

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
continued				
vitreous or retinal lesions, or resolution of uveit				
1.3 Following each 12-month treatment period, the				
prednisone to < 10mg daily, or steroid drops le	•		years old; a	ind
2 Adalimumab to be administered at doses no greater th Note: A trial withdrawal should be considered after every 24			nationt is de	eemed to have extremely
high risk of irreversible vision loss if adalimumab is withdrawn		3 110		
AFLIBERCEPT – Special Authority see SA1772 below – Ret	ail pharmacy			
Inj 40 mg per ml, 0.1 ml vial		1	🗸 E	Eylea
SA1772 Special Authority for Subsidy				
Initial application — (wet age related macular degeneration	on) only from an ophthali	molog	gist. Approv	vals valid for 3 months for
applications meeting the following criteria: Either:				
1 All of the following:				
1.1 Any of the following:				
1.1.1 Wet age-related macular degeneration	(wet AMD): or			
1.1.2 Polypoidal choroidal vasculopathy; or	(
1.1.3 Choroidal neovascular membrane from	causes other than wet Al	MD; a	ind	
1.2 Either:				
 1.2.1 The patient has developed severe endo bevacizumab; or 	phthalmitis or severe pos	sterio	r uveitis follo	owing treatment with
1.2.2 There is worsening of vision or failure or four weeks apart; and	f retina to dry despite thre	ee int	raocular inje	ections of bevacizumab
1.3 There is no structural damage to the central for				
1.4 Patient has not previously been treated with ra	nibizumab for longer thar	n 3 m	onths; or	
2 Either:				
 Patient has current approval to use ranibizuma ranibizumab within 3 months; or 				
 Patient has previously* (*before June 2018) red while on treatment. 	ceived treatment with ran	ibizur	nab for wAl	MD and disease was stable
Initial application — (diabetic macular oedema) only from meeting the following criteria:	an ophthalmologist. App	orova	ls valid for 4	I months for applications
All of the following:				
1 Patient has contro involving diabetic macular ordema	(DMO): and			

- 1 Patient has centre involving diabetic macular oedema (DMO); and
- 2 Patient's disease is non responsive to 4 doses of intravitreal bevacizumab when administered 4-6 weekly; and
- 3 Patient has reduced visual acuity between 6/9 6/36 with functional awareness of reduction in vision; and
- 4 Patient has DMO within central OCT (ocular coherence tomography) subfield > 350 micrometers; and
- 5 There is no centre-involving sub-retinal fibrosis or foveal atrophy.

Renewal — (wet age related macular degeneration) only from an ophthalmologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Documented benefit must be demonstrated to continue; and
- 2 Patient's vision is 6/36 or better on the Snellen visual acuity score; and
- 3 There is no structural damage to the central fovea of the treated eye.

Renewal — (diabetic macular oedema) only from an ophthalmologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price \$) Per	Fully Subsidised	Brand or Generic Manufacturer
ntinued				
 There is stability or two lines of Snellen visual acuity gain; There is structural improvement on OCT scan (with reduct 		usts ne	ntral retinal	thickness and sub-ret
fluid); and		yoto, oo	initial rotina	
3 Patient's vision is 6/36 or better on the Snellen visual acui	ty score; and			
4 There is no centre-involving sub-retinal fibrosis or foveal a	trophy; and			
5 After each consecutive 12 months treatment with (2nd line injection of bevacizumab and had no response.	e anti-VEGF agent),	patient	has retrialle	ed with at least one
ASIRIVIMAB AND IMDEVIMAB – [Xpharm] – Special Authority	see SA2096 below			
Inj 120 mg per ml casirivimab, 11.1 ml vial (1) and inj 120 mg				
per ml imdevimab, 11.1 ml vial (1)		1 OP	🗸 H	lonapreve
SA2096 Special Authority for Subsidy				
itial application — (Treatment of profoundly immunocompr	omised patients)	from an	y relevant p	practitioner. Approvals
lid for 2 weeks for applications meeting the following criteria:				
l of the following:				
1 Patient has confirmed (or probable) COVID-19; and				
2 The patient is in the community with mild to moderate dise				
3 Patient is profoundly immunocompromised** and is at risk	of not having moun	ted an	adequate re	esponse to vaccination
against COVID-19 or is unvaccinated; and				
4 Patient's symptoms started within the last 10 days; and				
5 Patient is not receiving high flow oxygen or assisted/mech	anical ventilation: a	nd		
6 Casirivimab and imdevimab is to be administered at a max	ximum dose of no g	reater tl	nan 2,400 n	ng.
6 Casirivimab and imdevimab is to be administered at a maximum otes: * Mild to moderate disease severity as described on the M	ximum dose of no g Ainistry of Health We	reater tl <u>ebsite</u>	,	ng.
6 Casirivimab and imdevimab is to be administered at a max	ximum dose of no g Ainistry of Health We	reater tl <u>ebsite</u>	,	ng.
6 Casirivimab and imdevimab is to be administered at a matrix otes: * Mild to moderate disease severity as described on the <u>M</u> Examples include B-cell depletive illnesses or patients receivin ETUXIMAB – PCT only – Specialist – Special Authority see SA	ximum dose of no g <u>Ainistry of Health We</u> g treatment that is E 1697 below	reater tl <u>ebsite</u>	,	ng.
6 Casirivimab and imdevimab is to be administered at a matrix otes: * Mild to moderate disease severity as described on the M Examples include B-cell depletive illnesses or patients receivin ETUXIMAB – PCT only – Specialist – Special Authority see SA Inj 5 mg per ml, 20 ml vial	ximum dose of no g <u>Ainistry of Health We</u> g treatment that is E 1697 below 	reater ti <u>ebsite</u> 3-Cell di 1	epleting.	rbitux
6 Casirivimab and imdevimab is to be administered at a matrix otes: * Mild to moderate disease severity as described on the <u>M</u> Examples include B-cell depletive illnesses or patients receivin ETUXIMAB – PCT only – Specialist – Special Authority see SA	ximum dose of no g <u>Ainistry of Health We</u> g treatment that is E 1697 below 	reater tl <u>ebsite</u> 3-Cell d	epleting.	
6 Casirivimab and imdevimab is to be administered at a matrix otes: * Mild to moderate disease severity as described on the M Examples include B-cell depletive illnesses or patients receivin ETUXIMAB – PCT only – Specialist – Special Authority see SA Inj 5 mg per ml, 20 ml vial	ximum dose of no g <u>Ainistry of Health Wa</u> g treatment that is E 1697 below 	reater ti <u>ebsite</u> 3-Cell di 1	epleting. ✓ E ✓ E	rbitux
6 Casirivimab and imdevimab is to be administered at a matrix otes: * Mild to moderate disease severity as described on the Examples include B-cell depletive illnesses or patients receivin ETUXIMAB – PCT only – Specialist – Special Authority see SA Inj 5 mg per ml, 20 ml vial Inj 5 mg per ml, 100 ml vial Inj 1 mg for ECP.	ximum dose of no g <u>Ainistry of Health Wa</u> g treatment that is E 1697 below 	reater ti <u>ebsite</u> 3-Cell de 1 1	epleting. ✓ E ✓ E	rbitux
6 Casirivimab and imdevimab is to be administered at a matrix otes: * Mild to moderate disease severity as described on the M Examples include B-cell depletive illnesses or patients receivin ETUXIMAB – PCT only – Specialist – Special Authority see SA Inj 5 mg per ml, 20 ml vial Inj 5 mg per ml, 100 ml vial Inj 1 mg for ECP SA1697 Special Authority for Subsidy	ximum dose of no g <u>Ainistry of Health Wr</u> g treatment that is E 1697 below 	reater ti e <u>bsite</u> 3-Cell d 1 1 1 mg	epleting.	rbitux rbitux axter
6 Casirivimab and imdevimab is to be administered at a matrix otes: * Mild to moderate disease severity as described on the M Examples include B-cell depletive illnesses or patients receivin ETUXIMAB – PCT only – Specialist – Special Authority see SA Inj 5 mg per ml, 20 ml vial Inj 5 mg per ml, 100 ml vial Inj 1 mg for ECP SA1697 Special Authority for Subsidy itial application only from a medical oncologist or medical prace	ximum dose of no g <u>Ainistry of Health Wr</u> g treatment that is E 1697 below 	reater ti e <u>bsite</u> 3-Cell d 1 1 1 mg	epleting.	rbitux rbitux axter
6 Casirivimab and imdevimab is to be administered at a matrix otes: * Mild to moderate disease severity as described on the Examples include B-cell depletive illnesses or patients receivin ETUXIMAB – PCT only – Specialist – Special Authority see SA Inj 5 mg per ml, 20 ml vial Inj 5 mg per ml, 100 ml vial	ximum dose of no g <u>Ainistry of Health Wr</u> g treatment that is E 1697 below 	reater ti e <u>bsite</u> 3-Cell d 1 1 1 mg	epleting.	rbitux rbitux axter
6 Casirivimab and imdevimab is to be administered at a matrix otes: * Mild to moderate disease severity as described on the M Examples include B-cell depletive illnesses or patients receivin ETUXIMAB – PCT only – Specialist – Special Authority see SA Inj 5 mg per ml, 20 ml vial Inj 5 mg per ml, 100 ml vial Inj 1 mg for ECP SA1697 Special Authority for Subsidy itial application only from a medical oncologist or medical prace porovals valid for 6 months for applications meeting the followin	ximum dose of no g <u>Ainistry of Health W</u> g treatment that is E 1697 below 	reater tl ebsite 3-Cell d 1 1 mg mmend	epleting.	rbitux rbitux axter
6 Casirivimab and imdevimab is to be administered at a material and imdevimab is to be administered at a material and the second severity as described on the Maxamples include B-cell depletive illnesses or patients receivin ETUXIMAB – PCT only – Specialist – Special Authority see SA Inj 5 mg per ml, 20 ml vial Inj 5 mg per ml, 20 ml vial Inj 5 mg per ml, 100 ml vial Inj 1 mg for ECP SA1697 Special Authority for Subsidy itial application only from a medical oncologist or medical prace porovals valid for 6 months for applications meeting the following:	ximum dose of no g <u>Ainistry of Health W</u> g treatment that is E 1697 below 	reater tl ebsite 3-Cell d 1 1 mg mmend	epleting.	rbitux rbitux axter
6 Casirivimab and imdevimab is to be administered at a maximum state of the second secon	ximum dose of no g <u>Ainistry of Health W</u> g treatment that is E 1697 below 	reater tl ebsite 3-Cell d 1 1 mg mmend	epleting.	rbitux rbitux axter
6 Casirivimab and imdevimab is to be administered at a maximum state of the moderate disease severity as described on the Mexamples include B-cell depletive illnesses or patients receiving ETUXIMAB – PCT only – Specialist – Special Authority see SA Inj 5 mg per ml, 20 ml vial	ximum dose of no g <u>Ainistry of Health W</u> g treatment that is E 1697 below 	reater tl ebsite 3-Cell d 1 1 mg mmend	epleting.	rbitux rbitux axter
 6 Casirivimab and imdevimab is to be administered at a maximum state of the moderate disease severity as described on the MEXamples include B-cell depletive illnesses or patients receivin ETUXIMAB – PCT only – Specialist – Special Authority see SA Inj 5 mg per ml, 20 ml vial	ximum dose of no g <u>Ainistry of Health W</u> g treatment that is E 1697 below 	reater tl ebsite 3-Cell d 1 1 mg mmend	epleting.	rbitux rbitux axter
 6 Casirivimab and imdevimab is to be administered at a maximum state of the moderate disease severity as described on the MEXamples include B-cell depletive illnesses or patients receivin ETUXIMAB – PCT only – Specialist – Special Authority see SA Inj 5 mg per ml, 20 ml vial	ximum dose of no g <u>Ainistry of Health Wr</u> g treatment that is E 1697 below 	reater tl ebsite 3-Cell d 1 1 mg mmend	epleting.	rbitux rbitux axter
 6 Casirivimab and imdevimab is to be administered at a maximum states: * Mild to moderate disease severity as described on the MEXamples include B-cell depletive illnesses or patients receivin ETUXIMAB – PCT only – Specialist – Special Authority see SA Inj 5 mg per ml, 20 ml vial Inj 5 mg per ml, 100 ml vial Inj 1 mg for ECP ESA1697 Special Authority for Subsidy Itial application only from a medical oncologist or medical prace provals valid for 6 months for applications meeting the following: 1 Patient has locally advanced, non-metastatic, squamous of 2 Patient is contraindicated to, or is intolerant of, cisplatin; a 3 Patient has good performance status; and 4 To be administered in combination with radiation therapy. FLIXIMAB – PCT only – Special Authority see SA2082 below Inj 100 mg 	ximum dose of no g <u>Ainistry of Health W</u> g treatment that is E 1697 below 	reater ti <u>ebsite</u> 3-Cell d 1 1 mg mmend ad and	epleting.	rbitux irbitux laxter nedical oncologist.
 6 Casirivimab and imdevimab is to be administered at a matches: * Mild to moderate disease severity as described on the MEXamples include B-cell depletive illnesses or patients receivin ETUXIMAB – PCT only – Specialist – Special Authority see SA Inj 5 mg per ml, 20 ml vial Inj 5 mg per ml, 20 ml vial Inj 6 mg per ml, 100 ml vial Inj 1 mg for ECP SA1697 Special Authority for Subsidy itial application only from a medical oncologist or medical practice of the following: 1 Patient has locally advanced, non-metastatic, squamous of the following: 2 Patient is contraindicated to, or is intolerant of, cisplatin; a 3 Patient has good performance status; and 4 To be administered in combination with radiation therapy. FLIXIMAB – PCT only – Special Authority see SA2082 below Inj 100 mg	ximum dose of no g <u>Ainistry of Health W</u> g treatment that is E 1697 below 	reater ti <u>ebsite</u> 3-Cell d 1 1 mg mmend ad and	epleting.	rbitux rbitux laxter nedical oncologist. lemicade
 6 Casirivimab and imdevimab is to be administered at a maximum states: * Mild to moderate disease severity as described on the MExamples include B-cell depletive illnesses or patients receivin ETUXIMAB – PCT only – Specialist – Special Authority see SA Inj 5 mg per ml, 20 ml vial Inj 5 mg per ml, 20 ml vial	ximum dose of no g <u>Ainistry of Health W</u> g treatment that is E 1697 below 	reater ti ebsite 1 1 mg mmend ad and 1 mg	epleting.	arbitux arbitux laxter nedical oncologist. emicade laxter
 6 Casirivimab and imdevimab is to be administered at a maxtes: * Mild to moderate disease severity as described on the MExamples include B-cell depletive illnesses or patients receivin CTUXIMAB – PCT only – Specialist – Special Authority see SA Inj 5 mg per ml, 20 ml vial Inj 5 mg per ml, 20 ml vial Inj 5 mg per ml, 100 ml vial Inj 6 mg per ml, 100 ml vial SA1697 Special Authority for Subsidy tial application only from a medical oncologist or medical prace provals valid for 6 months for applications meeting the following: 1 Patient has locally advanced, non-metastatic, squamous of the following: 2 Patient is contraindicated to, or is intolerant of, cisplatin; a 3 Patient has good performance status; and 4 To be administered in combination with radiation therapy. FLIXIMAB – PCT only – Special Authority see SA2082 below Inj 100 mg	ximum dose of no g <u>Ainistry of Health W</u> g treatment that is E 1697 below 	reater ti ebsite 1 1 1 mg mmend ad and 1 1 mg Practitic	epleting.	arbitux arbitux laxter nedical oncologist. emicade laxter

- 1 Patient has severe active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

- 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
- 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
- 2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate; and
- 5 Patient must be reassessed for continuation after 3 months of therapy.

Renewal — (Crohn's disease (adults)) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Any of the following:
 - 1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on infliximab; or
 - 1.2 CDAI score is 150 or less; or
 - 1.3 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle. Up to 10 mg/kg every 8 weeks (or equivalent) may be used for patients treated with this dose prior to 1 February 2019.

Initial application — (Crohn's disease (children)) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria: All of the following:

- 1 Paediatric patient has severe active Crohn's disease; and
- 2 Either:
 - 2.1 Patient has a Paediatric Crohn's Disease Activity Index (PCDAI) score of greater than or equal to 30; or
 - 2.2 Patient has extensive small intestine disease; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate; and
- 5 Patient must be reassessed for continuation after 3 months of therapy.

Renewal — (Crohn's disease (children)) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Any of the following:
 - 1.1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on infliximab; or
 - 1.2 PCDAI score is 15 or less; or
 - 1.3 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle. Up to 10 mg/kg every 8 weeks (or equivalent) may be used for patients treated with this dose prior to 1 February 2019.

Initial application — (Graft vs host disease) from any relevant practitioner. Approvals valid without further renewal unless notified where patient has steroid-refractory acute graft vs. host disease of the gut.

Initial application — (Pulmonary sarcoidosis) from any relevant practitioner. Approvals valid without further renewal unless notified where patient has life-threatening pulmonary sarcoidosis diagnosed by a multidisciplinary team that is refractory to other treatments.

Initial application - (acute severe fulminant ulcerative colitis) only from a gastroenterologist or Practitioner on the

[▲]Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

	Subsidy		Fully	Brand or
(Ma	nufacturer's Price)	Subs	idised	Generic
	\$	Per	1	Manufacturer

recommendation of a gastroenterologist. Approvals valid for 6 weeks for applications meeting the following criteria: Both:

- 1 Patient has acute, severe fulminant ulcerative colitis; and
- 2 Treatment with intravenous or high dose oral corticosteroids has not been successful.

Initial application - (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 3 months for applications meeting the following criteria: Both:

- - 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for ankylosing spondylitis; and 2 Either:
 - 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
 - 2.2 Following 12 weeks of adalimumab and/or etanercept treatment, the patient did not meet the renewal criteria for adalimumab and/or etanercept for ankylosing spondylitis.

Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Following 12 weeks of infliximab treatment, BASDAI has improved by 4 or more points from pre-infliximab baseline on a 10 point scale, or by 50%, whichever is less; and
- 2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 3 Infliximab to be administered at doses no greater than 5 mg/kg every 6-8 weeks.

Initial application — (chronic ocular inflammation) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Fither:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for chronic ocular inflammation; and 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for chronic ocular inflammation: or
- 2 Both:
 - 2.1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and
 - 2.2 Any of the following:
 - 2.2.1 Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective: or
 - 2.2.2 Patient is under 18 years and treatment with methotrexate has proven ineffective or is not tolerated at a therapeutic dose: or
 - 2.2.3 Patient is under 8 years and treatment with steroids or methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or disease requires control to prevent irreversible vision loss prior to achieving a therapeutic dose of methotrexate.

Renewal - (chronic ocular inflammation) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Any of the following:

- 1 The patient has had a good clinical response following 3 initial doses; or
- 2 Following each 12 month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < 1/2+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cvstoid macular oedema): or

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

3 Following each 12 month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.

Initial application — (fistulising Crohn's disease) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 4 months for applications meeting the following criteria: Both:

- 1 Patient has confirmed Crohn's disease; and
- 2 Either:
 - 2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
 - 2.2 Patient has one or more rectovaginal fistula(e).

Renewal — (fistulising Crohn's disease) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

1 Either:

- 1.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
- 1.2 There has been a marked reduction in drainage of all fistula(e) from baseline (in the case of adult patients, as demonstrated by a reduction in the Fistula Assessment score), together with less induration and patient reported pain; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle. Up to 10 mg/kg every 8 weeks (or equivalent) may be used for patients treated with this dose prior to 1 February 2019.

Initial application — (neurosarcoidosis) only from a neurologist or Practitioner on the recommendation of a neurologist.

Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with neurosarcoiosis by a multidisciplinary team; and
- 2 Patient has CNS involvement; and
- 3 Patient has steroid-refractory disease; and
- 4 Either:
 - 4.1 IV cyclophosphamide has been tried; or
 - 4.2 Treatment with IV cyclophosphamide is clinically inappropriate.

Renewal — (neurosarcoidosis) only from a neurologist or Practitioner on the recommendation of a neurologist. Approvals valid for 18 months for applications meeting the following criteria:

Either:

- 1 A withdrawal period has been tried and the patient has relapsed; or
- 2 All of the following:
 - 2.1 A withdrawal period has been considered but would not be clinically appropriate; and
 - 2.2 There has been a marked reduction in prednisone dose; and
 - 2.3 Either:
 - 2.3.1 There has been an improvement in MRI appearances; or
 - 2.3.2 Marked improvement in other symptomology.

Initial application — (plaque psoriasis) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 3 months for applications meeting the following criteria:

Either:

1 Both:

continued...

AThree months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subs		ully Bran	nd or
(Manufactur	rer's Price) Subsidi	sed Gen	eric
\$	Per	 Man 	ufacturer

continued...

- 1.1 The patient has had an initial Special Authority approval for adalimumab, etanercept or secukinumab for severe chronic plaque psoriasis; and
- 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects from adalimumab, etanercept or secukinumab; or
 - 1.2.2 Patient has received insufficient benefit from adalimumab, etanercept or secukinumab to meet the renewal criteria for adalimumab, etanercept or secukinumab for severe chronic plaque psoriasis; or
- 2 All of the following:
 - 2.1 Either:
 - 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
 - 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
 - 2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
 - 2.4 The most recent PASI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment. **Renewal — (plaque psoriasis)** only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 Both:
 - 1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 1.1.2 Following each prior infliximab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-infliximab treatment baseline value; or
 - 1.2 Both:
 - 1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 1.2.2 Either:
 - 1.2.2.1 Following each prior infliximab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 1.2.2.2 Following each prior infliximab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-infliximab treatment baseline value; and
- 2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

Initial application — (previous use) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

Subsidy		Fully	Brand or
(Manufacturer's Price)	S	Subsidised	Generic
\$	Per	1	Manufacturer

continued...

- 1 Patient was being treated with infliximab prior to 1 February 2019; and
- 2 Any of the following:
 - 2.1 Rheumatoid arthritis; or
 - 2.2 Ankylosing spondylitis; or
 - 2.3 Psoriatic arthritis; or
 - 2.4 Severe ocular inflammation; or
 - 2.5 Chronic ocular inflammation; or
 - 2.6 Crohn's disease (adults); or
 - 2.7 Crohn's disease (children); or
 - 2.8 Fistulising Crohn's disease; or
 - 2.9 Severe fulminant ulcerative colitis; or
 - 2.10 Severe ulcerative colitis; or
 - 2.11 Plaque psoriasis; or
 - 2.12 Neurosarcoidosis; or
 - 2.13 Severe Behcet's disease.

Initial application — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 4 months for applications meeting the following criteria: Both:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept and/or secukinumab for psoriatic arthritis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept and/or secukinumab; or
 - 2.2 Following 3-4 months' initial treatment with adalimumab and/or etanercept and/or secukinumab, the patient did not meet the renewal criteria for adalimumab and/or etanercept and/or secukinumab for psoriatic arthritis.

Renewal — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Either:
 - 1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior infliximab treatment in the opinion of the treating physician; and
- 2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

Initial application — (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 4 months for applications meeting the following criteria: All of the following:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
 - 2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept; and
- 3 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance.

Renewal — (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy		Fully	Brand or
(Manufacturer's Price)	Su	lbsidised	Generic
\$	Per	1	Manufacturer

toxicity or intolerance; and

- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 3 Infliximab to be administered at doses no greater than 3 mg/kg every 8 weeks.

Initial application — (severe Behcet's disease) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

1 The patient has severe Behcet's disease which is significantly impacting the patient's quality of life (see Notes); and

2 Either:

- 2.1 The patient has severe ocular, neurological and/or vasculitic symptoms and has not responded adequately to one or more treatment(s) appropriate for the particular symptom(s) (see Notes); or
- 2.2 The patient has severe gastrointestinal, rheumatologic and/or mucocutaneous symptoms and has not responded adequately to two or more treatment appropriate for the particular symptom(s) (see Notes); and
- 3 The patient is experiencing significant loss of quality of life.

Notes: Behcet's disease diagnosed according to the International Study Group for Behcet's Disease. Lancet

1990;335(8697):1078-80. Quality of life measured using an appropriate quality of life scale such as that published in Gilworth et al J Rheumatol. 2004;31:931-7.

Treatments appropriate for the particular symptoms are those that are considered standard conventional treatments for these symptoms, for example intravenous/oral steroids and other immunosuppressants for ocular symptoms; azathioprine, steroids, thalidomide, interferon alpha and ciclosporin for mucocutaneous symptoms; and colchicine, steroids and methotrexate for rheumatological symptoms.

Renewal — (severe Behcet's disease) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has had a good clinical response to initial treatment with measurably improved quality of life; and
- 2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

Renewal — (severe fulminant ulcerative colitis) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Where maintenance treatment is considered appropriate, infliximab should be used in combination with immunomodulators and reassessed every 6 months; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle. Up to 10 mg/kg every 8 weeks (or equivalent) may be used for patients treated with this dose prior to 1 February 2019.

Initial application — (severe ocular inflammation) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for severe ocular inflammation; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe ocular inflammation; or

Subsidy		Fully	Brand or
(Manufacturer's Price)	Sub	sidised	Generic
\$	Per	~	Manufacturer

continued...

- 2 Both:
 - 2.1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and
 - 2.2 Any of the following:
 - 2.2.1 Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms; or
 - 2.2.2 Patient developed new inflammatory symptoms while receiving high dose steroids; or
 - 2.2.3 Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms.

Renewal — (severe ocular inflammation) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Any of the following:

- 1 The patient has had a good clinical response following 3 initial doses; or
- 2 Following each 12 month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
- 3 Following each 12 month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.

Initial application — (ulcerative colitis) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria: All of the following:

- 1 Patient has histologically confirmed ulcerative colitis; and
- 2 Either:
 - 2.1 Patient is 18 years or older and the Simple Clinical Colitis Activity Index (SCCAI) is greater than or equal to 4; or
 - 2.2 Patient is under 18 years and the Paediatric Ulcerative Colitis Activity Index (PUCAI) score is greater than or equal to 65; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses for an adequate duration (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate.

Renewal — (ulcerative colitis) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient is continuing to maintain remission and the benefit of continuing infliximab outweighs the risks; and
- 2 Either:
 - 2.1 Patient is 18 years or older and the SCCAI score has reduced by 2 points or more from the SCCAI score when the patient was initiated on infliximab; or
 - 2.2 Patient is under 18 years and the PUCAI score has reduced by 30 points or more from the PUCAI score when the patient was initiated on infliximab; and
- 3 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle. Up to 10 mg/kg every 8 weeks (or equivalent) may be used for patients treated with this dose prior to 1 February 2019.

Initial application — (pyoderma gangrenosum) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

Subsidy		Fully	Brand or	
(Manufacturer's Price	ce) Si	ubsidised	Generic	
\$	Per	✓	Manufacturer	

continued...

- 1 Patient has pyoderma gangrenosum*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g.
- prednisone, ciclosporine, azathioprine, or methotrexate) and not received an adequate response; and
- 3 A maximum of 8 doses.
- Note: Note: Indications marked with * are unapproved indications.

Renewal — (pyoderma gangrenosum) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has shown clinical improvement; and
- 2 Patient continues to require treatment; and
- 3 A maximum of 8 doses.

MEPOLIZUMAB - Special Authority see SA1896 below - Retail pharmacy

Inj 100 mg prefilled pen	 1	 Nucala
Inj 100 mg vial	 1	Nucala

⇒SA1896 Special Authority for Subsidy

Initial application — (Severe eosinophilic asthma) only from a respiratory physician or clinical immunologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient must be aged 12 years or older; and
- 2 Patient must have a diagnosis of severe eosinophilic asthma documented by a respiratory physician or clinical immunologist; and
- 3 Conditions that mimic asthma eg. vocal cord dysfunction, central airway obstruction, bronchiolitis etc. have been excluded; and
- 4 Patient has a blood eosinophil count of greater than $0.5 \times 10^{\circ}9$ cells/L in the last 12 months; and
- 5 Patient must be adherent to optimised asthma therapy including inhaled corticosteroids (equivalent to at least 1000 mcg per day of fluticasone propionate) plus long acting beta-2 agonist, or budesonide/formoterol as part of the single maintenance and reliever therapy regimen, unless contraindicated or not tolerated; and
- 6 Either:
 - 6.1 Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral corticosteroids; or
 - 6.2 Patient has received continuous oral corticosteroids of at least the equivalent of 10 mg per day over the previous 3 months; and
- 7 Patient has an Asthma Control Test (ACT) score of 10 or less. Baseline measurements of the patient's asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 52 weeks after the first dose to assess response to treatment.

Renewal — (Severe eosinophilic asthma) only from a respiratory physician or clinical immunologist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 An increase in the Asthma Control Test (ACT) score of at least 5 from baseline; and
- 2 Either:
 - 2.1 Exacerbations have been reduced from baseline by 50% as a result of treatment with mepolizumab; or
 - 2.2 Reduction in continuous oral corticosteroid use by 50% or by 10 mg/day while maintaining or improving asthma control.

OBINUTUZUMAB - PCT only - Specialist - Special Author	rity see SA1627 on the	next page	
Inj 25 mg per ml, 40 ml vial		1	🖌 Gazyva
Inj 1 mg for ECP	6.21	1 mg	 Baxter

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🗸	Manufacturer	

⇒SA1627 Special Authority for Subsidy

Initial application — (chronic lymphocytic leukaemia) only from a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has progressive Binet stage A, B or C CD20+ chronic lymphocytic leukaemia requiring treatment; and
- 2 The patient is obinutuzumab treatment naive; and
- 3 The patient is not eligible for full dose FCR due to comorbidities with a score > 6 on the Cumulative Illness Rating Scale (CIRS) or reduced renal function (creatinine clearance < 70mL/min); and
- 4 Patient has adequate neutrophil and platelet counts* unless the cytopenias are a consequence of marrow infiltration by CLL; and
- 5 Patient has good performance status; and
- 6 Obinutuzumab to be administered at a maximum cumulative dose of 8,000 mg and in combination with chlorambucil for a maximum of 6 cycles.

Notes: Chronic lymphocytic leukaemia includes small lymphocytic lymphoma. Comorbidity refers only to illness/impairment other than CLL induced illness/impairment in the patient. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with obinutuzumab is expected to improve symptoms and improve ECOG score to < 2.

* Neutrophil greater than or equal to 1.5×10^{9} /L and platelets greater than or equal to 75×10^{9} /L.

OMALIZUMAB - Special Authority see SA1744 below - Retail pharmacy

Inj 150 mg prefilled syringe	 1	🗸 Xolair
Inj 150 mg vial	1	🗸 Xolair

⇒SA1744 Special Authority for Subsidy

Initial application — (severe asthma) only from a respiratory specialist or clinical immunologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient must be aged 6 years or older; and
- 2 Patient has a diagnosis of severe asthma; and
- 3 Past or current evidence of atopy, documented by skin prick testing or RAST; and
- 4 Total serum human immunoglobulin E (IgE) between 76 IU/mL and 1300 IU/ml at baseline; and
- 5 Proven adherence with optimal inhaled therapy including high dose inhaled corticosteroid (budesonide 1,600 mcg per day or fluticasone propionate 1,000 mcg per day or equivalent), plus long-acting beta-2 agonist therapy (at least salmeterol 50 mcg bd or eformoterol 12 mcg bd) for at least 12 months, unless contraindicated or not tolerated; and

6 Either:

- 6.1 Patient has received courses of systemic corticosteroids equivalent to at least 28 days treatment in the past 12 months, unless contraindicated or not tolerated; or
- 6.2 Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral steroids; and
- 7 Patient has an Asthma Control Test (ACT) score of 10 or less; and
- 8 Baseline measurements of the patient's asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 26 weeks after the first dose to assess response to treatment.

Initial application — (severe chronic spontaneous urticaria) only from a clinical immunologist or dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient must be aged 12 years or older; and
- 2 Either:
 - 2.1 Both:

continued...

197

Subsidy	F	ully	Brand or	
(Manufacturer's Price)	Subsidi	sed	Generic	
\$	Per	✓	Manufacturer	

continued...

- 2.1.1 Patient is symptomatic with Urticaria Activity Score 7 (UAS7) of 20 or above; and
- 2.1.2 Patient has a Dermatology life quality index (DLQI) of 10 or greater; or
- 2.2 Patient has a Urticaria Control Test (UCT) of 8 or less; and
- 3 Any of the following:
 - 3.1 Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and ciclosporin (> 3 mg/kg day) for at least 6 weeks; or
 - 3.2 Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and at least 3 courses of systemic corticosteroids (> 20 mg prednisone per day for at least 5 days) in the previous 6 months; or
 - 3.3 Patient has developed significant adverse effects whilst on corticosteroids or ciclosporin; and

4 Either:

- 4.1 Treatment to be stopped if inadequate response* following 4 doses; or
- 4.2 Complete response* to 6 doses of omalizumab.

Renewal — (severe asthma) only from a clinical immunologist or respiratory specialist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 An increase in the Asthma Control Test (ACT) score of at least 5 from baseline; and
- 2 A reduction in the maintenance oral corticosteroid dose or number of exacerbations of at least 50% from baseline.

Renewal — (severe chronic spontaneous urticaria) only from a clinical immunologist or dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Patient has previously adequately responded* to 6 doses of omalizumab; or

2 Both:

- 2.1 Patient has previously had a complete response* to 6 doses of omalizumab; and
- 2.2 Patient has relapsed after cessation of omalizumab therapy.

Note: *Inadequate response defined as less than 50% reduction in baseline UAS7 and DLQI score, or an increase in Urticaria Control Test (UCT) score of less than 4 from baseline. Patient is to be reassessed for response after 4 doses of omalizumab. Complete response is defined as UAS7 less than or equal to 6 and DLQI less than or equal to 5; or UCT of 16. Relapse of chronic urticaria on stopping prednisone/ciclosporin does not justify the funding of omalizumab.

PERTUZUMAB – PCT only – Specialist – Special Authority see SA1606 below

Inj 30 mg per ml, 14 ml vial	 1	 Perjeta
Inj 420 mg for ECP	 420 mg OP	 Baxter

⇒SA1606 Special Authority for Subsidy

Initial application — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and

2 Either:

- 2.1 Patient is chemotherapy treatment naïve; or
- 2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
- 3 The patient has good performance status (ECOG grade 0-1); and
- 4 Pertuzumab to be administered in combination with trastuzumab; and
- 5 Pertuzumab maximum first dose of 840 mg, followed by maximum of 420 mg every 3 weeks; and
- 6 Pertuzumab to be discontinued at disease progression.

Renewal --- (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a

Subsidy Fully Brand or (Manufacturer's Price) Subsidised Generic \$ Per ✓ Manufacturer	
--	--

continued...

relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

- Both:
 - 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 2 The cancer has not progressed at any time point during the previous 12 months whilst on pertuzumab and trastuzumab.

RITUXIMAB (MABTHERA) - PCT only - Specialist - Special Authority see SA1976 below

Inj 100 mg per 10 ml vial	1,075.50	2	 Mabthera
Inj 500 mg per 50 ml vial	2,688.30	1	 Mabthera
Inj 1 mg for ECP	5.64	1 mg	🗸 Baxter (Mabthera)

⇒SA1976 Special Authority for Subsidy

Initial application — (rheumatoid arthritis - TNF inhibitors contraindicated) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 4 months for applications meeting the following criteria: All of the following:

- 1 Treatment with a Tumour Necrosis Factor alpha inhibitor is contraindicated; and
- 2 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
- 3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
- 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
- 5 Any of the following:
 - 5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or
 - 5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
 - 5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
- 6 Either:
 - 6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
 - 6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

7 Either:

- 7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
- 7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months; and
- 8 Either:
 - 8.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
 - 8.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 9 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Initial application — (rheumatoid arthritis - prior TNF inhibitor use) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 4 months for applications meeting the following criteria: All of the following:

- 1 Both:
 - 1.1 The patient has had an initial community Special Authority approval for at least one of etanercept and/or adalimumab for rheumatoid arthritis; and

Subsidy	Fully	
(Manufacturer's Price)	Subsidised	I Generic
\$	Per 🗸	Manufacturer

- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
 - 1.2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for rheumatoid arthritis; and

2 Either:

- 2.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
- 2.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and3 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Renewal — (rheumatoid arthritis - re-treatment in 'partial responders' to rituximab) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 At 4 months following the initial course of rituximab infusions the patient had between a 30% and 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.2 At 4 months following the second course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.3 At 4 months following the third and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and
- 3 Either:
 - 3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
 - 3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Renewal — (rheumatoid arthritis - re-treatment in 'responders' to rituximab) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 4 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 At 4 months following the initial course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.2 At 4 months following the second and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and
- 3 Either:
 - 3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
 - 3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

RITUXIMAB (RIXIMYO) - PCT only - Specialist - Special Authority see SA2083 on the next page

Inj 100 mg per 10 ml vial		2	Riximyo
Inj 500 mg per 50 ml vial		1	 Riximyo
Inj 1 mg for ECP	1.38	1 mg	 Baxter (Riximyo)

Subsidy		Fully	Brand or
(Manufacturer's Price)	Su	bsidised	Generic
 \$	Per	1	Manufacturer

⇒SA2083 Special Authority for Subsidy

Initial application — (ABO-incompatible organ transplant) from any relevant practitioner. Approvals valid without further renewal unless notified where patient is to undergo an ABO-incompatible solid organ transplant*.

Note: Indications marked with * are unapproved indications.

Initial application — (ANCA associated vasculitis) from any relevant practitioner. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with ANCA associated vasculitis*; and
- 2 The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks; and
- 3 Any of the following:
 - 3.1 Induction therapy with daily oral or pulse intravenous cyclophosphamide has failed to achieve significant improvement of disease after at least 3 months; or
 - 3.2 Patient has previously had a cumulative dose of cyclophosphamide > 15 g or a further repeat 3 month induction course of cyclophosphamide would result in a cumulative dose > 15 g; or
 - 3.3 Cyclophosphamide and methotrexate are contraindicated; or
 - 3.4 Patient is a female of child-bearing potential; or
 - 3.5 Patient has a previous history of haemorrhagic cystitis, urological malignancy or haematological malignancy.

Note: Indications marked with * are unapproved indications.

Renewal — (ANCA associated vasculitis) from any relevant practitioner. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with ANCA associated vasculitis*; and
- 2 Patient has previously responded to treatment with rituximab but is now experiencing an acute flare of vasculitis; and
- 3 The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Initial application — (Antibody-mediated organ transplant rejection) from any relevant practitioner. Approvals valid without further renewal unless notified where patient has been diagnosed with antibody-mediated organ transplant rejection*. Note: Indications marked with * are unapproved indications.

Initial application — (Chronic lymphocytic leukaemia) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment; and
- 2 Any of the following:
 - 2.1 The patient is rituximab treatment naive; or
 - 2.2 Either:
 - 2.2.1 The patient is chemotherapy treatment naive; or
 - 2.2.2 Both:
 - 2.2.2.1 The patient's disease has relapsed following no more than three prior lines of chemotherapy treatment; and
 - 2.2.2.2 The patient has had a treatment-free interval of 12 months or more if previously treated with fludarabine and cyclophosphamide chemotherapy; or
 - 2.3 The patient's disease has relapsed within 36 months of previous treatment and rituximab treatment is to be used in combination with funded venetoclax; and
- 3 The patient has good performance status; and

4 Either:

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy		Fully	Brand or
(Manufacturer's F	Price) Sub	bsidised	Generic
\$	Per	1	Manufacturer

continued...

- 4.1 The patient does not have chromosome 17p deletion CLL; or
- 4.2 Rituximab treatment is to be used in combination with funded venetoclax for relapsed/refractory chronic lymphocytic leukaemia; and
- 5 Rituximab to be administered in combination with fludarabine and cyclophosphamide, bendamustine or venetoclax for a maximum of 6 treatment cycles; and
- 6 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration), bendamustine or venetoclax.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to < 2. **Renewal — (Chronic lymphocytic leukaemia)** from any relevant practitioner. Approvals valid for 12 months for applications

meeting the following criteria:

Both:

- 1 Either:
 - 1.1 The patient's disease has relapsed within 36 months of previous treatment and rituximab treatment is to be used in combination with funded venetoclax; or
 - 1.2 All of the following:
 - 1.2.1 The patient's disease has relapsed following no more than one prior line of treatment with rituximab for CLL; and
 - 1.2.2 The patient has had an interval of 36 months or more since commencement of initial rituximab treatment; and
 - 1.2.3 The patient does not have chromosome 17p deletion CLL; and
 - 1.2.4 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration) or bendamustine; and
- 2 Rituximab to be administered in combination with fludarabine and cyclophosphamide, bendamustine or venetoclax for a maximum of 6 treatment cycles.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

Initial application — (Neuromyelitis Optica Spectrum Disorder(NMOSD)) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m2 administered weekly for four weeks; and
- 2 Either:
 - 2.1 The patient has experienced a severe episode or attack of NMOSD (rapidly progressing symptoms and clinical investigations supportive of a severe attack of NMOSD); or
 - 2.2 All of the following:
 - 2.2.1 The patient has experienced a breakthrough attack of NMOSD; and
 - 2.2.2 The patient is receiving treatment with mycophenolate; and
 - 2.2.3 The patients is receiving treatment with corticosteroids.

Renewal — (Neuromyelitis Optica Spectrum Disorder) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: All of the following:

1 One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m2 administered weekly for four weeks; and

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

- 2 The patients has responded to the most recent course of rituximab; and
- 3 The patient has not received rituximab in the previous 6 months.

Initial application — (Post-transplant) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 2 To be used for a maximum of 8 treatment cycles.
- Note: Indications marked with * are unapproved indications.

Renewal — (Post-transplant) from any relevant practitioner. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 3 To be used for no more than 6 treatment cycles.

Note: Indications marked with * are unapproved indications.

Initial application — (Severe Refractory Myasthenia Gravis) only from a neurologist or medical practitioner on the recommendation of a neurologist. Approvals valid for 2 years for applications meeting the following criteria: Both:

- 1 One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart; and
- 2 Either:
 - 2.1 Treatment with corticosteroids and at least one other immunosuppressant for at least a period of 12 months has been ineffective; or
 - 2.2 Both:
 - 2.2.1 Treatment with at least one other immunosuppressant for a period of at least 12 months; and
 - 2.2.2 Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

Renewal — (Severe Refractory Myasthenia Gravis) only from a neurologist or medical practitioner on the recommendation of a neurologist. Approvals valid for 2 years for applications meeting the following criteria: All of the following:

- 1 One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Either:
 - 3.1 The patient has relapsed despite treatment with corticosteroids and at least one other immunosuppressant for a period of at least 12 months; or
 - 3.2 Both:
 - 3.2.1 The patient's myasthenia gravis has relapsed despite treatment with at least one immunosuppressant for a period of at least 12 months; and
 - 3.2.2 Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

Initial application — (Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)) only from a nephrologist or Practitioner on the recommendation of a nephrologist. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

1 Patient is a child with SDNS* or FRNS*; and

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy		Fully	Brand or
(Manufacturer's Price)	Subs	idised	Generic
\$	Per	1	Manufacturer

continued...

- 2 Treatment with steroids for at least a period of 3 months has been ineffective or associated with evidence of steroid toxicity; and
- 3 Treatment with ciclosporin for at least a period of 3 months has been ineffective and/or discontinued due to unacceptable side effects; and
- 4 Treatment with mycophenolate for at least a period of 3 months with no reduction in disease relapses; and
- 5 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.
- Note: Indications marked with * are unapproved indications.

Renewal — (Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)) only from a nephrologist or Practitioner on the recommendation of a nephrologist. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient who was previously treated with rituximab for nephrotic syndrome*; and
- 2 Treatment with rituximab was previously successful and has demonstrated sustained response for greater than 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Initial application — (Steroid resistant nephrotic syndrome (SRNS)) only from a nephrologist or Practitioner on the recommendation of a nephrologist. Approvals valid for 8 weeks for applications meeting the following criteria: All of the following:

- 1 Patient is a child with SRNS* where treatment with steroids and ciclosporin for at least 3 months have been ineffective; and
- 2 Treatment with tacrolimus for at least 3 months has been ineffective; and
- 3 Genetic causes of nephrotic syndrome have been excluded; and
- 4 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Renewal — (Steroid resistant nephrotic syndrome (SRNS)) only from a nephrologist or Practitioner on the recommendation of a nephrologist. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient who was previously treated with rituximab for nephrotic syndrome*; and
- 2 Treatment with rituximab was previously successful and has demonstrated sustained response for greater than 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.
- Note: Indications marked with * are unapproved indications.

Initial application — (aggressive CD20 positive NHL) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 The patient has treatment naive aggressive CD20 positive NHL; and
 - 1.2 To be used with a multi-agent chemotherapy regimen given with curative intent; and
 - 1.3 To be used for a maximum of 8 treatment cycles; or

2 Both:

- 2.1 The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy; and
- 2.2 To be used for a maximum of 6 treatment cycles.

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia

Renewal — (aggressive CD20 positive NHL) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has relapsed refractory/aggressive CD20 positive NHL; and
- 3 To be used with a multi-agent chemotherapy regimen given with curative intent; and
- 4 To be used for a maximum of 4 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia

Initial application — (haemophilia with inhibitors) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 4 months for applications meeting the following criteria:

Any of the following:

- 1 Patient has mild congenital haemophilia complicated by inhibitors; or
- 2 Patient has severe congenital haemophilia complicated by inhibitors and has failed immune tolerance therapy; or
- 3 Patient has acquired haemophilia.

Renewal — (haemophilia with inhibitors) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient was previously treated with rituximab for haemophilia with inhibitors; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Patient now requires repeat treatment.

Initial application — (immune thrombocytopenic purpura (ITP)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 Patient has immune thrombocytopenic purpura* with a platelet count of less than or equal to 20,000 platelets per microlitre; or
 - 1.2 Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding; and
- 2 Any of the following:
 - 2.1 Treatment with steroids and splenectomy have been ineffective; or
 - 2.2 Treatment with steroids has been ineffective and splenectomy is an absolute contraindication; or
 - 2.3 Other treatments including steroids have been ineffective and patient is being prepared for elective surgery (e.g. splenectomy); and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks.
- Note: Indications marked with * are unapproved indications.

Renewal — (immune thrombocytopenic purpura (ITP)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria:

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for immune thrombocytopenic purpura*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy	Fu	ly Brand or	
(Manufacturer's Price)	Subsidise	d Generic	
\$	Per	Manufacturer	

Initial application — (indolent, low-grade lymphomas or hairy cell leukaemia*) from any relevant practitioner. Approvals valid for 9 months for applications meeting the following criteria:

Either: 1 Both:

- 1.1 The patient has indolent low grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy; and
- 1.2 To be used for a maximum of 6 treatment cycles; or

2 Both:

- 2.1 The patient has indolent, low grade lymphoma or hairy cell leukaemia* requiring first-line systemic chemotherapy; and
- 2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. 'Hairy cell leukaemia' also includes hairy cell leukaemia variant.

Renewal — (indolent, low-grade lymphomas or hairy cell leukaemia*) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has indolent, low-grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy; and
- 3 To be used for no more than 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. 'Hairy cell leukaemia' also includes hairy cell leukaemia variant.

Initial application — (pure red cell aplasia (PRCA)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 6 weeks where patient has autoimmune pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder.

Note: Indications marked with * are unapproved indications.

Renewal — (pure red cell aplasia (PRCA)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 6 weeks where patient was previously treated with rituximab for pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder and demonstrated an initial response lasting at least 12 months.

Note: Indications marked with * are unapproved indications.

Initial application — (severe cold haemagglutinin disease (CHAD)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria: All of the following:

- 1 Patient has cold haemagglutinin disease*; and
- 2 Patient has severe disease which is characterized by symptomatic anaemia, transfusion dependence or disabling circulatory symptoms; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Renewal — (severe cold haemagglutinin disease (CHAD)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria:

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for severe cold haemagglutinin disease*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and

Subsidy	Fu	lly Brand	or
(Manufacturer's Price)	Subsidis	ed Generi	íC
\$	Per	 Manufa 	acturer

continued...

2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

Initial application — (thrombotic thrombocytopenic purpura (TTP)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria: Both:

- 1 The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks; and
- 2 Either:
 - 2.1 Patient has thrombotic thrombocytopenic purpura* and has experienced progression of clinical symptoms or persistent thrombocytopenia despite plasma exchange; or
 - 2.2 Patient has acute idiopathic thrombotic thrombocytopenic purpura* with neurological or cardiovascular pathology.

Note: Indications marked with * are unapproved indications.

Renewal — (thrombotic thrombocytopenic purpura (TTP)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient was previously treated with rituximab for thrombotic thrombocytopenic purpura*; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Patient now requires repeat treatment; and
- 4 The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Initial application — (treatment refractory systemic lupus erythematosus (SLE)) only from a rheumatologist, nephrologist or Practitioner on the recommendation of a rheumatologist or nephrologist. Approvals valid for 7 months for applications meeting the following criteria:

All of the following:

- 1 The patient has severe, immediately life- or organ-threatening SLE*; and
- 2 The disease has proved refractory to treatment with steroids at a dose of at least 1 mg/kg; and
- 3 The disease has relapsed following prior treatment for at least 6 months with maximal tolerated doses of azathioprine, mycophenolate mofetil and high dose cyclophosphamide, or cyclophosphamide is contraindicated; and
- 4 Maximum of four 1000 mg infusions of rituximab.
- Note: Indications marked with * are unapproved indications.

Renewal — (treatment refractory systemic lupus erythematosus (SLE)) only from a rheumatologist, nephrologist or Practitioner on the recommendation of a rheumatologist or nephrologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient's SLE* achieved at least a partial response to the previous round of prior rituximab treatment; and
- 2 The disease has subsequently relapsed; and
- 3 Maximum of two 1000 mg infusions of rituximab.

Note: Indications marked with * are unapproved indications.

Initial application — (warm autoimmune haemolytic anaemia (warm AIHA)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria: All of the following:

- 1 Patient has warm autoimmune haemolytic anaemia*; and
- 2 One of the following treatments has been ineffective: steroids (including if patient requires ongoing steroids at doses equivalent to > 5 mg prednisone daily), cytotoxic agents (e.g. cyclophosphamide monotherapy or in combination), intravenous immunoglobulin; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks.

Subsidy		Fully	Brand or	
(Manufacturer's Price)	S	Subsidised	Generic	
\$	Per	✓	Manufacturer	

Note: Indications marked with * are unapproved indications.

Renewal — (warm autoimmune haemolytic anaemia (warm AIHA)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria: Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for warm autoimmune haemolytic anaemia*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

Initial application — (severe antisynthetase syndrome) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed antisynthetase syndrome; and
- 2 Patient has severe, immediately life or organ threatening disease, including interstitial lung disease; and
- 3 Either:
 - 3.1 Treatment with at least 3 immunosuppressants (oral steroids, cyclophosphamide, methotrexate, mycophenolate, ciclosporin, azathioprine) has not be effective at controlling active disease; or
 - 3.2 Rapid treatment is required due to life threatening complications; and
- 4 Maximum of four 1,000mg infusions of rituximab.

Renewal — (severe antisynthetase syndrome) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient's disease has responded to the previous rituximab treatment with demonstrated improvement in inflammatory markers, muscle strength and pulmonary function; and
- 2 The patient has not received rituximab in the previous 6 months; and
- 3 Maximum of two cycles of 2 × 1,000mg infusions of rituximab given two weeks apart.

Initial application — (graft versus host disease) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has refractory graft versus host disease following transplant; and
- 2 Treatment with at least 3 immunosuppressants (oral steroids, ciclosporin, tacrolimus, mycophenolate, sirolimus) has not be effective at controlling active disease; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Initial application — (severe chronic inflammatory demyelinating polyneuropathy) only from a neurologist or medical practitioner on the recommendation of a neurologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Patient has severe chronic inflammatory demyelinating polyneuropathy (CIPD); and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Treatment with steroids and intravenous immunoglobulin and/or plasma exchange has not been effective at controlling active disease; and
 - 2.1.2 At least one other immunosuppressant (cyclophosphamide, ciclosporin, tacrolimus, mycophenolate) has not been effective at controlling active disease; or
 - 2.2 Rapid treatment is required due to life threatening complications; and

	Subsidy	Fully	Brand or
(Manu	ufacturer's Price) Subs	sidised	Generic
	\$ Per	1	Manufacturer

continued...

3 One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

Renewal — (severe chronic inflammatory demyelinating polyneuropathy) only from a neurologist or medical practitioner on the recommendation of a neurologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Patient's disease has responded to the previous rituximab treatment with demonstrated improvement in neurological function compared to baseline; and
- 2 The patient has not received rituximab in the previous 6 months; and
- 3 One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

Initial application — (anti-NMDA receptor autoimmune encephalitis) only from a neurologist or medical practitioner on the recommendation of a neurologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Patient has severe anti-NMDA receptor autoimmune encephalitis; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Treatment with steroids and intravenous immunoglobulin and/or plasma exchange has not been effective at controlling active disease; and
 - 2.1.2 At least one other immunosuppressant (cyclophosphamide, ciclosporin, tacrolimus, mycophenolate) has not been effective at controlling active disease; or
 - 2.2 Rapid treatment is required due to life threatening complications; and
- 3 One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

Renewal — (anti-NMDA receptor autoimmune encephalitis) only from a neurologist or medical practitioner on the recommendation of a neurologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Patient's disease has responded to the previous rituximab treatment with demonstrated improvement in neurological function; and
- 2 The patient has not received rituximab in the previous 6 months; and
- 3 The patient has experienced a relapse and now requires further treatment; and
- 4 One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

Initial application — (CD20+ low grade or follicular B-cell NHL) from any relevant practitioner. Approvals valid for 9 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has CD20+ low grade or follicular B-cell NHL with relapsed disease following prior chemotherapy; and
 - 1.2 To be used for a maximum of 6 treatment cycles; or
- 2 Both:
 - 2.1 The patient has CD20+ low grade or follicular B-cell NHL requiring first-line systemic chemotherapy; and
 - 2.2 To be used for a maximum of 6 treatment cycles.

Renewal — (CD20+ low grade or follicular B-cell NHL) from any relevant practitioner. Approvals valid for 24 months for applications meeting the following criteria:

Both:

1 Rituximab is to be used for maintenance in CD20+ low grade or follicular B-cell NHL following induction with first-line systemic chemotherapy; and

Subsidy	y Fu	ully Brand or
(Manufacturer	's Price) Subsidis	sed Generic
\$	Per	 Manufacturer

continued...

2 Patient is intended to receive rituximab maintenance therapy for 2 years at a dose of 375 mg/m2 every 8 weeks (maximum of 12 cycles).

Initial application — (Membranous nephropathy) only from a nephrologist or any relevant practitioner on the recommendation of a nephrologist. Approvals valid for 6 weeks for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 Patient has biopsy-proven primary/idiopathic membranous nephropathy*; or
 - 1.2 Patient has PLA2 antibodies with no evidence of secondary cause, and an eGFR of > 60ml/min/1.73m2; and
- 2 Patient remains at high risk of progression to end-stage kidney disease despite more than 3 months of treatment with conservative measures (see Note); and
- 3 The total rituximab dose would not exceed the equivalent of 375mg/m2 of body surface area per week for a total of 4 weeks.

Renewal — (Membranous nephropathy) only from a nephrologist or any relevant practitioner on the recommendation of a nephrologist. Approvals valid for 6 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient was previously treated with rituximab for membranous nephropathy*; and
- 2 Either:
 - 2.1 Treatment with rituximab was previously successful, but the condition has relapsed, and the patient now requires repeat treatment; or
 - 2.2 Patient achieved partial response to treatment and requires repeat treatment (see Note); and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks.

Notes:

- a) Indications marked with * are unapproved indications.
- b) High risk of progression to end-stage kidney disease defined as > 5g/day proteinuria.
- c) Conservative measures include renin-angiotensin system blockade, blood-pressure management, dietary sodium and protein restriction, treatment of dyslipidaemia, and anticoagulation agents unless contraindicated or the patient has experienced intolerable side effects.
- d) Partial response defined as a reduction of proteinuria of at least 50% from baseline, and between 0.3 grams and 3.5 grams per 24 hours.

Initial application — (B-cell acute lymphoblastic leukaemia/lymphoma*) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Patient has newly diagnosed B-cell acute lymphoblastic leukaemia/lymphoma*; and
- 2 Treatment must be in combination with an intensive chemotherapy protocol with curative intent; and
- 3 The total rituximab dose would not exceed the equivalent of 375 mg/m² per dose for a maximum of 18 doses.

Note: Indications marked with * are unapproved indications.

Initial application — (desensisation prior to transplant) from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:

Both:

- 1 Patient requires desensitisation prior to mismatched allogenic stem cell transplant*; and
- 2 Patient would receive no more than two doses at 375 mg/m2 of body-surface area.

Note: Indications marked with * are unapproved indications.

SECUKINUMAB - Special Authority see SA2084 on the next page - Retail pharmacy

 Cosentyx 	1	nj 150 mg per ml, 1 ml prefilled syringe799.50
 Cosentyx 	2	1,599.00

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
 \$	Per 🗸	Manufacturer

⇒SA2084 Special Authority for Subsidy

Initial application — (severe chronic plaque psoriasis – second-line biologic) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had an initial Special Authority approval for adalimumab or etanercept, or has trialled infliximab in a DHB hospital in accordance with the General Rules of the Pharmaceutical Schedule, for severe chronic plaque psoriasis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from adalimumab, etanercept or infliximab; or
 - 2.2 The patient has received insufficient benefit from adalimumab, etanercept or infliximab; and
- 3 A Psoriasis Area and Severity Index (PASI) assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 4 The most recent PASI or DQLI assessment is no more than 1 month old at the time of application.

Initial application — (severe chronic plaque psoriasis – first-line biologic) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

1 Either:

- 1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
- 1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- 2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
- 3 A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 4 The most recent PASI or DQLI assessment is no more than 1 month old at the time of application.

Note: A treatment course is defined as a minimum of 12 weeks of treatment. "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom sub scores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Renewal — (severe chronic plaque psoriasis – first and second-line biologic) only from a dermatologist or medical practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

1 Either:

- 1.1 Patient's PASI score has reduced by 75% or more (PASI 75) as compared to baseline PASI prior to commencing secukinumab; or
- 1.2 Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing secukinumab; and
- 2 Secukinumab to be administered at a maximum dose of 300 mg monthly.

Initial application — (ankylosing spondylitis – second-line biologic) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 3 months for applications meeting the following criteria: Both:

Subsidy		Fully	Brand or	
(Manufacturer's Price	e)	Subsidised	Generic	
\$	Per	1	Manufacturer	

continued...

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for ankylosing spondylitis; and 2 Either:
 - 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
 - 2.2 Following 12 weeks of adalimumab and/or etanercept treatment, the patient did not meet the renewal criteria for adalimumab and/or etanercept for ankylosing spondylitis.

Renewal — (ankylosing spondylitis – second-line biologic) only from a rheumatologist or medical practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Following 12 weeks initial treatment of secukinumab treatment, BASDAI has improved by 4 or more points from pre-secukinumab baseline on a 10 point scale, or by 50%, whichever is less; and
- 2 Physician considers that the patient has benefitted from treatment and that continued treatment is appropriate; and
- 3 Secukinumab to be administered at doses no greater than 150 mg monthly.

Initial application — (psoriatic arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 Patient has had an initial Special Authority approval for adalimumab, etanercept or infliximab for psoriatic arthritis; and
 - 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects from adalimumab, etanercept or infliximab; or
 - 1.2.2 Patient has received insufficient benefit from adalimumab, etanercept or infliximab to meet the renewal criteria for adalimumab, etanercept or infliximab for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
 - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.5 Any of the following:
 - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Renewal — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Fither
 - 1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior secukinumab treatment in the opinion of the treating physician; and

nan's Disease ffective; and g every 3 wee	Per weeks. 1 nonths fo ; and ks. where the	✓ S	Generic Manufacturer
ng/kg every 3 0.57 12.33 als valid for 6 i nan's Disease ffective; and ig every 3 wee or 12 months i	1 1 months fo ; and ks. where the	✓ S	ylvant
ng/kg every 3 0.57 12.33 als valid for 6 i nan's Disease ffective; and ig every 3 wee or 12 months i	1 1 months fo ; and ks. where the	✓ S	ylvant
0.57 12.33 als valid for 6 i nan's Disease ffective; and g every 3 wee or 12 months i	1 1 months fo ; and ks. where the	✓ S	ylvant
12.33 als valid for 6 i nan's Disease ffective; and g every 3 wee or 12 months i	nonths fo ; and ks. where the	✓ S	ylvant
als valid for 6 n nan's Disease ffective; and g every 3 wee or 12 months v	months fo ; and ks. where the	or applica	ations meeting the
nan's Disease ffective; and g every 3 wee or 12 months v	; and ks. where the		,
nan's Disease ffective; and g every 3 wee or 12 months v	; and ks. where the		Ţ
0.00	1	1 N	ctemra
20.00	I	✓ A	ctemra ctemra S29 529 oActemra S29 529
0.00	4	✓ B	oActemra S29 S29
0.00	1	✓ A	ctemra
		🗸 A	ctemra S29 S29
		🗸 R	oActemra S29 S29
0.00	1	🗸 A	ctemra
		🗸 A	ctemra S29 S29
		🗸 R	oActemra S29 S29
0.00	4	✓ R	oActemra S29 S29
	00.00)0.00 1	✓ R 00.00 1 ✓ A ✓ A ✓ R

Initial application — (cytokine release syndrome) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 The patient is enrolled in the Children's Oncology Group AALL1731 trial; and
 - 1.2 The patient has developed grade 3 or 4 cytokine release syndrome associated with the administration of blinatumomab for the treatment of acute lymphoblastic leukaemia; and
 - 1.3 Tocilizumab is to be administered at doses no greater than 8 mg/kg IV for a maximum of 3 doses (if less than 30kg, maximum of 12 mg/kg); or
- 2 All of the following:
 - 2.1 The patient is enrolled in the Malaghan Institute of Medical Research Phase I ENABLE trial; and
 - 2.2 The patient has developed CRS or CAR T-Cell Related Encephalopathy Syndrome (CRES) associated with the administration of CAR T-cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma; and
 - 2.3 Tocilizumab is to be administered according to the consensus guidelines for CRS and CRES for CAR T-cell therapy (Neelapu et al. Nat Rev Clin Oncol 2018;15:47-62) at doses no greater than 8 mg/kg IV for a maximum of 3 doses.

Initial application — (previous use) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	1	Manufacturer

Both:

- 1 Patient was being treated with tocilizumab prior to 1 February 2019; and
- 2 Any of the following:
 - 2.1 rheumatoid arthritis; or
 - 2.2 systemic juvenile idiopathic arthritis; or
 - 2.3 adult-onset Still's disease; or
 - 2.4 polyarticular juvenile idiopathic arthritis; or
 - 2.5 idiopathic multicentric Castleman's disease.

Initial application — (Rheumatoid Arthritis (patients previously treated with adalimumab or etanercept)) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
 - 2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for rheumatoid arthritis; and
- 3 Either:
 - 3.1 The patient is seronegative for both anti-cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor; or
 - 3.2 Both:
 - 3.2.1 The patient has been started on rituximab for rheumatoid arthritis in a DHB hospital in accordance with the Section H rules; and
 - 3.2.2 Either:
 - 3.2.2.1 The patient has experienced intolerable side effects from rituximab; or
 - 3.2.2.2 At four months following the initial course of rituximab the patient has received insufficient benefit such that they do not meet the renewal criteria for rheumatoid arthritis.

Initial application — (Rheumatoid Arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

- All of the following:
 - 1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
 - 2 Tocilizumab is to be used as monotherapy; and
 - 3 Either:
 - 3.1 Treatment with methotrexate is contraindicated; or
 - 3.2 Patient has tried and did not tolerate oral and/or parenteral methotrexate; and
 - 4 Either:
 - 4.1 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of ciclosporin alone or in combination with another agent; or
 - 4.2 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of leflunomide alone or in combination with another agent; and
 - 5 Either:
 - 5.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 active, swollen, tender joints; or
 - 5.2 Patient has persistent symptoms of poorly controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 6 Either:

Subsidy		Fully	Brand or
(Manufacturer's Pric	ce) S	Subsidised	Generic
\$	Per	✓	Manufacturer

continued...

- 6.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
- 6.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initial application — (systemic juvenile idiopathic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Patient diagnosed with systemic juvenile idiopathic arthritis; and
- 2 Patient has tried and not responded to a reasonable trial of all of the following, either alone or in combination: oral or parenteral methotrexate; non-steroidal anti-inflammatory drugs (NSAIDs); and systemic corticosteroids.

Initial application — (adult-onset Still's disease) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either: 1 Both:

- 1 1 Fit
 - 1.1 Either:
 - 1.1.1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for adult-onset Still's disease (AOSD); or
 - 1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the General Rules of the Pharmaceutical Schedule; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
 - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for AOSD; or
- 2 All of the following:
 - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
 - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and
 - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Initial application — (polyarticular juvenile idiopathic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 4 months for applications meeting the following criteria: Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for both etanercept and adalimumab for polyarticular course juvenile idiopathic arthritis (JIA); and
 - 1.2 The patient has experienced intolerable side effects, or has received insufficient benefit from, both etanercept and adalimumab; or
- 2 All of the following:
 - 2.1 Treatment with a tumour necrosis factor alpha inhibitor is contraindicated; and
 - 2.2 Patient has had polyarticular course JIA for 6 months duration or longer; and
 - 2.3 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.4 Any of the following:
 - 2.4.1 At least 5 active joints and at least 3 joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.4.2 Moderate or high disease activity (cJADAS10 score of at least 2.5) after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.4.3 Low disease activity (cJADAS10 score between 1.1 and 2.5) after a 6-month trial of methotrexate.

Subsidy (Manufacturer's	Ful Price) Subsidise	
`\$	Per	 Manufacturer

Initial application — (idiopathic multicentric Castleman's disease) only from a haematologist, rheumatologist or Practitioner on the recommendation of a haematologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has severe HHV-8 negative idiopathic multicentric Castleman's disease; and
- 2 Treatment with an adequate trial of corticosteroids has proven ineffective; and
- 3 Tocilizumab to be administered at doses no greater than 8 mg/kg IV every 3-4 weeks.

Initial application — (moderate to severe COVID-19*) from any relevant practitioner. Approvals valid for 4 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed (or probable) COVID-19; and
- 2 Oxygen saturation of < 92% on room air, or requiring supplemental oxygen; and
- 3 Patient is receiving adjunct systemic corticosteroids, or systemic corticosteroids are contraindicated; and
- 4 Tocilizumab is to be administered at doses no greater than 8mg/kg IV for a maximum of one dose; and
- 5 Tocilizumab is not to be administered in combination with barcitinib.

Note: Indications marked with * are unapproved indications.

Renewal — (Rheumatoid Arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Following 6 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.

Renewal — (systemic juvenile idiopathic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Either:

- 1 Following up to 6 months' initial treatment, the patient has achieved at least an American College of Rheumatology paediatric 30% improvement criteria (ACR Pedi 30) response from baseline; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing ACR Pedi 30 response from baseline.

Renewal — (adult-onset Still's disease) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months where the patient has a sustained improvement in inflammatory markers and functional status. Renewal — (polyarticular juvenile idiopathic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Renewal — (idiopathic multicentric Castleman's disease) only from a haematologist, rheumatologist or Practitioner on the recommendation of a haematologist or rheumatologist. Approvals valid for 12 months where the treatment remains appropriate and the patient has a sustained improvement in inflammatory markers and functional status.

TRASTUZUMAB - PCT only - Specialis	t - Special Authority see SA1632 on the	e next page	
Inj 150 mg vial		1	 Herceptin
Inj 440 mg vial		1	 Herceptin
Inj 1 mg for ECP		1 mg	 Baxter

Subs	sidy F	ully B	rand or
(Manufactur	rer's Price) Subsidi	sed G	eneric
\$	Per	✓ M	anufacturer

⇒SA1632 Special Authority for Subsidy

Initial application — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Either:
 - 2.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
 - 2.2 Both:
 - 2.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
 - 2.2.2 The cancer did not progress whilst on lapatinib; and
- 3 Either:
 - 3.1 Trastuzumab will not be given in combination with pertuzumab; or
 - 3.2 All of the following:
 - 3.2.1 Trastuzumab to be administered in combination with pertuzumab; and
 - 3.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
 - 3.2.3 The patient has good performance status (ECOG grade 0-1); and
- 4 Trastuzumab not to be given in combination with lapatinib; and
- 5 Trastuzumab to be discontinued at disease progression.

Renewal — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
- 3 Trastuzumab not to be given in combination with lapatinib; and
- 4 Trastuzumab to be discontinued at disease progression.

Initial application — (early breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 15 months for applications meeting the following criteria: All of the following:

- 1 The patient has early breast cancer expressing HER 2 IHC 3+ or ISH + (including FISH or other current technology); and
- 2 Maximum cumulative dose of 106 mg/kg (12 months' treatment); and
- 3 Any of the following:
 - 3.1 9 weeks' concurrent treatment with adjuvant chemotherapy is planned; or
 - 3.2 12 months' concurrent treatment with adjuvant chemotherapy is planned; or
 - 3.3 12 months' sequential treatment following adjuvant chemotherapy is planned; or
 - 3.4 12 months' treatment with neoadjuvant and adjuvant chemotherapy is planned; or
 - 3.5 Other treatment regimen, in association with adjuvant chemotherapy, is planned.

Renewal — (early breast cancer*) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The patient received prior adjuvant trastuzumab treatment for early breast cancer; and

Subsidy	,	Fully	Brand or
(Manufacturer's Pri	ce) Per	Subsidised	Generic Manufacturer
φ	rei	•	Manulacturer

continued...

- 3 Any of the following:
 - 3.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or 3.2 Both:
 - 3.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
 - 3.2.2 The cancer did not progress whilst on lapatinib; or
 - 3.3 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
- 4 Either:
 - 4.1 Trastuzumab will not be given in combination with pertuzumab; or
 - 4.2 All of the following:
 - 4.2.1 Trastuzumab to be administered in combination with pertuzumab; and
 - 4.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
 - 4.2.3 The patient has good performance status (ECOG grade 0-1); and
- 5 Trastuzumab not to be given in combination with lapatinib; and
- 6 Trastuzumab to be discontinued at disease progression.

Note: * For patients with relapsed HER-2 positive disease who have previously received adjuvant trastuzumab for early breast cancer.

Inj 100 mg vial2,320.00	1	Kadcyla
Inj 160 mg vial	1	Kadcyla
Inj 1 mg for ECP23.20	1 mg	 Baxter

⇒SA1871 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Patient has previously received trastuzumab and chemotherapy, separately or in combination; and
- 3 Either:
 - 3.1 The patient has received prior therapy for metastatic disease*; or
 - 3.2 The patient developed disease recurrence during, or within six months of completing adjuvant therapy*; and
- 4 Patient has a good performance status (ECOG 0-1); and
- 5 Either:
 - 5.1 Patient does not have symptomatic brain metastases; or
 - 5.2 Patient has brain metastases and has received prior local CNS therapy; and
- 6 Treatment to be discontinued at disease progression.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

- Both:
 - 1 The cancer has not progressed at any time point during the previous approval period whilst on trastuzumab emtansine; and
 - 2 Treatment to be discontinued at disease progression.

Note: *Note: Prior or adjuvant therapy includes anthracycline, other chemotherapy, biological drugs, or endocrine therapy.

	Subsidy (Manufacturer's Price) \$	Sı Per	Fully ubsidised	Brand or Generic Manufacturer
Programmed Cell Death-1 (PD-1) Inhibitors				
 NIVOLUMAB – PCT only – Specialist – Special Authority see S/ Inj 10 mg per ml, 4 ml vial	1,051.98 2,629.96 27.62 Ilid for 4 months for ap ling uveal) stage III or ersion 1.1; and		✓ C ✓ E	Dpdivo Dpdivo Baxter ng the following criteria:

- 4.2.1 Patient has received an initial Special Authority approval for pembrolizumab and has discontinued pembrolizumab within 12 weeks of starting treatment due to intolerance; and
- 4.2.2 The cancer did not progress while the patient was on pembrolizumab; and
- 5 Baseline measurement of overall tumour burden is documented (see Note); and
- 6 Documentation confirming that the patient has been informed and acknowledges that funded treatment with nivolumab will not be continued if their disease progresses.

Renewal only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 Any of the following:
 - 1.1.1 Patient's disease has had a complete response to treatment according to RECIST criteria (see Note); or
 - 1.1.2 Patient's disease has had a partial response to treatment according to RECIST criteria (see Note); or
 - 1.1.3 Patient has stable disease according to RECIST criteria (see Note); and
 - 1.2 Either:
 - 1.2.1 Response to treatment in target lesions has been determined by radiologic assessment (CT or MRI scan) following the most recent treatment period; or
 - 1.2.2 Both:
 - 1.2.2.1 Patient has measurable disease as defined by RECIST version 1.1; and
 - 1.2.2.2 Patient's disease has not progressed clinically and disease response to treatment has been clearly documented in patient notes; and
 - 1.3 No evidence of progressive disease according to RECIST criteria (see Note); and
 - 1.4 The treatment remains clinically appropriate and the patient is benefitting from the treatment; or
- 2 All of the following:
 - 2.1 Patient has previously discontinued treatment with nivolumab for reasons other than severe toxicity or disease progression; and
 - 2.2 Patient has signs of disease progression; and
 - 2.3 Disease has not progressed during previous treatment with nivolumab.

Notes: Baseline assessment and disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer EA, et al. Eur J Cancer 2009;45:228-47). Assessments of overall tumour burden and measurable disease to be undertaken on a minimum of one lesion and maximum of 5 target lesions (maximum two lesions per organ). Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, and suitable for reproducible repeated measurements. Measurable disease includes by CT or MRI imaging

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per	✓	Manufacturer	

continued...

or caliper measurement by clinical exam. Target lesion measurements should be assessed using the same method of assessment and the same technique used to characterise each identified and reported lesion at baseline and every 12 weeks. Response definitions as follows:

- Complete Response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target)
 must have reduction in short axis to < 10 mm.
- Partial Response: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
- Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
- Stable Disease: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.

PEMBROLIZUMAB – PCT only – Specialist – Special Authority see SA2007 below

Inj 25 mg per ml, 4 ml vial	 1	 Keytruda
Inj 1 mg for ECP	 1 mg	 Baxter

⇒SA2007 Special Authority for Subsidy

Initial application — (unresectable or metastatic melanoma) only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria: All of the following:

- 1 Patient has metastatic or unresectable melanoma (excluding uveal) stage III or IV; and
- 2 Patient has measurable disease as defined by RECIST version 1.1; and
- 3 The patient has ECOG performance score of 0-2; and
- 4 Either:
 - 4.1 Patient has not received funded nivolumab; or
 - 4.2 Both:
 - 4.2.1 Patient has received an initial Special Authority approval for nivolumab and has discontinued nivolumab within 12 weeks of starting treatment due to intolerance; and
 - 4.2.2 The cancer did not progress while the patient was on nivolumab; and
- 5 Baseline measurement of overall tumour burden is documented (see Note); and
- 6 Documentation confirming that the patient has been informed and acknowledges that funded treatment with pembrolizumab will not be continued if their disease progresses.

Renewal — (unresectable or metastatic melanoma) only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria: Either:

- 1 All of the following:
 - 1.1 Any of the following:
 - 1.1.1 Patient's disease has had a complete response to treatment according to RECIST criteria (see Note); or
 - 1.1.2 Patient's disease has had a partial response to treatment according to RECIST criteria (see Note); or
 - 1.1.3 Patient has stable disease according to RECIST criteria (see Note); and
 - 1.2 Either:
 - 1.2.1 Response to treatment in target lesions has been determined by radiologic assessment (CT or MRI scan) following the most recent treatment period; or
 - 1.2.2 Both:
 - 1.2.2.1 Patient has measurable disease as defined by RECIST version 1.1; and
 - 1.2.2.2 Patient's disease has not progressed clinically and disease response to treatment has been clearly documented in patient notes; and

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 1.3 No evidence of progressive disease according to RECIST criteria (see Note); and
- 1.4 The treatment remains clinically appropriate and the patient is benefitting from the treatment; or
- 2 All of the following:
 - 2.1 Patient has previously discontinued treatment with pembrolizumab for reasons other than severe toxicity or disease progression; and
 - 2.2 Patient has signs of disease progression; and
 - 2.3 Disease has not progressed during previous treatment with pembrolizumab.

Notes: Baseline assessment and disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer EA, et al. Eur J Cancer 2009;45:228-47). Assessments of overall tumour burden and measurable disease to be undertaken on a minimum of one lesion and maximum of 5 target lesions (maximum two lesions per organ). Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, and suitable for reproducible repeated measurements. Measurable disease includes by CT or MRI imaging or caliper measurement by clinical exam. Target lesion measurements should be assessed using the same method of assessment and the same technique used to characterise each identified and reported lesion at baseline and every 12 weeks. Response definitions as follows:

- Complete Response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.
- Partial Response: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
- Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
- Stable Disease: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.

Other Immunosuppressants

CICL	OSPORIN

Cap 25 mg		50	 Neoral
Cap 50 mg		50	 Neoral
Cap 100 mg		50	 Neoral
Oral liq 100 mg per ml		50 ml OP	 Neoral
EVEROLIMUS – Special Authority see SA2008 below – Re Wastage claimable	tail pharmacy		
Tab 10 mg	6,512.29	30	 Afinitor
Tab 5 mg	4,555.76	30	 Afinitor

SA2008 Special Authority for Subsidy

Initial application only from a neurologist or oncologist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient has tuberous sclerosis; and
- 2 Patient has progressively enlarging sub-ependymal giant cell astrocytomas (SEGAs) that require treatment.

Renewal only from a neurologist or oncologist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 Documented evidence of SEGA reduction or stabilisation by MRI within the last 3 months; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment; and
- 3 Everolimus to be discontinued at progression of SEGAs.

Note: MRI should be performed at minimum once every 12 months, more frequent scanning should be performed with new onset of symptoms such as headaches, visual complaints, nausea or vomiting, or increase in seizure activity.

	Subsidy (Manufacturer's Price \$			Brand or Generic Manufacturer
SIROLIMUS – Special Authority see SA2005 below – Retail pha		100	4 D	
Tab 1 mg Tab 2 mg Oral lig 1 mg per ml	1,499.99	100 100 60 ml OF	🗸 R	apamune apamune apamune

⇒SA2005 Special Authority for Subsidy

Initial application from any medical practitioner. Approvals valid without further renewal unless notified where the drug is to be used for rescue therapy for an organ transplant recipient.

Notes: Rescue therapy defined as unresponsive to calcineurin inhibitor treatment as defined by refractory rejection; or intolerant to calcineurin inhibitor treatment due to any of the following:

- GFR< 30 ml/min; or
- · Rapidly progressive transplant vasculopathy; or
- · Rapidly progressive obstructive bronchiolitis; or
- · HUS or TTP; or
- Leukoencepthalopathy; or
- Significant malignant disease

Initial application — (severe non-malignant lymphovascular malformations*) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has severe non-malignant lymphovascular malformation*; and
- 2 Any of the following:
 - 2.1 Malformations are not adequately controlled by sclerotherapy and surgery; or
 - 2.2 Malformations are widespread/extensive and sclerotherapy and surgery are not considered clinically appropriate; or
 - 2.3 Sirolimus is to be used to reduce malformation prior to consideration of surgery; and
- 3 Patient is being treated by a specialist lymphovascular malformation multi-disciplinary team; and
- 4 Patient has measurable disease as defined by RECIST version 1.1 (see Note).

Renewal — (severe non-malignant lymphovascular malformations*) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

- All of the following:
 - 1 Either:
 - 1.1 Patient's disease has had either a complete response or a partial response to treatment, or patient has stable disease according to RECIST version 1.1 (see Note); or
 - 1.2 Patient's disease has stabilised or responded clinically and disease response to treatment has been clearly documents in patient notes; and
 - 2 No evidence of progressive disease; and
 - 3 The treatment remains clinically appropriate and the patient is benefitting from the treatment.

Notes: Baseline assessment and disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer et al. Eur J Cancer 2009;45:228-47)

Indications marked with * are unapproved indications

Initial application — (renal angiomyolipoma(s) associated with tuberous sclerosis complex*) only from a nephrologist or urologist. Approvals valid for 6 months for applications meeting the following criteria:

- Both:
 - 1 Patient has tuberous sclerosis complex*; and

2 Evidence of renal angiomyolipoma(s) measuring 3 cm or greater and that have shown interval growth.

Renewal — (renal angiomyolipoma(s) associated with tuberous sclerosis complex*) from any relevant practitioner.

Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

1 Documented evidence of renal angiomyolipoma reduction or stability by magnetic resonance imaging (MRI) or ultrasound; and

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 2 Demonstrated stabilisation or improvement in renal function; and
- 3 The patient has not experienced angiomyolipoma haemorrhage or significant adverse effects to sirolimus treatment; and
- 4 The treatment remains appropriate and the patient is benefitting from treatment.
- Note: Indications marked with * are unapproved indications

Initial application — (refractory seizures associated with tuberous sclerosis complex*) only from a neurologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has epilepsy with a background of documented tuberous sclerosis complex; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Vigabatrin has been trialled and has not adequately controlled seizures; and
 - 2.1.2 Seizures are not adequately controlled by, or the patient has experienced unacceptable side effects from, optimal treatment with at least two of the following: sodium valproate, topiramate, levetiracetam, carbamazepine, lamotrigine, phenytoin sodium, and lacosamide (see Note); or

2.2 Both:

- 2.2.1 Vigabatrin is contraindicated; and
- 2.2.2 Seizures are not adequately controlled by, or the patient has experienced unacceptable side effects from, optimal treatment with at least three of the following: sodium valproate, topiramate, levetiracetam, carbamazepine, lamotrigine, phenytoin sodium, and lacosamide (see Note); and
- 3 Seizures have a significant impact on quality of life; and
- 4 Patient has been assessed and surgery is considered inappropriate for this patient, or the patient has been assessed and would benefit from mTOR inhibitor treatment prior to surgery.

Note: "Optimal treatment" is defined as treatment, which is indicated and clinically appropriate for the patient, given in adequate doses for the patients age, weight and other features affecting the pharmacokinetics of the drug, with good evidence of adherence. Women of childbearing age are not required to have a trial of sodium valproate.

Renewal — (refractory seizures associated with tuberous sclerosis complex*) only from a neurologist. Approvals valid for 12 months where demonstrated significant and sustained improvement in seizure rate (e.g. 50% reduction in seizure frequency) or severity and/or patient quality of life compared with baseline prior to starting sirolimus treatment.

Note: Indications marked with * are unapproved indications

TACROLIMUS – Special Authority see SA1745 below – Retail pharmacy

Cap 0.75 mg	Cap 0.5 mg		100	Tacrolimus Sandoz
eap might be a set of the set of	Cap 0.75 mg		100	 Tacrolimus Sandoz
Cap 5 mg 248 20 50 🖌 Tacrolimus Sandoz	Cap 1 mg		100	 Tacrolimus Sandoz
	Cap 5 mg	248.20	50	 Tacrolimus Sandoz

⇒SA1745 Special Authority for Subsidy

Initial application — (organ transplant) only from a relevant specialist. Approvals valid without further renewal unless notified where the patient is an organ transplant recipient.

Note: Subsidy applies for either primary or rescue therapy.

Initial application — (non-transplant indications*) only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient requires long-term systemic immunosuppression; and
- 2 Ciclosporin has been trialled and discontinued treatment because of unacceptable side effects or inadequate clinical response.

Note: Indications marked with * are unapproved indications

JAK inhibitors

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price)		Fully Subsidised	Brand or Generic
\$	Per	1	Manufacturer

► SA2079 Special Authority for Subsidy

Initial application — (Rheumatoid Arthritis (patients previously treated with adalimumab or etanercept)) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
 - 2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for rheumatoid arthritis; and
- 3 Either:
 - 3.1 The patient is seronegative for both anti-cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor; or
 - 3.2 Both:
 - 3.2.1 The patient has been started on rituximab for rheumatoid arthritis in a DHB hospital in accordance with the Section H rules; and

3.2.2 Either:

- 3.2.2.1 The patient has experienced intolerable side effects from rituximab; or
- 3.2.2.2 At four months following the initial course of rituximab the patient has received insufficient benefit such that they do not meet the renewal criteria for rheumatoid arthritis.

Renewal — (Rheumatoid Arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Either:

- 1 Following 6 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.

	Subsidy		Fully	Brand or
	(Manufacturer's Price)		Subsidised	Generic
	\$	Per	/	Manufacturer
Antiallergy Preparations				
Allergic Emergencies				
ICATIBANT – Special Authority see SA1558 below – Retail phan Inj 10 mg per ml, 3 ml prefilled syringe		1	√ F	irazyr
► SA1558 Special Authority for Subsidy				
Initial application only from a clinical immunologist or relevant sp	pecialist. Approvals v	alid f	or 12 month	is for applications meeting
the following criteria:				
Both:				
 Supply for anticipated emergency treatment of laryngeal/o angioedema (HAE) for patients with confirmed diagnosis c The patient has undergone product training and has agree 	of C1-esterase inhibito	or def	iciency; and	
Renewal from any relevant practitioner. Approvals valid for 12 m is benefiting from treatment.	onths where the treat	tment	remains ap	propriate and the patient

Allergy Desensitisation

➡SA1367 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both:

- 1 RAST or skin test positive; and
- 2 Patient has had severe generalised reaction to the sensitising agent.

Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

BEE VENOM ALLERGY TREATMENT - Special Authority see SA1367 above - Retail pharmacy

Cy
VENOX S29
VENOX S29
Venomil S29
 Albey
 Hymenoptera S29
nacy
 Albey
-
 Hymenoptera S29
Venomil S29
 Hymenoptera S29
_
 Albey
Venomil S29

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

			_ ·	
	Subsidy		Fully	
	(Manufacturer's Pr		ubsidised	
	\$	Per		Manufacturer
Antihistamines				
CETIRIZINE HYDROCHLORIDE				
* Tab 10 mg	1.12	100	1	Zista
* Oral liq 1 mg per ml		200 ml		Histaclear
CHLORPHENIRAMINE MALEATE				
* Oral lig 2 mg per 5 ml	0.37	500 ml	1	Histafen
		500 mi	•	mataien
DEXTROCHLORPHENIRAMINE MALEATE				
* Tab 2 mg		40		
	(8.40)			Polaramine
	1.01	20		D
	(5.99)	400 .		Polaramine
* Oral liq 2 mg per 5 ml		100 ml		Delementes
	(10.29)			Polaramine
FEXOFENADINE HYDROCHLORIDE				
* Tab 60 mg	4.34	20		
	(8.23)			Telfast
* Tab 120 mg	4.74	10		
	(8.23)			Telfast
	14.22	30		
	(26.44)			Telfast
LORATADINE				
* Tab 10 mg		100	1	Lorafix
* Oral liq 1 mg per ml		100 ml		Haylor syrup
PROMETHAZINE HYDROCHLORIDE				
* Tab 10 mg	1.69	50	1	Allersoothe
* Tab 10 mg		50		Allersoothe
* Oral lig 1 mg per 1 ml		100 ml		Allersoothe
 * Inj 25 mg per ml, 2 ml ampoule – Up to 5 inj available on a F 		5		Hospira
* IIIj 25 IIIg per IIIi, 2 III allipoule – Op to 5 IIIj available of a P	- 30 17.07	5	•	позрпа
Inhaled Corticosteroids				
BECLOMETHASONE DIPROPIONATE				
Aerosol inhaler, 50 mcg per dose	14.01	200 dose O	P 🗸	Qvar
Aerosol inhaler, 50 mcg per dose CFC-free		200 dose O	P 🗸	Beclazone 50
Aerosol inhaler, 100 mcg per dose	17.52	200 dose O	-	Qvar
Aerosol inhaler, 100 mcg per dose CFC-free		200 dose O	-	Beclazone 100
Aerosol inhaler, 250 mcg per dose CFC-free	22.67	200 dose O	P 🗸	Beclazone 250
BUDESONIDE				
Powder for inhalation, 100 mcg per dose		200 dose O	P 🗸	Pulmicort
,				Turbuhaler
Powder for inhalation, 200 mcg per dose	19.00	200 dose C	P 🗸	Pulmicort
· • · · · · · · · · · · · · · · · · · ·			•	Turbuhaler
Powder for inhalation, 400 mcg per dose	32.00	200 dose O		Pulmicort
1 omdet for initialation, 400 mby per dose		200 0036 0	'I V	Turbuhaler

	Subsidy			Fully	Brand or
	(Manufacturer's			ubsidised	
	\$		Per		Manufacturer
FLUTICASONE					
Aerosol inhaler, 50 mcg per dose	7.19	120 d	lose (DP 🗸	Flixotide
Powder for inhalation, 50 mcg per dose		60 do	ose C		Flixotide Accuhaler
Powder for inhalation, 100 mcg per dose		60 do			Flixotide Accuhaler
Aerosol inhaler, 125 mcg per dose		120 d			Flixotide
Aerosol inhaler, 250 mcg per dose		120 d			Flixotide
Powder for inhalation, 250 mcg per dose		60 do			Flixotide Accuhaler
		00 40		•	
Inhaled Long-acting Beta-adrenoceptor Agonist	2				
minuted Long dolling Deta durchoocptor Agomot	.5				
EFORMOTEROL FUMARATE					
Powder for inhalation, 12 mcg per dose, and monodose device	ce20.64	60	dose		
	(35.80)				Foradil
EFORMOTEROL FUMARATE DIHYDRATE	()				
Powder for inhalation 4.5 mcg per dose, breath activated			~	-	
(equivalent to eformoterol fumarate 6 mcg metered dose	·	60 do	ose C	P	0 · T · · ·
	(16.90)				Oxis Turbuhaler
INDACATEROL					
Powder for inhalation 150 mcg	61.00	30 do	ose C	P 🗸	Onbrez Breezhaler
Powder for inhalation 300 mcg		30 do	ose C	P 🗸	Onbrez Breezhaler
SALMETEROL					
Aerosol inhaler CFC-free, 25 mcg per dose	25.00	120 d	000	ע פר	Serevent
Powder for inhalation, 50 mcg per dose, breath activated		60 do			Serevent Accuhaler
Towder for initialation, so meg per dose, breath activated	25.00	00 00	036 0	•	Selevent Accunater
Inhaled Corticosteroids with Long-Acting Beta-	Adrenocent	tor Δa	onis	sts	
Initiation Controcolorondo Initia Eong Acting Dola A	anonocopi	ion Aig	Unic		
BUDESONIDE WITH EFORMOTEROL					
Powder for inhalation 160 mcg with 4.5 mcg eformoterol					
fumarate per dose (equivalent to 200 mcg budesonide w	ith				
6 mcg eformoterol fumarate metered dose)		120 d	lose (DP 🗸	DuoResp Spiromax
Powder for inhalation 320 mcg with 9 mcg eformoterol fumara					
per dose (equivalent to 400 mcg budesonide with 12 mcg					
eformoterol fumarate metered dose) – No more than 2	9				
dose per day	82 50	120 d	lose ()P 🗸	DuoResp Spiromax
Aerosol inhaler 100 mcg with eformoterol fumarate 6 mcg		120 d			Vannair
Powder for inhalation 100 mcg with eformoterol fumarate 6 m		120 d			Symbicort
Towact for initial alone for they will clothole of hand alo of	log00.74	120 u	1030 0		Turbuhaler 100/6
Across inhalar 200 mag with of armataral fumarata 6 mag	21.40	120 d			Vannair
Aerosol inhaler 200 mcg with eformaterol fumarate 6 mcg		120 d			
Powder for inhalation 200 mcg with eformoterol fumarate 6 m	icg 44.08	120 û	lose	JP V	Symbicort
Develop for the lation 400 m					Turbuhaler 200/6
Powder for inhalation 400 mcg with eformoterol fumarate			-		A 11 1
12 mcg – No more than 2 dose per day		60 do	ose C	P 🗸	Symbicort
					Turbuhaler 400/12
FLUTICASONE FUROATE WITH VILANTEROL					
Powder for inhalation 100 mcg with vilanterol 25 mcg		30 do	ose C	P 🗸	Breo Ellipta
- · ·					-

	Subsidy		Fully Brand or
	(Manufacturer's		idised Generic
	\$	Per	 Manufacturer
FLUTICASONE WITH SALMETEROL			
Aerosol inhaler 50 mcg with salmeterol 25 mcg	25.79	120 dose OP	 Seretide
Aerosol inhaler 125 mcg with salmeterol 25 mcg		120 dose OP	✓ Seretide
Powder for inhalation 100 mcg with salmeterol 50 mcg - No			
more than 2 dose per day		60 dose OP	 Seretide Accuhaler
Powder for inhalation 250 mcg with salmeterol 50 mcg – No			
more than 2 dose per day		60 dose OP	 Seretide Accuhaler
		00 0030 01	• Ocretitice Accumater
Beta-Adrenoceptor Agonists			
Bota Marchotopici Agemete			
SALBUTAMOL			
Oral liq 400 mcg per ml	40.00	150 ml	 Ventolin
Ventolin to be Principal Supply on 1 March 2022			
Infusion 1 mg per ml, 5 ml		10	 Ventolin
Inj 500 mcg per ml, 1 ml – Up to 5 inj available on a PSO	53.00	5	 Ventolin
Inhaled Beta-Adrenoceptor Agonists			
SALBUTAMOL			
Aerosol inhaler, 100 mcg per dose CFC free – Up to 1000 dose available on a PSO	2 00	200 dose OP	. Decembran
		200 00se OP	 ✓ Respigen ✓ SalAir
	(6.00)		Ventolin
Nebuliese sele 1 me see rel 0 5 milemenule	(6.00)		ventoim
Nebuliser soln, 1 mg per ml, 2.5 ml ampoule – Up to 30 neb available on a PSO	0.00	20	Aathalin
		20	 <u>Asthalin</u>
Nebuliser soln, 2 mg per ml, 2.5 ml ampoule – Up to 30 neb available on a PSO		00	Asthalin
	9.43	20	 <u>Asthalin</u>
TERBUTALINE SULPHATE			
Powder for inhalation, 200 mcg per dose (equivalent to			
250 mcg metered dose), breath activated	22.20	120 dose OP	 Bricanyl Turbuhaler
Anticholinergic Agents			
PRATROPIUM BROMIDE			
	-		
Aerosol inhaler, 20 mcg per dose CFC-free – Up to 400 dose			Atvoyont
available on a PSO		200 dose OP	 Atrovent
Nebuliser soln, 250 mcg per ml, 2 ml ampoule – Up to 40 ne		00	/ Halanat
available on a PSO	11.73	20	Univent
Inhaled Beta-Adrenoceptor Agonists with Antic	holinergic A	Agents	
SALBUTAMOL WITH IPRATROPIUM BROMIDE			
Aerosol inhaler, 100 mcg with ipratropium bromide, 20 mcg p	er		
dose CFC-free		200 dose OP	🗸 Duolin HFA
	12.13		
Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per	11 04	20	🖌 Dualin
vial, 2.5 ml ampoule – Up to 20 neb available on a PSO	11.04	20	Duolin

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✔	Brand or Generic Manufacturer
Long-Acting Muscarinic Antagonists			
 GLYCOPYRRONIUM – Subsidy by endorsement a) Inhaled glycopyrronium treatment will not be subsidised if pumeclidinium. b) Glycopyrronium powder for inhalation 50 mcg per dose is a having COPD using spirometry if spirometry is possible, an Powder for inhalation 50 mcg per dose	subsidised only for p id the prescription is id the prescription is id the prescription is o receiving treatment e been diagnosed a cordingly. Patients endorsed.	batients who have is endorsed accord dose OP ✓ Se at with subsidised in as having COPD us who had tiotropium 0 dose ✓ Sp dose OP ✓ Sp	been diagnosed as ingly. Bebri Breezhaler Inhaled glycopyrronium or sing spirometry if In dispensed before Diriva Diriva Respimat
b) Umeclidinium powder for inhalation 62.5 mcg per dose is s COPD using spirometry if spirometry is possible, and the p Powder for inhalation 62.5 mcg per dose	rescription is endors	sed accordingly.	been diagnosed as having cruse Ellipta
Long-Acting Muscarinic Antagonists with Long-	Acting Beta-Ad	Irenoceptor A	gonists

Combination long acting muscarinic antagonist and long acting beta-2 agonist will not be subsidised if patient is also receiving treatment with a combination inhaled corticosteroid and long acting beta-2 agonist.

➡SA1584 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

1 Patient has been stabilised on a long acting muscarinic antagonist; and

2 The prescriber considers that the patient would receive additional benefit from switching to a combination product.

Renewal from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

- 1 Patient is compliant with the medication; and
- 2 Patient has experienced improved COPD symptom control (prescriber determined).

GLYCOPYRRONIUM WITH INDACATEROL – Special Authority see SA1584 above – Retail pha Powder for Inhalation 50 mcg with indacaterol 110 mcg81.00 30 dose OP	,
TIOTROPIUM BROMIDE WITH OLODATEROL – Special Authority see SA1584 above – Retail Soln for inhalation 2.5 mcg with olodaterol 2.5 mcg	
UMECLIDINIUM WITH VILANTEROL – Special Authority see SA1584 above – Retail pharmacy Powder for inhalation 62.5 mcg with vilanterol 25 mcg	✓ Anoro Ellipta

Antifibrotics

NINTEDANIB - Special Authority see SA2012 on the nex	xt page – Retail pharmacy		
Note: Nintedanib not subsidised in combination with	subsidised pirfenidone.		
Cap 100 mg	2,554.00	60 OP	 Ofev
Cap 150 mg		60 OP	 Ofev

AThree months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy	Fu	y Brand or	
(Manufacturer's Price)	Subsidise	d Generic	
\$	Per	Manufacturer	

SA2012 Special Authority for Subsidy

Initial application — (idiopathic pulmonary fibrosis) only from a respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist; and
- 2 Forced vital capacity is between 50% and 90% predicted; and
- 3 Nintedanib is to be discontinued at disease progression (See Note); and
- 4 Nintedanib is not to be used in combination with subsidised pirfenidone; and
- 5 Any of the following:
 - 5.1 The patient has not previously received treatment with pirfenidone; or
 - 5.2 Patient has previously received pirfenidone, but discontinued pirfenidone within 12 weeks due to intolerance; or
 - 5.3 Patient has previously received pirfenidone, but the patient's disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with pirfenidone).

Renewal — (idiopathic pulmonary fibrosis) only from a respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment; and
- 2 Nintedanib is not to be used in combination with subsidised pirfenidone; and
- 3 Nintedanib is to be discontinued at disease progression (See Note).

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

PIRFENIDONE – Retail pharmacy-Specialist – Special Authority see SA2013 below

Note: Pirfenidone is not subsidised in combination with sub	sidised nintedanib.		
Tab 801 mg	3,645.00	90	 Esbriet
Tab 267 mg	1,215.00	90	 Esbriet

➡SA2013 Special Authority for Subsidy

Initial application — (idiopathic pulmonary fibrosis) only from a respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist; and
- 2 Forced vital capacity is between 50% and 90% predicted; and
- 3 Pirfenidone is to be discontinued at disease progression (See Note); and
- 4 Pirfenidone is not to be used in combination with subsidised nintedanib; and
- 5 Any of the following:
 - 5.1 The patient has not previously received treatment with nintedanib; or
 - 5.2 Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance; or
 - 5.3 Patient has previously received nintedanib, but the patient's disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with nintedanib).

Renewal — (idiopathic pulmonary fibrosis) only from a respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment; and
- 2 Pirfenidone is not to be used in combination with subsidised nintedanib; and
- 3 Pirfenidone is to be discontinued at disease progression (See Note).

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

	Subsidy (Manufacturer's Price		Fully Brand or osidised Generic
	\$	Per	Manufacturer
Leukotriene Receptor Antagonists			
MONTELUKAST	4 25	28	 Montelukast Mylan
* Tab 5 mg	4.25	28	 Montelukast Mylan
* Tab 10 mg	3.95	28	✓ Montelukast Mylan
Methylxanthines			
AMINOPHYLLINE			
* Inj 25 mg per ml, 10 ml ampoule – Up to 5 inj available on a PSO		5	 DBL Aminophylline
THEOPHYLLINE		5	
* Tab long-acting 250 mg		100	✓ <u>Nuelin-SR</u>
* Oral liq 80 mg per 15 ml		500 ml	✓ <u>Nuelin</u>
Mucolytics			
DORNASE ALFA - Special Authority see SA1978 below - Reta	il pharmacy		
Nebuliser soln, 2.5 mg per 2.5 ml ampoule		6	 Pulmozyme
All of the following: 1 Patient has a confirmed diagnosis of cystic fibrosis; and 2 Patient has previously undergone a trial with, or is curren 3 Any of the following:			
 3 Any of the following: 3.1 Patient has required one or more hospital inpatien 3.2 Patient has had 3 exacerbations due to CF, required 			
period; or 3.3 Patient has had 1 exacerbation due to CF, requirir	-		
Brasfield score of < 22/25; or 3.4 Patient has a diagnosis of allergic bronchopulmon	any aspergillosis (Al		
Renewal — (cystic fibrosis) only from a respiratory physician on notified where the treatment remains appropriate and the patient	or paediatrician. Ap	provals val	
IVACAFTOR – PCT only – Specialist – Special Authority see SA		50	/ Walasha a
Tab 150 mg Oral granules 50 mg, sachet		56 56	 ✓ Kalydeco ✓ Kalydeco
Oral granules 75 mg, sachet		56	✓ Kalydeco
SA2017 Special Authority for Subsidy Initial application only from a respiratory specialist or paediatric variations are special to following activity.	ian. Approvals vali	d without fu	urther renewal unless notified for
applications meeting the following criteria: All of the following:			
1 Patient has been diagnosed with cystic fibrosis; and 2 Either:			
2.1 Patient must have G551D mutation in the cystic fil least 1 allele; or	prosis transmembra	ne conduct	tance regulator (CFTR) gene on
2.2 Patient must have other gating (class III) mutation	(G1244E, G1349D,	G178R, G	551S, S1251N, S1255P, S549N
			continued

	Subsidy (Manufacturer's \$	Price) Sub Per	Fully sidised	Brand or Generic Manufacturer
continued				
and S549R) in the CFTR gene on at least 1 alle 3 Patients must have a sweat chloride value of at least 6 sweat collection system; and		itative pilocarpi	ne iontop	phoresis or by Macroduc
 4 Treatment with ivacaftor must be given concomitantly i 5 Patient must not have an acute upper or lower respirat (including antibiotics) for pulmonary disease in the last 6 The dose of ivacaftor will not exceed one tablet or one 7 Applicant has experience and expertise in the manage 	ory infection, pulm 4 weeks prior to co sachet twice daily;	onary exacerba ommencing trea and	tion, or c	hanges in therapy
SODIUM CHLORIDE Not funded for use as a nasal drop. Soln 7%	24 50	90 ml OP	🖌 Bi	omed
Nasal Preparations			. 51	
Allergy Prophylactics				
BUDESONIDE				
Metered aqueous nasal spray, 50 mcg per dose		200 dose OP 200 dose OP		eroClear
Metered aqueous nasal spray, 100 mcg per dose	2.84	200 dose OP	• 51	eroClear
Metered aqueous nasal spray, 50 mcg per dose	1.98	120 dose OP		ixonase Hayfever & Allergy
PRATROPIUM BROMIDE				
Aqueous nasal spray, 0.03%	5.23	15 ml OP	✓ <u>U</u>	nivent
Respiratory Devices				
MASK FOR SPACER DEVICE				
a) Up to 50 dev available on a PSO				
b) Only on a PSO				
 c) Only for children aged six years and under Small 	2.20	1	√ e-	chamber Mask
PEAK FLOW METER			-	
a) Up to 25 dev available on a PSO				
b) Only on a PSO	0.54		. / M	ini Wainht AFO
Low range	9.54	1		ini-Wright AFS Low Range
Normal range	9.54	1		ini-Wright
-				Standard
SPACER DEVICE				
a) Up to 50 dev available on a PSOb) Only on a PSO				
220 ml (single patient)	2.95	1	✔ e-	chamber Turbo
510 ml (single patient)		1	✓ e-	chamber La Grande
800 ml	6.50	1	🗸 Vo	olumatic

	Subsidy (Manufacturer's Price) \$	Subs Per	Fully idised	Brand or Generic Manufacturer
Respiratory Stimulants				
CAFFEINE CITRATE Oral liq 20 mg per ml (10 mg base per ml)		5 ml OP	✓ <u>Bi</u>	iomed

	Subsidy		Fully	Brand or
	(Manufacturer's Pr		sidised	Generic
	\$	Per		Manufacturer
Ear Preparations				
FLUMETASONE PIVALATE				
Ear drops 0.02% with clioquinol 1%	4.46	7.5 ml OP	1	Locacorten-Viaform
				ED's
			1	Locorten-Vioform
			•	
TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYC	IN AND NYSTATI	N		
Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate				
2.5 mg and gramicidin 250 mcg per g	5.16	7.5 ml OP	-	Kenacomb
0 0 01 0				
Ear/Eye Preparations				
DEXAMETHASONE WITH FRAMYCETIN AND GRAMICIDIN				
Ear/Eye drops 500 mcg with framycetin sulphate 5 mg and				
	4 50	0		
gramicidin 50 mcg per ml		8 ml OP		
	(9.27)			Sofradex
FRAMYCETIN SULPHATE				
Ear/Eye drops 0.5%	4 13	8 ml OP		
		01111 01		Soframucin
	(8.65)			Soframycin
E. B. Burn and the second				
Eye Preparations				
Eye preparations are only funded for use in the eye, unless expli	citly stated otherw	ise.		
Anti Infactiva Drenevationa				
Anti-Infective Preparations				
ACICLOVIR				
	14.00			ViewDOC
* Eye oint 3%	14.88	4.5 g OP	•	<u>ViruPOS</u>
CHLORAMPHENICOL				
Eye oint 1%		5 g OP	1	Devatis
Eye drops 0.5%		10 ml OP		Chlorafast
Funded for use in the ear*. Indications marked with * a			•	omoralast
		ioalio115.		
CIPROFLOXACIN				
Eye drops 0.3% – Subsidy by endorsement	9.73	5 ml OP	✓	Ciprofloxacin Teva
When prescribed for the treatment of bacterial keratitis		conjunctivitis	s resist	ant to chloramphenicol: or
for the second line treatment of chronic suppurative otiti				
Note: Indication marked with a * is an unapproved indic				
GENTAMICIN SULPHATE				
Eye drops 0.3%	11.40	5 ml OP	✓	Genoptic
PROPAMIDINE ISETHIONATE				
* Eye drops 0.1%	2 0 7	10 ml OP		
- x = ye ulups 0.1%				Dualana
	(14.55)			Brolene
SODIUM FUSIDATE (FUSIDIC ACID)				
Eye drops 1%		5 g OP	1	Fucithalmic
		0 9 01	-	
TOBRAMYCIN				
Eye oint 0.3%	10.45	3.5 g OP	✓	Tobrex
Eye drops 0.3%	11.48	5 ml OP	✓	Tobrex

	Subsidy (Manufacturer's Pr		Fully Brand or sidised Generic
	(Manulacturer's Pr	Per Sub	Manufacturer
Corticosteroids and Other Anti-Inflammatory	Preparations		
DEXAMETHASONE			
* Eye oint 0.1%		3.5 g OP	 Maxidex
* Eye drops 0.1%		5 ml OP	 Maxidex
Ocular implant 700 mcg – Special Authority see SA1680 – Retail pharmacy		1	✓ Ozurdex
SA1680 Special Authority for Subsidy			
Initial application — (Diabetic macular oedema) only from	an ophthalmologist.	Approvals va	alid for 12 months for applications
meeting the following criteria:			
All of the following:			
1 Patient has diabetic macular oedema with pseudopha			and the state of the second
2 Patient has reduced visual acuity of between 6/9 - 6/43 Either:			uction in vision; and
3.1 Patient's disease has progressed despite 3 inje3.2 Patient is unsuitable or contraindicated to treat			
4 Dexamethasone implants are to be administered not r maximum of 3 implants per eye per year.	nore frequently than o	once every 4	months into each eye, and up to a
Renewal - (Diabetic macular oedema) only from an ophth	almologist. Approva	s valid for 12	months for applications meeting
the following criteria: Both:			
1 Patient's vision is stable or has improved (prescriber d	etermined); and		
2 Dexamethasone implants are to be administered not r	nore frequently than o	once every 4	months into each eye, and up to a
maximum of 3 implants per eye per year.			
Initial application - (Women of child bearing age with dia	abetic macular oede	ma) only from	m an ophthalmologist. Approvals
valid for 12 months for applications meeting the following crite	eria:		
All of the following:			
1 Patient has diabetic macular oedema; and			
2 Patient has reduced visual acuity of between 6/9 - 6/4			uction in vision; and
3 Patient is of child bearing potential and has not yet co			
4 Dexamethasone implants are to be administered not r maximum of 2 implants par are per year	nore frequently than o	once every 4	months into each eye, and up to a
maximum of 3 implants per eye per year.		furne en enki	
Renewal — (Women of child bearing age with diabetic mathematications meeting the following criteria:	acular oedema) only	from an opn	thaimologist. Approvals valid for
All of the following:			
1 Patient's vision is stable or has improved (prescriber d	atorminad); and		
2 Patient is of child bearing potential and has not yet co	<i>,</i> .		
3 Dexamethasone implants are to be administered not r			months into each eve, and up to a
maximum of 3 implants per eye per year.			
DEXAMETHASONE WITH NEOMYCIN SULPHATE AND PC		ATE	
* Eye oint 0.1% with neomycin sulphate 0.35% and polymy			
sulphate 6,000 u per g		3.5 g OP	 Maxitrol
 Eye drops 0.1% with neomycin sulphate 0.35% and poly. 		0.0 9 01	
b sulphate 6,000 u per ml		5 ml OP	 Maxitrol
DICLOFENAC SODIUM			
Eye drops 0.1%	8 80	5 ml OP	 Voltaren Ophtha
	0.00		
FLUOROMETHOLONE * Eye drops 0.1%	2 00	5 ml OP	✓ FML
- Eye ulups 0.1%	3.U9 5.00	5 III OP	✓ FML

Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

5.20

*Three months or six months, as applicable, dispensed all-at-once

✓ Flucon

SENSORY ORGANS

SENSORY ORGANS

	Subsidy (Manufacturer's F \$	Price) Subs Per	Fully sidised	Brand or Generic Manufacturer
LEVOCABASTINE				
Eye drops 0.5 mg per ml	8.71 (10.34)	4 ml OP	L	ivostin
ODOXAMIDE Eye drops 0.1%		10 ml OP	✓ L	omide
PREDNISOLONE ACETATE				
Eye drops 1%	5.93 7.00	10 ml OP 5 ml OP	-	Prednisolone-AFT Pred Forte
PREDNISOLONE SODIUM PHOSPHATE - Special Auth	ority see SA1715 below	v – Retail pharr	nacv	
Eye drops 0.5%, single dose (preservative free)		20 dose		linims Prednisolone
nitial application only from an ophthalmologist or optome following criteria: Both: 1 Patient has severe inflammation; and 2 Patient has a confirmed allergic reaction to preserv Renewal from any relevant practitioner. Approvals valid for penefiting from treatment.	ative in eye drops.			
SODIUM CROMOGLICATE				
Eye drops 2%	1.79	5 ml OP	✓ <u>R</u>	lexacrom
Glaucoma Preparations - Beta Blockers				
BETAXOLOL * Eye drops 0.25% * Eye drops 0.5%		5 ml OP 5 ml OP		Betoptic S Betoptic
FIMOLOL	2.04	5 ml OP 5 ml OP 2.5 ml OP	🗸 🗸	<u>arrow-Timolol</u> arrow-Timolol ïmoptol XE
Glaucoma Preparations - Carbonic Anhydr	rase Inhibitors			
ACETAZOLAMIDE ✔ Tab 250 mg 3RINZOLAMIDE		100	✓ D	Diamox
HINZOLAMIDE ₭ Eye drops 1% DORZOLAMIDE HYDROCHLORIDE	7.30	5 ml OP	✓ <u>A</u>	zopt
Eye drops 2%		5 ml OP	-	

Glaucoma Preparations - Prostaglandin Analogues			
DORZOLAMIDE WITH TIMOLOL * Eye drops 2% with timolol 0.5%	2.73	5 ml OP	✓ Dortimopt
	(17.44)	0	Trusopt

Bimatoprost Multichem to be Principal Supply on 1 April 2022

SENSORY ORGANS

	Subsidy (Manufacturer's F \$	Price) Subs Per	Fully idised	Brand or Generic Manufacturer
ATANOPROST ≰ Eye drops 0.005%	1.82	2.5 ml OP	✓ <u>T</u>	eva
RAVOPROST € Eye drops 0.004%	9.75	2.5 ml OP	✓ <u>⊺</u>	ravatan
Glaucoma Preparations - Other				
RIMONIDINE TARTRATE ∉ Eye drops 0.2%	4.29	5 ml OP	✓ <u>A</u>	rrow-Brimonidine
RIMONIDINE TARTRATE WITH TIMOLOL MALEATE ∉ Eye drops 0.2% with timolol maleate 0.5%		5 ml OP	✓c	ombigan
ATANOPROST WITH TIMOLOL Eye drops 0.005% with timolol 0.5%	2.49	2.5 ml OP	✓ <u>A</u>	rrow - Lattim
ILOCARPINE HYDROCHLORIDE E Eye drops 1%		15 ml OP		opto Carpine
 Eye drops 2% Eye drops 4% Subsidised for oral use pursuant to the Standard Formu 	7.99	15 ml OP 15 ml OP		copto Carpine copto Carpine
Eye drops 2% single dose – Special Authority see SA0895 below – Retail pharmacy		20 dose	✓ М	linims Pilocarpine

SA0895 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

- 1 Patient has to use an unpreserved solution due to an allergy to the preservative; or
- 2 Patient wears soft contact lenses.

Note: Minims for a general practice are considered to be "tools of trade" and are not approved as special authority items. **Renewal** from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Mydriatics and Cycloplegics

ATROPINE SULPHATE * Eye drops 1%	17.36	15 ml OP	✓ <u>Atropt</u>
CYCLOPENTOLATE HYDROCHLORIDE * Eye drops 1%	8.76	15 ml OP	✓ Cyclogyl
 ¥ Eye drops 1%, single dose (preservative free) – Only on a prescription 	52.86	20 dose	 Minims Cyclopentolate
(Minims Cyclopentolate Eye drops 1%, single dose (preservative fre	e) to be delist	ed 1 April 2022	
TROPICAMIDE * Eye drops 0.5% * Eye drops 1%	7.15 8.66	15 ml OP 15 ml OP	✓ Mydriacyl✓ Mydriacyl
Preparations for Tear Deficiency			
For acetylcysteine eye drops refer Standard Formulae, page 241 HYPROMELLOSE			
* Eye drops 0.5% HYPROMELLOSE WITH DEXTRAN	19.50	15 ml OP	 Methopt

15 ml OP

✓ Poly-Tears

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

* Eye drops 0.3% with dextran 0.1%......2.30

	Subsidy (Manufacturer's Price \$	e) Sub Per	Fully sidised	Brand or Generic Manufacturer
Preservative Free Ocular Lubricants				
SA1388 Special Authority for Subsidy				
Initial application from any relevant practitioner. Approvals v Both:	valid for 12 months for	applications	s meetin	ig the following criteria:
 Confirmed diagnosis by slit lamp of severe secretory d Either: 	ry eye; and			
2.1 Patient is using eye drops more than four times2.2 Patient has had a confirmed allergic reaction to				
Renewal from any relevant practitioner. Approvals valid for 2 drops and has benefited from treatment.	4 months where the pa	tient contin	ues to r	equire lubricating eye
CARBOMER – Special Authority see SA1388 above – Retail Ophthalmic gel 0.3%, 0.5 g		30	✓ P	oly-Gel
MACROGOL 400 AND PROPYLENE GLYCOL – Special Aut Eye drops 0.4% and propylene glycol 0.3%, 0.4 ml		ove – Retail 24		acy Systane Unit Dose
SODIUM HYALURONATE [HYALURONIC ACID] – Special A Eye drops 1 mg per ml Hylo-Fresh has a 6 month expiry after opening. The month is not relevant and therefore only the prescribe		10 ml OP Manual res	ail pharr <u> <u>H</u> striction</u>	nacy Iylo-Fresh allowing one bottle per
Other Eye Preparations				
NAPHAZOLINE HYDROCHLORIDE X Eye drops 0.1%	4.15	15 ml OP	🗸 N	laphcon Forte
OLOPATADINE Eye drops 0.1%	2.20	5 ml OP	√ 0	Diopatadine Teva
PARAFFIN LIQUID WITH WOOL FAT			-	

* Eye oint 3% with wool fat 3%	3.63	3.5 g OP	 Poly-Visc
RETINOL PALMITATE			
Eye oint 138 mcg per g	3.80	5 g OP	 VitA-POS

VARIOUS

	Subsidy (Manufacturer's Price	.)	Fully Subsidised	Brand or Generic
	\$	Per		Manufacturer
Various				
PHARMACY SERVICES				
May only be claimed once per patient.				
Brand switch fee	4.50	1 fee	✓	BSF Clomipramine
				Teva
			✓	BSF Febuxostat
				multichem
			~	BSF Folic Acid
				Mylan
			•	BSF Lopinavir/
a) The Dharmoords for DCE Falis Asid Mulan is 2001		•		Ritonavir Mylan
 a) The Pharmacode for BSF Folic Acid Mylan is 26219 b) The Pharmacode for BSF Febuxostat multichem is 			7	
c) The Pharmacode for BSF Lopinavir/Ritonavir Mylar				
d) The Pharmacode for BSF Clomipramine Teva is 26			. 107	
3SF Febuxostat multichem Brand switch fee to be delisted 1 A		0 120		
BSF Folic Acid Mylan Brand switch fee to be delisted 1 March	, ,			
Agente Llood in the Treatment of Deisenings	,			
Agents Used in the Treatment of Poisonings				
Antidotes				
CETYLCYSTEINE				
Inj 200 mg per ml, 10 ml ampoule	58.76	10		DBL Acetylcysteine
			~	Martindale
				Pharma S29
IALOXONE HYDROCHLORIDE				
a) Up to 5 inj available on a PSO				
b) Only on a PSO				
Inj 400 mcg per ml, 1 ml ampoule	22.60	5	1	DBL Naloxone
				Hydrochloride
Removal and Elimination				
HARCOAL				
Oral liq 50 g per 250 ml		50 ml (OP 🗸	Carbosorb-X
a) Up to 250 ml available on a PSO				
b) Only on a PSO				
EFERASIROX – Special Authority see SA1492 below – Retain	il pharmacy			
Wastage claimable	,			
Tab 125 mg dispersible		28	1	Exjade
Tab 250 mg dispersible		28		Exjade
Tab 500 mg dispersible	1,105.00	28	1	Exjade
SA1492 Special Authority for Subsidy				

SA1492 Special Authority for Subsidy Initial application only from a haematologist. Approvals valid for 2 years for applications meeting the following criteria: All of the following:

1 The patient has been diagnosed with chronic iron overload due to congenital inherited anaemia; and

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

VARIOUS			
	Subsidy (Manufacturer's Price \$	Fully) Subsidised Per ✔	Generic
continued			
2 Deferasirox is to be given at a daily dose not exceeding3 Any of the following:	0 0 1		
 3.1 Treatment with maximum tolerated doses of defection combination therapy have proven ineffective as r 3.2 Treatment with deferiprone has resulted in sever 3.3 Treatment with deferiprone has resulted in arthriti 3.4 Treatment with deferiprone is contraindicated du 	neasured by serum fe e persistent vomiting o is; or	rritin levels, liver or diarrhoea; or	or cardiac MRI T2*; or
count (ANC) of < 0.5 cells per μL) or recurrent ep 0.5 - 1.0 cells per μL).			
Renewal only from a haematologist. Approvals valid for 2 year Either:	s for applications mee	eting the followin	g criteria:
 For the first renewal following 2 years of therapy, the tre improvement in all three parameters namely serum ferri For subsequent renewals, the treatment has been tolera in all three parameters namely serum ferritin, cardiac MI 	tin, cardiac MRI T2* a ted and has resulted	nd liver MRI T2* in clinical stabilit	levels; or
DEFERIPRONE – Special Authority see SA1480 below – Reta Tab 500 mg Oral liq 100 mg per 1 ml			Ferriprox Ferriprox
■ SA1480 Special Authority for Subsidy Initial application only from a haematologist. Approvals valid following criteria: Either:	without further renewa	al unless notified	for applications meeting the
 The patient has been diagnosed with chronic iron overlo The patient has been diagnosed with chronic iron overlo 	0		a; or
DESFERRIOXAMINE MESILATE			
* Inj 500 mg vial	84.53	10 🗸	DBL Desferrioxamine Mesylate for Inj BP
SODIUM CALCIUM EDETATE	50.01		

Calcium Disodium Versenate

Standard Formulae

ACETYLCYSTEINE EYE DROPS Acetylcysteine inj 200 mg per ml, 10 ml Suitable eye drop base	qs qs	PHENOBARBITONE ORAL LIQUID Phenobarbitone Sodium Glycerol BP Water	1 g 70 ml to 100 ml
CODEINE LINCTUS (3 mg per 5 ml) Codeine phosphate Glycerol Preservative	60 mg 40 ml qs	PHENOBARBITONE SODIUM PAEDIATRIC ORAL mg per ml) Phenobarbitone Sodium	400 mg
Water CODEINE LINCTUS (15 mg per 5 ml)	to 100 ml	Giycerol BP Water	4 ml to 40 ml
Codeine phosphate Glycerol Preservative Water	300 mg 40 ml qs to 100 ml	PILOCARPINE ORAL LIQUID Pilocarpine 4% eye drops Preservative Water	qs qs to 500 ml
FOLINIC MOUTHWASH Calcium folinate 15 mg tab Preservative	1 tab qs	(Preservative should be used if quantity supplied is than 5 days.) SALIVA SUBSTITUTE FORMULA	for more
Water (Preservative should be used if quantity supplied is than 5 days. Maximum 500 ml per prescription.)	to 500 ml for more	Methylcellulose Preservative Water	5 g qs to 500 ml
METHADONE MIXTURE Methadone powder	qs	(Preservative should be used if quantity supplied is than 5 days. Maximum 500 ml per prescription.)	for more
Glycerol Water	qs to 100 ml	SODIUM CHLORIDE ORAL LIQUID Sodium chloride inj 23.4%, 20 ml Water	qs qs
METHYL HYDROXYBENZOATE 10% SOLUTION Methyl hydroxybenzoate Propylene glycol	10 g to 100 ml	(Only funded if prescribed for treatment of hyponatr VANCOMYCIN ORAL SOLUTION (50 mg per ml)	aemia)
(Use 1 ml of the 10% solution per 100 ml of oral lique OMEPRAZOLE SUSPENSION		Vancomycin 500 mg injection Glycerol BP	10 vials 40 ml
Omeprazole sospension Omeprazole capules or powder Sodium bicarbonate powder BP Water	qs 8.4 g to 100 ml	Water (Only funded if prescribed for treatment of Clostridit following metronidazole failure)	to 100 ml um difficile

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

	Subsidy		Fully	Brand or
	(Manufacturer's Pr	ice) Sub	sidised	Generic
	\$	Per	~	Manufacturer
Extemporaneously Compounded Preparations	and Galenica	s		
CODEINE PHOSPHATE - Safety medicine; prescriber may det	ermine dispensing	frequency		
Powder – Only in combination		25 g		
····, ····	(90.09)	- 5	C	Douglas
Only in extemporaneously compounded codeine linctus			_	ougiao
COLLODION FLEXIBLE Note: This product is no longer being manufactured by the	supplier and will b	e delisted fror	n the S	chedule at a date to be
determined.				
Collodion flexible	19.30	100 ml	🖌 F	PSM
COMPOUND HYDROXYBENZOATE - Only in combination				
Only in extemporaneously compounded oral mixtures.				
Soln	30.00	100 ml	~ N	lidwest
		100 11	• "	indwest
GLYCERIN WITH SODIUM SACCHARIN – Only in combination	1			
Only in combination with Ora-Plus.				
Suspension		473 ml	✓	Dra-Sweet SF
GLYCERIN WITH SUCROSE – Only in combination				
Only in combination with Ora-Plus.				
Suspension		473 ml	✓ (Dra-Sweet
GLYCEROL			-	
	0.00	500 ml		asithE Clusseral BD
* Liquid – Only in combination		500 ml	• <u>n</u>	ealthE Glycerol BP
Only in extemporaneously compounded oral liquid prepa	arations.			
METHADONE HYDROCHLORIDE				
a) Only on a controlled drug form				
b) No patient co-payment payable				
 c) Safety medicine; prescriber may determine dispensing fr 	equency			
d) Extemporaneously compounded methadone will only be		rate of the ch	eanest	form available
(methadone powder, not methadone tablets).			oupoor	
Powder	7 84	1 g	✓ F	FT
		' g	• •	
METHYL HYDROXYBENZOATE				
Powder	8.98	25 g	✓ N	lidwest
METHYLCELLULOSE				
Powder		100 g	A A	/idWest
Suspension – Only in combination		473 ml		Dra-Plus
METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCH			-	
				Ve Bland CE
Suspension		473 ml	• •	Dra-Blend SF
METHYLCELLULOSE WITH GLYCERIN AND SUCROSE - On				
Suspension		473 ml	 ✓ 	Dra-Blend
PHENOBARBITONE SODIUM				
Powder – Only in combination	52 50	10 g	🗸 N	/idWest
	005.00	400		
Only in children up to 12 years	325.00	100 g	- 1	lidwest
PROPYLENE GLYCOL				
Only in extemporaneously compounded methyl hydroxyben		า.		
Liq	11.25	500 ml	🗸 I	lidwest
SODIUM BICARBONATE				
Powder BP – Only in combination	10.05	500 g	🖌 N	lidwest
Only in extemporaneously compounded omeprazole an			· <u>n</u>	
	a 10.100p102010 00	000101011.		

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

	Subsidy (Manufacturer's Price) \$	S Per	Fully ubsidised	Brand or Generic Manufacturer
SYRUP (PHARMACEUTICAL GRADE) - Only in combination Only in extemporaneously compounded oral liquid preparation	15			
Liq		500 ml	✓ <u>M</u>	idwest
WATER Tap – Only in combination	0.00	1 ml	🗸 Ta	ap water

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	1	Manufacturer

Nutrient Modules

Carbohydrate

⇒SA1930 Special Authority for Subsidy

Initial application — (Cystic fibrosis or kidney disease) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Fither:

- 1 cystic fibrosis; or
- 2 chronic kidney disease.

Initial application — (Indications other than cystic fibrosis or renal failure) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Any of the following:

- 1 cancer in children; or
- 2 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
- 3 faltering growth in an infant/child; or
- 4 bronchopulmonary dysplasia; or
- 5 premature and post premature infant; or
- 6 for use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula. **Initial application — (Inborn errors of metabolism)** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified where the patient has inborn errors of metabolism. **Renewal — (Cystic fibrosis or renal failure)** only from a dietitian, relevant specialist, vocationally registered general

practitioner or general practitioner on the recommendation of a dietitian, relevant specialist, vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

. Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis or renal failure) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

CARBOHYDRATE SUPPLEMENT	- Special Authority see SA1930 above -	Hospital pharmacy	[HP3]
Powder		400 g OP	Polycal

Carbohydrate And Fat

⇒SA1376 Special Authority for Subsidy

Initial application — (Cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Both:

Subsidy		Fully	Brand or	
(Manufacturer's Pr	ice)	Subsidised	Generic	
\$	Per	✓	Manufacturer	

continued...

- 1 Infant or child aged four years or under; and
- 2 cystic fibrosis.

Initial application — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 infant or child aged four years or under; and
- 2 Any of the following:
 - 2.1 cancer in children; or
 - 2.2 faltering growth; or
 - 2.3 bronchopulmonary dysplasia; or
 - 2.4 premature and post premature infants.

Renewal — (Cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

CARBOHYDRATE AND FAT SU	UPPLEMENT - Special Author	ity see SA1376 on t	he previous pag	ge -	Hospital pharmacy [HP3]
Powder (neutral)			400 g OP	1	Duocal Super
			-		Soluble Powder

Fat

⇒SA1523 Special Authority for Subsidy

Initial application — (Inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient has inborn errors of metabolism.

Initial application — (Indications other than inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Any of the following:

- 1 faltering growth in an infant/child; or
- 2 bronchopulmonary dysplasia; or
- 3 fat malabsorption; or
- 4 lymphangiectasia; or
- 5 short bowel syndrome; or
- 6 infants with necrotising enterocolitis; or
- 7 biliary atresia; or
- 8 for use in a ketogenic diet; or
- 9 chyle leak; or

Subsidy (Manufacturer's Price)	Subsi	Fully dised	Brand or Generic
 \$	Per	1	Manufacturer

continued...

- 10 ascites; or
- 11 for use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula. **Renewal — (Inborn errors of metabolism)** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Patho

- Both:
 - 1 The treatment remains appropriate and the patient is benefiting from treatment; and
 - 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than inborn errors of metabolism) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

FAT SUPPLEMENT - Special Autho	ity see SA1523 on the previous	page – Hospital pharmacy [HP3]
--------------------------------	--------------------------------	--------------------------------

Emulsion (neutral)		200 ml OP	✓ Calogen
	30.75	500 ml OP	 Calogen
Emulsion (strawberry)		200 ml OP	 Calogen
Oil		500 ml OP	 MCT oil (Nutricia)
Oil, 250 ml		4 OP	 Liquigen

Protein

⇒SA1524 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 protein losing enteropathy; or
- 2 high protein needs; or
- 3 for use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula. **Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

PROTEIN SUPPLEMENT – Special Authority see SA1524 above – Hospital	pharmacy [HP3]	
Powder	225 g OP	🗸 I
8.95	227 g OP	✓ I
	•	

 Protifar
 Resource Beneprotein

Subsidy (Manufacturer's Price)

\$

Per

Fully Subsidised

Generic Manufacturer

Brand or

Oral and Enteral Feeds

Diabetic Products

⇒SA1095 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient is a type I or and II diabetic who is suffering weight loss and malnutrition that requires nutritional support. Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

DIABETIC ENTERAL FEED 1KCAL/ML - Special Authority se	ee SA1095 above -	- Hospital pharm	nacy [HP3]
Liquid	3.75	500 ml OP	 Glucerna Select
	7.50	1,000 ml OP	🗸 Diason RTH
DIABETIC ORAL FEED 1KCAL/ML - Special Authority see S	A1095 above – Hos	spital pharmacy	[HP3]
Liquid (strawberry)	1.50	200 ml OP	🗸 Diasip
Liquid (vanilla)	1.50	200 ml OP	 Diasip
	2.10		 Nutren Diabetes

Fat Modified Products

⇒SA1525 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 Patient has metabolic disorders of fat metabolism; or
- 2 Patient has a chyle leak; or
- 3 Modified as a modular feed, made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule, for adults.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula. **Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

FAT MODIFIED FEED - Special Author	rity see SA1525 above – Hospital phari	macy [HP3]	
Powder		400 g OP	 Monogen

(Manu	Subsidy	Fully	Brand or
	facturer's Price)	Subsidised	Generic
·	\$ P	Per 🖌	Manufacturer

Paediatric Products For Children Awaiting Liver Transplant

⇒SA1098 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient is a child (up to 18 years) who requires a liver transplant.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.
- ENTERAL/ORAL FEED 1KCAL/ML Special Authority see SA1098 above Hospital pharmacy [HP3]

Paediatric Products For Children With Chronic Renal Failure

⇒SA1099 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient is a child (up to 18 years) with acute or chronic kidney disease.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL FEED 1KCAL/ML - Special Authority see	SA1099 above - Hos	pital pharmacy	[HP3]
Powder		400 g OP	 Kindergen

Paediatric Products

⇒SA1379 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Child is aged one to ten years; and
- 2 Any of the following:
 - 2.1 the child is being fed via a tube or a tube is to be inserted for the purposes of feeding; or
 - 2.2 any condition causing malabsorption; or
 - 2.3 faltering growth in an infant/child; or
 - 2.4 increased nutritional requirements; or
 - 2.5 the child is being transitioned from TPN or tube feeding to oral feeding.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for

	Subsidy (Manufacturer's Pric \$	e) Subsi Per	Fully dised	Brand or Generic Manufacturer
continued applications meeting the following criteria: Both:				
 The treatment remains appropriate and the patient is being General Practitioners must include the name of the dietiting practitioner and date contacted. 			nally re	egistered general
PAEDIATRIC ENTERAL FEED 1.5KCAL/ML – Special Authorit Liquid		<mark>e previous p</mark> a 500 ml OP		lospital pharmacy [HP3] Iutrini Energy RTH
PAEDIATRIC ENTERAL FEED 1KCAL/ML – Special Authority Liquid		previous page 500 ml OP	🗸 N	spital pharmacy [HP3] Iutrini RTH Yediasure RTH
PAEDIATRIC ENTERAL FEED WITH FIBRE 1.5KCAL/ML – Sp pharmacy [HP3]	pecial Authority see	SA1379 on th	ne prev	vious page – Hospital
Liquid	6.00	500 ml OP	✓ N	lutrini Energy Multi Fibre
PAEDIATRIC ORAL FEED 1.5KCAL/ML – Special Authority se Liquid (strawberry) Liquid (vanilla)	1.60	evious page - 200 ml OP 200 ml OP	✓ F	ital pharmacy [HP3] Fortini Fortini
PAEDIATRIC ORAL FEED 1KCAL/ML – Special Authority see Liquid (chocolate) Liquid (strawberry) Liquid (vanilla)	1.07 1.07 1.07	ious page – H 200 ml OP 200 ml OP 200 ml OP 250 ml OP	✓ P ✓ P ✓ P	al pharmacy [HP3] Pediasure Pediasure Pediasure Pediasure
PAEDIATRIC ORAL FEED WITH FIBRE 1.5KCAL/ML – Specia pharmacy [HP3]	al Authority see SA1	379 on the pr	evious	s page – Hospital
Liquid (unflavoured) Liquid (chocolate) Liquid (strawberry) Liquid (vanilla)	1.60 1.60	200 ml OP 200 ml OP 200 ml OP 200 ml OP	✓ F ✓ F	ortini Multi Fibre ortini Multi Fibre ortini Multi Fibre ortini Multi Fibre
PEPTIDE-BASED ORAL FEED – Special Authority see SA137 Powder		<mark>ige</mark> – Hospital 400 g OP		nacy [HP3] Peptamen Junior

Renal Products

⇒SA1101 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient has acute or chronic kidney disease.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

RENAL ENTERAL FEED 1.8 KCAL/ML – Special Authority see SA110	1 above -	Hospital pharmacy	/ [HP3]
Liquid	6.08	500 ml OP 🖌	Nepro HP RTH

SPECIAL FOODS

(1	Subsidy /Ianufacturer's P \$		
RENAL ORAL FEED 1.8 KCAL/ML – Special Authority see SA110 Liquid		220 ml OP •	I pharmacy [HP3] Nepro HP (strawberry) Nepro HP (vanilla)
RENAL ORAL FEED 2 KCAL/ML – Special Authority see SA1101 Liquid		s page – Hospital 237 ml OP	oharmacy [HP3] NovaSource Renal
Liquid (apricot) 125 ml Liquid (caramel) 125 ml	11.52		Renilon 7.5

Specialised And Elemental Products

⇒SA1377 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 malabsorption; or
- 2 short bowel syndrome; or
- 3 enterocutaneous fistulas; or
- 4 eosinophilic oesophagitis; or
- 5 inflammatory bowel disease; or
- 6 patients with multiple food allergies requiring enteral feeding.

Notes: Each of these products is highly specialised and would be prescribed only by an expert for a specific disorder. The alternative is hospitalisation.

Elemental 028 Extra is more expensive than other products listed in this section and should only be used where the alternatives have been tried first and/or are unsuitable.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL SEMI-ELEMENTAL FEED 1.5KCAL/ML – Spec Liquid		e SA1377 abov 1,000 ml OP	
ORAL ELEMENTAL FEED 0.8KCAL/ML - Special Authority see	SA1377 above	- Hospital phar	macy [HP3]
Liquid (grapefruit), 250 ml carton	171.00	18 OP	 Elemental 028 Extra
Liquid (pineapple & orange), 250 ml carton	171.00	18 OP	 Elemental 028 Extra
Liquid (summer fruits), 250 ml carton	171.00	18 OP	 Elemental 028 Extra
ORAL ELEMENTAL FEED 1KCAL/ML – Special Authority see SA	1377 above –	Hospital pharm	acy [HP3]
Powder (unflavoured)		80 g OP	 Vivonex TEN
SEMI-ELEMENTAL ENTERAL FEED 1KCAL/ML – Special Autho Liquid			bital pharmacy [HP3] ✓ Peptisorb

Subsidy		Fully	Brand or
(Manufacturer's Price)	S	ubsidised	Generic
\$	Per	1	Manufacturer

Paediatric Products For Children With Low Energy Requirements

⇒SA1196 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Child aged one to eight years; and
- 2 The child has a low energy requirement but normal protein and micronutrient requirements.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

PAEDIATRIC ENTERAL FEED WITH FIBRE 0.76 KCAL/ML	- Special Authority	see SA1196 a	above -	- Hospital pharmacy [HP3]
Liquid	4.00	500 ml OP	✓	Nutrini Low Energy
				Multi Fibre

Standard Supplements

⇒SA1859 Special Authority for Subsidy

Initial application — (Children - indications other than exclusive enteral nutrition for Crohn's disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following:

- 1 The patient is under 18 years of age; and
- 2 Any of the following:
 - 2.1 The patient has a condition causing malabsorption; or
 - 2.2 The patient has failure to thrive; or
 - 2.3 The patient has increased nutritional requirements; and
- 3 Nutrition goal has been set (eg reach a specific weight or BMI).

Renewal — (Children - indications other than exclusive enteral nutrition for Crohn's disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The patient is under 18 years of age; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment; and
- 3 A nutrition goal has been set (eg reach a specific weight or BMI).

Initial application — (Children - exclusive enteral nutrition for Crohn's disease) only from a gastroenterologist or dietitian on the recommendation of a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria: All of the following:

- 1 The patient is under 18 years of age; and
- 2 It is to be used as exclusive enteral nutrition for the treatment of Crohn's disease; and
- 3 Dietitians must include the name of the gastroenterologist recommending treatment and the date the gastroenterologist was contacted.

Renewal — (Children - exclusive enteral nutrition for Crohn's disease) from any relevant practitioner on the recommendation of a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per	1	Manufacturer	

continued...

All of the following:

- 1 The patient is under 18 years of age; and
- 2 It is to be used as exclusive enteral nutrition for the treatment of Crohn's disease; and
- 3 General Practitioners and dietitians must include the name of the gastroenterologist recommending treatment and the date the gastroenterologist was contacted.

Initial application — (Adults) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - Patient is Malnourished
 - 1.1 Patient has a body mass index (BMI) of less than 18.5 kg/m²; or
 - 1.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
 - 1.3 Patient has a BMI of less than 20 kg/m² and unintentional weight loss greater than 5% within the last 3-6 months; and
- 2 Any of the following:
 - Patient has not responded to first-line dietary measures over a 4 week period by:
 - 2.1 Increasing their food intake frequency (eg snacks between meals); or
 - 2.2 Using high-energy foods (e.g. milkshakes, full fat milk, butter, cream, cheese, sugar etc); or
 - 2.3 Using over the counter supplements (e.g. Complan); and
- 3 A nutrition goal has been set (e.g. to reach a specific weight or BMI).

Renewal — (Adults) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 A nutrition goal has been set (eg reach a specific weight or BMI); and
- 2 Any of the following:
 - Patient is Malnourished
 - 2.1 Patient has a body mass index (BMI) of less than 18.5 kg/m²; or
 - 2.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
 - 2.3 Patient has a BMI of less than 20 kg/m² and unintentional weight loss greater than 5% within the last 3-6 months.

Initial application — (Short-term medical condition) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 Is being fed via a nasogastric tube or a nasogastric tube is to be inserted for feeding; or
- 2 Malignancy and is considered likely to develop malnutrition as a result; or
- 3 Is undergoing a bone marrow transplant; or
- 4 Tempomandibular surgery or glossectomy; or
- 5 Both:
 - 5.1 Pregnant; and
 - 5.2 Any of the following:
 - 5.2.1 Patient is in early pregnancy (< 13 weeks) and has severe clinical hyperemesis gravidarum requiring admission to hospital and is unlikely to meet her nutritional requirements due to continuing hyperemesis gravidarum; or</p>
 - 5.2.2 Patient has clinical hyperemesis gravidarum continuing past 13 weeks and either there is concern that the patient is unlikely to meet the Institute of Medicine's (1990) recommended weight gain guidelines for pregnancy or the patient's weight has not increased past her booking/pre-pregnancy weight; or
 - 5.2.3 Patient is having multiple births and is under the care of an obstetric team who consider the nutritional needs of the patient are not being met.

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Sub	sidised	Generic	
\$	Per	✓	Manufacturer	

Renewal — (Short-term medical condition) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 Is being fed via a nasogastric tube; or
- 2 Malignancy and is considered likely to develop malnutrition as a result; or
- 3 Has undergone a bone marrow transplant; or
- 4 Tempomandibular surgery or glossectomy; or
- 5 Both:
 - 5.1 Pregnant; and
 - 5.2 Any of the following:
 - 5.2.1 Patient is in early pregnancy (< 13 weeks) and has severe clinical hyperemesis gravidarum requiring admission to hospital and is unlikely to meet her nutritional requirements due to continuing hyperemesis gravidarum; or</p>
 - 5.2.2 Patient has clinical hyperemesis gravidarum continuing past 13 weeks and either there is concern that the patient is unlikely to meet the Institute of Medicine's (1990) recommended weight gain guidelines for pregnancy or the patient's weight has not increased past her booking/pre-pregnancy weight; or
 - 5.2.3 Patient is having multiple births and is under the care of an obstetric team who consider the nutritional needs of the patient are not being met.

Initial application — (Long-term medical condition) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube refer to specific medical condition criteria); or
- 2 Cystic Fibrosis; or
- 3 Liver disease; or
- 4 Chronic Renal failure; or
- 5 Inflammatory bowel disease; or
- 6 Chronic obstructive pulmonary disease with hypercapnia; or
- 7 Short bowel syndrome; or
- 8 Bowel fistula; or
- 9 Severe chronic neurological conditions; or
- 10 Epidermolysis bullosa; or
- 11 AIDS (CD4 count < 200 cells/mm³); or
- 12 Chronic pancreatitis.

Renewal — (Chronic disease OR tube feeding for patients who have previously been funded under Special Authority

forms SA0702 or SA0583) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube refer to specific medical condition criteria); or
- 2 Cystic Fibrosis; or
- 3 Liver disease; or
- 4 Chronic Renal failure; or
- 5 Inflammatory bowel disease; or
- 6 Chronic obstructive pulmonary disease with hypercapnia; or
- 7 Short bowel syndrome; or
- 8 Bowel fistula; or
- 9 Severe chronic neurological conditions.

	Subsidy (Manufacturer's F \$		Fully Brand or sidised Generic ✓ Manufacturer
ENTERAL FEED 1.5KCAL/ML – Special Authority see SA1859 (Liquid	1 0	ospital pharmac 250 ml OP 1,000 ml OP	cy [HP3] ✓ Ensure Plus HN ✓ Ensure Plus RTH ✓ Nutrison Energy
ENTERAL FEED 1KCAL/ML – Special Authority see SA1859 on Liquid		spital pharmacy 250 ml OP 1,000 ml OP	 [HP3] Isosource Standard Nutrison Standard RTH Osmolite RTH
ENTERAL FEED WITH FIBRE 0.83 KCAL/ML – Special Authori Liquid		n page 251 – H 1,000 ml OP	Iospital pharmacy [HP3] Vutrison 800 Complete Multi Fibre
ENTERAL FEED WITH FIBRE 1 KCAL/ML – Special Authority s Liquid		age 251 – Hosp 1,000 ml OP	pital pharmacy [HP3] ✓ Jevity RTH ✓ Nutrison Multi Fibre
ENTERAL FEED WITH FIBRE 1.2KCAL/ML – Special Authority Liquid		<mark>page 251</mark> – Hos 1,000 ml OP	spital pharmacy [HP3] ✓ Jevity Plus
ENTERAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority Liquid		page 251 – Hos 1,000 ml OP	spital pharmacy [HP3] ✓ Jevity HiCal RTH ✓ Nutrison Energy Multi Fibre
ORAL FEED (POWDER) – Special Authority see SA1859 on pa Powder (chocolate)	•	al pharmacy [HP 840 g OP	P3] ✓ Sustagen Hospital
Powder (vanilla)	26.00 14.00	850 g OP 840 g OP	Formula Active ✓ Ensure ✓ Sustagen Hospital Formula Active
	26.00	850 g OP	✓ Ensure

	Subsidy (Manufacturer's F \$		ully Brand or sed Generic ✓ Manufacturer
ORAL FEED 1.5KCAL/ML – Special Authority see SA1859 on pa Additional subsidy by endorsement is available for patients b epidermolysis bullosa, or as exclusive enteral nutrition in chil disease, or for patients with COPD and hypercapnia, defined endorsed accordingly.	eing bolus fed the dren under the a	nrough a feeding t age of 18 years fo	ube, who have severe r the treatment of Crohn's
Liquid (banana) – Higher subsidy of \$1.26 per 200 ml with Endorsement	0.72 (1.26) (1.26)	200 ml OP	Ensure Plus Fortisip
Liquid (chocolate) – Higher subsidy of \$1.26 per 200 ml with Endorsement		200 ml OP	Ensure Plus Fortisip
Liquid (fruit of the forest) – Higher subsidy of \$1.26 per 200 with Endorsement	0.72 (1.26)	200 ml OP	Ensure Plus
Liquid (strawberry) – Higher subsidy of \$1.26 per 200 ml wit Endorsement Liquid (vanilla) – Higher subsidy of up to \$1.33 per 237 ml w	0.72 (1.26)	200 ml OP	Fortisip
Endorsement		237 ml OP 200 ml OP	Ensure Plus Ensure Plus
ORAL FEED WITH FIBRE 1.5 KCAL/ML – Special Authority see Additional subsidy by endorsement is available for patients b epidermolysis bullosa. The prescription must be endorsed a	eing bolus fed th ccordingly.		
Liquid (chocolate) – Higher subsidy of \$1.26 per 200 ml with Endorsement Liquid (strawberry) – Higher subsidy of \$1.26 per 200 ml wit	0.72 (1.26)	200 ml OP	Fortisip Multi Fibre
Endorsement		200 ml OP	Fortisip Multi Fibre
Endorsement	0.72 (1.26)	200 ml OP	Fortisip Multi Fibre

High Calorie Products

➡SA1195 Special Authority for Subsidy

Initial application — (Cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: All of the following:

- 1 Cystic fibrosis; and
- 2 other lower calorie products have been tried; and
- 3 patient has substantially increased metabolic requirements.

continued...

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Si	ubsidised	Generic	
\$	Per	✓	Manufacturer	

Initial application — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 any condition causing malabsorption; or
 - 1.2 faltering growth in an infant/child; or
 - 1.3 increased nutritional requirements; or
 - 1.4 fluid restricted; and
- 2 other lower calorie products have been tried; and
- 3 patient has substantially increased metabolic requirements or is fluid restricted.

Renewal — (Cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL FEED 2 KCAL/ML - Special Authority see SA1195 on the previous	bage – Hospital p	harmacy [HP3]
Liquid	500 ml OP	 Nutrison Concentrated
11.00	1,000 ml OP	 Ensure Two Cal HN RTH
ORAL FEED 2 KCAL/ML – Special Authority see SA1195 on the previous page Additional subsidy by endorsement is available for patients being bolus fed epidermolysis bullosa. The prescription must be endorsed accordingly. Liquid (vanilla) – Higher subsidy of \$1.90 per 200 ml with		, , ,
Endorsement	200 ml OP	Two Cal HN

Food Thickeners

⇒SA1106 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient has motor neurone disease with swallowing disorder.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Subsidy Fully Brand or (Manufacturer's Price) Subsidised Generic \$ Per Manufacturer FOOD THICKENER - Special Authority see SA1106 on the previous page - Hospital pharmacy [HP3] 300 g OP Nutilis 380 g OP Feed Thickener 7.25 Karicare Aptamil

SPECIAL FOODS

Gluten Free Foods

The funding of gluten free foods is no longer being actively managed by Pharmac from 1 April 2011. This means that we are no longer considering the listing of new products, or making subsidy, or other changes to the existing listings. As a result we anticipate that the range of funded items will reduce over time. Management of Coeliac disease with a gluten free diet is necessary for good outcomes. A range of gluten free options are available through retail outlets.

⇒SA1729 Special Authority for Subsidy

Initial application — (all patients) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either:

- 1 Gluten enteropathy has been diagnosed by biopsy; or
- 2 Patient suffers from dermatitis herpetiformis.

Initial application — (paediatric patients diagnosed by ESPGHAN criteria) only from a paediatric gastroenterologist. Approvals valid without further renewal unless notified where the paediatric patient fulfils ESPGHAN criteria for biopsy free diagnosis of coeliac disease.

GLUTEN FREE BAKING MIX – Special Authority see SA1729 abo Powder		pharmacy [HP3] 1.000 g OP	
	(5.15)	1,000 g Ol	Healtheries Simple Baking Mix
GLUTEN FREE BREAD MIX - Special Authority see SA1729 abo	ve – Hospital	pharmacy [HP3]	
Powder		1,000 g OP	
	(7.32)	-	NZB Low Gluten Bread Mix
	3.51		
	(10.87)		Horleys Bread Mix
GLUTEN FREE FLOUR - Special Authority see SA1729 above -			
Powder	5.62	2,000 g OP	
	(18.10)		Horleys Flour

	Subsidy (Manufacturer's Pric \$		Fully dised	Brand or Generic Manufacturer
GLUTEN FREE PASTA - Special Authority see SA1729 on the	previous page - H	ospital pharma	acy [HP	3]
Buckwheat Spirals		250 g OP		
	(3.11)	-	Or	gran
Corn and Vegetable Shells	2.00	250 g OP		-
	(2.92)		Or	gran
Corn and Vegetable Spirals	2.00	250 g OP		
	(2.92)		Or	gran
Rice and Corn Lasagne Sheets	1.60	200 g OP		
	(3.82)		Or	gran
Rice and Corn Macaroni	2.00	250 g OP		
	(2.92)		Or	gran
Rice and Corn Penne	2.00	250 g OP		
	(2.92)		Or	gran
Rice and Maize Pasta Spirals	2.00	250 g OP		
	(2.92)		Or	gran
Rice and Millet Spirals	2.00	250 g OP		
	(3.11)		Or	gran
Rice and corn spaghetti noodles	2.00	375 g OP		
	(2.92)		Or	gran
Vegetable and Rice Spirals	2.00	250 g OP		
	(2.92)		Or	gran
Italian long style spaghetti	2.00	220 g OP		
	(3.11)		Or	gran

Foods And Supplements For Inborn Errors Of Metabolism

⇒SA1108 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Dietary management of homocystinuria; or
- 2 Dietary management of maple syrup urine disease; or
- 3 Dietary management of phenylketonuria (PKU); or
- 4 For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

Supplements For Homocystinuria

AMINOACID FORMULA WITHOUT METHIONINE - S	Special Authority see SA1108	<mark>3 above –</mark> Hospital	pharmacy [HP3]
Powder		500 g OP 🛛 🗸	XMET Maxamum

Supplements For MSUD

Powder 437.22	500 a OP	MSUD Maxamum
pharmacy [HP3]		
AMINOACID FORMULA WITHOUT VALINE, LEUCINE AND ISOLEUCINE - S	pecial Authority se	ee SA1108 above – Hospital

	Subsidy (Manufacturer's Pr \$	ice) Subs Per	idised G	and or eneric anufacturer
Supplements For PKU				
/INOACID FORMULA WITHOUT PHENYLALANINE - armacy [HP3]	Special Authority see S/	A1108 on the j	previous pa	<mark>ge</mark> – Hospital
Tabs		75 OP	🗸 Phle	ку 10
Powder (orange) 36 g sachet		30		Anamix Junior
Powder (berry) 28 g sachets		30		Lophlex wder
Powder (chocolate) 36 g sachet		30		Anamix Junior ocolate
Powder (orange) 28 g sachets		30		Lophlex wder
Powder (unflavoured) 28 g sachets		30		Lophlex wder
Powder (unflavoured) 36 g sachets		30	🗸 PKU	Anamix Junior
Powder (vanilla) 36 g sachet		30	-	Anamix Junior nilla
Infant formula		400 g OP	🗸 PKU	Anamix Infant
Powder (orange)		500 g OP	🖌 XP N	laxamum
Powder (unflavoured)		500 g OP	🖌 XP N	laxamum
Liquid (berry)		125 ml OP	✓ PKU LQ	Anamix Junior
Liquid (orange)		125 ml OP	✓ PKU LQ	Anamix Junio
Liquid (unflavoured)		125 ml OP	✓ PKU LQ	Anamix Junior
Liquid (forest berries), 250 ml carton		18 OP	🗸 Easi	ohen Liquid
Liquid (juicy tropical) 125 ml		30 OP		Lophlex LQ 20
Oral semi-solid (berries) 109 g		36 OP	🖌 PKU	Lophlex nsation 20
Liquid (juicy berries) 62.5 ml		60 OP	🖌 PKU	Lophlex LQ 10
Liquid (juicy citrus) 62.5 ml		60 OP		Lophlex LQ 10
Liquid (juicy orange) 62.5 ml		60 OP		Lophlex LQ 10
Liquid (juicy berries) 125 ml		30 OP	🗸 PKU	Lophlex LQ 20
Liquid (juicy orange) 125 ml		30 OP	🗸 PKU	Lophlex LQ 20

Foods

LOW PROTEIN BAKING MIX – Special Authority see SA1108 on 1 Powder			oharmacy [HP3] ✓ Loprofin Mix
LOW PROTEIN PASTA - Special Authority see SA1108 on the pro	evious page –	Hospital pharm	acy [HP3]
Animal shapes	11.91	500 g OP	 Loprofin
Lasagne	5.95	250 g OP	 Loprofin
Low protein rice pasta	11.91	500 g OP	 Loprofin
Macaroni	5.95	250 g OP	 Loprofin
Penne	11.91	500 g OP	 Loprofin
Spaghetti	11.91	500 g OP	 Loprofin
Spirals	11.91	500 g OP	 Loprofin

SPECIAL FOODS

	Subsidy (Manufacturer's Price \$	e) Subs Per	Fully idised	Brand or Generic Manufacturer
Infant Formulae				
For Williams Syndrome				
 SA1110 Special Authority for Subsidy itial application only from a dietitian, relevant specialist or vo vor where the patient is an infant suffering from Williams Syndr enewal only from a dietitian, relevant specialist, vocationally re commendation of a dietitian, relevant specialist or vocationally opplications meeting the following criteria: oth:	rome and associated egistered general pra registered general p nefiting from treatme ian, relevant speciali A1110 above – Hosp	hypercalcad actitioner or g oractitioner. nt; and st or vocatio	emia. general Approv nally re sy [HP3	practitioner on the vals valid for 1 year for
Gastrointestinal and Other Malabsorptive Prob				
•				
MINO ACID FORMULA – Special Authority see SA2092 below Powder		cy [HP3] 400 g OP	-	Ifamino Ifamino Junior
Powder (unflavoured)	53.00	400 g OP	✓ E ✓ E ✓ N ✓ N	lecare lecare LCP leocate Gold leocate Junior Unflavoured leocate SYNEO
Powder (vanilla)	53.00	400 g OP	✓ E	leccare leocate Junior Vanilla

⇒SA2092 Special Authority for Subsidy

Initial application — (Infants under 12 months of age) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Any of the following:

- 1 History of anaphylaxis to cow's milk protein formula or dairy products; or
- 2 Eosinophilic oesophagitis; or
- 3 Ultra-short gut; or
- 4 Severe Immune deficiency; or
- 5 Extensively hydrolysed formula has been trialled in an inpatient setting and is clinically inappropriate; or
- 6 Both:
 - 6.1 Extensively hydrolysed formula has been reasonably trialled for 2-4 weeks and is inappropriate due to documented severe intolerance or allergy or malabsorption; and
 - 6.2 Either:
 - 6.2.1 The patient has a valid Special Authority approval for extensively hydrolysed formula: approval number; or
 - 6.2.2 Patient has IgE mediated allergy.

Initial application - (Children 12 months of age and over) only from a paediatrician, paediatric gastroenterologist, paediatric

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Subs	idised	Generic	
\$	Per	~	Manufacturer	

immunologist or dietitian on the recommendation of a paediatrician, paediatric gastroenterologist or paediatric immunologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

1 Fither:

- 1.1 Applicant is a paediatrician, paediatric gastroenterologist or paediatric immunologist; or
- 1.2 Applicant is a dietitian and confirms that a paediatrician, paediatric gastroenterologist or paediatric immunologist has been consulted within the last 12 months and has recommended treatment for the patient; and
- 2 Any of the following:
 - 2.1 History of anaphylaxis to cow's milk protein formula or dairy products; or
 - 2.2 Eosinophilic oesophagitis; or
 - 2.3 Ultra-short gut; or
 - 2.4 Severe Immune deficiency; or
 - 2.5 Extensively hydrolysed formula has been trialled in an inpatient setting and is clinically inappropriate; or
 - 2.6 Both:
 - 2.6.1 Extensively hydrolysed formula has been reasonably trialled for 2-4 weeks and is inappropriate due to documented severe intolerance or allergy or malabsorption; and
 - 2.6.2 Either:
 - 2.6.2.1 The patient has a valid Special Authority approval for extensively hydrolysed formula: approval number; or
 - 2.6.2.2 Patient has IgE mediated allergy.

Renewal — (Infants up to 12 months of age) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 Patient has IgE mediated allergy; and
 - 1.2 All of the following:
 - 1.2.1 Patient remains allergic to cow's milk; and
 - 1.2.2 An assessment as to whether the infant can be transitioned to a cow's milk protein, soy or extensively hydrolysed infant formula has been undertaken; and
 - 1.2.3 The outcome of the assessment is that the infant continues to require an amino acid infant formula; and
 - 1.2.4 Amino acid formula is required for a nutritional deficit; and
 - 1.2.5 It has been more than three months from the previous approval; or
- 2 Both:
 - Patient has non IgE mediated severe gastrointestinal intolerance (including eosinophilic oesophagitis, ultra-short gut and severe immune deficiency); and
 - 2.2 All of the following:
 - 2.2.1 An assessment as to whether the infant can be transitioned to a cow's milk protein, soy, or extensively hydrolysed infant formula has been undertaken; and
 - 2.2.2 The outcome of the assessment is that the infant continues to require an amino acid infant formula; and
 - 2.2.3 Amino acid formula is required for a nutritional deficit; and
 - 2.2.4 It has been more than three months from the previous approval.

Renewal — (Children 12 months of age and over) only from a paediatrician, paediatric gastroenterologist, paediatric immunologist or dietitian on the recommendation of a paediatrician, paediatric gastroenterologist or paediatric immunologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

1 Either:

1.1 Applicant is a paediatrician, paediatric gastroenterologist or paediatric immunologist; or

Subsidy		Fully	Brand or	
(Manufacturer's Price)	:	Subsidised	Generic	
\$	Per	✓	Manufacturer	

- 1.2 Applicant is a dietitian and confirms that a paediatrician, paediatric gastroenterologist or paediatric immunologist has been consulted within the last 12 months and has recommended treatment for the patient; and
- 2 Any of the following:
 - 2.1 History of anaphylaxis to cow's milk protein formula or dairy products; or
 - 2.2 Eosinophilic oesophagitis; or
 - 2.3 Ultra-short gut; or
 - 2.4 Severe Immune deficiency; or
 - 2.5 Extensively hydrolysed formula has been trialled in an inpatient setting and is clinically inappropriate; or
 - 2.6 Both:
 - 2.6.1 Extensively hydrolysed formula has been reasonably trialled for 2-4 weeks and is inappropriate due to documented severe intolerance or allergy or malabsorption; and
 - 2.6.2 Either:
 - 2.6.2.1 The patient has a valid Special Authority approval for extensively hydrolysed formula: approval number; or
 - 2.6.2.2 Patient has IgE mediated allergy.

Initial application — (for patients who have a current funding under Special Authority form SA1557) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a valid Special Authority approval for extensively hydrolysed formula (SA1557); and
- 2 Extensively hydrolysed formula (Aptamil Gold+ Pepti Junior, AllerPro SYNEO 1 and 2) is unable to be supplied at this time; and
- 3 The approval only applies to funded dispensings of Neocate Gold and Neocate Syneo.

Note: This criteria is short term funding to cover an out-of-stock situation on some extensively hydrolysed formula powder funded under Special Authority form SA1557. There is no renewal criteria under this restriction.

Liquid 1 kcal/ml	 500 ml OP	 Nutrini Peptisorb
Liquid 1.5 kcal/ml	 500 ml OP	 Nutrini Peptisorb
		Energy

⇒SA1953 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has impaired gastrointestinal function and either cannot tolerate polymeric feeds, or polymeric feeds are unsuitable; and
- 2 Any of the following:
 - 2.1 Severe malabsorption; or
 - 2.2 Short bowel syndrome; or
 - 2.3 Intractable diarrhoea; or
 - 2.4 Biliary atresia; or
 - 2.5 Cholestatic liver diseases causing malabsorption; or
 - 2.6 Cystic fibrosis; or
 - 2.7 Proven fat malabsorption; or
 - 2.8 Severe intestinal motility disorders causing significant malabsorption; or
 - 2.9 Intestinal failure; or

2.10 Both:

2.10.1 The patient is currently receiving funded amino acid formula; and

(Ma	Subsidy nufacturer's Price)	Sut	Fully bsidised	Brand or Generic
	\$	Per	✓	Manufacturer

- 2.10.2 The patient is to be trialled on, or transitioned to, an enteral liquid peptide formula; and
- 3 Either:
 - 3.1 A semi-elemental or partially hydrolysed powdered feed has been reasonably trialled and considered unsuitable; or
 - 3.2 For step down from intravenous nutrition.

Note: A reasonable trial is defined as a 2-4 week trial.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 An assessment as to whether the patient can be transitioned to a cows milk protein or soy infant formula or extensively hydrolysed formula has been undertaken; and
- 2 The outcome of the assessment is that the patient continues to require an enteral liquid peptide formula; and
- 3 General practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

EXTENSIVELY HYDROLYSED FORMULA - Special Authority	see SA1557 belo	w – Hospital pł	narmacy [HP3]
Powder	15.21	450 g OP	 Aptamil Gold+ Pepti Junior
	30.42	900 g OP	 Aptamil AllerPro SYNEO 1
			 Aptamil AllerPro SYNEO 2

⇒SA1557 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Any of the following:

- 1 Both:
 - 1.1 Cows milk formula is inappropriate due to severe intolerance or allergy to its protein content; and
 - 1.2 Either:
 - 1.2.1 Soy milk formula has been reasonably trialled without resolution of symptoms; or
 - 1.2.2 Soy milk formula is considered clinically inappropriate or contraindicated; or
- 2 Severe malabsorption; or
- 3 Short bowel syndrome; or
- 4 Intractable diarrhoea; or
- 5 Biliary atresia; or
- 6 Cholestatic liver diseases causing malsorption; or
- 7 Cystic fibrosis; or
- 8 Proven fat malabsorption; or
- 9 Severe intestinal motility disorders causing significant malabsorption; or
- 10 Intestinal failure; or
- 11 All of the following:
 - 11.1 For step down from Amino Acid Formula; and
 - 11.2 The infant is currently receiving funded amino acid formula; and
 - 11.3 The infant is to be trialled on, or transitioned to, an extensively hydrolysed formula; and
 - 11.4 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

Note: A reasonable trial is defined as a 2-4 week trial, or signs of an immediate IgE mediated allergic reaction.

continued...

Subsidy		Fully	Brand or	
(Manufacturer's Price)	5	Subsidised	Generic	
\$	Per	✓	Manufacturer	

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 An assessment as to whether the infant can be transitioned to a cows milk protein or soy infant formula has been undertaken: and
- 2 The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula; and
- 3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

Fluid Restricted

PAEDIATRIC ORAL/ENTERAL FEED 1 KCAL/ML - Special Authority see SA1698 below - Hospital pharmacy [HP3]

Liquid	2.35	125 ml OP	 Infatrini
--------	------	-----------	-------------------------------

SA1698 Special Authority for Subsidy

Initial application only from a paediatrician, dietitian or general practitioner on the recommendation of a paediatrician or dietitian. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient is fluid restricted or volume intolerant and has been diagnosed with faltering growth; and
- 2 Patient is under the care of a paediatrician or dietitian who has recommended treatment with a high energy infant formula; and
- 3 Patient is under 18 months of age or weighs less than 8 kg.

Note: 'Volume intolerant' patients are those who are unable to tolerate an adequate volume of infant formula to achieve expected growth rate. These patients should have first trialled appropriate clinical alternative treatments, such as concentrating, fortifying and adjusting the frequency of feeding.

Renewal only from a paediatrician, dietitian or general practitioner on the recommendation of a paediatrician or dietitian. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient continues to be fluid restricted or volume intolerant and has faltering growth; and
- 2 Patient is under the care of a hospital paediatrician or dietitian who has recommended treatment with a high energy infant formula: and
- 3 Patient is under 18 months of age or weighs less than 8 kg.

Note: 'Volume intolerant' patients are those who are unable to tolerate an adequate volume of infant formula to achieve expected growth rate. These patients should have first trialled appropriate clinical alternative treatments, such as concentrating, fortifying and adjusting the frequency of feeding.

Ketogenic Diet

SA1197 Special Authority for Subsidy

Initial application only from a metabolic physician or paediatric neurologist. Approvals valid for 3 months where the patient has intractable epilepsy, pyruvate dehydrogenase deficiency or glucose transported type-1 deficiency and other conditions requiring a ketogenic diet.

Renewal only from a metabolic physician or paediatric neurologist. Approvals valid for 2 years where the patient is on a ketogenic diet and the patient is benefiting from the diet.

HIGH FAT LOW CARBOHYDRATE FORMULA - Special Authority see SA119	7 above – Retail	pharmacy
Powder (unflavoured)	300 g OP	KetoCal 4:1
		 Ketocal 3:1
Powder (vanilla)35.50	300 g OP	 KetoCal 4:1

SECTION I: NATIONAL IMMUNISATION SCHEDULE

Per

Subsidy (Manufacturer's Price)

\$

Brand or Generic Manufacturer

BCG Vaccine

Fully

Subsidised

Vaccinations

BACILLUS CALMETTE-GUERIN VACCINE - [Xpharm]

For infants at increased risk of tuberculosis. Increased risk is defined as:

- 1) living in a house or family with a person with current or past history of TB; or
- having one or more household members or carers who within the last 5 years lived in a country with a rate of TB > or equal to 40 per 100,000 for 6 months or longer; or

3) during their first 5 years will be living 3 months or longer in a country with a rate of TB > or equal to 40 per 100,000 Note a list of countries with high rates of TB are available at www.health.govt.nz/tuberculosis (search for downloads) or www.bcgatlas.org/index.php.

Inj Mycobacterium bovis BCG (Bacillus Calmette-Guerin),

Danish strain 1331, live attenuated, vial with diluent.....0.00 10

DIPHTHERIA, TETANUS AND PERTUSSIS VACCINE - [Xpharm]

Funded for any of the following criteria:

- 1) A single dose for pregnant women in the second or third trimester of each pregnancy; or
- A single dose for parents or primary caregivers of infants admitted to a Neonatal Intensive Care Unit or Specialist Care Baby Unit for more than 3 days, who had not been exposed to maternal vaccination at least 14 days prior to birth; or
- A course of up to four doses is funded for children from age 7 up to the age of 18 years inclusive to complete full primary immunisation; or
- 4) An additional four doses (as appropriate) are funded for (re-)immunisation for patients post haematopoietic stem cell transplantation or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
- 5) A single dose for vaccination of patients aged from 65 years old; or
- 6) A single dose for vaccination of patients aged from 45 years old who have not had 4 previous tetanus doses; or
- 7) For vaccination of previously unimmunised or partially immunised patients; or
- 8) For revaccination following immunosuppression; or
- 9) For boosting of patients with tetanus-prone wounds.

Notes: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.

Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg

pertussis toxoid, 8 mcg pertussis filamentous

haemagglutinin and 2.5 mcg pertactin in 0.5 ml syringe0.00) 10	 Boostrix
	1	Boostrix

DIPHTHERIA, TETANUS, PERTUSSIS AND POLIO VACCINE - [Xpharm]

Funded for any of the following:

- 1) A single dose for children up to the age of 7 who have completed primary immunisation; or
- A course of four vaccines is funded for catch up programmes for children (to the age of 10 years) to complete full primary immunisation; or
- An additional four doses (as appropriate) are funded for (re-)immunisation for patients post HSCT, or chemotherapy; pre- or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
- 4) Five doses will be funded for children requiring solid organ transplantation.

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.

Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg

pertussis toxoid, 25 mcg pertussis filamentous baemagolutinin, 8 mcg pertactin and 80 D-antigen units

naonnaggiainni, o niog p	onaoan ana oo b anagon anao			
poliomyelitis virus in 0.5r	nl syringe	0.00	10	Infanrix IPV

	Subsidy (Manufacturer's Price) \$	Subs Per	Fully sidised	Brand or Generic Manufacturer
DIPHTHERIA, TETANUS, PERTUSSIS, POLIO, HEPATITIS B	AND HAEMOPHILUS	INFLUEN	ZAE TY	PE B VACCINE -
Xpharm]				
Funded for patients meeting any of the following criteria:				
1) Up to four doses for children up to and under the age				
An additional four doses (as appropriate) are funded f	· · /		•	•
10 who are patients post haematopoietic stem cell tra		1.271		1 1 1 1 1
post solid organ transplant, renal dialysis and other se				
3) Up to five doses for children up to and under the age				
Note: A course of up-to four vaccines is funded for catch u				
to complete full primary immunisation. Please refer to the I	mmunisation Handboo	k for the a	ppropri	ate schedule for catch u
programmes.				
Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg)			
pertussis toxoid, 25 mcg pertussis filamentous				
haemagglutinin, 8 mcg pertactin, 80 D-Ag U polio virus 10 mcg hepatitis B surface antigen in 0.5 ml syringe		10	1 1	nfanrix-hexa
	0.00	10	• 11	
AEMOPHILUS INFLUENZAE TYPE B VACCINE – [Xpharm]				
One dose for patients meeting any of the following:				
1) For primary vaccination in children; or	mmunication for nation	to post be	amata	aiotia atom call
 An additional dose (as appropriate) is funded for (re-)i transplantation, or chemotherapy; functional asplenic; 				
or post cochlear implants, renal dialysis and other sev				oliu organ transplant, pr
 For use in testing for primary immunodeficiency disea 				nal medicine nhysician c
paediatrician.				
F				
Haemophilus Influenzae type B polysaccharide 10 mcg				
conjugated to tetanus toxoid as carrier protein 20-40 m	cg;			
prefilled syringe plus vial 0.5 ml	0.00	1	. ⊾	liberix
EPATITIS A VACCINE – [Xpharm]				
Funded for patients meeting any of the following criteria:				
1) Two vaccinations for use in transplant patients; or				
2) Two vaccinations for use in children with chronic liver				
One dose of vaccine for close contacts of known hepa	atitis A cases.			
Inj 1440 ELISA units in 1 ml syringe	0.00	1	/ 4	lavrix
ing 1770 LEIOA unito in 1 nii synnye	0.00	1	• [

IIIJ 1440 ELISA units III 1 III synnige	1	
Inj 720 ELISA units in 0.5 ml syringe0.00	1	 Havrix Junior

		Subsidy		Fully	Brand or
		(Manufacturer's Price) \$	Per	Subsidised	Generic Manufacturer
		Ψ	rei	•	Manulaclurei
	COMBINANT VACCINE – [Xpharm]	0.00			Ta marily D
	er 0.5 ml prefilled syringe or patients meeting any of the following criteria		1	•	Engerix-B
	household or sexual contacts of known acute		0000	itio D corrio	ro: or
	children born to mothers who are hepatitis B s				15, 01
	children up to and under the age of 18 years in				a achieved a nositive
	ology and require additional vaccination or rec				
	HIV positive patients; or				
	hepatitis C positive patients; or				
	patients following non-consensual sexual inter	rcourse; or			
7) for	patients following immunosuppression; or				
	solid organ transplant patients; or				
,	post-haematopoietic stem cell transplant (HSC	CT) patients; or			
10) follo	owing needle stick injury.				
lni 20 mca ne	er 1 ml prefilled syringe	0.00	1		Engerix-B
	for patients meeting any of the following criteria		'	• !	
	household or sexual contacts of known acute		enat	titis R carrie	rs: or
	children born to mothers who are hepatitis B s				10, 01
	children up to and under the age of 18 years i				e achieved a positive
	ology and require additional vaccination or rec				
	HIV positive patients; or				
	hepatitis C positive patients; or				
	patients following non-consensual sexual inter	rcourse; or			
	patients following immunosuppression; or				
	solid organ transplant patients; or				
	post-haematopoietic stem cell transplant (HSC	() patients; or			
	owing needle stick injury; or dialysis patients; or				
	liver or kidney transplant patients.				
12) 101					
	DMAVIRUS (6, 11, 16, 18, 31, 33, 45, 52 AND	58) VACCINE [HPV] -	[Xn	harml	
Any of the fol			[/ P	lannj	
	im of two doses for children aged 14 years and	d under: or			
	im of three doses for patients meeting any of t				
,	eople aged 15 to 26 years inclusive; or	Ū			
2) Ei					
Pe	eople aged 9 to 26 years inclusive				
	1) Confirmed HIV infection; or				
	2) Transplant (including stem cell) patients:	or			
3) Maximu	Im of four doses for people aged 9 to 26 years	inclusive post chemoth	nerap	у	

Inj 270 mcg in 0.5 ml syringe0.00 10 🖌 Gardasil

		Subsidy (Manufacturer's Price) \$	Subsi Per	Fully dised	Brand or Generic Manufacturer
IFLUENZA V	ACCINE				
	in 0.25 ml syringe (paediatric quadrivalent vacc				
– [Xpl	narm]	9.00	1	✓ A	fluria Quad Junior (2021 Formulation)
A)	NFLUENZA VACCINE – child aged 6 months	to 35 months			
	s available each year for patients aged 6 month	s to 35 months who mee	et the follow	ving cri	teria, as set by Pharma
	i) have any of the following cardiovascular di	seases			
	a) ischaemic heart disease, or				
	b) congestive heart failure, or				
	c) rheumatic heart disease, or				
	d) congenital heart disease, or				
	e) cerebo-vascular disease; or	le e e Perere e			
	ii) have either of the following chronic respira	•			
	 a) asthma, if on a regular preventative t b) other chronic respiratory disease with 		or		
	iii) have diabetes; or	r impaired lung lunction,	01		
	iv) have chronic renal disease: or				
	 v) have any cancer, excluding basal and square 	amous skin cancers if no	t invasive	or	
	vi) have any of the following other conditions:			01	
	a) autoimmune disease, or				
	b) immune suppression or immune defi	ciency, or			
	c) HIV, or	-			
	 d) transplant recipients, or 				
	e) neuromuscular and CNS diseases/di	sorders, or			
	f) haemoglobinopathies, or				
	g) on long term aspirin, orh) have a cochlear implant, or				
	i) errors of metabolism at risk of major	metaholic decompensati	on or		
	j) pre and post splenectomy, or		011, 01		
	k) down syndrome, or				
	vii) have been hospitalised for respiratory illne	ss or have a history of si	gnificant r	espirate	ory illness;
	Unless meeting the criteria set out above, the fo	•	-		•
	a) asthma not requiring regular preventative t	herapy,			-
	b) hypertension and/or dyslipidaemia without	evidence of end-organ of	lisease.		
B)	Doctors are the only Contractors entitled to clain	n payment from the Fund	der for the	supply	of influenza vaccine in
	30 mcg in 0.25 ml syringe (paediatric quadrivale				
	subsidised immunisation and they may only do s	so in respect of the influe	enza vaccii	ne liste	d in the Pharmaceutica
	Schedule.				

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer	
Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine)	90.00	10	√	Afluria Quad (2021 Formulation)	

- a) Only on a prescription
- b) No patient co-payment payable
- C)

A) INFLUENZA VACCINE – people 5 years and over

- is available each year for patients aged 5 years and over who meet the following criteria, as set by Pharmac:
 - a) all people 65 years of age and over; or
 - b) people under 65 years of age who:
 - i) have any of the following cardiovascular diseases:
 - a) ischaemic heart disease, or
 - b) congestive heart failure, or
 - c) rheumatic heart disease, or
 - d) congenital heart disease, or
 - e) cerebo-vascular disease; or
 - ii) have either of the following chronic respiratory diseases:
 - a) asthma, if on a regular preventative therapy, or
 - b) other chronic respiratory disease with impaired lung function; or
 - iii) have diabetes; or
 - iv) have chronic renal disease; or
 - v) have any cancer, excluding basal and squamous skin cancers if not invasive; or
 - vi) have any of the following other conditions:
 - a) autoimmune disease, or
 - b) immune suppression or immune deficiency, or
 - c) HIV, or
 - d) transplant recipients, or
 - e) neuromuscular and CNS diseases/disorders, or
 - f) haemoglobinopathies, or
 - g) are children on long term aspirin, or
 - h) have a cochlear implant, or
 - i) errors of metabolism at risk of major metabolic decompensation, or
 - j) pre and post splenectomy, or
 - k) down syndrome, or
 - vii) are pregnant;
- Unless meeting the criteria set out above, the following conditions are excluded from funding:
 - a) asthma not requiring regular preventative therapy,
 - b) hypertension and/or dyslipidaemia without evidence of end-organ disease.
- B) Contractors will be entitled to claim payment from the Funder for the supply of influenza vaccine to patients eligible under the above criteria pursuant to their contract with their DHB for subsidised immunisation, and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule.
- C) Contractors may only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.

Inj 60 mcg in 0.5 ml syringe (adjuvanted quadrivalent vaccine)90.00

10

 Fluad Quad (2021 Formulation)

Subsidy		Fully	Brand or
(Manufacturer's Pri		Subsidised	Generic
\$	Per	<u> </u>	Manufacturer

a) Only on a prescription

b) No patient co-payment payable

C)

A) INFLUENZA VACCINE – people 65 years and over

is available each year for patients aged 65 years and over

- B) Contractors will be entitled to claim payment from the Funder for the supply of influenza vaccine to patients eligible under the above criteria pursuant to their contract with their DHB for subsidised immunisation, and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule.
- C) Contractors may only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.

1

Inj 60 mcg in 0.5 ml syringe (paediatric quadrivalent vaccine) -

[Xpharm]9.00

 Influvac Tetra (2021 Formulation)

Subsid	у	Fully	Brand or	
(Manufacture	's Price) Subsid	dised	Generic	
\$	Per	1	Manufacturer	

A) INFLUENZA VACCINE – people 3 and 4 years of age (inclusive)

is available each year for patients aged 3 and 4 years of age (inclusive) who meet the following criteria, as set by Pharmac:

- i) have any of the following cardiovascular diseases
 - a) ischaemic heart disease, or
 - b) congestive heart failure, or
 - c) rheumatic heart disease, or
 - d) congenital heart disease, or
 - e) cerebo-vascular disease; or
- ii) have either of the following chronic respiratory diseases:
 - a) asthma, if on a regular preventative therapy, or
 - b) other chronic respiratory disease with impaired lung function; or
- iii) have diabetes; or
- iv) have chronic renal disease; or
- v) have any cancer, excluding basal and squamous skin cancers if not invasive; or
- vi) have any of the following other conditions:
 - a) autoimmune disease, or
 - b) immune suppression or immune deficiency, or
 - c) HIV, or
 - d) transplant recipients, or
 - e) neuromuscular and CNS diseases/disorders, or
 - f) haemoglobinopathies, or
 - g) are children on long term aspirin, or
 - h) have a cochlear implant, or
 - i) errors of metabolism at risk of major metabolic decompensation, or
 - j) pre and post splenectomy, or
 - k) down syndrome, or

vii) have been hospitalised for respiratory illness or have a history of significant respiratory illness;

Unless meeting the criteria set out above, the following conditions are excluded from funding:

- a) asthma not requiring regular preventative therapy,
- b) hypertension and/or dyslipidaemia without evidence of end-organ disease.
- B) Doctors are the only Contractors entitled to claim payment from the Funder for the supply of influenza vaccine inj 60 mcg in 0.5 ml syringe (paediatric quadrivalent vaccine) to patients eligible under the above criteria for subsidised immunisation and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule.

Subsidy (Manufacturer's Pric		Fully Subsidised	Brand or
(Manufacturer's Pric	Per	Subsidised	Generic Manufacturer

MEASLES, MUMPS AND RUBELLA VACCINE

- a) Only on a prescription
- b) No patient co-payment payable
- c)

A) Measles, mumps and rubella vaccine

A maximum of two doses for any patient meeting the following criteria:

- 1) For primary vaccination in children; or
- 2) For revaccination following immunosuppression; or
- 3) For any individual susceptible to measles, mumps or rubella; or
- 4) A maximum of three doses for children who have had their first dose prior to 12 months.

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes. Although a price is listed for the vaccine, doctors can still order measles mumps and rubella vaccine free of charge, as with other Schedule vaccines.

- B) Contractors will be entitled to claim payment from the Funder for the supply of measles, mumps and rubella vaccine to patients eligible under the above criteria pursuant to their contract with their DHB for subsidised immunisation, and they may only do so in respect of the measles, mumps and rubella vaccine listed in the Pharmaceutical Schedule.
- C) Contractors can only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.
- Inj, measles virus 1,000 CCID50, mumps virus 5,012 CCID50, Rubella virus 1,000 CCID50; prefilled syringe/ampoule of diluent 0.5 ml

diluent 0.5 ml	.112.50	5	🗸 WWK II
	250.00	10	✓ Priorix

MENINGOCOCCAL (GROUPS A, C, Y AND W-135) CONJUGATE VACCINE - [Xpharm]

Either:

- A) Any of the following:
 - Up to three doses and a booster every five years for patients pre- and post splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre or post solid organ transplant; or
 - 2) One dose for close contacts of meningococcal cases of any group; or
 - 3) One dose for person who has previously had meningococcal disease of any group; or
 - 4) A maximum of two doses for bone marrow transplant patients; or
 - 5) A maximum of two doses for person pre- and post-immunosuppression*; or
- B) Both:
 - 1) Person is aged between 13 and 25 years, inclusive; and
 - 2) Either:
 - One dose for individuals who are entering within the next three months, or in their first year of living in boarding school hostels, tertiary education halls of residence, military barracks, or prisons; or
 - ii) One dose for individuals who are currently living in boarding school hostels, tertiary education halls of residence, military barracks, or prisons, from 1 December 2019 to 30 November 2021.

Note: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly.

*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days. Inj 4 mcg of each meningococcal polysaccharide conjugated to

a total of approximately 48 mcg of diphtheria toxoid ca	rrier		
per 0.5 ml vial	0.00	1	 Menactra

Subsidy	Full	/ Brand or
(Manufacturer's Price)	Subsidise	d Generic
\$	Per 🗸	Manufacturer

MENINGOCOCCAL B MULTICOMPONENT VACCINE - [Xpharm]

Either:

- A) Both:
 - 1) Child is under one year of age; and
 - 2) Any of the following:
 - i) up to three doses and a booster every five years for patients pre- and post-splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre- or post-solid organ transplant; or
 - ii) up to three doses for close contacts of meningococcal cases of any group; or
 - iii) up to three doses for child who has previously had meningococcal disease of any group; or
 - iv) up to three doses for bone marrow transplant patients; or
 - v) up to three doses for child pre- and post-immunosuppression*; or
- B) Both:

N

- 1) Person is one year of age or over; and
- 2) Any of the following:
 - i) up to two doses and a booster every five years for patients pre- and post-splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre- or post-solid organ transplant; or
 - ii) up to two doses for close contacts of meningococcal cases of any group; or
 - iii) up to two doses for person who has previously had meningococcal disease of any group; or
 - iv) up to two doses for bone marrow transplant patients; or
 - v) up to two doses for person pre- and post-immunosuppression*.

*Immunosuppression due to corticosteroid or other immunosuppressive therapy must be for a period of greater than 28 days.

Inj 175 mcg per 0.5 ml prefilled syringe	0.00	1	 Bexsero
<pre>//ENINGOCOCCAL C CONJUGATE VACCINE - [Xpharm] Both:</pre>			

- 1) The child is under 9 months of age; and
- 2) Any of the following:
 - Up to three doses for patients pre- and post splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre or post solid organ transplant; or
 - 2) Two doses for close contacts of meningococcal cases of any group; or
 - 3) Two doses for child who has previously had meningococcal disease of any group; or
 - 4) A maximum of two doses for bone marrow transplant patients; or
 - 5) A maximum of two doses for child pre- and post-immunosuppression*.

Note: children under nine months of age require two doses 8 weeks apart. Refer to the Immunisation Handbook for booster schedules with meningococcal ACWY vaccine.

*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

Inj 10 mcg in 0.5 ml syringe......0.00 1 **Veisvac-C** PNEUMOCOCCAL (PCV10) CONJUGATE VACCINE – [Xpharm]

 A primary course of three doses for previously unvaccinated individuals up to the age of 59 months inclusive Note: please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes Ini 1 mgg of pneumococcal polysaccharide services 1, 5, 6B.

7F, 9V, 14 and 23F; 3 mcg of pneumococcal		
polysaccharide serotypes 4, 18C and 19F in 0.5 ml		
prefilled syringe0.00	10	 Synflorix

*Three months or six months, as applicable, dispensed all-at-once

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Subsi	dised	Generic	
\$	Per	1	Manufacturer	

PNEUMOCOCCAL (PCV13) CONJUGATE VACCINE - [Xpharm]

Any of the following:

- Two doses are funded for high risk children (over the age of 12 months and under 18 years) who have previously
 received two doses of the primary course of PCV10; or
- 2) Up to an additional four doses (as appropriate) are funded for high risk children aged under 5 years for (re-)immunisation of patients with any of the following:
 - a) on immunosuppressive therapy or radiation therapy, vaccinate when there is expected to be a sufficient immune response; or
 - b) with primary immune deficiencies; or
 - c) with HIV infection; or
 - d) with renal failure, or nephrotic syndrome; or
 - e) who are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant); or
 - f) with cochlear implants or intracranial shunts; or
 - g) with cerebrospinal fluid leaks; or
 - receiving corticosteroid therapy for more than two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; or
 - i) with chronic pulmonary disease (including asthma treated with high-dose corticosteroid therapy); or
 - j) pre term infants, born before 28 weeks gestation; or
 - k) with cardiac disease, with cyanosis or failure; or
 - with diabetes; or
 - m) with Down syndrome; or
 - n) who are pre-or post-splenectomy, or with functional asplenia; or
- 3) Up to an additional four doses (as appropriate) are funded for (re-)immunisation of patients 5 years and over with HIV, for patients pre or post haematopoietic stem cell transplantation, or chemotherapy; pre- or post splenectomy; functional asplenia, pre- or post- solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, intracranial shunts, cerebrospinal fluid leaks or primary immunodeficiency; or
- For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.
- Note: please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes

Inj 30.8 mcg of pneumococcal polysaccharide serotypes 1, 3, 4,	
5. 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in 0.5ml	

5, 6A, 6D, 7F, 9V, 14, 16C, 19A, 19F and 25F in 0.5mi		
syringe0.00	10	Prevenar 13
	1	Prevenar 13

		Subsidy (Manufacturer's Price)	Fully Subsidised Per ✓	Brand or Generic Manufacturer
NELIMOCOC	CAL (PPV23) POLYSACCHARIDE VACCINE -	v [Xnharm]	rei 💌	Manulacturer
Either:		[Apham]		
cher	o three doses (as appropriate) for patients with HI notherapy; pre- or post-splenectomy or with functi plement deficiency (acquired or inherited), cochle f the following:	ional asplenia, pre- or p	oost-solid organ ti	ransplant, renal dialysis,
,	Patient is a child under 18 years for (re-)immunis	sation; and		
,	Treatment is for a maximum of two doses; and			
c)	Any of the following: i) on immunosuppressive therapy or radiation	n therany, vaccinate wh	on there is expe	cted to be a sufficient
	immune response; or	i inciapy, vaccillate wi	ien mere is expe	

- ii) with primary immune deficiencies; or
- iii) with HIV infection; or
- iv) with renal failure, or nephrotic syndrome; or
- v) who are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant); or
- vi) with cochlear implants or intracranial shunts; or
- vii) with cerebrospinal fluid leaks; or
- viii) receiving corticosteroid therapy for more than two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; or
- ix) with chronic pulmonary disease (including asthma treated with high-dose corticosteroid therapy); or
- x) pre term infants, born before 28 weeks gestation; or
- xi) with cardiac disease, with cyanosis or failure; or
- xii) with diabetes; or
- xiii) with Down syndrome; or
- xiv) who are pre-or post-splenectomy, or with functional asplenia.

Inj 575 mcg in 0.5 ml prefilled syringe (25 mcg of each

23 pneumococcal serotype)	0.00	1	Pneumovax 2	23
POLIOMYELITIS VACCINE – [Xpharm]				
Up to three doses for patients meeting either of the followin	g:			
1) For partially vaccinated or previously unvaccinated in	dividuals; or			
For revaccination following immunosuppression.				
Note: Please refer to the Immunisation Handbook for appre	opriate schedule for a	catch-up pi	rogrammes.	
Inj 80D antigen units in 0.5 ml syringe	0.00	1	✓ IPOL	
ROTAVIRUS ORAL VACCINE – [Xpharm]				
Maximum of two doses for patients meeting the following:				
1) first dose to be administered in infants aged under 14	weeks of age; and			
no vaccination being administered to children aged 24	weeks or over.			
Oral susp live attenuated human rotavirus				
1,000,000 CCID50 per dose, prefilled oral applicator	0.00	10	Rotarix	

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
VARICELLA VACCINE [CHICKENPOX VACCINE] – [Xpharm Either:	ח]			
1) Maximum of one dose for primary vaccination for eit	ther:			
 Any infant born on or after 1 April 2016; or 				
b) For previously unvaccinated children turning 1 varicella infection (chickenpox), or	1 years old on or after 1	July 2	2017, who h	ave not previously had a
2) Maximum of two doses for any of the following:				
a) Any of the following for non-immune patients:				
i) with chronic liver disease who may in fut	ure be candidates for tra	inspla	ntation; or	
ii) with deteriorating renal function before tr	ansplantation; or			
iii) prior to solid organ transplant; or				
iv) prior to any elective immunosuppression				
v) for post exposure prophylaxis who are in				
b) For patients at least 2 years after bone marrow				
c) For patients at least 6 months after completiond) For HIV positive non immune to varicella with				
e) For patients with inborn errors of metabolism a				
varicella, or	a non of major motabolic		mponoadon	
f) For household contacts of paediatric patients	who are immunocompror	mised	, or undergo	bing a procedure leading to
immune compromise where the household cor				
g) For household contacts of adult patients who h				
immunocompromised, or undergoing a proced	lure leading to immune c	compro	omise where	e the household contact
has no clinical history of varicella.			1	and of an other these
* immunosuppression due to steroid or other immunosupp 28 days	pressive inerapy must be	eiora	treatment p	beriod of greater than
Inj 1350 PFU prefilled syringe	0.00	1	 V 	arivax
		10		arivax
VARICELLA ZOSTER VIRUS (OKA STRAIN) LIVE ATTENUA	ATED VACCINE (SHING	I ES V	ACCINF1	- [Xnharm]
Funded for patients meeting either of the following criteria			inconte _j	[xpitain]
1) One dose for all people aged 65 years; or				
2) One dose for all people aged between 66 and 80 ye	ars inclusive from 1 Apri	il 2018	3 and 31 De	cember 2021.
Inj 19,400 PFU prefilled syringe plus vial	0.00	1	_	ostavax
		10	✓ Z	ostavax
Diagnostic Agents				
IUBERCULIN PPD [MANTOUX] TEST – [Xpharm] Inj 5 TU per 0.1 ml, 1 ml vial	0.00	1	1 T	ubersol
	0.00	I	▼ <u>I</u>	uber 501

- Symbols -

UK Synacthen81
3TC
- A -
A-Scabies69
Abacavir sulphate 106
Abacavir sulphate with
lamivudine 106
Abiraterone acetate 165
Acarbose11
Accarb11
Accuretic
Accuretic 10
Accuretic 20
Acetazolamide
Acetec
Acetic acid with hydroxyquinoline and
ricinoleic acid
Acetylcysteine
Aci-Jel
Aciclovir
Infection102
Sensory234
Acidex6
Acipimox55
Acitretin
Aclasta115
Actemra213
Actemra S29213
Actinomycin D152
Actrapid 10
Actrapid Penfill 10
Acupan
Adalimumab176
Adapalene62
ADR Cartridge 1.8
Adrenaline
Advantan65
Advate
Adynovate41
Afinitor
Aflibercept187
Afluria Quad
(2021 Formulation)
Afluria Quad Junior
(2021 Formulation)
AFT-Pyrazinamide
Agents Affecting the
Renin-Angiotonein Svetom 47
Renin-Angiotensin System
Disorders 119
Agents Used in the Treatment of
Poisonings
Agrylin

Albendazole	
Albey	
Albustix	.78
Alchemy Oxybutynin	.78
Aldurazyme	.29
Alecensa	158
Alectinib	158
Alendronate sodium	112
Vendronate sodium with	
colecalciferol	112
Alfacalcidol	.33
Alfamino	
Alfamino Junior	260
Alginic acid	. 6
Alglucosidase alfa	26
Alkeran	
Alkeran S29	48
Allersoothe	
Allmercap	150
Allopurinol	
Alpha-Adrenoceptor Blockers	47
Alpha-Keri Lotion	
Alphamox	
Alphamox 125	.00 Q3
Alphamox 250	03
Alprolix	30
Alu-Tab	00. A
Aluminium hydroxide	0 6
	0 E0
Alvogen	. 50
Ambrisentan	E0
Ambrisentan Mylan	
Amiloride hydrochloride	50
Amiloride hydrochloride with	.04
furosemide	E /
Amiloride hydrochloride with	54
hydrochlorothiazide	54
Aminophylline	04 101
Amiodarone hydrochloride	40
Amisulpride	
Amisulpride Mylan	
Amitriptyline	102
Amlodipine	E0
Amneal	
Amorolfine	.03
Amoxicillin Amoxicillin with clavulanic acid	.93
Amphotericin B	
Amsacrine	
AmsaLyo	
Amsidine	
Amzoate	
Anaesthetics	121
Anagrelide hydrochloride	151

Analgesics	121
Anastrozole	169
Anatrole	169
Andriol Testocaps	
Androderm	<mark>81</mark>
Anoro Ellipta	
Antabuse	143
Antacids and Antiflatulents	6
Anthelmintics	90
Antiacne Preparations	62
Antiallergy Preparations	225
Antianaemics	37
Antiandrogen Oral	
Contraceptives	76
Antiarrhythmics	
Antibacterials	
Antibacterials Topical	
Anticholinergic Agents	
Anticholinesterases	
Antidepressants	
Antidiarrhoeals	
Antiepilepsy Drugs	
Antifibrinolytics, Haemostatics and	
Local Sclerosants	38
Antifibrotics	
Antifungals	
Antifungals Topical	63
Antihistamines	
Antihypotensives	50
Antimalarials	99
Antimigraine Preparations	131
Antinausea and Vertigo Agents	131
Antipruritic Preparations	64
Antipsychotics	132
Antiretrovirals	
Antirheumatoid Agents	112
Antispasmodics and Other Agents	
Altering Gut Motility	<mark>8</mark>
Antithrombotic Agents	41
Antithymocyte globulin	
(equine)	176
Antitrichomonal Agents	100
Antituberculotics and	
Antileprotics	100
Antiulcerants	
Antivirals	
Anxiolytics	
Anzatax	
Apidra	
Apidra SoloStar	11
Apo-Azithromycin	91
Apo-Bromocriptine	
Apo-Ciclopirox	
Apo-Diclo SR	111

Apo-Diltiazem CD52
Apo-Doxazosin
Apo-Folic Acid
Apo-Furosemide53
Apo-Megestrol 166
Apo-Metoprolol51
Apo-Nadolol51
Apo-Oxybutynin78
Apo-Pindolol51
Apo-Prazosin47
Apo-Prednisone81
Apo-Primidone129
Apo-Propranolol51
Apo-Pyridoxine
Apo-Selegiline S29120
Apo-Temozolomide 156
Apomorphine hydrochloride
Aprepitant
Apresoline
Aptamil AllerPro SYNEO 1
Aptamil AllerPro SYNEO 2
Aptamil AllerPro St NEO 2
Aptamil Gold+ Pepti Junior
Aqueous cream
Aratac
Arava
Arginine27
Aripiprazole132
Aripiprazole Sandoz 132
Aristocort65
Arrotex-Prazosin S2947
Arrow - Lattim
Arrow-Amitriptyline 126
Arrow-Bendrofluazide54
Arrow-Brimonidine
Arrow-Diazepam136
Arrow-Doxorubicin
Arrow-Losartan &
Hydrochlorothiazide 48
Arrow-Norfloxacin 110
Arrow-Ornidazole
Arrow-Quinapril 10
Arrow-Quinapril 20
Arrow-Quinapril 5
Arrow-Roxithromycin
Arrow-Timolol
Arrow-Topiramate
Arrow-Tramadol
Arsenic trioxide
Asacol
Asamax
Ascorbic acid
Aspen Adrenaline
Aspirin
Blood41
Nervous121
Asthalin

Atazanavir sulphate 107
Atenolol50
Atenolol AFT50
Atenolol AFT S2950
ATGAM176
Ativan136
Atomoxetine139
Atorvastatin55
Atropine sulphate
Cardiovascular
Sensory
Atropt
All Synacthen81
Aubagio138 Augmentin93
Augmentin
AutoSoft 3023
AutoSoft 9023
AutoSoli 9025 Avelox
Avenox
Avonex Pen
Azacitidine148
Azacitidine Dr Reddy's148
Azamun
Azathioprine169
Azilect
Azithromycin
Azopt
AZT
- B -
3-D Micro-Fine15
3-D Ultra Fine16
3-D Ultra Fine II16
Bacillus Calmette-Guerin (BCG)
vaccine 176
Bacillus Calmette-Guerin
vaccine 265
Baclofen
Bactroban63
Balance
Basic AquaCream66 BCG Vaccine265
Beclazone 100226
Beclazone 250226
Beclazone 50226
DecidZone 50
Beclomethasone dipropionate
Bee venom allergy treatment
Bendrofluazide54
Bendroflumethiazide
[Bendrofluazide]54
Benzathine benzylpenicillin
Benzatropine mesylate
Benzbromaron AL 100

Benzbromarone	117
Benztrop	20
Benzydamine hydrochloride	32
Benzylpenicillin sodium [Penicillin	
G]	93
Beta Cream	64
Beta Ointment	64
Beta Scalp	71
Beta-Adrenoceptor Agonists	228
Beta-Adrenoceptor Blockers	
Betadine	67
Betadine Skin Prep	67
Betaferon	137
Betahistine dihydrochloride	131
Betaine	
Betaloc CR	50
Betamethasone dipropionate	6/
Betamethasone dipropionate with	.04
calcipotriol	60
	09
Betamethasone sodium phosphate with betamethasone acetate	00
Betamethasone valerate	71
Detametriasone valerate with a diverse	/ 1
Betamethasone valerate with sodium	~~
fusidate [fusidic acid]	65
Betaxolol	
Betnovate	64
Betoptic	236
Betoptic S	
Bexsero	
Bezafibrate	
Bezalip	55
Bezalip Retard	
Bicalutamide	
Bicillin LA	
BiCNU	47
Bicnu Heritage	47
Bile and Liver Therapy	9
Biltricide	
Bimatoprost	236
Bimatoprost Multichem	
Binarex	66
Binocrit	38
Biodone	23
Biodone Extra Forte	23
Biodone Forte	23
Bisacodyl	
Bisoprolol fumarate	
Bisoprolol Mylan	
BK Lotion	67
Bleomycin sulphate	
Blood Colony-stimulating	
Factors	44
Blood glucose diagnostic test	
meter	14
Blood glucose diagnostic test	
strip	15

Blood glucose test strips (visually	
impaired)	15
Blood Ketone Diagnostic Test	
Strip	13
Bonjela	32
Boostrix	265
Bortezomib	
Bortezomib Dr Reddy's S29	152
Bortezomib Dr-Reddy's	152
Bortezomib Juno	152
Bortezomib Juno S29	152
Bosentan	<mark>58</mark>
Bosentan Dr Reddy's	
Bplex	33
Breo Ellipta	
Brevinor 1/28	75
Bricanyl Turbuhaler	
Brilinta	42
Brimonidine tartrate	237
Brimonidine tartrate with timolol	
maleate	
Brinzolamide	
Brolene	234
Bromocriptine mesylate	119
Brufen SR	111
BSF Clomipramine Teva	
BSF Febuxostat multichem	
BSF Folic Acid Mylan	239
BSF Lopinavir/Ritonavir Mylan	239
Buccastem	132
Budesonide	
Alimentary	6
Respiratory22	6, 232
Budesonide with eformoterol	
Bumetanide	
Buprenorphine Naloxone BNM	
Buprenorphine with naloxone	142
Bupropion hydrochloride	143
Burinex	
Burinex S29	
Buscopan	8
Buspirone hydrochloride	
Buspirone Viatris	
Busulfan	147
Cabergoline	00
Cabergoline	
Caffeine citrate	
Calamine Calamine-AFT	04
Calci-Tab 500	
Calcipotriol	
Calcitriol	
Calcitriol-AFT	
Calcium carbonate	.0,34

Calcium Channel Blockers	52
Calcium Disodium Versenate	
Calcium folinate	1/0
Calcium Folinate Ebewe	149
Calcium Folinate Sandoz	149
Calcium Folinate Sandoz S29	
Calcium gluconate	34
Calcium Homeostasis	79
Calcium lactate gluconate with	
calcium carbonate	34
Calcium polystyrene sulphonate	46
Calcium Resonium	
Calcium-Sandoz Forte	34
Calogen	246
Candesartan cilexetil	18
Candestar	
Canesten	
Capecitabine	
Capercit	
Capoten	47
Capsaicin	
Musculoskeletal	
Nervous	122
Captopril	
Carafate	9
Carbaccord	147
Carbamazepine	
Carbimazole	
Carbomer	
Carboplatin	
Carboplatin Ebewe	147
Carbosorb-X	
Cardinol LA	
Cardizem CD	
CareSens Dual	14
CareSens N14	-15
CareSens N POP	14
CareSens N Premier	14
CareSens PRO	15
Carmellose sodium with gelatin and	
pectin	
Carmustine	
Carvedilol	
Carvedilol Sandoz	
Casirivimab and imdevimab	
Catapres	53
CeeNU	147
Cefaclor monohydrate	90
Cefalexin	90
Cefalexin Sandoz	90
Cefazolin	
Ceftriaxone	
Ceftriaxone-AFT	90
Cefuroxime axetil	
Celebrex	
Celecoxib	
	114

Celecoxib Pfizer	112
Celestone Chronodose	
Cellcept	160
Centrally-Acting Agents	100
Cephalexin ABM	00
	90
Cetirizine hydrochloride	226
Cetomacrogol	66
Cetomacrogol with glycerol	66
Cetomacrogol-AFT	66
Cetuximab	
Charcoal	239
Chemotherapeutic Agents	146
Chickenpox vaccine	276
Chlorafast	234
Chlorambucil	147
Chloramphenicol	234
Chlorothiazide	54
Chlorpheniramine maleate	
Chlorpromazine hydrochloride	100
Chlortelidere [Chlorthelidere]	100
Chlortalidone [Chlorthalidone]	54
Chlorthalidone	54
Chlorvescent	
Choice Load 375	
Choice TT380 Short	74
Choice TT380 Standard	74
Choline salicylate with cetalkonium	
chloride	32
Ciclopirox olamine	00
Ciclosporin	221
Ciclosporin Cilazapril	221 47
Ciclosporin Cilazapril Cilicaine	221 47 94
Ciclosporin Cilazapril Cilicaine Cilicaine VK	221 47 94 94
Ciclosporin Cilazapril Cilicaine Cilicaine VK Cinacalcet	221 94 94 94 79
Ciclosporin Cilazapril Cilicaine Cilicaine VK Cinacalcet Cipflox	221 94 94 94 79
Ciclosporin Cilazapril Cilicaine Cilicaine VK Cinacalcet Cipflox Ciprofloxacin	221 94 94 94 79 95
Ciclosporin Cilazapril Cilicaine Cilicaine VK Cinacalcet Cipflox Ciprofloxacin Infection	221 94 94 94 79 95
Ciclosporin Cilazapril Cilicaine Cilicaine VK Cinacalcet Cipflox Ciprofloxacin Infection Sensory	221 94 94 95 95 95 234
Ciclosporin Cilazapril Cilicaine VK Cinacalcet Cipflox Ciprofloxacin Infection Sensory Ciprofloxacin Teva	221 47 94 94 95 95 95 234 234
Ciclosporin Cilazapril Cilicaine VK Cinacalcet. Cipflox. Ciprofloxacin Infection Sensory. Ciprofloxacin Teva. Ciprofloxacin Teva.	221 47 94 94 95 95 95 234 234 138
Ciclosporin Cilazapril Cilicaine VK Cinacalcet. Cipflox. Ciprofloxacin Infection Sensory. Ciprofloxacin Teva. Ciprofloxacin Teva. Ciprofloxacin Teva. Ciprofloxacin Teva. Ciprofloxacin Teva.	221 47 94 94 79 95 95 234 234 138 147
Ciclosporin Cilazapril Cilicaine VK Cinacalcet. Cipflox. Ciprofloxacin Infection Sensory Ciprofloxacin Teva Ciprofloxacin Teva Ciprofloxacin Teva Cisplatin. Cisplatin.	221 47 94 94 95 95 234 234 138 147 147
Ciclosporin Cilazapril Cilicaine VK Cinacalcet. Cipflox. Ciprofloxacin Infection Sensory Ciprofloxacin Teva Ciprofloxacin Teva Ciprofloxacin Teva Cisplatin. Cisplatin. Cisplatin Ebewe. Citalooram hydrobromide	221 47 94 94 79 95 95 234 234 138 147 147 127
Ciclosporin Cilazapril Cilicaine VK Cinacalcet. Cipflox. Ciprofloxacin Infection Sensory Ciprofloxacin Teva Ciprofloxacin Teva Cisplatin. Cisplatin Ebewe. Citalopram hydrobromide Cladribine	221 47 94 94 79 95 95 234 234 138 147 147 127
Ciclosporin Cilazapril Cilicaine VK Cinacalcet Cipflox Ciprofloxacin Infection Sensory Ciprofloxacin Teva Ciprofloxacin Teva Ciprofloxacin Teva Ciprofloxacin Teva Cisplatin Cisplatin Ebewe Citalopram hydrobromide Cladribine Clarithromycin	221 47 94 95 95 95 95 234 138 147 149
Ciclosporin Cilazapril Cilicaine VK Cinacalcet. Cipflox. Ciprofloxacin Infection Sensory Ciprofloxacin Teva Ciprofloxacin Teva Cisplatin. Cisplatin Ebewe. Citalopram hydrobromide Cladribine	221 47 94 95 95 95 95 234 138 147 149
Ciclosporin Cilazapril Cilicaine VK Cinacalcet Cipflox Ciprofloxacin Infection Sensory Ciprofloxacin Teva Ciprofloxacin Teva Ciprofloxacin Teva Ciprofloxacin Teva Cisplatin Cisplatin Ebewe Citalopram hydrobromide Cladribine Clarithromycin	221 47 94 95 95 95 234 234 138 147 147 127 99
Ciclosporin Cilazapril Cilicaine VK Cinacalcet Cipflox Ciprofloxacin Infection Sensory Ciprofloxacin Teva Ciprofloxacin Teva Ciprofloxacin Teva Ciprofloxacin Teva Cisplatin Cisplatin Ebewe Citalopram hydrobromide Cladribine Clarithromycin Alimentary Infection	221 47 94 99 95 234 138 147 147 149 99 91
Ciclosporin Cilazapril Cilicaine VK Cinacalcet Cipflox Ciprofloxacin Infection Sensory Ciprofloxacin Teva Circadin Cisplatin Cisplatin Ebewe Citalopram hydrobromide Cladribine Clarithromycin Alimentary Infection Clexane	221
Ciclosporin Cilazapril Cilicaine VK Cinacalcet Cipflox Ciprofloxacin Infection Sensory Ciprofloxacin Teva Ciprofloxacin Teva Ciprofloxacin Teva Cisplatin Cisplatin Ebewe Citalopram hydrobromide Cladribine Cladribine Cladribine Cladribine Clarithromycin Alimentary Infection Clexane Clexane Forte	221
Ciclosporin Cilazapril Cilicaine VK Cinacalcet. Cipflox Ciprofloxacin Infection Sensory Ciprofloxacin Teva. Circadin Cisplatin Ebewe Cisplatin Ebewe Cisplatin Ebewe Cialopram hydrobromide Cladribine Cladribine Cladribine Clarithromycin Alimentary Infection Clexane Forte Clindamycin	221
Ciclosporin Cilazapril Cilicaine VK Cinacalcet. Cipflox. Ciprofloxacin Infection Sensory Ciprofloxacin Teva. Ciprofloxacin Teva. Circadin Cisplatin Ebewe. Citalopram hydrobromide Cidalopram hydrobromide Cladribine Cladribine Cladribine Cladribine Clarithromycin Alimentary Infection Clexane Forte Clindamycin. Clinicians	221
Ciclosporin Cilazapril Cilicaine VK Cinacalcet. Cipfolox. Ciprofloxacin Infection Sensory Ciprofloxacin Teva. Circadin Cisplatin Ebewe. Citalopram hydrobromide Cladribine Cladribine Cladribine Cladribine Cladribine Cladribine Cladribine Cladribre Cladriber Cladribre Cladrib	221
Ciclosporin Cilazapril Cilicaine VK Cinacalcet. Cipfolox. Ciprofloxacin Infection Sensory Ciprofloxacin Teva. Circadin Cisplatin Ebewe. Citalopram hydrobromide Cladribine Cladribine Cladribine Cladribine Cladribine Cladribine Cladribine Cladribre Cladriber Cladribre Cladrib	221
Ciclosporin Cilazapril Cilicaine VK Cinacalcet Cipflox Ciprofloxacin Infection Sensory Ciprofloxacin Teva Ciprofloxacin Teva Cisplatin	221 47 94 95 234 138 147 147 147 99 91
Ciclosporin Cilazapril Cilicaine VK Cinacalcet. Cipflox. Ciprofloxacin Infection Sensory Ciprofloxacin Teva. Circadin Cisplatin Ebewe. Citalopram hydrobromide Cladribine Cladribine Cladribine Cladribine Cladribine Cladribine Cladribine Cladribre Cladriber Cladribre Cladribr	221 47 94 95 95 234 234 234 138 147 147 149 91

Clomazol

Ciomazoi
Dermatological63
Genito-Urinary76
Clomifene citrate
Clomipramine hydrochloride126
Clomipramine Teva 126
Clonazepam 127–128, 136
Clonidine53
Clonidine BNM53
Clonidine hydrochloride
Clonidine Teva
Clopidogrel
Clopidogrel Multichem
Clopine
Clopixol
Clotrimazole
Dermatological63
Genito-Urinary76
Clozapine133
Clozaril
Co-trimoxazole97
Coal tar70
Coal tar with allantoin, menthol,
phenol and sulphur
Coal tar with salicylic acid and
sulphur
Coco-Scalp
Codeine phosphate
Extemporaneous242
Nervous122
Coenzyme Q1028
Colchicine 117
Colecalciferol
Colestid55
Colestipol hydrochloride55
Colgout
Colifoam7
Colistin sulphomethate95
Colistin-Link
Collodion flexible
Colloidal bismuth subcitrate
Colofac
Coloxyl
Combigan
Compound electrolytes46
Compound electrolytes with glucose
[Dextrose] 46
Compound hydroxybenzoate242
Comtan119
Concerta 141
Condoms73
Condyline71
Contraceptives - Hormonal74
Contraceptives - Non-hormonal72
Copaxone
Corticosteroids and Related Agents
Contrologication and Trolated Agents

	80
for Systemic Use Corticosteroids Topical	64
Cortifoam	7
Cosentyx	
Cosmegen	. 152
Coumadin	
Country Life	29
Coversyl	
Creon 10000	24
Creon 25000	24
Creon Micro	
Crotamiton	
Crystaderm	62
Curam	
Curam Duo 500/125	
Cvite	
Cyclizine hydrochloride	.131
Cyclizine lactate	.131
Cyclogyl	.237
Cyclonex	.147
Cyclopentolate hydrochloride	.237
Cyclophosphamide	147
Cyclorin	100
Cycloserine	
Cyproterone acetate	
	01
Cyproterone acetate with ethinyloestradiol	70
etninyloestradioi	/6
Cystadane	27
Cytarabine	149
Cytotec	8
	8
Cytotec Cytoxan - D -	8 .147
Cytotec Cytoxan - D -	8 .147
Cytotec Cytoxan	8 .147 .112
Cytotec Cytoxan	8 .147 .112 44
CytotecCytoxan	8 .147 .112 44 .152
CytotecCytoxan	8 .147 .112 44 .152 .152
CytotecCytoxan	8 .147 .112 44 .152 .152 .152
CytotecCytoxan	8 .147 .112 44 .152 .152 .152 69
CytotecCytoxan	8 .147 .112 44 .152 .152 .152 69 69
CytotecCytoxan	8 .147 .112 44 .152 .152 69 69 69
Cytotec	8 .147 .112 44 .152 .152 69 69 64 95
CytotecCytoxan	8 .147 .112 44 .152 .152 69 69 64 95 61
Cytotec	8 .147 .112 44 .152 .152 69 69 64 95 61
CytotecCytoxan	8 .147 .112 44 .152 .152 .152 69 64 95 .118 .118
CytotecCytoxan	8 .147 .112 .152 .152 .152 69 69 64 95 .118 .118 .118
CytotecCytoxan	8 .147 .112 .152 .152 .152 69 69 64 95 .118 .118 11
CytotecCytotec	8 .147 .112 .152 .152 .152 69 69 95 .118 .118 .118 11 54
CytotecCytoxan	
Cytotec	
CytotecCytoxan	
Cytotec	

DBL Aminophylline	.231
DBL Bleomycin Sulfate	. 152
DBL Carboplatin	. 147
DBL Cisplatin	. 147
DBL Dacarbazine	. 152
DBL Desferrioxamine Mesylate for In	nj
BP	240
DBL Docetaxel	
DBL Ergometrine	
DBL Gemcitabine	150
DBL Gentamicin	
DBL Heparin Sodium	44
DBL Leucovorin Calcium	149
DBL Methotrexate Onco-Vial	
DBL Morphine Sulphate	124
DBL Naloxone Hydrochloride	239
DBL Octreotide	167
DBL Pethidine Hydrochloride	
DBL Vincristine Sulfate	
Decozol	
Deferasirox	230
Deferiprone	
Denosumab	112
Deolate	00
Deoxycoformycin	
Depo-Medrol	
Depo-Provera	
Depo-Testosterone	
Deprim	
Dermol6	5.71
Desferrioxamine mesilate	.240
Desmopressin	
Desmopressin acetate	88
Desmopressin-PH&T	88
Desuric	
Detection of Substances in	
Urine	78
Dexamethasone	
Hormone	80
Sensory	.235
Dexamethasone phosphate	80
Dexamethasone Phosphate	
Panpharma	80
Dexamethasone with framycetin and	Ł
gramicidin	234
Dexamethasone with neomycin	
sulphate and polymyxin B	
sulphate	235
Dexamfetamine sulfate	. 139
Dexmethsone	
Dextrochlorpheniramine	
maleate	
Dextrose4	
DHC Continus	
Diabetes	10
Diabetes Management	13

INDEX: Generic Ch	emicals and	d Brands
-------------------	-------------	----------

Diacomit129
Diagnostic Agents276
Diamide Relief6
Diamox
Diasip247
Diason RTH247
Diazepam 128, 136
Diazoxide10
Dibenzyline
Diclofenac Sandoz111
Diclofenac sodium
Musculoskeletal 111
Sensory235
Differin
Difflam
Diflucan
Digestives Including Enzymes24
Digoxin
Dihydrocodeine tartrate
Dilantin
Dilantin Infatab
Diltiazem hydrochloride
Dimethicone
Dimethyl fumarate
Dipentum
Diphtheria, tetanus and pertussis
vaccine
Diphtheria, tetanus, pertussis and
polio vaccine
polio vaccine 265 Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine 266 Diprosone 64 Diprosone OV 64 Dipyridamole 42 Disopyramide phosphate 49 Disuffiram 143 Diuretics 53 Docetaxel 152 Docetaxel Accord 152 Docusate Sodium 25 Dolucegravir 107 Domperidone 132 Donepezil hydrochloride 142
polio vaccine 265 Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine 266 Diprosone 64 Diprosone OV 64 Dipyridamole 42 Disopyramide phosphate 49 Disuffiram 143 Diuretics 53 Docetaxel 152 Docetaxel Accord 152 Docusate Sodium 25 Dolutegravir 107 Domperidone 132 Donepezil hydrochloride 142
polio vaccine 265 Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine 266 Diprosone 64 Diprosone OV 64 Diprosone OV 64 Diprosone OV 64 Diprosone OV 64 Diprosone 42 Disopyramide phosphate 49 Disulfiram 143 Diuretics 53 Docetaxel 152 Docetaxel Accord 152 Docetaxel Sandoz 152 Docusate sodium 25 Dolutegravir 107 Domperzil Nydrochloride 142 Donepezil Nydrochloride 142 Dornese alfa 231
polio vaccine 265 Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine 266 Diprosone 64 Diprosone OV 64 Diprosone OV 64 Diprosone 42 Disopyramide phosphate 49 Disulfiram 143 Diuretics 53 Docetaxel 152 Docetaxel Accord 152 Docusate sodium 25 Docusate sodium 25 Dolutegravir 107 Domperidone 132 Donepezil hydrochloride 142 Donepezil Chex 142 Donepezil Agaz 142 Donepezil Rex 142 Dortimopt 236
polio vaccine 265 Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine 266 Diprosone 64 Diprosone OV 64 Disopyramide phosphate 49 Disulfiram 143 Diuretics 53 Docetaxel 152 Docetaxel Accord 152 Docusate Sodium 25 Docusate sodium with sennosides 25 Dolutegravir 107 Domperidone 132 Donepezil hydrochloride 142 Dornepezil-Rex 142 Dornase alfa 231 Dortimopt 236
polio vaccine 265 Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine 266 Diprosone 64 Diprosone OV 64 Diprosone OV 64 Diprosone 42 Disopyramide phosphate 49 Disulfiram 143 Divretics 53 Docetaxel 152 Docetaxel Accord 152 Docusate sodium 25 Docusate sodium with sennosides 25 Dolutegravir 107 Domperidone 132 Donepezil-Rex 142 Donepezil-Rex 142 Dorase alfa 231 Dortimopt 236 Dorzolamide hydrochloride 236 Dorzolamide with timolol 236
polio vaccine 265 Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine 266 Diprosone 64 Diprosone OV 64 Dipyridamole 42 Disopyramide phosphate 49 Disulfiram 143 Diuretics 53 Docetaxel 152 Docetaxel Accord 152 Docetaxel Sandoz 152 Docusate sodium 25 Docusate sodium 25 Dolutegravir 107 Domperidone 132 Donepezil hydrochloride 142 Dornepezil-Rex 142 Dornase alfa 231 Dortimopt 236 Dorzolamide hydrochloride 236 Dorzolamide with timolol 236
polio vaccine 265 Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine 266 Diprosone 64 Diprosone OV 64 Disufiram 42 Disufiram 143 Diuretics 53 Docetaxel Accord 152 Docetaxel Sandoz 152 Docusate sodium with sennosides 25 Dolutegravir 107 Domperidone 132 Donepezil hydrochloride 142 Dornepezil-Rex 142 Dornase alfa 236 Dorzolamide hydrochloride 236 <t< td=""></t<>
polio vaccine 265 Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine 266 Diprosone 64 Diprosone OV 64 Dipyridamole 42 Disopyramide phosphate 49 Disulfiram 143 Diuretics 53 Docetaxel 152 Docetaxel Accord 152 Docetaxel Sandoz 152 Docusate sodium 25 Docusate sodium 25 Dolutegravir 107 Domperidone 132 Donepezil hydrochloride 142 Dornepezil-Rex 142 Dornase alfa 231 Dortimopt 236 Dorzolamide hydrochloride 236 Dorzolamide with timolol 236

Dothiepin	126
Doxazosin	47
Doxazosin Clinect	47
Doxine	94
Doxorubicin Ebewe	153
Doxorubicin hydrochloride	
Doxycycline	
DP Lotion	
DP Lotn HC	
DP-Allopurinol	
Dr Reddy's Omeprazole	9
Drofate	
Druas Affectina Bone	
Metabolism	112
Dual blood glucose and blood ketor	
diagnostic test meter	
Dulaglutide	
Dulcolax SP Drop	
Duocal Super Soluble Powder	
Duolin	
Duolin HFA	
DuoResp Spiromax	227
Duride	
-E-	
e-chamber La Grande	232
e-chamber Mask	232
e-chamber Turbo	232
E-Mycin	
Ear Preparations	
Ear/Eye Preparations	
Easiphen Liquid	250
Econazole nitrate	63
Efavirenz	
Efavirenz with emtricitabine and	100
tenofovir disoproxil	107
Eformoterol fumarate	. 107
Eformoterol fumarate dihydrate	221
Eftrenonacog alfa [Recombinant	00
factor IX]	38
Efudix	
Egopsoryl TA	/0
Elaprase	28
Eldepryl	120
Elecare	260
Elecare LCP	260
Electral	
Elelyso	
Elemental 028 Extra	
Elidel	
Elocon	
Elocon Alcohol Free	
Eltrombopag	
Eltroxin	
EMB Fatol	
Emend Tri-Pack	
Emicizumab	39

EMLA12	21
Empagliflozin1	3
Empagliflozin with metformin	
hydrochloride 1	3
Emtricitabine10)7
Emtricitabine with tenofovir	
disoproxil 10	м
Emtriva 10	יק דו
Emulsifying ointment	
Emulsifying Ointment ADE6	00
Enalapril maleate4	7
Enbrel 16	5 9
Endocrine Therapy 16	65
Endoxan14	7
Engerix-B26	67
Enlafax XR 12	27
Enoxaparin sodium4	3
Enstilar	
Ensure	
Ensure Plus	5
Elisule Flus	. v
Ensure Plus HN	•4
Ensure Plus RTH	94
Ensure Two Cal HN RTH25	
Entacapone 11	9
Entapone 11	
Entecavir10)1
Entecavir Sandoz 10	
Entocort CIR	6
Entresto 24/264	
Entresto 49/51 4	8
Entresto 97/103 4	
Epilim12	
Epilim Crushable12	
Epilim IV12	
Epilim S/F Liquid12	q
Epilim Syrup	0
Epirubicin Ebewe15	2
Epirubicin hydrochloride	:0
Eplerenone5	: 4
Epierenone	94 00
Epoetin alfa	
Epoprostenol	0
Eptacog alfa [Recombinant factor VIIa]4	
VIIa]4	0
ERA)2
Erbitux	88
Ergometrine maleate7	
Erlotinib15	59
Erythrocin IV9)2
Erythromycin (as lactobionate)9)2
Erythromycin ethyl succinate9	
Erythromycin stearate9	
Esbriet	
Escitalopram12	
Escitalopram (Ethics)	7
Eskazole	., ∩
Essential Generics	
	v

Essential Prednisolone8
Estradiol TDP Mylan82
Estradot
Estradot 50 mcg82
Estrofem
Etanercept
Ethambutol hydrochloride
Ethics Aspirin
Ethics Aspirin EC41
Ethics Lisinopril
Ethinyloestradiol
Ethinyloestradiol with
desogestrel74
Ethinyloestradiol with
levonorgestrel 75
Ethinyloestradiol with
norethisterone75
Ethosuximide 128
Etopophos 153
Etoposide153
Etoposide phosphate153
Etravirine
Eumovate
Everet
Everolimus
Evista
Exemestane
Exjade
Extemporaneously Compounded
Extemporaneously Compounded Preparations and
Extemporaneously Compounded Preparations and Galenicals
Extemporaneously Compounded Preparations and Galenicals 242 Eye Preparations 234 Eylea 187 Ezetimibe 56 Ezetimibe 56 Ezetimibe Sandoz 56 Ezetimibe Sandoz 57 - F - Factor eight inhibitor bypassing fraction 40 Famotidine 9 Faslodex Fabolex 166 Febuxostat 117 Feed Thickener Karicare 117
Extemporaneously Compounded Preparations and Galenicals 242 Eye Preparations 234 Eylea 187 Ezetimibe 56 Ezetimibe 56 Ezetimibe Sandoz 56 56 Ezetimibe with simvastatin 57 - F - Factor eight inhibitor bypassing fraction 40 Famotidine 9 Famotidine Faslodex 166 Febuxostat 117 Febuxostat multichem 117 Feduxostat 117 Feed Thickener Karicare Aptamil 257
Extemporaneously Compounded Preparations and Galenicals 242 Eye Preparations 234 Eylea 187 Ezetimibe 56 Ezetimibe 56 Ezetimibe Sandoz 56 57 - F - Factor eight inhibitor bypassing fraction 40 9 Famotidine 9 9 Faslodex 166 Febuxostat 117 Febuxostat 117 Feed Thickener Karicare Aptamil 257 FEIBA NF 40 40
Extemporaneously Compounded Preparations and Galenicals 242 Eye Preparations 234 Eylea 187 Ezetimibe 56 56 Ezetimibe Sandoz 56 Ezetimibe with simvastatin 57 - F - Factor eight inhibitor bypassing fraction 40 Famotidine 9 Famotidine 9 Faslodex 166 Febuxostat 117 Feed Thickener Karicare Aptamil 257 FEIBA NF 40 Felo 10 ER 52 52 52 53
Extemporaneously Compounded Preparations and Galenicals 242 Eye Preparations 234 Eylea 187 Ezetimibe 56 Ezetimibe Sandoz 56 Ezetimibe Sandoz 57 - F - Factor eight inhibitor bypassing fraction 40 Famotidine 9 Famotidine 9 Faslodex 166 Febuxostat 117 Feed Thickener Karicare Aptamil 257 FEIBA NF 40 Felo 10 ER 52 Felo 5 ER 52 52
Extemporaneously Compounded Preparations and Galenicals 242 Eye Preparations 234 Eylea 187 Eyelea 187 Ezetimibe 56 Ezetimibe Sandoz 56 Ezetimibe 57 Eyelea - F - Factor eight inhibitor bypassing fraction 40 Famotidine 9 Famotidine 9 Faslodex 166 Febuxostat 117 Feduxostat 117 Febuxostat 117 Fela NF 40 Factorial 257 FEIBA NF 40 Felo 10 ER 52 Felo 15 ER 52 Felo 15 ER 52 Felo 16 ER 52 Felo 10 ER 52 Felodipine 52 Felodipine 52
Extemporaneously Compounded Preparations and Galenicals 242 Eye Preparations 234 Eylea 187 Ezetimibe 56 Ezetimibe Sandoz 56 Ezetimibe Sandoz 57 - F - Factor eight inhibitor bypassing fraction 40 Famotidine 9 Famotidine 9 Faslodex 166 Febuxostat 117 Feed Thickener Karicare Aptamil 257 FEIBA NF 40 Felo 10 ER 52 Felo 5 ER 52 52
Extemporaneously Compounded Preparations and Galenicals 242 Eye Preparations 234 Eylea 187 Ezetimibe 56 Ezetimibe Sandoz 56 Ezetimibe With simvastatin 57 - F - Factor eight inhibitor bypassing fraction 40 Famotidine 9 Famotidine 9 Faslodex 166 Febuxostat 117 Feed Thickener Karicare Aptamil. 257 FEIBA NF 40 75 Felo 10 ER 52 Felo 5 ER 52 Felo 5 ER 52 Felodipine 52 Felodipine 52 Felodipine 52
Extemporaneously Compounded Preparations and Galenicals 242 Eye Preparations 234 Eylea 187 Ezetimibe 56 Ezetimibe Sandoz 56 Ezetimibe Sandoz 57 - F - Factor eight inhibitor bypassing fraction 40 Famotidine 9 Faslodex 166 Febuxostat 117 Febuxostat 117 Febuxostat 257 FEIBA NF 40 Felo 10 ER 52 Felo 5 ER 52 Felodipine 52 Felodipine 52 Fentanyl 123
Extemporaneously Compounded Preparations and Galenicals 242 Eye Preparations 234 Eylea 187 Ezetimibe 56 Ezetimibe Sandoz 56 Ezetimibe Sandoz 57 - F - Factor eight inhibitor bypassing fraction 40 Famotidine 9 Faslodex 166 Febuxostat 117 Febuxostat 117 Febuxostat 117 Febuxostat 117 Febuxostat 52 Felo Thickener Karicare Aptamil Aptamil 257 Felba NF 40 Felo 10 ER 52 Felo 5 ER 52 Felodipine 52 Felodipine 52 Fentanyl 123 Fentanyl 213
Extemporaneously Compounded Preparations and Galenicals 242 Eye Preparations 234 Eylea 187 Ezetimibe 56 Ezetimibe Sandoz 56 Ezetimibe Sandoz 57 - F - Factor eight inhibitor bypassing fraction 40 Famotidine 9 Faslodex 166 Febuxostat 117 Felo A D FR 40 Felo 10 ER 52 Felo 5 ER 52 Felodipine 52 Felodipine 52 Fentanyl 123 Fentanyl 123 Fentanyl 123 Ferinject 35
Extemporaneously Compounded Preparations and Galenicals 242 Eye Preparations 234 Eylea 187 Ezetimibe 56 Ezetimibe Sandoz 56 Ezetimibe Sandoz 57 - F - Factor eight inhibitor bypassing fraction 40 Famotidine 9 Faslodex 166 Febuxostat 117 Febuxostat 117 Febuxostat 117 Febuxostat 117 Febuxostat 52 Felo Thickener Karicare Aptamil Aptamil 257 Felba NF 40 Felo 10 ER 52 Felo 5 ER 52 Felodipine 52 Felodipine 52 Fentanyl 123 Fentanyl 213

Larra L Taba	05
Ferro-F-Tabs	
Ferro-tab	
Ferrograd	35
Ferrosig	36
Ferrous fumarate	35
Ferrous fumarate with folic acid	
Ferrous sulfate	35
Fexofenadine hydrochloride	226
Fibro-vein	
Filgrastim	
Finasteride	
Fingolimod	
Firazyr	
Flagyl	
FlagyI-S	. 100
Flamazine	63
Flecainide acetate	
Flecainide BNM	
Flecainide Controlled Release	
Teva	40
Fleet Bleese bate Freeze	49
Fleet Phosphate Enema	26
Flixonase Hayfever & Allergy	
Flixotide	227
Flixotide Accuhaler	227
Florinef	80
Fluad Quad	
(2021 Formulation)	269
Fluanxol	
Flucil	
Flucil	94
Flucloxacillin	94 94
Flucloxacillin Flucloxacillin-AFT	94 94 94
Flucloxacillin Flucloxacillin-AFT Flucloxin	94 94 94 94
Flucloxacillin Flucloxacillin-AFT Flucloxin Flucon	94 94 94 94 235
Flucloxacillin Flucloxacillin-AFT Flucloxin Flucon Fluconazole	94 94 94 235 97
Flucloxacillin Flucloxacillin-AFT Flucloxin Flucon Fluconazole Fludara Oral	94 94 94 235 97 149
Flucloxacillin Flucloxacillin-AFT Flucloxin Flucon Fluconazole Fludara Oral Fludarabine Ebewe	94 94 94 235 97 149 149
Flucloxacillin Flucloxacillin-AFT Flucloxin Flucon Fluconazole Fludara Oral Fludarabine Ebewe Fludarabine phosphate	94 94 94 235 97 149 149 149
Flucloxacillin Flucloxacillin-AFT Flucloxin Flucon Fluconazole Fludara Oral Fludarabine Ebewe Fludarabine phosphate	94 94 94 235 97 149 149 149
Flucloxacillin Flucloxacillin-AFT Flucloxin Flucon Fluconazole Fludara Oral Fludarabine Ebewe Fludarabine phosphate Fludarocortisone acetate	94 94 94 235 97 149 149 149 80
Flucloxacillin Flucloxacillin-AFT Flucloxin Flucon Fluconazole Fludara Oral Fludarabine Ebewe Fludarabine phosphate Fludrocortisone acetate Fludrocortisone acetate Fludas and Electrolytes	94 94 94 235 97 149 149 149 80 45
Flucloxacillin Flucloxacillin-AFT Flucloxin Flucon Fluconazole Fludara Oral Fludarabine Ebewe Fludarabine phosphate Fludarabine phosphate Fludrocortisone acetate Fludas and Electrolytes Flumetasone pivalate	94 94 94 235 97 149 149 149 80 45
Flucloxacillin Flucloxacillin-AFT Flucloxin Fluconazole Fludara Oral Fludarabine Ebewe Fludarabine phosphate Fludarabine phosphate Fludrocortisone acetate Fludrocortisone acetate Fludrocortisone acetate Fludrocortisone acetate Fludrocortisone acetate Fludrocortisone acetate Fludrocortisone acetate Fludrocortisone acetate Fludrocortisone acetate	94 94 94 235 97 149 149 149 80 45
Flucloxacillin Flucloxacillin-AFT Flucloxin Fluconazole Fludara Oral Fludarabine Ebewe Fludarabine phosphate Fludrabine phosphate Fludrocortisone acetate Fludrocortisone acetate Fluetasone pivalate Fluocortolone caproate with fluocortolone pivalate and	94 94 94 94 97 149 149 149 45 234
Flucloxacillin Flucloxacillin-AFT Flucloxin Fluconazole Fludara Oral Fludarabine Ebewe Fludarabine phosphate Fludarabine phosphate Fludrocortisone acetate Fludrocortisone acetate Fluetasone pivalate Fluocortolone caproate with fluocortolone caproate with fluocortolone pivalate and cinchocaine	94 94 94 94 97 149 45 234
Flucloxacillin Flucloxacillin-AFT Flucloxin Fluconazole Fludara Oral Fludara Oral Fludarabine Ebewe Fludarabine phosphate Fludracortisone acetate Fludrocortisone acetate Fludrocortisone pivalate Flucortolone caproate with fluocortolone caproate with fluocortolone pivalate and cinchocaine Fluorometholone	94 94 94 94 97 149 149 149 80 45 234
Flucloxacillin Flucloxacillin-AFT Flucloxin Fluconazole Fluconazole Fludara Oral Fludarabine Ebewe Fludarabine phosphate Fludarabine phosphate Fludrocortisone acetate Fludrocortisone acetate Fludrocortisone acetate Fludrocortisone pivalate Fluocortolone caproate with fluocortolone pivalate and cinchocaine Fluorometholone Fluorometholone Fluoromacil.	94 94 94 94 97 149 149 45 234
Flucloxacillin Flucloxacillin-AFT Flucloxin Fluconazole Fluconazole Fludara Oral Fludara Oral Fludarabine Ebewe Fludarabine phosphate Fludarabine phosphate Fludrocortisone acetate Fludrocortisone acetate Fludrocortisone acetate Fludrocortisone acetate Fludrocortisone acetate Fluorotolone caproate with fluocortolone pivalate and cinchocaine Fluorometholone Fluorouracil. Fluorouracil Accord	94 94 94 94 97 149 45 234 8
Flucloxacillin	94 94 94 94 97 149 49 80 80 8
Flucloxacillin	94 94 94 94 235 97 149 149 80 45 234
Flucloxacillin	94 94 94 94 235 97 149 149 80 45 234
Flucloxacillin	94 94 94 235 97 149 49 49 49 49 49 45 234
Flucloxacillin	94 94 94 235 97 149 149 49 80 45 234
Flucloxacillin	94 94 94 94 97 149 45 234 8
Flucloxacillin	94 94 94 94 97 149 45 234 8
Flucloxacillin	94 94 94 94 97 149 45 234 8
Flucloxacillin	94 94 94 94 97 149 45 8 234 8 235 49 8 235 49 71 71 71
Flucloxacillin	94 94 94 94 97 149 49 45 234 8 235 49 8 8 235 49 71 71 71 71 71 71 71

Fluticasone with salmeterol	
FML	235
Foban	63
Folic acid	
Folic Acid multichem	38
Folic Acid Mylan	
Food Thickeners	
	256
Foods And Supplements For Inborn	
Errors Of Metabolism	
Foradil	227
Forteo	.114
Fortini	249
Fortini Multi Fibre	249
Fortisip	255
Fortisip Multi Fibre	
Fosamax	110
Fosamax Plus	110
Framycetin sulphate	.234
Frisium	
Frumil	
Frusemide	
Fucicort	
Fucidin	96
Fucithalmic	234
Fulvestrant	166
Fungilin	32
Furosemid-Ratiopharm	. 53
Furosemide [Frusemide]	53
Furosemide-Baxter	
fusidic acid	
Dermatological	
Infection	
Sensory	234
- G -	
Gabapentin	
Gacet	
Galsulfase	
Galvumet	12
Galvus	12
Gardasil 9	267
Gastrodenol	
Gaviscon Double Strength	6
Gaviscon Infant	
Gazyva	
Gefitinib	
GEM Aqueous Cream	
Gemeitabing Ebaug	100
Gemcitabine Ebewe	150
Gemcitabine hydrochloride	150
Genoptic	234
Gentamicin sulphate	
Infection	95
Sensory	234
Gilenya	
Ginet	
Glatiramer acetate	
Glecaprevir with pibrentasvir	

Glibenclamide	11
Gliclazide	11
Glipizide	11
Glivec	.160
Glizide	11
Glucagen Hypokit	10
Glucagon hydrochloride	
Glucerna Select	
Glucose [Dextrose]	
Gluten Free Foods	
Glycerin with sodium saccharin	
Glycerin with sucrose	
Glycerol	
Alimentary	26
Extemporaneous	242
Glyceryl trinitrate	
Alimentary	8
Cardiovascular	
Glycopyrronium	
Glycopyrronium bromide	. 220
Glycopyrronium with	
indacaterol	220
Go Healthy	
Gold Knight	
Gold Knight XL7	3_74
Goserelin	
Gutron	
Gynaecological Anti-infectives	
-H-	
- H - Habitrol	
- H - Habitrol Haemophilus influenzae type B	. 144
- H - Habitrol Haemophilus influenzae type B vaccine	. 144 . 266
- H - Habitrol Haemophilus influenzae type B vaccine Haldol	. 144 . 266 . 134
- H - Habitrol Haemophilus influenzae type B vaccine Haldol Haldol Concentrate	. 144 . 266 . 134 . 134
- H - Habitrol Haemophilus influenzae type B vaccine Haldol Haldol Concentrate Haldol Decanoas	. 144 . 266 . 134 . 134 . 134
- H - Habitrol Haemophilus influenzae type B vaccine Haldol Haldol Concentrate Haldol Decanoas Haloperidol	. 144 . 266 . 134 . 134 . 134 . 133
- H - Habitrol Haemophilus influenzae type B vaccine Haldol Haldol Concentrate Haldol Decanoas Haloperidol Haloperidol decanoate	. 144 . 266 . 134 . 134 . 134 . 133 . 134
- H - Habitrol Haemophilus influenzae type B vaccine Haldol Haldol Concentrate Haldol Decanoas Haloperidol Haloperidol decanoate Harvoni	. 144 . 266 . 134 . 134 . 134 . 133 . 134 . 103
- H - Habitrol Haemophilus influenzae type B vaccine Haldol Haldol Concentrate Haldo Decanoas Haloperidol Haloperidol Haloperidol decanoate. Harvoni Harvix	. 144 . 266 . 134 . 134 . 134 . 133 . 134 . 103 . 266
- H - Habitrol Haemophilus influenzae type B vaccine Haldol Haldol Concentrate Haldol Decanoas Haloperidol decanoate Harvoni Harvix Junior	. 144 . 266 . 134 . 134 . 134 . 133 . 134 . 103 . 266 . 266
- H - Habitrol Haemophilus influenzae type B vaccine Haldol Haldol Concentrate Haldol Decanoas Haloperidol decanoate Harvoni Havrix Junior Haylor syrup	. 144 . 266 . 134 . 134 . 134 . 133 . 134 . 103 . 266 . 266
- H - Habitrol Haemophilus influenzae type B vaccine Haldol Haldol Concentrate Haldol Decanoas Haloperidol decanoate Harvoni Havrix Junior Havrix Junior Haylor syrup healthE Calamine Aqueous Cream	. 144 . 266 . 134 . 134 . 133 . 134 . 103 . 266 . 266 . 226
- H - Habitrol Haemophilus influenzae type B vaccine Haldol Concentrate Haldol Decanoas Haloperidol decanoate Haloperidol decanoate Harvoni Havrix Junior Havrix Junior Haylor syrup healthE Calamine Aqueous Cream BP	. 144 . 266 . 134 . 134 . 133 . 134 . 133 . 266 . 226 226
- H - Habitrol Haemophilus influenzae type B vaccine Haldol Concentrate Haldol Decanoas Haloperidol decanoate Haloperidol decanoate Harvoni Havrix Junior Havrix Junior Havrix Junior Haylor syrup healthE Calamine Aqueous Cream BP healthE Dimethicone 10%	. 144 . 266 . 134 . 134 . 133 . 134 . 103 . 266 . 266 . 226 . 226 64
- H - Habitrol Haemophilus influenzae type B vaccine Haldol Concentrate Haldol Decanoas Haldol Decanoas Haloperidol decanoate Haloperidol decanoate Havroni Havrix Junior Havrix Junior Havrix Junior healthE Calamine Aqueous Cream BP healthE Dimethicone 10% healthE Dimethicone 4% Lotion	. 144 . 266 . 134 . 134 . 133 . 134 . 103 . 266 . 266 . 226 . 226 64 64 64
- H - Habitrol Haemophilus influenzae type B vaccine Haldol Concentrate Haldol Decanoas Haloperidol decanoate Haloperidol decanoate Haloperidol decanoate Havroni Havrix Junior Havrix Junior Havrix Junior healthE Calamine Aqueous Cream BP healthE Dimethicone 10% healthE Dimethicone 4% Lotion healthE Dimethicone 5%	. 144 . 266 . 134 . 134 . 133 . 134 . 133 . 266 . 266 . 226 . 226
- H - Habitrol Haemophilus influenzae type B vaccine Haldol Concentrate Haldol Decanoas Haldol Decanoas Haloperidol decanoate Haloperidol decanoate Havroni Havrix Junior Havrix Junior Havrix Junior Havrix Junior Havtis Calamine Aqueous Cream BP healthE Calamine Aqueous Cream BP healthE Dimethicone 10% healthE Dimethicone 5% healthE Dimethicone 5%	. 144 . 266 . 134 . 134 . 133 . 134 . 103 . 266 . 266 . 266 . 266 . 266 . 266
- H - Habitrol Haemophilus influenzae type B vaccine Haldol Haldol Concentrate Haldo Decanoas Haloperidol Haloperidol decanoate. Harvoni Havrix Junior. Havrix Junior. Havrix Junior. Havrix Junior. Havlor syrup healthE Calamine Aqueous Cream BP healthE Dimethicone 10% healthE Dimethicone 4% Lotion healthE Dimethicone 5% healthE Dimethicone 5% healthE Glycerol BP	. 144 . 266 . 134 . 134 . 133 . 134 . 133 . 266 . 266 . 226 64 64 67 66 . 242 66
- H - Habitrol Haemophilus influenzae type B vaccine Haldol Haldol Concentrate Haldo Decanoas Haloperidol Haloperidol decanoate. Harvoni Havrix Junior. Havrix Junior. Havrix Junior. Havrix Junior. Havrix Junior. Havrix Junior. Havrix Junior. Havrix Junior. HathE Calamine Aqueous Cream BP healthE Dimethicone 10% healthE Dimethicone 4% Lotion healthE Dimethicone 5% healthE Dimethicone 5% healthE Glycerol BP healthE Urea Cream. Healtheries Simple Baking Mix.	. 144 . 266 . 134 . 134 . 133 . 134 . 133 . 266 . 266 . 266 . 226
- H - Habitrol Haemophilus influenzae type B vaccine Haldol Haldol Concentrate Haldoperidol decanoas Haloperidol decanoate Haloperidol decanoate Harvoni Havrix Junior Havrix Junior Healthe Dimethicone 10% healthe Dimethicone 4% Lotion healthe Dimethicone 5% healthe Glycerol BP healthe Urea Cream Healtheries Simple Baking Mix	. 144 . 266 . 134 . 134 . 133 . 134 . 103 . 266 . 226
- H - Habitrol Haemophilus influenzae type B vaccine Haldol Haldol Concentrate Haldol Decanoas Haloperidol decanoate Haloperidol decanoate Havrix Junior Havrix Junior Healthe Clamine Aqueous Cream BP healthe Dimethicone 10% healthe Dimethicone 5% healthe Glycerol BP healtheries Simple Baking Mix Hemastix Hemibra	. 144 . 266 . 134 . 134 . 133 . 134 . 266 . 226 226
- H - Habitrol	. 144 . 266 . 134 . 134 . 133 . 134 . 103 . 266 . 267
- H - Habitrol	. 144 . 266 . 134 . 134 . 133 . 134 . 103 . 266 . 267
- H - Habitrol	. 144 . 266 . 134 . 134 . 133 . 266 . 226 66 . 226 66 67 66 242 66 257 78 39 44 44 248
- H - Habitrol	. 144 . 266 . 134 . 134 . 133 . 266 . 226 66 . 226 66 67 66 242 66 257 78 39 44 44 248

vaccine	267
Herceptin	
Hiberix	266
Hiprex	110
Histaclear	
Histafen	
Holoxan	
Horleys Bread Mix	
Horleys Flour	257
Hormone Replacement Therapy -	
Systemic	82
HPV	. 267
Humalog	
Humalog Mix 25	11
Humalog Mix 50	11
Human papillomavirus (6, 11, 16, 18	R
31, 33, 45, 52 and 58) vaccine	σ,
[HPV]	267
Humatin Humira	
HumiraPen	
Humulin 30/70	
Humulin NPH	
Humulin R	
Hyaluronic acid	
Hydralazine	58
Hydralazine hydrochloride	58
Hydrocortisone	
Dermatological	
Hormone	80
Hydrocortisone (PSM)	65
Hydrocortisone acetate	
Hydrocortisone acetate with	
pramoxine hydrochloride	
Hydrocortisone and paraffin liquid	
and lanolin	65
Hydrocortisone butyrate	5 71
Hydrocortisone with cinchocaine	J, 71
Hydrocortisone with miconazole	
Hydrocortisone with natamycin and	00
neomycin	65
Hydrogen peroxide	
Hydroxocobalamin	30
Hydroxocobalamin Mercury	
Pharma	33
hydroxycarbamide	. 153
Hydroxychloroquine	. 112
Hydroxyurea	
[hydroxycarbamide]	. 153
Hygroton	54
Hylo-Fresh	
Hymenoptera	
Hyoscine butylbromide	
Hyoscine hydrobromide	
Hypam	
Hyperuricaemia and Antigout	117
	/

Hypromellose	237
Hypromellose with dextran	237
-1-	
lbiamox	93
Ibrance	161
lbuprofen	
Icatibant	
Idarubicin hydrochloride	153
ldursulfase	
lfosfamide	147
Igroton	54
lkorel	
lloprost	
Imatinib mesilate	
Imatinib-Rex	160
Imigran	
Imipramine hydrochloride	126
Imiquimod	
Immune Modulators	
Immunosuppressants	160
Imuran	
Incruse Ellipta	
Indacaterol	
Indapamide	221 54
Infanrix IPV	265
Infanrix-hexa	
Infant Formulae	200
Infatrini	264
Infliximab	189
Influenza vaccine	
Influvac Tetra	200
(2021 Formulation)	270
Inhaled Corticosteroids	
Inhaled Long-acting	220
Beta-adrenoceptor Agonists	207
Inspra	
Instillagel Lido	04 101
Insulin aspart	121 11
Insulin aspart with insulin aspart	1 1
protamine	10
Insulin glargine	
Insulin glulisine	11 11
Insulin isophane	10
Insulin isophane with insulin	10
neutral	10
Insulin lispro	
Insulin lispro with insulin lispro	1 1
protamine	
Insulin neutral	
Insulin pen needles	
Insulin pump	טו ייני
Insulin pump cartridge Insulin pump infusion set (steel	21
cannula)	01
Insulin pump infusion set (steel	21
cannula. straight insertion)	01
ou in uia. Si aiul It in Sei tiun i	4

Insulin pump infusion set (teflon
cannula)22
Insulin pump infusion set (teflon
cannula, angle insertion with
insertion device) 23
Insulin pump infusion set (teflon
cannula, angle insertion) 23
Insulin pump infusion set (teflon
cannula, straight insertion with
insertion device) 23
Insulin pump infusion set (teflon
cannula, straight insertion)
Insulin pump reservoir
Insulin syringes, disposable with
attached needle
Intelence
Interferon beta-1-alpha
Interferon beta-1-beta
Intra-uterine device
Invega Sustenna
IPCA-Frusemide
IPCA-Prosentide
IPCA-INICIOPIOIOI
IPCA-Propranolol
IPOL
Ipratropium bromide
Iressa
Irinotecan Accord
Irinotecan Actavis 100
Irinotecan hydrochloride 150
Irinotecan-Rex
Iron (as ferric carboxymaltose)
Iron polymaltose
Isentress
Isentress HD107
Ismo 20
Ismo 40 Retard
Isoniazid 101
Isoniazid with rifampicin101
Isoptin
Isoptin Retard
Isoptin SR53
Isopto Carpine
Isosorbide mononitrate
Isosource Standard254
Isotretinoin62
Ispaghula (psyllium) husk25
Itch-Soothe64
Itraconazole98
Itrazole98
Ivacaftor231
Ivermectin67
- J -
Jadelle
Jakavi
Jardiamet13
Jardiance13

Jaydess83
Jevity HiCal RTH
Jevity Plus
Jevity RTH254
Juno Pemetrexed 151
- K -
Kadcyla218
Kaletra 107
Kalydeco231
Kemadrin 120
Kenacomb234
Kenacort-A 1081
Kenacort-A 4081
Kenalog in Orabase
Ketocal 3:1
KetoCal 4:1
Ketoconazole
Dermatological71
Infection98
Ketogenic Diet264
Ketoprofen 111
KetoSens13
Keytruda
Kindergen
Kivexa
Klacid
Alimentary9
Infection91
Kliogest83
Kliovance83
Kogenate FS41
Konakion MM41
Konsyl-D25
Kuvan
-L-
Labetalol
Lacosamide
Lactulose
Laevolac
Lamictal
Lamivudine 102, 107
Lamivudine Alphapharm107
Lamotrigine129
Lamprene 100
Lanoxin
Lanoxin Paediatric Elixir49
Lanoxin PG49
Lanoxin S2949
Lansoprazole
Lantus
Lantus SoloStar11
Lanvis
Lanzol Relief
Lapatinib ditosylate161
Largactil 133
Laronidase29

Lasix	53
Latanoprost	237
Latanoprost with timolol	237
Lax-Suppositories	26
Lax-Tab	
Laxatives	
Laxsol	
Ledipasvir with sofosbuvir	
Leflunomide	
Lenalidomide	
Letrole	
Letrozole	
Leukeran FC	
Leukotriene Receptor	147
	001
Antagonists	231
Leuprorelin	
Leustatin	
Levetiracetam	129
Levetiracetam-AFT	129
Levlen ED	
Levocabastine	
Levocarnitine	29
Levodopa with benserazide	
Levodopa with carbidopa	119
Levomepromazine	133
Levomepromazine	
hydrochloride	133
Levonorgestrel	
Genito-Urinary	75–76
Hormone	
Levothyroxine	
Lidocaine [Lignocaine]	
Lidocaine [Lignocaine]	
Lidocaine [Lignocaine] hydrochloride	121
Lidocaine [Lignocaine] with	121
chlorhexidine	101
Lidocaine [Lignocaine] with	121
prilocaine	101
Lidocaine-Baxter	
Lidocaine-Claris	
Life Extension	
Lignocaine	
Lioresal Intrathecal	
Lipid-Modifying Agents	55
Liquigen	246
Lisinopril	
Lithium carbonate	133
Livostin	236
LMX4	121
Locacorten-Viaform ED's	
Local preparations for Anal and	
Rectal Disorders	8
Locasol	
Locoid	
Locoid Crelo	
Locoid Lipocream	
Looola Lipoolouin	

Locorten-Vioform
Lodoxamide236
Logem
Lomide
Lomustine
Loniten
Loperamide hydrochloride
Lopinavir with ritonavir
Lopinavir/Ritonavir Mylan 107
Loprofin
Loprofin Mix259
Lorafix
Loratadine
Lorazepam
Lorstat
Losartan Actavis
Losartan potassium
Losartan potassium with
hydrochlorothiazide 48
Lovir
Loxamine
Lucrin Depot 1-month
Lucrin Depot 3-month
Lyderm69
Lynparza154
Lyrica129
- M -
m-Eslon
Mabthera 199
Mabthera
Mabthera 199 Macro Organic Psyllium Husk 25 Macrobid 110
Mabthera 199 Macro Organic Psyllium Husk 25 Macrobid 110 Macrogol 3350 with potassium
Mabthera 199 Macro Organic Psyllium Husk 25 Macrobid 110
Mabthera 199 Macro Organic Psyllium Husk 25 Macrobid 110 Macrogol 3350 with potassium
Mabthera
Mabthera
Mabthera 199 Macro Organic Psyllium Husk 25 Macrobid 110 Macrogol 3350 with potassium 110 chloride, sodium bicarbonate and 26 Macrogol 400 and propylene glycol glycol 238
Mabthera 199 Macro Organic Psyllium Husk 25 Macrobid 110 Macrogol 3350 with potassium 110 chloride, sodium bicarbonate and 26 Macrogol 400 and propylene 21 glycol 238 Madopar 125 119
Mabthera 199 Macro Organic Psyllium Husk 25 Macrobid 110 Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride 26 Macrogol 400 and propylene glycol 238 Madopar 125 119 Madopar 250 119
Mabthera 199 Macro Organic Psyllium Husk 25 Macrobid 110 Macrogol 3350 with potassium 110 chloride, sodium bicarbonate and 26 Macrogol 400 and propylene 238 Madopar 125 119 Madopar 250 119 Madopar 62.5 119
Mabthera 199 Macro Organic Psyllium Husk 25 Macrobid 110 Macrogol 3350 with potassium 110 chloride, sodium bicarbonate and 26 Macrogol 400 and propylene 238 Madopar 125 119 Madopar 250 119 Madopar 62.5 119 Madopar HBS 119
Mabthera 199 Macro Organic Psyllium Husk 25 Macrobid 110 Macrogol 3350 with potassium 110 chloride, sodium bicarbonate and sodium chloride sodium chloride 26 Macrogol 400 and propylene glycol glycol 238 Madopar 125 119 Madopar 62.5 119 Madopar HBS 119 Madopar Rapid 119
Mabthera 199 Macro Organic Psyllium Husk 25 Macrobid 110 Macrogol 3350 with potassium 110 chloride, sodium bicarbonate and sodium chloride sodium chloride 26 Macrogol 400 and propylene glycol glycol 238 Madopar 125 119 Madopar 62.5 119 Madopar HBS 119 Madopar Rapid 119 Magnesium hydroxide 36
Mabthera 199 Macro Organic Psyllium Husk 25 Macrobid 110 Macrogol 3350 with potassium 110 chloride, sodium bicarbonate and sodium chloride sodium chloride 26 Macrogol 400 and propylene glycol glycol 238 Madopar 125 119 Madopar 62.5 119 Madopar HBS 119 Madopar Rapid 119 Magnesium hydroxide 36 Magnesium sulphate 36
Mabthera 199 Macro Organic Psyllium Husk 25 Macrobid 110 Macrogol 3350 with potassium 110 chloride, sodium bicarbonate and sodium chloride sodium chloride 26 Macrogol 400 and propylene glycol glycol 238 Madopar 125 119 Madopar 250 119 Madopar HBS 119 Madopar Rapid 119 Magnesium hydroxide 36 Magnesium sulphate 36
Mabthera 199 Macro Organic Psyllium Husk 25 Macrobid 110 Macrogol 3350 with potassium 110 chloride, sodium bicarbonate and sodium chloride sodium chloride 26 Macrogol 400 and propylene glycol glycol 238 Madopar 125 119 Madopar 250 119 Madopar 62.5 119 Madopar Rapid 119 Magnesium hydroxide 36 Mantoux 276 Marevan 44
Mabthera 199 Macro Organic Psyllium Husk 25 Macrobid 110 Macrogol 3350 with potassium 110 chloride, sodium bicarbonate and sodium chloride sodium chloride 26 Macrogol 400 and propylene glycol glycol 238 Madopar 125 119 Madopar 250 119 Madopar 62.5 119 Madopar Rapid 119 Magnesium hydroxide 36 Mantoux 276 Marevan 44 Marine Blue Lotion SPF 50+ 71
Mabthera 199 Macro Organic Psyllium Husk 25 Macrobid 110 Macrogol 3350 with potassium 110 Macrogol 3350 with potassium 25 Macrogol 400 and propylene 26 glycol 238 Madopar 125 119 Madopar 250 119 Madopar 425 119 Madopar 8apid 119 Madopar 8apid 119 Madopar 8apid 276 Martinux 276 Marevan 44 Marine Blue Lotion SPF 50+ 71 Martindale Pharma 239
Mabthera 199 Macro Organic Psyllium Husk 25 Macrobid 110 Macrogol 3350 with potassium 110 chloride, sodium bicarbonate and sodium chloride sodium chloride 26 Macrogol 400 and propylene glycol glycol 238 Madopar 125 119 Madopar 250 119 Madopar Rapid 119 Madopar Rapid 119 Magnesium hydroxide 36 Mantoux 276 Marevan 44 Marine Blue Lotion SPF 50+ 71 Mask for spacer device 232
Mabthera 199 Macro Organic Psyllium Husk 25 Macrobid 110 Macrogol 3350 with potassium 110 Macrogol 3350 with potassium 26 Macrogol 400 and propylene 26 glycol 238 Madopar 125 119 Madopar 250 119 Madopar 62.5 119 Madopar Rapid 119 Madopar Rapid 119 Madopar Bapid 276 Marevan 44 Marine Blue Lotion SPF 50+ 71 Martindale Pharma 239 Mask for spacer device 232 Maviret 103
Mabthera 199 Macro Organic Psyllium Husk 25 Macrobid 110 Macrogol 3350 with potassium 110 Macrogol 3350 with potassium 26 Macrogol 400 and propylene 26 glycol 238 Madopar 125 119 Madopar 250 119 Madopar 62.5 119 Madopar Rapid 119 Madopar Rapid 119 Madopar Bapid 276 Marevan 44 Marine Blue Lotion SPF 50+ 71 Matindale Pharma 239 Mask for spacer device 232 Maviret 103 Maxidex 235
Mabthera 199 Macro Organic Psyllium Husk 25 Macrobid 110 Macrogol 3350 with potassium 110 Macrogol 3350 with potassium 26 Macrogol 400 and propylene 26 glycol 238 Madopar 125 119 Madopar 62.5 119 Madopar Rapid 119 Magnesium hydroxide 36 Marevan 44 Marine Blue Lotion SPF 50+ 71 Martindale Pharma 239 Mask for spacer device 232 Maviret 103 Maxitrol 235
Mabthera 199 Macro Organic Psyllium Husk 25 Macrobid 110 Macrogol 3350 with potassium 110 Macrogol 3350 with potassium 26 Macrogol 400 and propylene 26 glycol 238 Madopar 125 119 Madopar 62.5 119 Madopar Rapid 119 Magnesium hydroxide 36 Marevan 44 Marine Blue Lotion SPF 50+ 71 Martindale Pharma 239 Maxitex 235 Maviret 103 Maxitex 235 Martinol 235
Mabthera 199 Macro Organic Psyllium Husk 25 Macrobid 110 Macrogol 3350 with potassium 110 Macrogol 3350 with potassium 26 Macrogol 400 and propylene 26 glycol 238 Madopar 125 119 Madopar 62.5 119 Madopar Rapid 119 Madopar Rapid 119 Magnesium hydroxide 36 Marevan 44 Marine Blue Lotion SPF 50+ 71 Martindale Pharma 239 Maxidex 235 Maxitrol 246 <tr td=""> </tr>
Mabthera 199 Macro Organic Psyllium Husk 25 Macrobid 110 Macrogol 3350 with potassium 110 chloride, sodium bicarbonate and sodium chloride 26 Macrogol 400 and propylene glycol 238 Madopar 125 119 Madopar 250 119 Madopar 62.5 119 Madopar Rapid 119 Madopar HBS 119 Madopar Rapid 119 Madopar Bapid 119 Madopar Bapid 119 Maticus
Mabthera 199 Macro Organic Psyllium Husk 25 Macrobid 110 Macrogol 3350 with potassium 110 Macrogol 3350 with potassium 26 Macrogol 400 and propylene 26 glycol 238 Madopar 125 119 Madopar 62.5 119 Madopar Rapid 119 Madopar Rapid 119 Magnesium hydroxide 36 Marevan 44 Marine Blue Lotion SPF 50+ 71 Martindale Pharma 239 Maxidex 235 Maxitrol 246 <tr td=""> </tr>

Medco6	6
Medrol80	0
Medroxyprogesterone acetate	
Genito-Urinary70	6
Hormone 82–83	
Mefenamic acid11	
Megace160	
Megestrol acetate 16	
Melatonin 13	
Melphalan 14	
Menactra272	2
Meningococcal (groups A, C, Y and	
W-135) conjugate vaccine 272	2
Meningococcal B multicomponent	
vaccine 273	3
Meningococcal C conjugate	
vaccine 273	
Menthol64	
Mepolizumab 196	
Mercaptopurine150	
Mercilon 2874	
Mesalazine	
Mesna154	
Mestinon 11	1
Metabolic Disorder Agents20	6
Metformin hydrochloride1	
Metformin Mylan1	1
Methadone hydrochloride	_
Extemporaneous242	2
Nervous123	
Methatabs123	3
Methenamine (hexamine)	_
hippurate110	
Methopt23	
Methotrexate	0
Methotrexate DBL Onco-Vial	
Methotrexate Ebewe	
Methotrexate Sandoz 150	0
Methyl hydroxybenzoate24	
Methylcellulose	2
Methylcellulose with glycerin and	_
sodium saccharin	2
Methylcellulose with glycerin and	_
sucrose	
Methyldopa	
Methyldopa Mylan	3
Methyldopa Mylan S29	3
Methylnaltrexone bromide	
Methylphenidate ER - Teva	
Methylphenidate hydrochloride 14	U
Methylphenidate hydrochloride	4
extended-release	
Methylprednisolone	U
Methylprednisolone (as sodium	^
succinate)	
Methylprednisolone aceponate6	C

Mathulau alaisalau a sastata	01
Methylprednisolone acetate	
Methylxanthines	.231
Metoclopramide Actavis 10	. 132
Metoclopramide hydrochloride	.132
Metolazone	
Metopirone	
Metoprolol IV Mylan	51
Metoprolol succinate	
Metoprolol tartrate	50
Metopioloi tartrate	100
Metrogyl	. 100
Metronidazole	
Metyrapone	89
Mexiletine hydrochloride	
Miacalcic	
Micolette	26
Miconazole	32
Miconazole nitrate	
Dermatological	64
Genito-Urinary	76
Micreme	76
Micreme H	
Microgynon 20 ED	
Microgynon 30	75
Microgynon 50 ED	75
Microgynon 50 ED	/ 5
Microlut	
Midazolam	
Midazolam-Baxter	
Midodrine	
Mifegyne	78
Mifepristone	
Minerals	34
Mini-Wright AFS Low Range	.232
Mini-Wright Standard	
Minidiab	11
MiniMed 1.8 Reservoir	
MMT-326A	23
MiniMed 3.0 Reservoir	
MMT-332A	23
MiniMed 770G	16
MiniMed Mio MMT-921A	22
MiniMed Mio MMT-923A	
MiniMed Mio MMT-925A	
MiniMed Mio MMT-941A	22
MiniMed Mio MMT-943A	
MiniMed Mio MMT-945A	<u>-</u>
MiniMed Mio MMT-965A	<u>22</u>
MiniMed Mio MMT-905A	<u>22</u>
MiniMed Quick-Set MMT-386A	22
MiniMed Quick-Set MMT-387A	22
MiniMed Quick-Set MMT-396A	
MiniMed Quick-Set MMT-397A	
MiniMed Quick-Set MMT-398A	
MiniMed Quick-Set MMT-399A	
MiniMed Silhouette MMT-368A	
MiniMed Silhouette MMT-377A	22
MiniMed Silhouette MMT-378A	22

MiniMed Silhouette MMT-381A22	
MiniMed Silhouette MMT-382A	2
MiniMed Silhouette MMT-383A	2
MiniMed Silhouette MMT-384A	
MiniMed Sure-T MMT-864A2	1
MiniMed Sure-T MMT-866A2	
MiniMed Sure-T MMT-874A2	1
MiniMed Sure-T MMT-876A21	1
MiniMed Sure-T MMT-884A2	1
MiniMed Sure-T MMT-886A2	
Minims Cyclopentolate 237	7
Minims Pilocarpine	7
Minims Prednisolone 236	6
Minirin	3
Minirin Melt88	3
Mino-tabs94	4
Minocycline hydrochloride94	4
Minomycin94	4
Minor Śkin Infections67	7
Minoxidil	3
Mirena83	
Mirtazapine 127	
Misoprostol	
Mitomycin C154	4
Mitozantrone154	4
Mitozantrone Ebewe154	4
Mixtard 3010)
MMR II	
Moclobemide 127	7
Modafinil	
Modavigil142	
Moduretic54	
Molaxole	
Moments73	
Mometasone furoate	5
Monogen247	7
Montelukast	
Montelukast Mylan23	
Moroctocog alfa [Recombinant factor	
	h
VIII]	J
VIII] 40 Morphine hydrochloride	л З
Morphine hydrochloride 123	3
Morphine hydrochloride	3 4
Morphine hydrochloride	3 4)
Morphine hydrochloride 123 Morphine sulphate 124 Motetis 120 Mouth and Throat 32	3 4 2
Morphine hydrochloride 123 Morphine sulphate 124 Motetis 120 Mouth and Throat 32 Movapo 115	3 4 2 9
Morphine hydrochloride 123 Morphine sulphate 124 Motetis 120 Mouth and Throat 32	340295
Morphine hydrochloride 123 Morphine sulphate 124 Motetis 120 Mouth and Throat 32 Movapo 115 Moxifloxacin 95	340295
Morphine hydrochloride 123 Morphine sulphate 124 Motetis 120 Mouth and Throat 32 Movapo 115 Moxifloxacin 95 MSUD Maxamum 256	3402953
Morphine hydrochloride 123 Morphine sulphate 124 Motetis 120 Mouth and Throat 32 Movapo 115 Moxifloxacin 95 MSUD Maxamum 256 Mucilaginous laxatives with stimulants 256	
Morphine hydrochloride 123 Morphine sulphate 124 Motetis 122 Mouth and Throat 33 Movapo 115 Moxifloxacin 95 MSUD Maxamum 256 Mucilaginous laxatives with 256 Mucilaginous laxatives with 266 Mucolytics 237	3402953 51
Morphine hydrochloride 123 Morphine sulphate 124 Motetis 120 Mouth and Throat 33 Movapo 115 Moxifloxacin 95 MSUD Maxamum 255 Mucilaginous laxatives with stimulants 25 Mucolytics 23 Mucosothe 12	3402953 511
Morphine hydrochloride 123 Morphine sulphate 124 Motetis 126 Mouth and Throat 33 Movapo 115 Moxifloxacin 95 MSUD Maxamum 256 Mucilaginous laxatives with stimulants 257 Mucolytics 237 Mucosothe 127 Multiple Sclerosis Treatments 136	3402953 51116
Morphine hydrochloride 123 Morphine sulphate 124 Motetis 120 Mouth and Throat 33 Movapo 115 Moxifloxacin 95 MSUD Maxamum 255 Mucilaginous laxatives with stimulants 25 Mucolytics 23 Mucosothe 12	3402953 511633
Morphine hydrochloride 123 Morphine sulphate 124 Motetis 126 Mouth and Throat 32 Movapo 115 Moxifloxacin 95 MSUD Maxamum 256 Mucilaginous laxatives with stimulants 25 Mucolytics 23 Mucosothe 12 Multiple Sclerosis Treatments 136 Multivitamin renal. 33	3402958 5116343

Mvite	.34
Myambutol	
Mycobutin	
MycoNail	.63
Mycophenolate mofetil	
Mydriacyl	
Mylan (12 hr release)	52
Mylan (24 hr release)	52
Mylan Atenolol	50
Mylan Clomiphen	
Mylan Indapamide	
Mylan Italy (24 hr release)	52
Myleran	
Myometrial and Vaginal Hormone	147
Preparations	76
Myozyme	.20
Nadolol	E 1
	.01
Nadolol BNM	
Naglazyme	
Nalcrom	
Naloxone hydrochloride	239
Naltraccord	143
Naltrexone hydrochloride	143
Naphazoline hydrochloride	238
Naphcon Forte	238
Naprosyn SR 1000	
Naprosyn SR 750	
Naproxen	
Narcaricin mite	117
Nasal Preparations	232
Natalizumab	137
Natulan	155
Nausafix	132
Nausicalm	131
Navelbine	158
Nefopam hydrochloride	122
Neisvac-C	273
Neo-B12	.33
Neo-Mercazole	.84
Neocate Gold	260
Neocate Junior Unflavoured	260
Neocate Junior Vanilla	
Neocate SYNEO	
Neoral	
Neostigmine metilsulfate	111
Nepro HP (strawberry)	
Nepro HP (vanilla)	
Nepro HP RTH	240
Neulactil	
Neulastim	
NeuroTabs	
Nevirapine	
Nevirapine Alphapharm	
Nicorandil	
Nicotine	144

Nifedipine	
Nifuran1	
Nilotinib1	61
Nilstat	
Alimentary	32
Genito-Urinary	76
Infection	
Nintedanib2	
Nipent1	55
Nitrates	57
Nitroderm TTS	
Nitrofurantoin1	
Nitrolingual Pump Spray	57
Nivestim	44
Nivolumab2	
Nizoral	
Nodia	
Noflam 2501	
Noflam 5001	
Non-Steroidal Anti-Inflammatory	
Drugs1	11
Nonacog gamma, [Recombinant	
Factor IX]	41
Norethisterone	
Genito-Urinary	76
Hormone	
Norflex1	
Norfloxacin1	
Noriday 28	
Norimin	
Normacol Plus	
Normison1	39
Norpress1	20
Nortriptyline hydrochloride1	26
Norvir 1	
Noumed1	
Noumed Paracetamol1	
NovaSource Renal2	
Novatretin	69
NovoMix 30 FlexPen	
NovoRapid	11
NovoRapid FlexPen	
NovoRapid Penfill	11
NovoSeven RT	
Noxafil	98
Nozinan1	33
Nozinan (Swiss)1	
Nucala1	
Nuelin2	31
Nuelin-SR2	
Nupentin1	
Nutilis2	57
Nutren Diabetes2	47
Nutrient Modules2	44
Nutrini Energy Multi Fibre2	49
Nutrini Energy RTH2	

INDEX:	Generic	Chemicals	and	Brands
--------	---------	-----------	-----	--------

Nutrini Low Energy Multi Fibre 251
Nutrini Peptisorb
Nutrini Peptisorb Energy262
Nutrini RTH249
Nutrison 800 Complete Multi
Fibre
Nutrison Concentrated256
Nutrison Energy254
Nutrison Energy Multi Fibre 254
Nutrison Multi Fibre254
Nutrison Standard RTH254
Nyefax Retard52
Nystatin
Alimentary32
Genito-Urinary76
Infection98
NZB Low Gluten Bread Mix257
- 0 -
O/W Fatty Emulsion Cream66
Obinutuzumab 196
Obstetric Preparations78
Ocrelizumab
Ocrevus
Octocog alfa [Recombinant factor
VIII] (Advate) 41
Octocog alfa [Recombinant factor
VIII] (Kogenate FS) 41
Octreotide
Octreotide (Sun) 167
Octreotide Depot Teva 167
Octreotide GH167
Octreotide long-acting 167
Octreotide MaxRx167
Oestradiol82
Oestradiol valerate
Oestradiol with norethisterone
Oestriol
Genito-Urinary76
Hormone
Oestrogens
Ofev
Oil in water emulsion
Olanzapine
Olbetam
Olopatadine
Olopatadine Teva
Olsalazine
Omalizumab
Omeprazole
Omeprazole actavis 109 Omeprazole actavis 209
Omeprazole actavis 209 Omeprazole actavis 409
Omnitrope
Onbrez Breezhaler

=

Oncaspar LYO1	55
OncoTICE1	76
Ondansetron1	
Ondansetron ODT-DRLA1	32
One-Alpha	33
Onrex1	32
Opdivo	19
Ora-Blend	42
Ora-Blend SF2	42
Ora-Plus	42
Ora-Sweet	
Ora-Sweet SF2	
Orabase	32
Oral and Enteral Feeds	
Oratane	62
Ordine1	202
Orgran	20
Ornidazole 1	00
Ornhonodring gitrate	10
Orphenadrine citrate1	10
Ortho-tolidine	10
Oruvail SR 1	
Osmolite RTH	
Other Endocrine Agents	89
Other Oestrogen Preparations	83
Other Progestogen	~~
Preparations	83
Other Skin Preparations	71
Ovestin	
Genito-Urinary	/6
Hormone	83
Ox-Pam1	36
Oxaliplatin1	48
Oxaliplatin Accord1	
Oxaliplatin Actavis 1001	
Oxaliplatin Ebewe1	48
Oxazepam 1	36
Oxis Turbuhaler	27
Oxpentifylline	58
Oxybutynin	78
Oxycodone hydrochloride1	25
Oxycodone Sandoz 1	25
Oxycodone Sandoz S291	
OxyContin1	25
OxyNorm1	25
Oxytocin	77
Oxytocin BNM	77
Oxytocin with ergometrine	
maleate	77
Ozurdex2	35
- P -	
Pacifen1	
Pacimol1	
Paclitaxel1	
Paclitaxel Actavis1	
Paclitaxel Ebewe 1	
Paediatric Seravit	34

Palbociclib	161
Paliperidone	135
Pamidronate disodium	113
Pamisol	
Pancreatic enzyme	24
Pantoprazole	
Panzop Relief	
Panzytrat	24
Papaverine hydrochloride	
Para-amino salicylic acid	
Paracare	122
Paracare Double Strength	122
Paracetamol	
Paracetamol + Codeine	
(Relieve)	125
Paracetamol with codeine	125
Paraffin	
Paraffin liquid with wool fat	
Parasiticidal Preparations	
Parlodel	110
Parnate	106
Parnate S29	100
Paromomycin	
Paroxetine	107
Paroxeune	101
Paxam	100
Pazopanib	160
Peak flow meter	
Pedialyte - Bubblegum	
Pediasure Pediasure RTH	249
Pegaspargase	100
Pegasys	501
Pegfilgrastim	44
Pegylated interferon alfa-2a	000
Pembrolizumab	
Pemetrexed	
Penicillamine	
Penicillin G	93
PenMix 30	
PenMix 40	10
PenMix 50	
Pentasa	/
Pentostatin [Deoxycoformycin]	155
Pentoxifylline [Oxpentifylline]	
Peptamen Junior	249
Peptisorb	
Perhexiline maleate	
Pericyazine	
Perindopril	
Perjeta	
Permethrin	
Perrigo	/1
Pertuzumab	
Peteha	101
Pethidine hydrochloride	126

Pevaryl63
Pexsig
Pfizer Exemestane 169
Pharmacy Health Sorbolene with
Glycerin66
Pharmacy Services
Pheburane
Phenasen151
Phenobarbitone 129
Phenoharhitone sodium
Extemporaneous242
Nervous
Phenoxybenzamine
hydrochloride
Phenoxymethylpenicillin (Penicillin
V)
Phenytoin sodium
Phillips Milk of Magnesia
Phlexy 10259 Phosphate Phebra46
Phosphorus
Phytomenadione
Pilocarpine hydrochloride
Pimafucort
Pimecrolimus
Pindolol
Pine tar with trolamine laurilsulfate
and fluorescein
Pinetarsol
Pioglitazone
Pirfenidone
Pizotifen131
PKU Anamix Infant259
PKU Anamix Junior259
PKU Anamix Junior Chocolate 259
PKU Anamix Junior LQ259
PKU Anamix Junior Orange259
PKU Anamix Junior Vanilla259
PKU Lophlex LQ 10259
PKU Lophlex LQ 20259
PKU Lophlex Powder259
PKU Lophlex Sensation 20259
Plaquenil112
Plendil ER52
Pneumococcal (PCV10) conjugate
vaccine 273
Pneumococcal (PCV13) conjugate
vaccine 274
Pneumococcal (PPV23)
polysaccharide vaccine 275
Pneumovax 23275
Podophyllotoxin71
Polaramine226
Poliomyelitis vaccine275
Poloxamer25
Poly-Gel238

Poly-Tears	237
Poly-Visc	
Polycal	
Ponstan	
Posaconazole	98
Postinor-1	
Potassium chloride	
Potassium citrate	
Potassium iodate	70
Povidone iodine	
Pradaxa	
Pramipexole hydrochloride	
Pravastatin	55
Pravastatin Mylan	
Praziquantel	
Prazosin	
Pred Forte	
Prednisolone	
Prednisolone acetate	
Prednisolone sodium	8
Prednisolone sodium	
phosphate Prednisolone-AFT	236
Prednisolone-AFT	236
Prednisone	81
Prednisone Clinect	
Pregabalin	
Pregabalin Pfizer	129
Pregnancy Tests - hCG Urine	77
Premarin	
Prevenar 13	
Priadel	
Primaguine	
Primidone	
Primolut N	
Priorix	
Probenecid	
Probenecid-AFT	110
Procaine penicillin	
Procarbazine hydrochloride	
Prochlorperazine	
Proctofoam	
Proctosedyl	8
Procyclidine hydrochloride	
Progesterone	
Proglicem	
Proglycem	
Progynova	
Prolia	
Promethazine hydrochloride	226
Propafenone hydrochloride	
Propamidine isethionate	234
Propranolol	
Propylene glycol	
Propylthiouracil	
Prostacur	
Protaphane	

Protaphane Penfill	10
Protifar	.246
Protionamide	101
Provera	
Provera HD	
PSM Citalopram	127
Peoriacie and Eczoma	. 121
Psoriasis and Eczema Preparations	60
PTU	03
Pulmicort Turbuhaler	200
Pulmozyme	001
Puri-nethol	150
Puria	. 100
Pyrazinamide	101
Pyrazinarino bromido	. 101
Pyridostigmine bromide	
Pyridoxine hydrochloride	
Pyridoxine multichem	
Pyrimethamine	96
Pytazen SR	42
-Q-	
Quetapel	.134
Quetiapine	.134
Quick-Set MMT-392	23
Quick-Set MMT-393	
Quinapril	48
Quinapril with	40
hydrochlorothiazide	48
Qvar	. 220
-R-	100
RA-Morph	. 123
Raloxifene hydrochloride	. 113
Raltegravir potassium	. 107
Ramipex	. 119
Ranbaxy-Cefaclor	90
Ranbaxy-Cefaclor S29	90
Rapamune	.222
Rasagiline	
Reandron 1000	
Recombinant factor IX	8, 41
Recombinant factor VIIa4	40
Rectogesic	۵
Redipred	81
Relieve	. 111
Relistor	
Remicade	
Renilon 7.5	
Resonium-A	
Resource Beneprotein	
Respigen	
Respiratory Devices	
Respiratory Stimulants	
Retinol palmitate	
ReTrieve	62
Retrovir Revlimid	. 107

INDEX: Generic Chemicals and Brands

	20
Revolade Rexacrom	
Riboflavin	
Ribomustin	
Ricit	
Rifabutin	
Rifadin	
Rifampicin	
Rifaximin	9
Rifinah	101
Rilutek	120
Riluzole	120
RINVOQ	223
Riodine	.67
Risedronate Sandoz	114
Risedronate sodium	
Risperdal Consta	
Risperidone 134–	135
Risperidone (Teva)	124
Risperon	104
Ritalin	1.04
Ritalin LA	
Ritonavir	
Rituximab (Mabthera)	199
Rituximab (Riximyo)	
Rivaroxaban	
Rivastigmine	
Rivastigmine Patch BNM 10	
Rivastigmine Patch BNM 5	
Rivotril	
	128
Riximyo	
	200
Riximyo	200 . 41
Riximyo RIXUBIS Rizamelt	200 .41 131
Riximyo RIXUBIS Rizamelt Rizatriptan	200 .41 131 131
Riximyo RIXUBIS Rizamelt Rizatriptan RoActemra S29	200 . 41 131 131 213
Riximyo RIXUBIS Rizamelt Rizatriptan RoActemra S29 Ronapreve	200 .41 131 131 213 188
Riximyo RIXUBIS Rizamelt Rizatriptan RoActemra S29 Ronapreve Ropin	200 .41 131 131 213 188 119
Riximyo	200 .41 131 131 213 188 119 119
Riximyo	200 .41 131 131 213 188 119 119 .55
Riximyo	200 .41 131 213 188 119 119 .55 .55
Riximyo	200 .41 131 131 213 188 119 .55 .55 275
Riximyo	200 .41 131 131 213 188 119 119 .55 .55 275 275
Riximyo	200 .41 131 131 213 188 119 119 .55 .55 275 275 6
Riximyo	200 .41 131 131 213 188 119 .55 .55 275 275 6 .51
Riximyo	200 .41 131 131 213 188 119 .55 275 275 6 .51 .92
Riximyo	200 .41 131 213 188 119 .55 .55 275 275 6 .51 .92 140
Riximyo	200 .41 131 213 188 119 .55 .55 275 275 6 .51 .92 140
Riximyo A RIXUBIS A Rizamelt A Rizatriptan B RoActemra S29 A Ronapreve B Ropin B Rosuvastatin B Rosuvastatin Viatris Rotarix A Rotarix oral vaccine A Roxane B Roxane B Roxithromycin B Rubifen B Rubifen B Rubifen B Rubifen B Rubifen SR B Rugby Capsaicin Topical B	200 .41 131 131 213 188 119 .55 .55 275 6 .51 .92 140 140
Riximyo A RIXUBIS A Rizamelt A Rizatriptan B RoActemra S29 B Ropin B Ropin B Rosuvastatin B Rotarix B Rotarix B Roxane B Roxane B Roxithromycin B Rubifen B Rubifen SR B Rugby Capsaicin Topical Cream	200 .41 131 131 213 188 119 119 .55 275 275 6 .51 .92 140 140
Riximyo 1 RIXUBIS 1 Rizamelt 1 Rizatriptan 1 RoActemra S29 1 Ropareve 1 Ropinicole hydrochloride 1 Rosuvastatin 1 Rosuvastatin 1 Rotarix 1 Roxane 1 Roxane 1 Roxane 1 Roxane 1 Roxane 1 Roxane 1 Royane 1 Rubifen 1 Ruby 2 Ruby 2 Ruby 2 Ruby 2 Ruby 2 Rub	200 .41 131 131 213 188 119 119 .55 275 275 6 .51 .92 140 140
Riximyo	200 .41 131 131 213 188 119 .55 .55 275 6 .51 .92 140 140 122 .92
Riximyo	200 .41 131 131 213 188 119 .55 .55 275 6 .51 .92 140 140 122 .92
Riximyo	200 .41 131 131 213 188 119 119 .55 275 275 275 6 .51 .92 140 140 122 .92 .41
Riximyo	200 .41 131 131 213 188 119 119 .55 275 275 275 6 .51 .92 140 140 122 .92 .41
Riximyo	200 .41 131 131 213 188 119 119 .55 275 6 .51 .92 140 140 122 .92 .41 163 .49

Sacubitril with valsartan......48 Sagent 158 Salazopyrin......8 Salazopyrin EN......8 Salbutamol......228 Salbutamol with ipratropium Salicylic acid70 Sandomigran 131 Sandostatin LAR.....167 Scalp Preparations71 Scopoderm TTS 132 Sebizole.....71 Secukinumab......210 Sedatives and Hypnotics 138 Seebri Breezhaler.....229 Selegiline hydrochloride 120 Senokot26 SensoCard.....15 Seretide Accuhaler 228 Serevent Accuhaler 227 Setrona 127 Setrona AU.....127 Sevredol 124 Sex Hormones Non Shield XL73 shingles vaccine276 SII-Onco-BCG176 Sildenafil......59 Silhouette MMT-37323 Siltuximab......213 Simvastatin.....56 Simvastatin Mylan56 Sinemet119 Sinemet CR 119 Sirolimus......222 Siterone81 Slow-Lopresor51 Smith BioMed Rapid Pregnancy Test......77 Sodibic......46 Sodium acid phosphate26 Sodium alginate.....6

Sodium benzoate	30
Sodium bicarbonate	
Blood	15–46
Extemporaneous	242
Sodium calcium edetate	
Sodium chloride	
Blood	45
Respiratory	232
Sodium citrate with sodium lauryl	
sulphoacetate	26
Sodium citro-tartrate	78
Sodium cromoglicate	
Alimentary	8
Sensory	236
Sodium fluoride	
Sodium Fusidate [fusidic acid]	
Dermatological	63
Infection	00
Sensory	90 A C C
Sodium hyaluronate [Hyaluronic	204
acid]	000
Sodium phenylbutyrate	200 مەر
Sodium picosulfate	00
Sodium polystyrene sulphonate	20
Sodium tetradecyl sulphate	40 11
Sodium valproate	120
Sofradex	129 004
Soframycin	204 004
Solgar	204
Solifenacin Mylan	27-30 70
Solifenacin succinate	
Some actin succinate	
Solu Cortof	00
Solu-Cortef	80
Solu-Medrol	80 80
Solu-Medrol Solu-Medrol-Act-O-Vial	80 80 80
Solu-Medrol Solu-Medrol-Act-O-Vial Somatropin (Omnitrope)	80 80 80 84
Solu-Medrol Solu-Medrol-Act-O-Vial Somatropin (Omnitrope) Sotalol.	80 80 80 84 52
Solu-Medrol Solu-Medrol-Act-O-Vial Somatropin (Omnitrope) Sotalol Spacer device	80 80 80 84 52 232
Solu-Medrol Solu-Medrol-Act-O-Vial Somatropin (Omnitrope) Sotalol. Spacer device. Span-K.	80 80 84 52 232 46
Solu-Medrol Solu-Medrol-Act-O-Vial Somatropin (Omnitrope) Sotalol Spacer device Span-K Spiolto Respimat	80 80 84 52 232 46 229
Solu-Medrol Solu-Medrol-Act-O-Vial Somatropin (Omnitrope) Sotalol. Spacer device. Span-K. Spiolto Respimat Spiractin.	80 80 84 52 232 46 229 54
Solu-Medrol Solu-Medrol-Act-O-Vial Somatropin (Omnitrope) Sotalol. Spacer device Span-K. Spiolto Respimat Spiractin. Spira.	80 80 84 52 232 46 229 54 54
Solu-Medrol Solu-Medrol-Act-O-Vial Somatropin (Omnitrope) Sotalol. Spacer device Span-K Spiolto Respimat Spiriva. Spiriva Respimat	80 80 84 52 232 46 229 54 54 229 54
Solu-Medrol Solu-Medrol-Act-O-Vial Somatropin (Omnitrope) Sotalol Spacer device Span-K Spinto Respimat Spiriva Respimat Spironolactone	80 80 84 52 232 46 229 54 229 54
Solu-Medrol Solu-Medrol-Act-O-Vial Somatropin (Omnitrope) Sotalol Spacer device Span-K Spioto Respimat Spiriva Respimat Spironolactone Sporanox	80 80 84 52 232 46 229 54 229 54 54 98
Solu-Medrol Solu-Medrol-Act-O-Vial Somatropin (Omnitrope) Sotalol. Spacer device. Span-K. Spiolto Respimat Spiriva Respimat Spiriva Respimat Spironolactone Sporanox Sprycel.	80 80 84 52 232 46 229 54 229 54
Solu-Medrol Solu-Medrol-Act-O-Vial Somatropin (Omnitrope) Sotalol. Spacer device Span-K. Spiolto Respimat Spiriva Spiriva Spiriva Respimat Spironolactone Sporanox. Sprycel. Staphlex	80 80 84 52 232 46 229 54 54 98 159 94
Solu-Medrol Solu-Medrol-Act-O-Vial Somatropin (Omnitrope) Sotalol. Spacer device Span-K. Spiolto Respimat Spiriva Spiriva Respimat Spironolactone Sporanox. Sporanox. Sprycel. Staphlex Stemetil.	80
Solu-Medrol Solu-Medrol-Act-O-Vial Somatropin (Omnitrope) Sotalol. Spacer device Span-K. Spiolo Respimat Spirota Respimat Spiriva Respimat Spironolactone Sporanox Sporanox Sprycel. Staphlex Stemetil	80 80
Solu-Medrol Solu-Medrol-Act-O-Vial Somatropin (Omnitrope) Sotalol. Spacer device. Span-K. Spiolto Respimat Spiractin. Spirata Respimat Spirava Respimat Spironolactone Sporanox. Sporanox. Sprycel. Staphlex. Stemetil. SteroClear Stesolid.	
Solu-Medrol Solu-Medrol-Act-O-Vial Somatropin (Omnitrope) Sotalol Spacer device Span-K. Spiolto Respimat Spiractin Spiriva. Spirava Respimat Spironolactone Sporanox Sporanox Staphlex Staphlex Stemetil SteroClear Stesolid Stimulants/ADHD Treatments	80 80
Solu-Medrol Solu-Medrol-Act-O-Vial Somatropin (Omnitrope) Sotalol. Spacer device. Span-K. Spiolto Respimat Spirva. Spirva Respimat Spirva Respimat Spirva Respimat Spironolactone Sporanox Sporanox Stervetil. Stervetil. Stervetil. SteroClear Stesolid. Stimulants/ADHD Treatments Stiripentol.	80 80 80 52 232 24 60 229 54 229 54 229 54 29 98 98 94 159 94 132 232 232 128 139 94 129 94 132 232 232 232 232 232 232 232 232 232
Solu-Medrol	80 80 80 52 232 246 229 54 229 54 29 98 98 94 159 94 132 232 232 128 139 94 132 232 128 139 94 139 94 132 129 94 132 129 94 132 129 129 129 129 129 129 129 129 129 12
Solu-Medrol	
Solu-Medrol	
Solu-Medrol	

Sucralfate9
Sulfadiazine Silver63
Sulfadiazine sodium97
Sulfasalazine8
Sulindac111
Sulphur
Sulprix
Sumagran
Sumatriptan 131
Sunitinib164
Sunitinib Pfizer164
Sunscreens71
Sunscreens, proprietary71
Sure-T MMT-86321
Sure-T MMT-87321
Sustagen Hospital Formula
Active
Sustanon Ampoules81
Sutent
Sylvant213
Symbicort Turbuhaler 100/6 227
Symbicort Turbuhaler 200/6 227
Symbicort Turbuhaler 400/12 227
Symmetrel 119
Sympathomimetics
Synacthen81
Synacthen Depot81
Synacthene Retard81
Synflorix
Synthroid
Syntometrine
Syrup (pharmaceutical grade)
Systane Unit Dose238
-T-
Tacrolimus
Dermatological
Oncology
Tacrolimus Sandoz
Taliglucerase alfa
Tambocor
Tamoxifen citrate
Tamoxifen Sandoz 169
Tamsulosin hydrochloride77
Tamsulosin-Rex
Tandem Cartridge21
Tandem t:slim X2 with Basal-IQ 16
Tap water
Tarceva
Tasigna
Tasmar
Taurine
Tecfidera
Tegretol
Tegretol CR
Telfast
Teligent
10%gont

Temaccord	156
Temazepam	
Temozolomide	
Tenofovir disoproxil	
Tenofovir Disoproxil Teva	
Tenoxicam	111
Tensipine MR10	52
Tepadina	148
Terbinafine	
Terbutaline sulphate	
Teriflunomide	138
Teriparatide	114
Testosterone	
Testosterone cipionate	
Testosterone esters	
Testosterone undecanoate	01
Tetrabenazine	
Tetrabromophenol	/8
Tetracosactrin	
Tetracycline	
Thalidomide	
Thalomid	
Theophylline	231
Thiamine hydrochloride	33
THIO-TEPA	
Thioguanine	151
Thiotepa	148
Thyroid and Antithyroid Agents	84
Ticagrelor	42
Tilcotil	111
Timolol	236
Timoptol XE	
Tiotropium bromide	
Tiotronium bromide with	
olodaterol	229
Tivicay	107
TMP	
Tobramycin	
Infection	07
Sensory	
Tobramycin BNM	204
Tobramucin Mulan	97
Tobramycin Mylan	
Tobrex	
Tocilizumab	
Tofranil	
Tolcapone	120
Topamax	130
Topical Products for Joint and	
Muscular Pain	
Topiramate	
Topiramate Actavis	130
Total parenteral nutrition (TPN)	45
TPN	
Tramadol hydrochloride	
Tramal SR 100	
Tramal SR 150	126

Tramal SR 200	
Trandate	
Tranexamic acid	
Tranylcypromine sulphate	
Trastuzumab	216
Trastuzumab emtansine	
Travatan	
Travoprost	
Treatments for Dementia	142
Treatments for Substance	
Dependence	142
Trental 400	58
Tretinoin	
Dermatological	
Oncology	
Trexate	150
Triamcinolone acetonide	
Alimentary	32
Dermatological	65
Hormone	81
Triamcinolone acetonide with	
gramicidin, neomycin and nystatir	۱
Dermatological	66
Sensory	
Triazolam	139
Trimethoprim	
Trimethoprim with	
sulphamethoxazole	
[Co-trimoxazole]	. 97
Trisequens	83
Trisul	97
Trophic Hormones	84
Tropicamide	
Trulicity	12
Trusopt	
TruSteel	
Tuberculin PPD [Mantoux] test	276
Tubersol	
Two Cal HN	256
Tykerb	
Tysabri	137
- U -	
Ultibro Breezhaler	229
Ultraproct	8
Umeclidinium	229
Umeclidinium with vilanterol	229
Univent	232
Upadacitinib	223
Ural	
Urea	
Urex Forte	
Urinary Agents	77
Urinary Tract Infections	110
Urinorm	
Uromitexan	154
Ursodeoxycholic acid	24

INDEX: Generic Chemicals and Brands

Ursosan24
Utrogestan
- V -
Vaccinations
Vaccinations
Valaciclovir
Valganciclovir
Valganciclovir Mylan102
Vancomycin
Vannair
Varenicline Pfizer144
Varenicline tartrate
Varicella vaccine [Chickenpox
vaccine] 276
Varicella zoster virus (Oka strain) live
attenuated vaccine [shingles
vaccine] 276
Various
Varivax276
Vasodilators58
Vasopressin Agonists
Vasorex
Vedafil59
Veletri60
Venclexta157
Venetoclax157
Venlafaxine127
Venomil
VENOX
Ventavis61
Ventolin
Vepesid153
Verapamil hydrochloride53
Vergo 16131
Vermox
Versacloz
Versacio2
Vesariolu
Vexa201e
Viaderm KC
Vidaza
Vigabatrin 130
Vigabaliiii
Vigisom
Vildagliptin
Vildagliptin with metformin
hydrochloride
Vimpat 128
Vinblastine sulphate158
Vincristine sulphate 158
Vinorelbine
Vinorelbine Ebewe158
Viramune Suspension 106
ViruPOS234
Vit.D3
Vita-B12
VitA-POS

Vitabdeck34
Vital250
Vitamin B complex33
Vitamin B6 25 33
Vitamins33–34
Vivonex TEN250
Voltaren 111
Voltaren D111
Voltaren Ophtha235
Voltaren SR 111
Volumatic
Voriconazole
Votrient
Vttack
- w - Warfarin sodium
Wart Preparations
Wasp venom allergy treatment
Wasp venom allergy treatment
Blood45
Extemporaneous
Wool fat with mineral oil
- X -
Xarelto
Xifaxan
XMET Maxamum
Xolair
XP Maxamum
Xylocaine121
Xylocaine 2% Jelly 121
Xyntha40
- Z -
Zapril47
Zarontin128
Zaroxolyn54
Zavedos153
Zeffix102
Zematop
Zetlam
Ziagen
Zidovudine [AZT] 107 Zidovudine [AZT] with
lamivudine
Zimybe
Zinc and castor oil
Zinc sulphate
Zincaps
Zinnat
Ziprasidone
Zista
Zithromax
Zoledronic acid
Hormone
Musculoskeletal 115
Zoledronic acid Mylan
Zopiclone 139

Zopiclone Actavis	139
Zostavax	276
Zostrix	112
Zostrix HP	122
Zuclopenthixol decanoate	135
Zuclopenthixol hydrochloride	134
Zusdone	134
Zyban	143
Zypine	133
Zypine ODT	133
Zyprexa Relprevv	134
Zytiga	1 <mark>65</mark>













